

Modulators of G-Protein Coupled Receptors

PRIORITY CLAIM

This application claims the benefit of U.S. Provisional Application Serial No. 62/647,604, filed on March 23, 2018, which is incorporated herein by reference in its entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on March 22, 2019, is named 41517-0002WO1_SL.txt and is 39,811 bytes in size.

TECHNICAL FIELD

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize or partially agonize or antagonize) glucagon-like peptide-1 receptor ("GLP-1R") and/or the gastric inhibitory polypeptide receptor ("GIPR"). The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP-1R and/or GIPR activities is beneficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, the modulation results in an enhancement of (e.g., an increase in) existing levels (e.g., normal or below normal levels) of GLP-1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) β -arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.

BACKGROUND

Diabetes mellitus type 2 (type-2 diabetes) is characterized by high blood glucose and insulin resistance. Type 2 diabetes as well as conditions that are co-morbid or sequela with type-2 diabetes affect tens of millions of people in the United States alone. Type-2
5 diabetes is frequently associated with obesity.

Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease (NAFLD). NASH and NAFLD tend to develop in patients having one of the following risk factors: obesity, dyslipidemia, and glucose intolerance and appears to be
10 linked to insulin resistance (e.g., as in obesity or metabolic syndrome).

Incretin hormones are hormones that provide glycemic control in response to food intake. Gastric inhibitory polypeptide ("GIP") and glucagon-like peptide-1 ("GLP-1") are primary incretin hormones secreted from small intestinal L cells and K cells, respectively, on ingestion of glucose or nutrients to stimulate insulin secretion from pancreatic β cells.
15 GIP and GLP-1 undergo degradation by dipeptidyl peptidase-4 (DPP-4), and rapidly lose their biological activities (see, e.g., Y. Sieno, et. al, *Journal of Diabetes Investigation* **2013**, 4, 108-130).

The actions of GIP and GLP-1 are believed to be mediated by their specific receptors, the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R), respectively, which
20 both belong to the G-protein coupled receptor family and are expressed in pancreatic β -cells, as well as in various tissues and organs. GLP-1 activities include, without limitation, stimulation of insulin synthesis and secretion, inhibition of glucagon secretion, and inhibition of food intake. GIP activities include, without limitation, stimulation of glucose-dependent insulin secretion, an increase in β -cell mass, stimulation of glucagon secretion,
25 and a decrease in gastric acid secretion. See, e.g., WO 2016/131893.

GLP-1 and GLP-1 analogues, acting as agonists at the GLP-1 receptor, have been shown to be effective in glycemic control, e.g., type-2 diabetes. See, e.g., WO 2016/131893. In addition to their insulinotropic effects, GIP and GLP-1 are believed to be involved in various biological processes in different tissues and organs that express GIPR
30 and GLP-1R, including, e.g., the pancreas, fat, bone, brain, heart, kidney, eye, nerves, and

liver. By way of example, investigations using mice lacking GIPR and/or GLP-1R, as well as mice lacking DPP-4, showed involvement of GIP and GLP-1 in divergent biological activities. The results of these investigations point to involvement of GIP and GLP-1 in treating and/or preventing diabetes-related microvascular complications (e.g., retinopathy, nephropathy and neuropathy) and macrovascular complications (e.g., coronary artery disease, peripheral artery disease and cerebrovascular disease), as well as diabetes-related comorbidity (e.g., obesity, non-alcoholic fatty liver disease, bone fracture and cognitive dysfunction). See, e.g., Sieno at page 108.

SUMMARY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize or partially agonize or antagonize) glucagon-like peptide-1 receptor ("GLP-1R") and/or the gastric inhibitory polypeptide receptor ("GIPR"). The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP-1R and/or GIPR activities is beneficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, the modulation results in an enhancement of (e.g., an increase in) existing levels (e.g., normal or below normal levels) of GLP-1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) β -arrestin signaling relative to what is observed with the native ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.

An "agonist" of GLP-1R includes compounds that, at the protein level, directly bind or modify GLP-1R such that an activity of GLP-1R is increased, e.g., by activation, stabilization, altered distribution, or otherwise relative to GLP-1R activity in absence of ligand.

Certain compounds described herein that agonize GLP-1R to a lesser extent (partial agonists) than a GLP-1R full agonist (e.g. native GLP-1) can function in assays as antagonists as well as agonists. These compounds antagonize activation of GLP-1R by a GLP-1R full agonist because they prevent the full effect of GLP-1R interaction. However, the compounds also, on their own, activate some GLP-1R activity, typically less than a corresponding amount of the GLP-1R full agonist. Such compounds are sometimes referred to herein as "partial agonists of GLP-1R".

An "antagonist" of GLP-1R includes compounds that, at the protein level, directly bind or modify GLP-1R such that an activity of GLP-1R is decreased, e.g., by inhibition, blocking or dampening agonist-mediated responses, altered distribution, or otherwise relative to GLP-1R activity in absence of ligand.

In some embodiments, the compounds described herein are agonists (e.g. full agonists) of GLP-1R. In other embodiments, the compounds described herein are partial agonists or antagonists of GLP-1R.

An "agonist" of GIPR includes compounds that, at the protein level, directly bind or modify GIPR such that an activity of GIPR is increased, e.g., by activation, stabilization, altered distribution, or otherwise relative to GIPR activity in absence of ligand.

Certain compounds described herein that agonize GIPR to a lesser extent than native GIP (s full agonist) can function as antagonists as well as agonists. These compounds are partial antagonists as they reduce activation of GIPR by native GIP because they reduce the full effect of native GIP. However, the compounds also, on their own, activate some GIPR activity, typically less than a corresponding amount of native GIP. Such compounds are sometimes referred to herein as "partial agonists of GIPR".

An "antagonist" of GIPR includes compounds that, at the protein level, directly bind or modify GIPR such that an activity of GIPR is decreased, e.g., by inhibition, blocking or dampening agonist-mediated responses, altered distribution, or otherwise relative to GIPR activity in absence of ligand.

In some embodiments, the compounds described herein are agonists (e.g. full agonists) of GIPR. In other embodiments, the compounds described herein are partial

agonists of GIPR. In still other embodiments, the compounds described herein are or antagonists of GIPR.

5 In some embodiments, the compounds described herein are full agonists of both GLP-1R and GIPR. In some embodiments, the compounds described herein are partial agonists of both GLP-1R and GIPR. This disclosure also contemplates chemical entities that (i) agonize one of GLP-1R and GIPR (e.g., GLP-1R); and antagonize the other of GLP-1R and GIPR (e.g., GIPR). For example, this disclosure contemplates chemical entities that (i) fully agonize one of GLP-1R and GIPR (e.g., GLP-1R); and partially agonize or antagonize the other of GLP-1R and GIPR (e.g., GIPR). In certain embodiments, the chemical entities that are full agonists of GLP-1R and partial agonists or antagonists of GIPR; or that are partial agonists or antagonists of GLP-1R and full agonists of GIPR.

Generally, a receptor exists in an active (Ra) and an inactive (Ri) conformation. Certain compounds that affect the receptor can alter the ratio of Ra to Ri (Ra/Ri). For example, a full agonist increases the ratio of Ra/Ri and can cause a "maximal", saturating effect. A partial agonist, when bound to the receptor, gives a response that is lower than that elicited by a full agonist (e.g., an endogenous agonist). Thus, the Ra/Ri for a partial agonist is less than for a full agonist. However, the potency of a partial agonist may be greater or less than that of the full agonist.

20 In some embodiments, the chemical entities described herein further modulate (e.g., reduce, e.g., attenuate, disrupt, inhibit) β -arrestin coupling and/or β -arrestin signaling, and GLP-1R and/or GIPR internalization. In certain embodiments, the chemical entities described herein modulate (e.g., reduce, e.g., attenuate, disrupt, inhibit) recruitment of β -arrestin to a G-protein coupled receptor (e.g., GLP-1R). In certain embodiments, the chemical entities described herein modulate (e.g., reduce, e.g., attenuate, disrupt, inhibit) formation of a complex ("coupling") (e.g., a signaling complex) between β -arrestin and a G-protein coupled receptor (e.g., GLP-1R or GIPR). The effects of the chemical entities described herein on β -arrestin signaling and associated downstream processes (e.g., those delineated above) can be assessed using conventional methods, e.g., PathHunter β -arrestin Assay for determining β -arrestin coupling (see Examples section). By way of example,

a value of β -arrestin (GLP-1R) $EC_{50} < 1 \mu M$ in the aforementioned assay indicates a compound that induces β -arrestin recruitment to GLP-1R. GLP-1, the native ligand for GLP-1R, and therapeutic analogs thereof, such a liraglutide, are potent recruiters of β -arrestin. As another example, a value of β -arrestin (GLP1R) $EC_{50} > 1 \mu M$ (e.g., $> 10 \mu M$) indicates a compound that does not substantially induce β -arrestin recruitment to GLP-1R. Therapeutic agents that modulate G-protein coupled receptors (e.g., GLP-1R and/or GIPR) can produce a variety of effects depending on the degree of cAMP activation versus β -arrestin-based signaling. It has been shown that β -arrestin coupling is a key step in receptor internalization and subsequent de-sensitization and attenuation of signaling. Both GLP-1 (and the liraglutide analog) and GIP have been shown to produce rapid receptor internalization. Thus, compounds that activate GLP-1R and/or GIPR cAMP signaling but do not substantially couple to β -arrestin have the potential to prolong receptor signaling and extend pharmacological benefits. In some embodiments, the chemical entities described herein exhibit relatively strong GLP-1R and/or GIPR mediated cAMP activation with minimal or no detectable β -arrestin coupling. In some embodiments, the chemical entities described herein exhibit relatively strong GLP-1R mediated cAMP activation and no or little GIPR mediated cAMP activation with minimal or no detectable β -arrestin coupling.

In some embodiments, the compounds described herein show reduced activity in a rodent aversion model, while maintaining a relatively high potency in glucose clearance assay. Aversion models, such as conditioned taste aversion, are commonly used to identify compounds with adverse effects such as nausea. Nausea causing agents, such as Exendin-4 and liraglutide, are known to have a strong signal in conditioned taste aversion models. Advantageously, some of the chemical entities described herein are therefore expected to have a reduced likelihood of producing unwanted side effects, such as nausea, when administered to a patient, while maintaining full pharmacological benefit.

Accordingly, in one aspect, this disclosure features peptide-based chemical entities (e.g., N-protected peptide-based chemical entities; e.g., peptide-based chemical entities

having from 30-50 amino acids, 30-45 amino acids, 30-40 amino acids, 35-40 amino acids; e.g., an N-protected peptide-based chemical entities having from 30-50 amino acids, 30-45 amino acids, 30-40 amino acids, 35-40 amino acids). The peptide-based chemical entities modulate (e.g., agonize or partially agonize or antagonize) glucagon-like peptide-1 receptor (“GLP-1R”) and/or the gastric inhibitory polypeptide receptor (“GIPR”) and optionally further modulate (e.g., uncouple, attenuate,) β -arrestin signaling and/or aversion as described herein.

In some embodiments, the peptide-based chemical entities agonize or partially agonize GLP-1R.

In some embodiments, the peptide-based chemical entities agonize or partially agonize or antagonize GIPR.

In some embodiments, said peptide-based chemical entities reduce (e.g., uncouple, attenuate, inhibit) β -arrestin signaling; e.g., reduce (e.g., uncouple, attenuate, inhibit) the recruitment of β -arrestin to a G-protein coupled receptor (e.g., GLP-1R); e.g., reduce (e.g., attenuate, disrupt, inhibit) the formation of a complex (e.g., a signaling complex) between β -arrestin and a G-protein coupled receptor (e.g., GLP-1R).

In certain embodiments, the peptide-based chemical entities:

- agonize or partially agonize GLP-1R;
- agonize or partially agonize or antagonize GIPR;
- reduce (e.g., uncouple, attenuate, inhibit) β -arrestin signaling; e.g., reduce (e.g., attenuate, disrupt, inhibit) the recruitment of β -arrestin to a G-protein coupled receptor (e.g., GLP-1R and/or GIPR); e.g., reduce (e.g., attenuate, disrupt, inhibit) the formation of a complex (e.g., a signaling complex) between β -arrestin and a G-protein coupled receptor (e.g., GLP-1R and/or GIPR); and
- stimulate glucose clearance in vivo (GTT test) without causing aversion.

In some embodiments, the peptide-based chemical entities exhibit a value of cAMP (GLP1R) EC₅₀ of less than about 10 nM, 5 nM, or 1 nM (e.g., less than about 1 nM).

In some embodiments, the peptide-based chemical entities exhibit a value of cAMP (GIPR) EC₅₀ of less than about 100 nM, 50 nM, or 10 nM (e.g., less than about 10 nM).


5 In some embodiments, the peptide-based chemical entities inhibit GIP induced cAMP production (GIPR antagonism).

In some embodiments, the compounds described herein exhibit a value of β -arrestin (GLP1R) EC₅₀ > 1 μ M.

10 In some embodiments, the peptide-based chemical entities:

- exhibit a value of cAMP (GLP1R) EC₅₀ of less than about 10 nM, 5 nM, or 1 nM (e.g., less than about 1 nM);
- exhibit a value of cAMP (GIPR) EC₅₀ of less than about 100 nM, 50 nM, or 10 nM (e.g., less than about 10 nM) or are GIPR antagonists;
- 15 • exhibit a value of β -arrestin (GLP1R) EC₅₀ > 1 μ M; and
- stimulate glucose clearance in vivo (GTT test) without causing aversion (nausea)

20 In one aspect, the featured peptide-based chemical entities include compounds of Formula (IAA), or a pharmaceutically acceptable salt thereof:



in which ring A, G, L, W, R¹, R², R^{2'}, and R⁴ can be as defined anywhere herein.

25 In one aspect, pharmaceutical compositions are featured that include a chemical entity described herein (e.g., a compound described generically or specifically herein or a

pharmaceutically acceptable salt thereof or compositions containing the same) and one or more pharmaceutically acceptable excipients.

5 In one aspect, methods for modulating (e.g., agonizing, partially agonizing, or antagonizing) GLP-1R and/or GIPR activities are featured that include contacting GLP-1R and/or GIPR with a chemical entity described herein (e.g., a compound described generically or specifically herein or a pharmaceutically acceptable salt thereof or compositions containing the same). Methods include *in vitro* methods, e.g., contacting a sample that includes one or more cells, each independently comprising one or more of
10 GLP-1R and/or GIPR with the chemical entity. Methods can also include *in vivo* methods; e.g., administering the chemical entity to a subject (e.g., a human) having a disease, disorder, or condition in which modulation of GLP-1R and/or GIPR signaling is beneficial for the treatment of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition (e.g., diabetes; e.g., NASH; e.g., obesity). *In vivo* methods
15 include, but are not limited to modulating (e.g., increasing) insulin levels and modulating (e.g., decreasing) glucose levels in a subject (e.g., a human). In some of the foregoing embodiments, said methods of modulating are achieved without substantially stimulating β -arrestin signaling; e.g., without stimulating the recruitment of β -arrestin to a G-protein coupled receptor (e.g., GLP-1R); e.g., without stimulating the formation of a complex (e.g.,
20 a signaling complex) between β -arrestin and a G-protein coupled receptor (e.g., GLP-1R). In some of the foregoing embodiments, said methods of modulating are achieved without causing aversion or nausea.

25 In a further aspect, methods of treatment of a disease, disorder, or condition are featured, in which modulation of GLP-1R and/or GIPR signaling is beneficial for the treatment of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. The methods include administering to a subject in need of such treatment an effective amount of a chemical entity described herein (e.g., a compound described generically or specifically herein, a pharmaceutically acceptable salt thereof, or
30 compositions containing the same).

In another aspect, this disclosure features methods of treating a subject having a disease, disorder, or condition in which modulation of GLP-1R and/or GIPR signaling is beneficial for the treatment of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. The methods include administering a chemical entity described herein (e.g., a compound described generically or specifically herein, a pharmaceutically acceptable salt thereof or compositions containing the same) in an amount effective to treat the disease, disorder, or condition.

In a further aspect, methods of treatment are featured that include administering to a subject chemical entity described herein (e.g., a compound described generically or specifically herein, a pharmaceutically acceptable salt thereof, or compositions containing the same). The methods include administering the chemical entity in an amount effective to treat a disease, disorder, or condition, wherein modulation of GLP-1R and/or GIPR is beneficial for the treatment of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition, thereby treating the disease, disorder, or condition.

In another aspect, methods of treatment can further include:

(i) administering a first therapeutic agent that modulates (e.g., agonizes, partially agonizes, or antagonizes) GLP-1R and/or GIPR to a subject as defined anywhere herein;

(ii) determining that the subject is suffering from one or more side effects (e.g., aversion, nausea or vomiting); and

(iii) ceasing administration of the first therapeutic agent and administering a chemical entity as described herein (e.g., a compound having formula (IAA), (IA), or (I)).

Non-limiting examples of such diseases, disorders, and conditions include metabolic syndrome; diabetes (e.g., type 2 diabetes); obesity; obesity-related disorders; impaired glucose tolerance; insulin resistance; non-alcoholic steatohepatitis (NASH); fatty liver disease; steatohepatitis; and other forms of inflammation in metabolically important tissues including, liver, fat, pancreas, kidney, and gut.

Other non-limiting examples of such diseases, disorders, and conditions include neurological disorders include brain insulin resistance, mild cognitive impairment (MCI), Alzheimer's disease (AD), Parkinson's disease (PD), anxiety, dementia (e.g., senile dementia), traumatic brain injury, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania, Morbus Parkinson, steel-Richard syndrome, Down's syndrome, myasthenia gravis, nerve trauma, brain trauma, vascular amyloidosis, cerebral hemorrhage I with amyloidosis, brain inflammation, Friedrich's ataxia, acute confusion disorder, amyotrophic lateral sclerosis (ALS), glaucoma, and apoptosis-mediated degenerative diseases of the central nervous system (e.g., Creutzfeld-Jakob Disease, bovine spongiform encephalopathy (mad cow disease), and chronic wasting syndrome).

Still other non-limiting examples of such diseases, disorders, and conditions include bone disorder characterized by altered bone metabolism, such as osteoporosis, including post-menopausal osteoporosis, poor bone strength, osteopenia, Paget's disease, osteolytic metastasis in cancer patients, osteodystrophy in liver disease and the altered bone metabolism caused by renal failure or haemodialysis, bone fracture, bone surgery, aging, pregnancy, protection against bone fractures, and malnutrition.

In certain embodiments, the disease, disorder, or condition is diabetes.

In other embodiments, the disease, disorder, or condition is NASH.

In still other embodiments, the disease, disorder, or condition is obesity.

In other embodiments, the disease, disorder, or condition is Alzheimer's disease (AD) or Parkinson's disease (PD).

In still other embodiments, the disease, disorder, or condition is a bone disorder characterized by altered bone metabolism, such as osteoporosis, including post-menopausal osteoporosis, poor bone strength, osteopenia, Paget's disease, osteolytic metastasis in cancer patients, osteodystrophy in liver disease and the altered bone metabolism caused by renal failure or haemodialysis, bone fracture, bone surgery, aging, or pregnancy.

In certain embodiments, the chemical entities described herein are useful for protection against bone fractures.

The methods described herein can further include treating one or more conditions associated, co-morbid or sequela with any one or more of the conditions described herein. By way of non-limiting example, the methods can further include treating one or more conditions that are co-morbid or sequela with diabetes (e.g., type 2 diabetes), such as obesity, obesity-related disorders, metabolic syndrome, impaired glucose tolerance; insulin resistance; cardiovascular risk factors. (e.g., coronary artery disease, peripheral artery disease, cerebrovascular disease, hypertension, and risk factors related to unmanaged cholesterol and/or lipid levels, and/or inflammation), retinopathy, nephropathy, neuropathy, NASH, bone fracture and cognitive dysfunction.

In another aspect, this disclosure features methods for screening a candidate compound for treatment of a disease, disorder, or condition, in which modulation of GLP-1R and/or GIPR is beneficial for the treatment of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition; the method comprising:

(a) contacting the candidate compound with (i) a β -Arrestin-coupled GPCR receptor signaling complex or (ii) one or more GPCR receptor signaling complexes that are not complexed with β -arrestin (e.g., uncoupled GLP-1R and/or uncoupled GIPR); and

(b) detecting (i) the disruption of the β -arrestin coupled complex; or (ii) detecting the formation of the signaling complex in the absence of β -arrestin coupling; wherein the candidate compound modulates (e.g., agonizes, partially agonizes,) GLP-1R and/or GIPR.

In certain embodiments, the methods further include selecting a candidate compound that exhibits a value of β -arrestin (GLP-1R) $EC_{50} > 1 \mu M$.

The methods can further include identifying the subject.

The methods can further include administering one or more other therapeutic agents (e.g., in combination with a chemical entity described herein).

Embodiments can include one of more of the following advantageous properties.

In some embodiments, the compounds described herein exhibit a value of AUC Score of 0-25% of vehicle, which corresponds to a finding of maximal decrease in glucose excursion compared to control.

5 In some embodiments, the compounds described herein exhibit a value of cAMP (GLP-1R) EC₅₀ of less than about 1 nM, which is indicative that the compound is a relatively potent GLP-1R agonist.

In some embodiments, the compounds described herein exhibit a value of cAMP (GLP-1R) E_{max} of greater than about 80%, which is indicative that the compound is an agonist that can fully activate GLP-1R.

10 In some embodiments, the compounds described herein exhibit a value of cAMP (GIPR) EC₅₀ of less than about 10 nM, which is indicative that the compound is a relatively potent GIPR agonist.

In some embodiments, the compounds described herein exhibit a value of cAMP (GIPR) EC₅₀ of less than about 10 nM, which is indicative that the compound is a relatively
15 potent GIPR antagonist.

GLP-1 and GIP are susceptible to rapid degradation by dipeptidyl peptidase-IV (DPP-IV) (see, e.g., Deacon, et al. Journal of Clinical Endocrinology & Metabolism, 1995, 80, 952-957). As such, GLP-1 and GIP have been shown to exhibit relatively short half-life times in human due to DPP-IV degradation. Advantageously, the compounds
20 described herein exhibit relatively long half-life times in the presence of DPP-IV when compared to those of GLP-1 and GIP.

In some embodiments, the compounds described herein exhibit a value of β -arrestin coupling (GLP-1R) EC₅₀ > 1 μ M in a β -arrestin (GLP1R) assay that measures the formation of a complex between GLP-1R and β -arrestin in cells. A value of β -arrestin
25 (GLP1R) EC₅₀ > 1 μ M indicates a compound that does not substantially induce β -arrestin recruitment to GLP-1R.

In some embodiments, the compounds described herein exhibit a value of conditioned taste aversion ("CTA") = 0.6-1.0, which indicates no measurable aversion to a compound, which is desired. A value of CTA = 0.0-0.6 indicates significant aversion to

a compound. The conditioned taste aversion assay measures the preference for a dilute saccharin solution that is associated with compound administration.

In some embodiments, the compounds described herein have a reduced likelihood of producing unwanted side effects when administered to a patient. A non-limiting
5 example of such a side effect is nausea.

Other embodiments include those described in the Detailed Description, drawings, and/or in the claims.

10

DESCRIPTION OF DRAWINGS

FIG. 1 depicts representative compounds of Formula (IAA).

Additional Definitions

To facilitate understanding of the disclosure set forth herein, a number of additional
15 terms are defined below. Generally, the nomenclature used herein and the laboratory procedures in organic chemistry, medicinal chemistry, and pharmacology described herein are those well-known and commonly employed in the art. Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Each of the
20 patents, applications, published applications, and other publications that are mentioned throughout the specification and the attached appendices are incorporated herein by reference in their entireties.

As used herein, the term “GLP-1R” is meant to include, without limitation, nucleic acids, polynucleotides, oligonucleotides, sense and antisense polynucleotide strands,
25 complementary sequences, peptides, polypeptides, proteins, homologous and/or orthologous GLP-1R molecules, isoforms, precursors, mutants, variants, derivatives, splice variants, alleles, different species, and active fragments thereof.

As used herein, the term “GIPR” is meant to include, without limitation, nucleic acids, polynucleotides, oligonucleotides, sense and antisense polynucleotide strands,

complementary sequences, peptides, polypeptides, proteins, homologous and/or orthologous GIPR molecules, isoforms, precursors, mutants, variants, derivatives, splice variants, alleles, different species, and active fragments thereof.

5 The term “acceptable” with respect to a formulation, composition or ingredient, as used herein, means having no persistent detrimental effect on the general health of the subject being treated.

“API” refers to an active pharmaceutical ingredient.

10 The term “IC₅₀” or “EC₅₀” refers an amount, concentration, or dosage of a compound that is required for 50% inhibition or activation of a maximal response observed for such compound (or that of a reference compound as the case may be) in an assay that measures such response.

15 The terms “effective amount” or “therapeutically effective amount,” as used herein, refer to a sufficient amount of a chemical entity (e.g., a compound described generically or specifically herein, a pharmaceutically acceptable salt thereof, or compositions containing the same) being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated. The result includes reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an “effective amount” for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide
20 a clinically significant decrease in disease symptoms. An appropriate “effective” amount in any individual case is determined using any suitable technique, such as a dose escalation study.

25 The term “excipient” or “pharmaceutically acceptable excipient” means a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, carrier, solvent, or encapsulating material. In one embodiment, each component is “pharmaceutically acceptable” in the sense of being compatible with the other ingredients of a pharmaceutical formulation, and suitable for use in contact with the tissue or organ of humans and animals without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, commensurate with a
30 reasonable benefit/risk ratio. *See, e.g., Remington: The Science and Practice of Pharmacy,*

21st ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2005; *Handbook of Pharmaceutical Excipients*, 6th ed.; Rowe et al., Eds.; The Pharmaceutical Press and the American Pharmaceutical Association: 2009; *Handbook of Pharmaceutical Additives*, 3rd ed.; Ash and Ash Eds.; Gower Publishing Company: 2007; *Pharmaceutical*
5 *Preformulation and Formulation*, 2nd ed.; Gibson Ed.; CRC Press LLC: Boca Raton, FL, 2009.

The term “pharmaceutically acceptable salt” refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound. In certain instances,
10 pharmaceutically acceptable salts are obtained by reacting a compound described herein, with acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. In some instances, pharmaceutically acceptable salts are obtained by reacting a compound having acidic group described herein with a base to form
15 a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, *N*-methyl-D-glucamine, tris(hydroxymethyl)methylamine, and salts with amino acids such as arginine, lysine, and the like, or by other methods previously determined. The pharmacologically acceptable salt s not specifically limited as
20 far as it can be used in medicaments. Examples of a salt that the compounds described herein form with a base include the following: salts thereof with inorganic bases such as sodium, potassium, magnesium, calcium, and aluminum; salts thereof with organic bases such as methylamine, ethylamine and ethanolamine; salts thereof with basic amino acids such as lysine and ornithine; and ammonium salt. The salts may be acid addition salts,
25 which are specifically exemplified by acid addition salts with the following: mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, and ethanesulfonic acid; acidic amino acids such as
30 aspartic acid and glutamic acid.

The term "pharmaceutical composition" refers to a mixture of a compound described herein with other chemical components (referred to collectively herein as "excipients"), such as carriers, stabilizers, diluents, dispersing agents, suspending agents, and/or thickening agents. The pharmaceutical composition facilitates administration of the compound to an organism. Multiple techniques of administering a compound exist in the art including, but not limited to rectal, oral, intravenous, aerosol, parenteral, ophthalmic, pulmonary, and topical administration.

The term "subject" refers to an animal, including, but not limited to, a primate (*e.g.*, human), monkey, cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse. The terms "subject" and "patient" are used interchangeably herein in reference, for example, to a mammalian subject, such as a human.

The terms "treat," "treating," and "treatment," in the context of treating a disease, disorder, or condition, are meant to include alleviating or abrogating a disorder, disease, or condition, or one or more of the symptoms associated with the disorder, disease, or condition; or to slowing the progression, spread or worsening of a disease, disorder or condition or of one or more symptoms thereof.

The term "halo" refers to fluoro (F), chloro (Cl), bromo (Br), or iodo (I).

The term "alkyl" refers to a hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms. For example, C₁₋₁₀ indicates that the group may have from 1 to 10 (inclusive) carbon atoms in it. Non-limiting examples include methyl, ethyl, *iso*-propyl, *tert*-butyl, *n*-hexyl.

The term "haloalkyl" refers to an alkyl, in which one or more hydrogen atoms is/are replaced with an independently selected halo.

The term "alkoxy" refers to an -O-alkyl radical (*e.g.*, -OCH₃).

The term "haloalkoxy" refers to an -O-haloalkyl radical (*e.g.*, -OCH₃).

The term "alkylene" refers to a branched or unbranched divalent alkyl (*e.g.*, -CH₂-).

The term "arylene" and the like refer to divalent forms of the ring system, here divalent aryl.

The term "alkenyl" refers to a hydrocarbon chain that may be a straight chain or branched chain having one or more carbon-carbon double bonds. The alkenyl moiety contains the indicated number of carbon atoms. For example, C₂₋₆ indicates that the group may have from 2 to 6 (inclusive) carbon atoms in it.

5 The term "alkynyl" refers to a hydrocarbon chain that may be a straight chain or branched chain having one or more carbon-carbon triple bonds. The alkynyl moiety contains the indicated number of carbon atoms. For example, C₂₋₆ indicates that the group may have from 2 to 6 (inclusive) carbon atoms in it.

10 The term "aryl" refers to a 6-carbon monocyclic, 10-carbon bicyclic, or 14-carbon tricyclic aromatic ring system wherein 0, 1, 2, 3, or 4 atoms of each ring may be substituted by a substituent, and wherein the ring comprising a monocyclic radical is aromatic and wherein at least one of the fused rings comprising a bicyclic or tricyclic radical is aromatic e.g. tetrahydronaphthyl. Examples of aryl groups also include phenyl, naphthyl and the like.

15 The term "cycloalkyl" as used herein includes saturated cyclic hydrocarbon groups having 3 to 10 carbons, preferably 3 to 8 carbons, and more preferably 3 to 6 carbons, wherein the cycloalkyl group may be optionally substituted. Preferred cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.

20 The term "heteroaryl" refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2, 3, or 4 atoms of each
25 ring may be substituted by a substituent, and wherein the ring comprising a monocyclic radical is aromatic and wherein at least one of the fused rings comprising a bicyclic or tricyclic radical is aromatic (but does not have to be a ring which contains a heteroatom, e.g. tetrahydroisoquinoliny. Examples of heteroaryl groups also include pyridyl, furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, thiophenyl or thienyl, quinoliny, indolyl, thiazolyl, and the like.
30

The term "heterocyclyl" refers to a nonaromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent. Examples of heterocyclyl groups include piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, tetrahydrofuranyl, and the like.

In addition, atoms making up the compounds of the present embodiments are intended to include all isotopic forms of such atoms. Isotopes, as used herein, include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium, and isotopes of carbon include ^{13}C and ^{14}C .


The details of one or more embodiments of the invention are set forth in the description below and in the drawings. Other features and advantages will also be apparent from the claims.

DETAILED DESCRIPTION

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize or partially agonize or antagonize) glucagon-like peptide-1 receptor ("GLP-1R") and/or the gastric inhibitory polypeptide receptor ("GIPR"). The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP-1R and/or GIPR activities is beneficial for the treatment or prevention of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, the modulation results in an enhancement of (e.g., an increase in) existing levels (e.g., normal or below normal levels) of GLP-1R and/or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) β -arrestin signaling relative to what is observed with the native

ligand. This disclosure also features compositions as well as other methods of using and making the said chemical entities.

In one aspect, the disclosure provides a compound having formula (IAA), or a pharmaceutically acceptable salt thereof:



wherein:

ring A is:

(i) a saturated or unsaturated monocyclic ring that includes from 3-8 ring atoms (inclusive of **G** and the nitrogen atom labelled **N***); or

(ii) a saturated or unsaturated bicyclic or tricyclic ring that includes from 6-14 ring atoms (inclusive of **G** and the nitrogen atom labelled **N***), wherein:

- **G** is C(O), S(O), or SO₂; and
- the dotted, circular line connecting **G** and **N*** is a divalent group that includes from 1-6 ring atoms; wherein:

(a) from 0-2 of the divalent group's ring atoms are ring heteroatoms, which are each independently selected from the group consisting of N, N(**R^a**), O, S, and SO₂; and

(b) from 1-6 of the divalent group's ring atoms are ring carbon atoms, which are each independently selected from the group consisting of C, CH, CH₂, CR^b, C(R^b)₂, and CHR^b;

wherein:

(1) when **ring A** is a monocyclic ring, then each of the divalent group's 1-6 ring carbon atoms is independently selected from the group consisting of CH, CH₂, CR^b, C(R^b)₂, and CHR^b; and

(2) when **ring A** is a bicyclic or tricyclic ring, then (A) or (B) applies:

(A) two or three adjacent ring carbon atoms of the divalent group are each independently selected from the group consisting of C, CH, CH₂, CR^b, C(R^b)₂, and CHR^b and are fused to a second ring that is selected from the group consisting of:

- 5 (a) C₆₋₁₀ aryl optionally substituted with from 1-5 independently selected R^c;
 (b) heteroaryl including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, N(R^a), O, and S, wherein the heteroaryl is optionally substituted with from 1-3 independently selected R^c;
 (c) C₃₋₁₀ cycloalkyl optionally substituted with from 1-4 independently selected R^d;
 10 (d) heterocyclyl including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(R^a), O, and S, wherein the heterocyclyl is optionally substituted with from 1-4 independently selected R^d; or

(B) one of the divalent group's ring carbon atoms is C and is spiro-fused to a second ring that is selected from the group consisting of:

- 15 (a) C₃₋₁₀ cycloalkyl optionally substituted with from 1-4 independently selected R^d;
 (b) heterocyclyl including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(R^a), O, and S, wherein the heterocyclyl is optionally substituted with from 1-4 independently selected R^d;

20 L is:

- (i) -(CH₂)_m-X¹-(CH₂)_n-X²-(CH₂)_p- (formula VIII), wherein m is from 1-6; n is from 0-2; and p is from 0-8;
 (ii) -C(O)-(CH₂)_n-X³-(CH₂)_p- (formula IX), wherein n is from 0-2; and p is from 0-8;
 25 (iii) -(CH₂)_q-, wherein q is from 1-10;
 (iv) -C(O)-; or
 (v) -(CH₂)_m-X¹-(CH₂)_p- (formula VIII), wherein m is from 1-6; and p is from 0-8;

X¹ is -C(O)-; -N(R')C(O)-; -C(O)N(R')-; or -N(R')C(O)NR'-; wherein each
 30 occurrence of R' is independently selected from the group consisting of: H and C₁₋₄ alkyl;

X^2 is:

(i) -O-;

(ii) -S-;

5 (iii) -S(O)_t-, wherein **t** is 1 or 2;

(iv) -C(Q¹)(Q²)-, wherein each of **Q**¹ and **Q**² is independently selected from the group consisting of H and C₁₋₄ alkyl; or **Q**¹ and **Q**², together with the carbon atom to which each is attached forms C₃₋₁₀ cycloalkyl that is optionally substituted with from 1-4 independently selected **R**^d and optionally fused to phenyl;

10 (v) C₆₋₁₀ arylene optionally substituted with from 1-5 independently selected **R**^c;

(vi) heteroarylene including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, N(**R**^a), O, and S; and which is optionally substituted with from 1-5 independently selected **R**^c;

15 (vii) C₃₋₁₀ cycloalkylene optionally substituted with from 1-4 independently selected **R**^d;

(viii) heterocycloalkylene including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(**R**^a), O, and S; and which is optionally substituted with from 1-5 independently selected **R**^d;

(ix) C₂-C₄ alkenylene optionally substituted with from 1-2 **R**^c; or


20 (x) C₂-C₄ alkynylene optionally substituted with from 1-2 **R**^c;

X^3 is: -O-; -S-; or -S(O)_t-, wherein **t** is 1 or 2;

25 each of **R**¹, **R**², and **R**⁴ is independently selected from the group consisting of H and unsubstituted C₁₋₃ alkyl;

R^{2'} is as defined according to (AA) or (BB) below:

(AA)



$R^{2'}$ is , wherein:

R^3 is $-C(O)OH$, $-C(O)OR^{31}$, $-CH(C(O)OH)_2$ or a carboxylic acid isostere (e.g., amide or tetrazolyl);

a is 0-5;

5 a' is 0 or 1; and

each of R^{3a} and R^{3b} is independently H or C_{1-3} alkyl;

(BB)

$R^{2'}$ and R^4 taken together with the atoms connecting them form a ring including
 10 from 5-8 ring atoms, wherein from 3-7 are ring carbon atoms each substituted with from 1-2 substituents independently selected from H, halo, hydroxy, oxo, and C_{1-3} alkyl; and from 0-1 is a heteroatom (in addition to the N attached to R^1) selected from O, $-NH$, $-N(C_{1-3}$ alkyl), and S (e.g., R^4 and R^3 , taken together with the atoms to which each is attached form a ring including 5-8 ring atoms);

15

R^{31} is:

(i) C_{1-6} alkyl optionally substituted with from 1-2 independently selected R^e ;

(ii) $-(C_{0-3}$ alkylene)- C_{3-10} cycloalkyl, wherein the cycloalkyl is optionally substituted with from 1-4 independently selected R^d ;

20 (iii) $-(C_{0-3}$ alkylene)-heterocyclyl including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of $N(R^a)$, O, and S, wherein the heterocyclyl is optionally substituted with from 1-4 independently selected R^d ;

(iv) $-(C_{0-3}$ alkylene)- C_{6-10} aryl, wherein the aryl is optionally substituted with from
 25 1-5 independently selected R^e ; or

(v) $-(C_{0-3}$ alkylene)-heteroaryl including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, $N(R^a)$, O, and

S, wherein the heteroaryl is optionally substituted with from 1-3 independently selected **R^c**;

each occurrence of **R^a** is independently selected from the group consisting of: H;
5 C₁₋₄ alkyl; C₃₋₆ cycloalkyl; -C(=O)(C₁₋₆ alkyl); -C(=O)O(C₁₋₆ alkyl); and -S(O)₁₋₂(C₁₋₆ alkyl);

each occurrence of **R^b** is independently selected from the group consisting of: **R³¹**;
C₁₋₄ haloalkyl; -OH; oxo; -F; -N(R^a)(R''); C₁₋₄ alkoxy; C₁₋₄ haloalkoxy; -C(=O)(C₁₋₄
10 alkyl); -C(=O)O(C₁₋₆ alkyl); -C(=O)OH, -C(=O)N(R''')(R''''), -S(O)₁₋₂(C₁₋₆ alkyl); and cyano;

each occurrence of **R^c** is independently selected from the group consisting of: C₁₋₆
alkyl optionally substituted with from 1-2 independently selected **R^e**; C₃₋₆ cycloalkyl; C₁₋₄
15 haloalkyl; -OH; -halo; -NO₂; N₃; -N(R^a)(R''); C₁₋₄ alkoxy; C₁₋₄ thioalkoxy; C₁₋₄ haloalkoxy; -OC(=O)(C₁₋₆ alkyl); -C(=O)(C₁₋₆ alkyl); -C(=O)O(C₁₋₆ alkyl); -C(=O)OH, -C(=O)N(R''')(R''''), -S(O)₁₋₂(C₁₋₆ alkyl); and cyano;


each occurrence of **R^d** is independently selected from the group consisting of: C₁₋₆
20 alkyl optionally substituted with from 1-2 independently selected **R^e**; C₁₋₄ haloalkyl; -OH; -F; Cl; -N(R^a)(R''); oxo; C₁₋₄ alkoxy; C₁₋₄ haloalkoxy; -OC(=O)(C₁₋₆ alkyl); -C(=O)(C₁₋₆ alkyl); -C(=O)O(C₁₋₆ alkyl); -C(=O)OH, -C(=O)N(R''')(R''''), -S(O)₁₋₂(C₁₋₆ alkyl); and cyano;

each occurrence of **R^e** is independently selected from the group consisting of: -OH; -N(R^a)(R''); C₁₋₄ alkoxy; C₁₋₄ haloalkoxy; -OC(=O)(C₁₋₆ alkyl); -C(=O)O(C₁₋₆ alkyl); -C(=O)OH, -C(=O)N(R''')(R''''), -S(O)₁₋₂(C₁₋₆ alkyl); and cyano;


each occurrence of **R''**, **R'''**, and **R''''** is independently selected from the group
30 consisting of: H and C₁₋₆ alkyl; and

W is a peptide having the formula $W'-R^5$, wherein **W'** is a sequence of from 5-60 amino acids, and **R**⁵ is a C-terminal amino acid, amino acid ester, or amino acid amide that is optionally substituted with from 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group).


In some embodiments, the compound has Formula (IIAA):



In some embodiments, the compound has Formula (IIAA-B):



In some embodiments, the compound has Formula (IA):



wherein:
ring **A** is:

(i) a saturated or unsaturated monocyclic ring that includes from 3-8 ring atoms (inclusive of **G** and the nitrogen atom labelled N*); or

(ii) a saturated or unsaturated bicyclic or tricyclic ring that includes from 6-14 ring atoms (inclusive of **G** and the nitrogen atom labelled N*), wherein:

- 5
- **G** is C(O), S(O), or SO₂; and
 - the dotted, circular line connecting **G** and N* is a divalent group that includes from 1-6 ring atoms; wherein:

(a) from 0-2 of the divalent group's ring atoms are ring heteroatoms, which are each independently selected from the group consisting of N, N(**R^a**), O, S, and SO₂; and

- 10
- (b) from 1-6 of the divalent group's ring atoms are ring carbon atoms, which are each independently selected from the group consisting of C, CH, CH₂, CR^b, C(**R^b**)₂, and CHR^b;

wherein:

- (1) when **ring A** is a monocyclic ring, then each of the divalent group's 1-6 ring carbon atoms is independently selected from the group consisting of CH, CH₂, CR^b, C(**R^b**)₂, and CHR^b; and
- 15

(2) when **ring A** is a bicyclic or tricyclic ring, then (A) or (B) applies:

- (A) two or three adjacent ring carbon atoms of the divalent group are each independently selected from the group consisting of C, CH, and, CR^b and are fused to a second ring that is selected from the group consisting of:
- 20

(a) C₆₋₁₀ aryl optionally substituted with from 1-5 independently selected **R^c**;

(b) heteroaryl including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, N(**R^a**), O, and S, wherein the heteroaryl is optionally substituted with from 1-3 independently selected **R^c**;

- 25
- (c) C₃₋₁₀ cycloalkyl optionally substituted with from 1-4 independently selected **R^d**;

(d) heterocyclyl including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(**R^a**), O, and S, wherein the heterocyclyl is optionally substituted with from 1-4 independently selected **R^d**; or

- (B) one of the divalent group's ring carbon atoms is C and is spiro-fused to a second ring that is selected from the group consisting of:
- 30

(a) C₃₋₁₀ cycloalkyl optionally substituted with from 1-4 independently selected **R^d**,
 (b) heterocyclyl including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(**R^a**), O, and S, wherein the heterocyclyl is optionally substituted with from 1-4 independently selected **R^d**;

5

L is:

(i) -(CH₂)_m-**X¹**-(CH₂)_n-**X²**-(CH₂)_p- (formula VIII), wherein **m** is from 1-6; **n** is from 0-2; and **p** is from 0-8;

(ii) -C(O)-(CH₂)_n-**X³**-(CH₂)_p- (formula IX), wherein **n** is from 0-2; and **p** is from 0-8;

10

(iii) -(CH₂)_q-, wherein **q** is from 1-10;

(iv) -C(O)-; or

(v) -(CH₂)_m-**X¹**-(CH₂)_p- (formula VIII), wherein **m** is from 1-6; and **p** is from 0-8;

15

X¹ is -C(O)-; -N(**R'**)C(O)-; -C(O)N(**R'**)-; or -N(**R'**)C(O)NR'-; wherein each occurrence of **R'** is independently selected from the group consisting of: H and C₁₋₄ alkyl;

X² is:

(i) -O-;

20

(ii) -S-;

(iii) -S(O)_t-, wherein **t** is 1 or 2;

(iv) -C(Q¹)(Q²)-, wherein each of **Q¹** and **Q²** is independently selected from the group consisting of H and C₁₋₄ alkyl; or **Q¹** and **Q²**, together with the carbon atom to which each is attached forms C₃₋₁₀ cycloalkyl that is optionally substituted with from 1-4 independently selected **R^d** and optionally fused to phenyl;

25

(v) C₆₋₁₀ arylene optionally substituted with from 1-5 independently selected **R^c**;

(vi) heteroarylene including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, N(**R^a**), O, and S; and which is optionally substituted with from 1-5 independently selected **R^c**;

(vii) C₃₋₁₀ cycloalkylene optionally substituted with from 1-4 independently selected **R^d**;

(viii) heterocycloalkylene including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(**R^a**), O, and S; and
5 which is optionally substituted with from 1-5 independently selected **R^d**;

(ix) C₂₋₄ alkenylene optionally substituted with from 1-2 **R^e**; or

(x) C₂₋₄ alkynylene optionally substituted with from 1-2 **R^e**;

X³ is: -O-; -S-; or -S(O)_t, wherein **t** is 1 or 2;

10

each of **R¹**, **R²**, and **R⁴** is independently selected from the group consisting of H and unsubstituted C₁₋₃ alkyl;

R³ is -C(O)OH, -C(O)OR³¹, -CH(C(O)OH)₂ or a carboxylic acid isostere (e.g.,
15 amide or tetrazolyl);

a is 0-5;

a' is 0 or 1;

each of **R^{3a}** and **R^{3b}** is independently H or C₁₋₃ alkyl;

20

R³¹ is:

(i) C₁₋₆ alkyl optionally substituted with from 1-2 independently selected **R^e**;

(ii) -(C₀₋₃ alkylene)-C₃₋₁₀ cycloalkyl, wherein the cycloalkyl is optionally substituted with from 1-4 independently selected **R^d**;

(iii) -(C₀₋₃ alkylene)-heterocyclyl including from 3-10 ring atoms, wherein from 1-
25 3 ring atoms are each independently selected from the group consisting of N(**R^a**), O, and S, wherein the heterocyclyl is optionally substituted with from 1-4 independently selected **R^d**;

(iv) -(C₀₋₃ alkylene)-C₆₋₁₀ aryl, wherein the aryl is optionally substituted with from 1-5 independently selected **R^e**; or

(v) $-(C_{0-3} \text{ alkylene})$ -heteroaryl including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, N(R^a), O, and S, wherein the heteroaryl is optionally substituted with from 1-3 independently selected R^c ;

5

each occurrence of R^a is independently selected from the group consisting of: H; C_{1-4} alkyl; C_{3-6} cycloalkyl; $-C(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)O(C_{1-6} \text{ alkyl})$; and $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$;

10

each occurrence of R^b is independently selected from the group consisting of: R^{31} ; C_{1-4} haloalkyl; $-OH$; oxo; $-F$; $-N(R^a)(R'')$; C_{1-4} alkoxy; C_{1-4} haloalkoxy; $-C(=O)(C_{1-4} \text{ alkyl})$; $-C(=O)O(C_{1-6} \text{ alkyl})$; $-C(=O)OH$; $-C(=O)N(R''')(R''''')$; $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$; and cyano;

15

each occurrence of R^c is independently selected from the group consisting of: C_{1-6} alkyl optionally substituted with from 1-2 independently selected R^e ; C_{3-6} cycloalkyl; C_{1-4} haloalkyl; $-OH$; $-halo$; $-NO_2$; N_3 ; $-N(R^a)(R'')$; C_{1-4} alkoxy; C_{1-4} thioalkoxy; C_{1-4} haloalkoxy; $-OC(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)O(C_{1-6} \text{ alkyl})$; $-C(=O)OH$; $-C(=O)N(R''')(R''''')$; $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$; and cyano;

20

each occurrence of R^d is independently selected from the group consisting of: C_{1-6} alkyl optionally substituted with from 1-2 independently selected R^e ; C_{1-4} haloalkyl; $-OH$; $-F$; $-Cl$; $-N(R^a)(R'')$; oxo; C_{1-4} alkoxy; C_{1-4} haloalkoxy; $-OC(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)O(C_{1-6} \text{ alkyl})$; $-C(=O)OH$; $-C(=O)N(R''')(R''''')$; $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$; and cyano;

25


each occurrence of R^e is independently selected from the group consisting of: $-OH$; $-N(R^a)(R'')$; C_{1-4} alkoxy; C_{1-4} haloalkoxy; $-OC(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)O(C_{1-6} \text{ alkyl})$; $-C(=O)OH$; $-C(=O)N(R''')(R''''')$; $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$; and cyano;

30


each occurrence of R'' , R''' , and R'''' is independently selected from the group consisting of: H and C_{1-6} alkyl; and

W is a peptide having the formula $W'-R^5$, wherein W' is a sequence of from 5-60 amino acids, and R^5 is a C-terminal amino acid, amino acid ester, or amino acid amide that is optionally substituted with from 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group).

In some embodiments, the compound has Formula (IIA):



In some embodiments, the compound has Formula (I):



wherein:

ring A is:

(i) a saturated or unsaturated monocyclic ring that includes from 3-8 ring atoms (inclusive of G and the nitrogen atom labelled N^*); or

(ii) a saturated or unsaturated bicyclic or tricyclic ring that includes from 6-14 ring atoms (inclusive of G and the nitrogen atom labelled N^*), wherein:

- **G** is C(O), S(O), or SO₂; and
- the dotted, circular line connecting **G** and N* is a divalent group that includes from 1-6 ring atoms; wherein:

5 (a) from 0-2 of the divalent group's ring atoms are ring heteroatoms, which are each independently selected from the group consisting of N, N(**R^a**), O, S, and SO₂; and

(b) from 1-6 of the divalent group's ring atoms are ring carbon atoms, which are each independently selected from the group consisting of C, CH, CH₂, CR^b, C(R^b)₂, and CHR^b;
10 wherein:

(1) when **ring A** is a monocyclic ring, then each of the divalent group's 1-6 ring carbon atoms is independently selected from the group consisting of CH, CH₂, CR^b, C(R^b)₂, and CHR^b; and

(2) when **ring A** is a bicyclic or tricyclic ring, then (A) or (B) applies:

15 (A) two or three adjacent ring carbon atoms of the divalent group are each independently selected from the group consisting of C, CH, and, CR^b and are fused to a second ring that is selected from the group consisting of:

(a) C₆₋₁₀ aryl optionally substituted with from 1-5 independently selected **R^c**;

20 (b) heteroaryl including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, N(**R^a**), O, and S, wherein the heteroaryl is optionally substituted with from 1-3 independently selected **R^c**;

(c) C₃₋₁₀ cycloalkyl optionally substituted with from 1-4
25 independently selected **R^d**;

(d) heterocyclyl including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(**R^a**), O, and S, wherein the heterocyclyl is optionally substituted with from 1-4 independently selected **R^d**; or

(B) one of the divalent group's ring carbon atoms is C and is spiro-fused to a second ring that is selected from the group consisting of:

(a) C₃₋₁₀ cycloalkyl optionally substituted with from 1-4 independently selected R^d;

5 (b) heterocyclyl including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(R^a), O, and S, wherein the heterocyclyl is optionally substituted with from 1-4 independently selected R^d;

10 L is:

(i) -(CH₂)_m-X¹-(CH₂)_n-X²-(CH₂)_p- (formula VIII), wherein m is from 1-6; n is from 0-2; and p is from 0-8;

(ii) -C(O)-(CH₂)_n-X³-(CH₂)_p- (formula IX), wherein n is from 0-2; and p is from 0-8;

15 (iii) -(CH₂)_q-, wherein q is from 1-10;

(iv) -C(O)-; or

(v) -(CH₂)_m-X¹-(CH₂)_p- (formula VIII), wherein m is from 1-6; and p is from 0-8;

20 X¹ is -C(O)-; -N(R')C(O)-; -C(O)N(R')-; or -N(R')C(O)NR'-; wherein each occurrence of R' is independently selected from the group consisting of: H and C₁₋₄ alkyl;

X² is:

25 (i) -O-;

(ii) -S-;

(iii) -S(O)_t-, wherein t is 1 or 2;

(iv) -C(Q¹)(Q²)-, wherein each of Q¹ and Q² is independently selected from the group consisting of H and C₁₋₄ alkyl; or Q¹ and Q², together with the carbon atom to

which each is attached forms C₃₋₁₀ cycloalkyl that is optionally substituted with from 1-4 independently selected **R^d** and optionally fused to phenyl;

(v) C₆₋₁₀ arylene optionally substituted with from 1-5 independently selected **R^c**;

(vi) heteroarylene including from 5-10 ring atoms, wherein from 1-4 ring atoms
5 are each independently selected from the group consisting of N, N(**R^a**), O, and S; and
which is optionally substituted with from 1-5 independently selected **R^c**;

(vii) C₃₋₁₀ cycloalkylene optionally substituted with from 1-4 independently
selected **R^d**;

(viii) heterocycloalkylene including from 3-10 ring atoms, wherein from 1-3 ring
10 atoms are each independently selected from the group consisting of N(**R^a**), O, and S; and
which is optionally substituted with from 1-5 independently selected **R^d**;

(ix) C₂-C₄ alkenylene optionally substituted with from 1-2 **R^c**; or

(x) C₂-C₄ alkynylene optionally substituted with from 1-2 **R^c**;

15 **X³** is: -O-; -S-; or -S(O)_t-, wherein **t** is 1 or 2;

each of **R¹**, **R²**, and **R⁴** is independently selected from the group consisting of H
and unsubstituted C₁₋₃ alkyl;

20 **R³** is -C(O)OH, -C(O)OR³¹, or a carboxylic acid isostere; wherein **R³¹** is:

(i) C₁₋₆ alkyl optionally substituted with from 1-2 independently selected **R^c**;

(ii) -(C₀₋₃ alkylene)-C₃₋₁₀ cycloalkyl, wherein the cycloalkyl is optionally
substituted with from 1-4 independently selected **R^d**;

(iii) -(C₀₋₃ alkylene)-heterocyclyl including from 3-10 ring atoms, wherein from
25 1-3 ring atoms are each independently selected from the group consisting of N(**R^a**), O,
and S, wherein the heterocyclyl is optionally substituted with from 1-4 independently
selected **R^d**;

(iv) -(C₀₋₃ alkylene)-C₆₋₁₀ aryl, wherein the aryl is optionally substituted with from
1-5 independently selected **R^c**; or

(v) $-(C_{0-3} \text{ alkylene})$ -heteroaryl including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, $N(R^a)$, O, and S, wherein the heteroaryl is optionally substituted with from 1-3 independently selected R^c ;

5

a is 0-5;

each occurrence of R^a is independently selected from the group consisting of: H; C_{1-4} alkyl; C_{3-6} cycloalkyl; $-C(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)O(C_{1-6} \text{ alkyl})$; and $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$;

10

each occurrence of R^b is independently selected from the group consisting of: R^{31} ; C_{1-4} haloalkyl; $-OH$; oxo; $-F$; $-N(R^a)(R'')$; C_{1-4} alkoxy; C_{1-4} haloalkoxy; $-C(=O)(C_{1-4} \text{ alkyl})$; $-C(=O)O(C_{1-6} \text{ alkyl})$; $-C(=O)OH$; $-C(=O)N(R''')(R''''')$; $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$; and cyano;

15

each occurrence of R^c is independently selected from the group consisting of: C_{1-6} alkyl optionally substituted with from 1-2 independently selected R^e ; C_{3-6} cycloalkyl; C_{1-4} haloalkyl; $-OH$; $-halo$; $-NO_2$; N_3 ; $-N(R^a)(R'')$; C_{1-4} alkoxy; C_{1-4} thioalkoxy; C_{1-4} haloalkoxy; $-OC(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)O(C_{1-6} \text{ alkyl})$; $-C(=O)OH$; $-C(=O)N(R''')(R''''')$; $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$; and cyano;

20

each occurrence of R^d is independently selected from the group consisting of: C_{1-6} alkyl optionally substituted with from 1-2 independently selected R^e ; C_{1-4} haloalkyl; $-OH$; $-F$; Cl ; $-N(R^a)(R'')$; oxo; C_{1-4} alkoxy; C_{1-4} haloalkoxy; $-OC(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)O(C_{1-6} \text{ alkyl})$; $-C(=O)OH$; $-C(=O)N(R''')(R''''')$; $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$; and cyano;

25

each occurrence of **R^e** is independently selected from the group consisting of: – OH; – N(R^a)(R^{''}); C₁₋₄ alkoxy; C₁₋₄ haloalkoxy; –OC(=O)(C₁₋₆ alkyl); –C(=O)O(C₁₋₆ alkyl); –C(=O)OH; –C(=O)N(R^{'''})(R^{''''}), –S(O)₁₋₂(C₁₋₆ alkyl); and cyano;

5 each occurrence of **R''**, **R'''**, and **R''''** is independently selected from the group consisting of: H and C₁₋₆ alkyl; and

W is a peptide having the formula W'-R⁵, wherein **W'** is a sequence of from 5-60 amino acids, and **R⁵** is a C-terminal amino acid, amino acid ester, or amino acid amide
10 that is optionally substituted with from 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group).

In some embodiments, one or more of the compound provisions delineated herein (e.g., as delineated in the section below) apply.


15

Compound Provisions

In some embodiments, the compound is other than CAS RN 1401463-49-7; and/or CAS RN 1116465-43-0; and/or CAS RN 1614237-35-2, and/or CAS RN 1614237-36-3; and/or CAS RN 1353718-57-6; and/or CAS Registry Number: 1083307-90-7, in which
20 each of the registered chemical structures is incorporated herein by reference.

In some embodiments, the compound is not any of the compounds disclosed in Nacheva et al., *Organic & Biomolecular Chemistry*, **2012**, 10 (38), 7840-7846, Chopra et al., *Bioconjugate Chemistry*, **2009**, 20 (2), 231-240, and PCT application publication No. WO 2013/148579, each of which is incorporated by reference.


25 In some embodiments, **ring A** is other than unsubstituted maleimid-1-yl, i.e.:



In certain embodiments, when **L** is $-(\text{CH}_2)_2-$, $-(\text{CH}_2)_5-\text{C}(\text{O})\text{NH}-\text{CH}_2-$, or $-(\text{CH}_2)_2-\text{C}(\text{O})\text{NH}-(\text{CH}_2)_6-$, then **ring A** is other than unsubstituted maleimid-1-yl.

In certain embodiments, when **L** is $-(\text{CH}_2)_2-$, $-(\text{CH}_2)_5-\text{C}(\text{O})\text{NH}-\text{CH}_2-$, or $-(\text{CH}_2)_2-\text{C}(\text{O})\text{NH}-(\text{CH}_2)_6-$, and **a** is 1, then **ring A** is other than unsubstituted maleimid-1-yl.


In some embodiments, **ring A** is other than substituted maleimid-1-yl (e.g., other than 3,4-*bis*(2,4-difluorophenyl)-maleimid-1-yl, i.e.:



In certain embodiments, when **L** is $-(\text{CH}_2)_3-$, then **ring A** is other than substituted maleimid-1-yl (e.g., other than 3,4-*bis*(2,4-difluorophenyl)-maleimid-1-yl).

In certain embodiments, when **L** is $-(\text{CH}_2)_3-$, and **a** is 1, then **ring A** is other than substituted maleimid-1-yl (e.g., other than 3,4-*bis*(2,4-difluorophenyl)-maleimid-1-yl).

In some embodiments, **ring A** is other than optionally substituted N-[2-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl, (e.g., other than unsubstituted N-[2-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl, i.e.:



In certain embodiments, when **L** is $-(CH_2)_3-$, then **ring A** is other than optionally substituted N-[2-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl), (e.g., other than unsubstituted N-[2-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl).

5 In certain embodiments, when **L** is $-(CH_2)_3-$, and **a** is 0, then **ring A** is other than optionally substituted N-[2-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl, (e.g., unsubstituted N-[2-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl).

In some embodiments, **ring A** is other than:

- 10 (i) unsubstituted maleimid-1-yl; and
 (ii) substituted maleimid-1-yl (e.g., other than 3,4-*bis*(2,4-difluorophenyl)-maleimid-1-yl).

In some embodiments, **ring A** is other than:

- 15 (i) unsubstituted maleimid-1-yl;
 (ii) substituted maleimid-1-yl (e.g., other than 3,4-*bis*(2,4-difluorophenyl)-maleimid-1-yl), and
 (iii) optionally substituted N-[2-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl, (e.g., other than unsubstituted N-[2-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl).

20 In some embodiments:

- (i) when **L** is $-(CH_2)_2-$, $-(CH_2)_5-C(O)NH-CH_2-$, or $-(CH_2)_2-C(O)NH-(CH_2)_6-$, then **ring A** is other than unsubstituted maleimid-1-yl; and
 (ii) when **L** is $-(CH_2)_3-$, then **ring A** is other than substituted maleimid-1-yl (e.g.,
 25 other than 3,4-*bis*(2,4-difluorophenyl)-maleimid-1-yl).

In some embodiments:

(i) when **L** is $-(\text{CH}_2)_2-$, $-(\text{CH}_2)_5-\text{C}(\text{O})\text{NH}-\text{CH}_2-$, or $-(\text{CH}_2)_2-\text{C}(\text{O})\text{NH}-(\text{CH}_2)_6-$, and **a** is 1, then **ring A** is other than unsubstituted maleimid-1-yl; and

(ii) when **L** is $-(\text{CH}_2)_3-$, and **a** is 1, then **ring A** is other than substituted maleimid-1-yl (e.g., other than 3,4-*bis*(2,4-difluorophenyl)-maleimid-1-yl).

5

In some embodiments:

(i) when **L** is $-(\text{CH}_2)_2-$, $-(\text{CH}_2)_5-\text{C}(\text{O})\text{NH}-\text{CH}_2-$, or $-(\text{CH}_2)_2-\text{C}(\text{O})\text{NH}-(\text{CH}_2)_6-$, then **ring A** is other than unsubstituted maleimid-1-yl;

(ii) when **L** is $-(\text{CH}_2)_3-$, then **ring A** is other than substituted maleimid-1-yl (e.g., other than 3,4-*bis*(2,4-difluorophenyl)-maleimid-1-yl); and

10

(iii) when **L** is $-(\text{CH}_2)_3-$, then **ring A** is other than optionally substituted N-[2-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl, (e.g., other than unsubstituted N-[2-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl).

15

In some embodiments:

(i) when **L** is $-(\text{CH}_2)_2-$, $-(\text{CH}_2)_5-\text{C}(\text{O})\text{NH}-\text{CH}_2-$, or $-(\text{CH}_2)_2-\text{C}(\text{O})\text{NH}-(\text{CH}_2)_6-$, and **a** is 1, then **ring A** is other than unsubstituted maleimid-1-yl;

(ii) when **L** is $-(\text{CH}_2)_3-$, and **a** is 1, then **ring A** is other than substituted maleimid-1-yl (e.g., other than 3,4-*bis*(2,4-difluorophenyl)-maleimid-1-yl); and

20

(iii) when **L** is $-(\text{CH}_2)_3-$, and **a** is 0, then **ring A** is other than optionally substituted N-[2-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl, (e.g., unsubstituted N-[2-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl.

In some embodiments, the first three amino acids in **W'** must be glycine-threonine-phenylalanine (GTF).

25

In some embodiments, **W'** must include 11 or more amino acids (e.g., 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, 20 or more, 25 or more, 30 or more amino acids).

In some embodiments, the first three amino acids in W' must be glycine-threonine-phenylalanine (GTF); and W' must include 11 or more amino acids (e.g., 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, 20 or more, 25 or more, 30 or more amino acids).

5

In certain of these embodiments, one or more of the following applies. **Ring A** is unsubstituted maleimid-1-yl, and L is $-(CH_2)_2-$, $-(CH_2)_5-C(O)NH-CH_2-$, or $-(CH_2)_2-C(O)NH-(CH_2)_6-$ (optionally, **a** is 1). **Ring A** is substituted maleimid-1-yl (e.g., 3,4-*bis*(2,4-difluorophenyl)-maleimid-1-yl), and L is $-(CH_2)_3-$ (optionally, **a** is 1). **Ring A** is optionally substituted N-[2-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl), (e.g.,
10 unsubstituted N-[2-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl) (optionally, **a** is 0).

In certain embodiments, when L is $(CH_2)_q$, q is not 3. In certain embodiments, when ring A is substituted with 2 R^b groups, the R^b groups are not both *o,p*-(di-fluoro)phenyl, or ring A is substituted with 2 *o,p*-(di-fluoro)phenyl groups, the first amino
15 acid in the sequence W' is not valine, or when ring A is substituted with 2 *o,p*-(di-fluoro)phenyl groups, L is not $(CH_2)_3$; or when L is $(CH_2)_3$, the first amino acid is the sequence W' is not valine.

In certain embodiments, when L is $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$, m is 5, X^1 is $-C(O)NH-$, n and p are each zero, and X^2 is CQ^1Q^2 , at least one of Q^1 and Q^2 is not H. In certain embodiments, when L is $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$, m is 5, X^1 is $-C(O)NH-$,
20 n and p are each zero, and X^2 is CH_2 , ring A is not $-N$ -maleimide. or In certain embodiments, when L is $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$, m is 5, X^1 is $-C(O)NH-$, n and p are each zero, X^2 is CH_2 , and ring A is $-N$ -maleimide, the first amino acid is the sequence
25 W' is not glycine.

In certain embodiments, when L is $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$, m is 2, X^1 is $-C(O)NH-$, the sum of n and p is 5, and X^2 is CQ^1Q^2 , at least one of Q^1 and Q^2 is not H. In
30 certain embodiments, when L is $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$, m is 2, X^1 is $-C(O)NH-$,

the sum of n and p is 5, and $\mathbf{X}^2$ is CH_2 , ring A is not -N-maleimide . In certain embodiments, when L is $\text{-(CH}_2\text{)}_m\text{-X}^1\text{-(CH}_2\text{)}_n\text{-X}^2\text{-(CH}_2\text{)}_p\text{-}$, m is 2, $\mathbf{X}^1$ is -C(O)NH- , the sum of n and p is 5, $\mathbf{X}^2$ is CH_2 , and ring A is -N-maleimide , the first amino acid in the sequence W' is not alanine.


5

In certain embodiments, when L is $\text{(CH}_2\text{)}_q$, q is not 2; or when L is $\text{(CH}_2\text{)}_2$, ring A is not -N-maleimide ; or when L is $\text{(CH}_2\text{)}_2$ and ring A is -N-maleimide , the first amino acid in the sequence W' is not alanine.


10


Ring A

In some embodiments, G is C(O). By way of non-limiting example, such compounds can include those having formula (I-A), (I-AA), or (I-AB):




15






(I-AB)


Further non-limiting examples include compounds having formula (IA-A), (IA-AA), or (IA-AB):



(IA-A)






(IA-AA)






(IA-AB)

In some embodiments, **G** is S(O) or SO₂. By way of non-limiting example, such compounds can include those having formula (I-B), (I-BA), or (I-BB):



Further non-limiting examples include compounds having formula (IA-B), (IA-BA), or (IA-BB):



5

In some embodiments, ring A is a saturated or unsaturated monocyclic ring that includes from 3-8 (e.g., 4-8, 4-7, 5-6) ring atoms.

In certain of these embodiments, ring A is saturated. In other embodiments, ring A is unsaturated. In certain of these embodiments, ring A includes 4-7 ring atoms or 5-6 ring atoms.


In certain embodiments, ring A is a saturated monocyclic ring that includes from 3-8 (e.g., 4-8, 4-7, 5-6) ring atoms.

In certain embodiments, ring A is a saturated monocyclic ring that includes from 5-7 ring atoms.

In certain embodiments, ring A is a saturated monocyclic ring that includes from 5-6 ring atoms.

5

In certain embodiments, ring A has the following formula (III):



wherein:

A_1 is a bond, $A^{1A}-A^{1B}$, C(O), CH₂, CHR^b, or C(R^b)₂;

10 each of A^{1A} and A^{1B} is independently C(O), CH₂, CHR^b, or C(R^b)₂;


A_2 is C(O), CH₂, CHR^b, or C(R^b)₂;

A_3 is C(O), CH₂, CHR^b, or C(R^b)₂; O; S; SO₂; or N(R^a);

A_4 is C(O), CH₂, CHR^b, or C(R^b)₂; O; S; or N(R^a); provided that A_3 and A_4 cannot both be O; S; or N(R^a); or a combination thereof.

15

In certain embodiments, ring A has formula (III):



wherein:

A_1 is a bond, C(O), CH₂, CHR^b, or C(R^b)₂;

20 A_2 is C(O), CH₂, CHR^b, or C(R^b)₂;

A_3 is C(O), CH₂, CHR^b, or C(R^b)₂; O; S; SO₂; or N(R^a); and

A₄ is CH₂, CHR^b, or C(R^b)₂; O; S; or N(R^a); provided that **A₃** and **A₄** cannot both be O; S; or N(R^a); or a combination thereof.

5 In certain embodiments of formula (III), **A₁** is other than a bond (i.e., **A₁** is C(O), CH₂, CHR^b, or C(R^b)₂), and ring A includes 6 ring atoms (i.e., ring A is a 6-membered ring).

In certain formula (III), 6-membered ring embodiments, **A₁** is CH₂, CHR^b, or C(R^b)₂. For example, **A₁** can be CH₂. In other embodiments, **A₁** is C(O).

10 In certain formula (III), 6-membered ring embodiments, **A₂** is CH₂, CHR^b, or C(R^b)₂. For example, **A₂** can be CH₂.

In certain formula (III), 6-membered ring embodiments, **A₃** is CH₂, CHR^b, or C(R^b)₂. For example, **A₃** can be CH₂. In other embodiments, **A₃** is O; S; SO₂; or N(R^a).

15 In certain formula (III), 6-membered ring embodiments, **A₄** is CH₂, CHR^b, or C(R^b)₂. For example, **A₄** can be CH₂. In other embodiments, **A₄** is O; S; or N(R^a).

In certain formula (III), 6-membered ring embodiments, **A₂**, **A₃** and **A₄** are each independently selected from the group consisting of CH₂, CHR^b, or C(R^b)₂.

20 In certain embodiments, one or two (e.g., one) of **A₂**, **A₃** and **A₄** are independently selected from the group consisting of CHR^b and C(R^b)₂, and the other(s) is/are CH₂.

In certain formula (III), 6-membered ring embodiments, **A₂**, **A₃** and **A₄** are each CH₂.

25 In certain formula (III), 6-membered ring embodiments, **A₂** and **A₄** are each independently selected from the group consisting of CH₂, CHR^b, and C(R^b)₂; and **A₃** is O; S; SO₂; or N(R^a). In certain of these embodiments, one or two (e.g., one) of **A₂** and **A₄** are independently selected from the group consisting of CHR^b and C(R^b)₂, and the other (where applicable) is CH₂. In other embodiments, **A₂** and **A₄** are both CH₂. In certain of these embodiments, **A₃** is N(R^a) (e.g., **A₃** can be NH). In other embodiments, **A₃** is O. In still other embodiments, **A₃** is SO₂.

In certain formula (III), 6-membered ring embodiments, **A**₂ and **A**₃ are each independently selected from the group consisting of CH₂, CHR^b, and C(R^b)₂; and **A**₄ is O; S; or N(R^a). In certain of these embodiments, one or two (e.g., one) of **A**₂ and **A**₃ are independently selected from the group consisting of CHR^b and C(R^b)₂, and the other (where applicable) is CH₂. In other embodiments, **A**₂ and **A**₃ are both CH₂. In certain of these
5 embodiments, **A**₄ is N(R^a) (e.g., **A**₄ can be NH). In other embodiments, **A**₄ is O.

In certain formula (III), 6-membered ring embodiments, **A**₁, **A**₂, **A**₃ and **A**₄ are each independently selected from the group consisting of CH₂, CHR^b, or C(R^b)₂.

10 In certain formula (III), 6-membered ring embodiments, one or two (e.g., one) of **A**₁, **A**₂, **A**₃ and **A**₄ are independently selected from the group consisting of CHR^b and C(R^b)₂, and the others are CH₂.

In certain formula (III), 6-membered ring embodiments, **A**₁, **A**₂, **A**₃ and **A**₄ are each CH₂.

15 In certain formula (III), 6-membered ring embodiments, **A**₁, **A**₂ and **A**₄ are each independently selected from the group consisting of CH₂, CHR^b, and C(R^b)₂; and **A**₃ is O; S; SO₂; or N(R^a). In certain of these embodiments, one or two (e.g., one) of **A**₂ and **A**₄ are independently selected from the group consisting of CHR^b and C(R^b)₂, and the other (where applicable) is CH₂. In other embodiments, **A**₂ and **A**₃ are both CH₂. In certain of these
20 embodiments, **A**₁ is CH₂. In certain of these embodiments, **A**₃ is N(R^a) (e.g., **A**₃ can be NH). In other embodiments, **A**₃ is O. In still other embodiments, **A**₃ is SO₂.

In certain formula (III), 6-membered ring embodiments, **A**₁, **A**₂ and **A**₃ are each independently selected from the group consisting of CH₂, CHR^b, and C(R^b)₂; and **A**₄ is O; S; or N(R^a). In certain of these embodiments, one or two (e.g., one) of **A**₂ and **A**₄ are
25 independently selected from the group consisting of CHR^b and C(R^b)₂, and the other (where applicable) is CH₂. In other embodiments, **A**₂ and **A**₃ are both CH₂. In certain of these embodiments, **A**₁ is CH₂. In certain of these embodiments, **A**₄ is N(R^a) (e.g., **A**₄ can be NH). In other embodiments, **A**₄ is O.

In certain formula (III), 6-membered ring embodiments, **A**₁ is C(O); and **A**₂, **A**₃ and **A**₄ are each independently selected from the group consisting of CH₂, CHR^b, or C(R^b)₂. In certain of these embodiments, one or two (e.g., one) of **A**₂, **A**₃ and **A**₄ are independently selected from the group consisting of CHR^b and C(R^b)₂, and the other(s) is/are CH₂.


5 In certain formula (III), 6-membered ring embodiments, **A**₁ is C(O); and **A**₂, **A**₃ and **A**₄ are each CH₂.

In certain formula (III), 6-membered ring embodiments, **A**₁ is C(O); **A**₂ and **A**₄ are each independently selected from the group consisting of CH₂, CHR^b, and C(R^b)₂; and **A**₃ is O; S; SO₂; or N(R^a). In certain of these embodiments, one or two (e.g., one) of **A**₂ and **A**₄ are independently selected from the group consisting of CHR^b and C(R^b)₂, and the other (where applicable) is CH₂. In other embodiments, **A**₂ and **A**₄ are both CH₂. In certain of these embodiments, **A**₃ is N(R^a) (e.g., **A**₃ can be NH). In other embodiments, **A**₃ is O. In still other embodiments, **A**₃ is SO₂.

In certain formula (III), 6-membered ring embodiments, **A**₁ is C(O); **A**₂ and **A**₃ are each independently selected from the group consisting of CH₂, CHR^b, and C(R^b)₂; and **A**₄ is O; S; or N(R^a). In certain of these embodiments, one or two (e.g., one) of **A**₂ and **A**₃ are independently selected from the group consisting of CHR^b and C(R^b)₂, and the other (where applicable) is CH₂. In other embodiments, **A**₂ and **A**₃ are both CH₂. In certain of these embodiments, **A**₄ is N(R^a) (e.g., **A**₄ can be NH). In other embodiments, **A**₄ is O.

20

In certain embodiments of formula (III), **A**₁ is a bond, and ring A includes 5 ring atoms (i.e., ring A is a 5-membered ring), and ring A has formula (III-A):



25 In certain formula (III-A) embodiments, **A**₂ is C(=O). In other embodiments, **A**₂ is CH₂, CHR^b, or C(R^b)₂; for example, **A**₂ can be CH₂.

In certain formula (III-A) embodiments, A_3 is O; S; or $N(R^e)$. For example, A_3 can be S. As another example, A_3 can be $N(R^a)$ (e.g., A_3 can be NH).

In certain formula (III-A) embodiments, A_4 is CH_2 , CHR^b , or $C(R^b)_2$. For example, A_4 can be CHR^b or $C(R^b)_2$. As another example, A_4 can be CH_2 .

5

In certain formula (III-A) embodiments, A_2 is $C(=O)$; A_3 is O; S; or $N(R^e)$; and A_4 is CH_2 , CHR^b , or $C(R^b)_2$. In certain of these embodiments, A_3 is S. In other embodiments, A_3 is $N(R^a)$ (e.g., A_3 is NH). In certain of these embodiments, A_4 is CH_2 . In other embodiments, A_4 is CHR^b or $C(R^b)_2$.

10

In certain formula (III-A) embodiments, A_2 is $C(=O)$; and each of A_3 and A_4 is independently selected from CH_2 , CHR^b , or $C(R^b)_2$. In certain of these embodiments, each of A_3 and A_4 is CH_2 . In other embodiments, one of A_3 and A_4 is CH_2 , and the other of A_3 and A_4 is CHR^b or $C(R^b)_2$. In still other embodiments, each of A_3 and A_4 is independently selected from CHR^b or $C(R^b)_2$.

15

In certain formula (III-A) embodiments, A_2 is CH_2 , CHR^b , or $C(R^b)_2$, e.g., A_2 can be CH_2 ; and each of A_3 and A_4 is independently selected from CH_2 , CHR^b , or $C(R^b)_2$ (e.g., each of A_3 and A_4 is CH_2).

20

In certain of formula (III) embodiments, A^1 is $A^{1A}-A^{1B}$.

In certain of the foregoing formula (III) embodiments, each of A^{1A} and A^{1B} is independently CH_2 , CHR^b , or $C(R^b)_2$. As a non-limiting example, each of A^{1A} and A^{1B} can be independently CH_2 .

25

In certain of formula (III) embodiments (when A^1 is $A^{1A}-A^{1B}$), A^2 is CH_2 , CHR^b , or $C(R^b)_2$. As a non-limiting example, A^2 can be CH_2 .

In certain of formula (III) embodiments (when A^1 is $A^{1A}-A^{1B}$), A^3 is CH_2 , CHR^b , or $C(R^b)_2$. As a non-limiting example, A^3 can be CH_2 .

In certain of formula (III) embodiments (when A^1 is $A^{1A}-A^{1B}$), A^4 is CH_2 , CHR^b , or $C(R^b)_2$. As a non-limiting example, A^4 is CH_2 .

30

In certain of the foregoing formula (III) and (III-A) embodiments, each occurrence of $\mathbf{R}^b$ is independently selected from the group consisting of:

- (i) C_{1-6} alkyl optionally substituted with from 1-2 independently selected $\mathbf{R}^c$;
- 5 (ii) $-(\text{C}_{0-3} \text{ alkylene})-\text{C}_{6-10}$ aryl, wherein the aryl is optionally substituted with from 1-5 independently selected $\mathbf{R}^c$;
- (iii) $-(\text{C}_{0-3} \text{ alkylene})$ -heteroaryl including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, $\text{N}(\mathbf{R}^a)$, O, and S, wherein the heteroaryl is optionally substituted with from 1-3 independently selected
- 10 $\mathbf{R}^c$;
- (iv) $-\text{OH}$;
- (v) $-\text{N}(\mathbf{R}^a)(\mathbf{R}'')$;
- (vi) C_{1-4} alkoxy; and
- (vii) C_{1-4} haloalkoxy; and
- 15 (viii) $-\text{F}$.

In certain of the formula (III) and (III-A) embodiments, each occurrence of $\mathbf{R}^b$ is independently selected from the group consisting of:

- (i) C_{1-6} alkyl;
- 20 (iv) $-\text{OH}$;
- (v) $-\text{N}(\mathbf{R}^a)(\mathbf{R}'')$;
- (vi) C_{1-4} alkoxy;
- (vii) C_{1-4} haloalkoxy; and
- (viii) $-\text{F}$.

25 In certain of the foregoing formula (III) embodiments, each occurrence of $\mathbf{R}^b$ is independently selected from the group consisting of: C_{1-6} alkyl optionally substituted with from 1-2 independently selected $\mathbf{R}^c$; phenyl optionally substituted with from 1-5 independently selected $\mathbf{R}^c$; $-\text{OH}$; $-\text{F}$; $-\text{N}(\mathbf{R}^a)(\mathbf{R}'')$; and C_{1-4} alkoxy.

30

Non-limiting examples of ring A moieties having formula (III) or (III-A) are delineated in tabular format in Table 1 below.

Table 1.

Example	A ₁	A ₂	A ₃	A ₄
III-1	Bond	C(O)	S	CH ₂
III-2	CH ₂	CH ₂	CH ₂	CH ₂
III-3	Bond	C(O)	NH	CH ₂
III-4	CH ₂	CH ₂	S	CH ₂
III-5	CH ₂	CH ₂	SO ₂	CH ₂
III-6	CH ₂ -CH ₂	CH ₂	CH ₂	CH ₂
III-7	CH ₂	CH ₂	CH ₂	C(O)
III-8	CH ₂	CH ₂	O	CH ₂

5

In some embodiments, ring A is an unsaturated monocyclic ring that includes from 4-8 (e.g., 4-7, 5-6) ring atoms.


In certain embodiments, ring A is an unsaturated monocyclic ring that includes from 4-7 ring atoms.

10 In certain embodiments, ring A is an unsaturated monocyclic ring that includes from 5-6 ring atoms.

In certain embodiments, ring A is an unsaturated monocyclic ring that includes 6 ring atoms.

15 In certain embodiments, ring A is other than an unsaturated monocyclic ring that includes 5 ring atoms (e.g., other than maleimide, e.g. unsubstituted or di-substituted maleimide).

In certain of these embodiments, ring A has formula (IV):




wherein:

each of **A₆**, and **A₇** is independently selected from CH and CR^b; and

each of **A₅** and **A₈** is independently N, CH, or CR^b.

5

In certain of these embodiments, ring A has formula (IV):



wherein:

each of **A₅**, **A₆**, and **A₇** is independently selected from CH and CR^b; and

A₈ is N, CH, or CR^b.

10

In certain formula (IV) embodiments, **A₅**, **A₆**, **A₇**, and **A₈** are each independently selected from CH and CR^b. For example, one or two of **A₅**, **A₆**, **A₇**, and **A₈** are an independently selected CR^b, and the others are CH. As another example, **A₅**, **A₆**, **A₇**, and **A₈** are each CH.

15

In other formula (IV) embodiments, **A₅**, **A₆**, and **A₇** are each independently selected from CH and CR^b, and **A₈** is N. For example, one or two of **A₅**, **A₆**, and **A₇** are an independently selected CR^b, and the others are CH. As another example, **A₅**, **A₆**, and **A₇** are each CH.

20

In still other formula (IV) embodiments, **A₅** is N; and each of **A₆**, **A₇**, and **A₈** is independently selected from CH and CR^b (e.g., one of **A₆**, **A₇**, and **A₈** is CR^b (e.g., C-OH)).

In certain of the foregoing formula (IV) embodiments, each occurrence of $\mathbf{R}^b$ is independently selected from the group consisting of: $\mathbf{R}^{31}$, C_{1-4} haloalkyl; $-\text{OH}$; $-\text{N}(\mathbf{R}^a)(\mathbf{R}'')$; C_{1-4} alkoxy; and C_{1-4} haloalkoxy.

5

In certain of the foregoing formula (IV) embodiments, each occurrence of $\mathbf{R}^b$ is independently selected from the group consisting of: $\mathbf{R}^{31}$; $-\text{OH}$; $-\text{N}(\mathbf{R}^a)(\mathbf{R}'')$; C_{1-4} alkoxy; and C_{1-4} haloalkoxy.

10 In certain of the foregoing formula (IV) embodiments, each occurrence of $\mathbf{R}^b$ is independently selected from the group consisting of:

(i) C_{1-6} alkyl optionally substituted with from 1-2 independently selected $\mathbf{R}^c$;

(ii) $-(\text{C}_{0-3} \text{ alkylene})-\text{C}_{6-10}$ aryl, wherein the aryl is optionally substituted with from 1-5 independently selected $\mathbf{R}^c$;

15 (iii) $-(\text{C}_{0-3} \text{ alkylene})$ -heteroaryl including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, $\text{N}(\mathbf{R}^a)$, O, and S, wherein the heteroaryl is optionally substituted with from 1-3 independently selected $\mathbf{R}^c$;

(iv) $-\text{OH}$;


20 (v) $-\text{N}(\mathbf{R}^a)(\mathbf{R}'')$;

(vi) C_{1-4} alkoxy;

(vii) C_{1-4} haloalkoxy; and

(viii) $-\text{F}$.

25 In certain of these embodiments, ring A has formula (V):



52

wherein:

each of **A₆** and **A₇** is independently selected from CH and CR^b; and

A₈ is N, CH, or CR^b.

5 In other formula (V) embodiments, **A₆** and **A₇** are each CH. In other formula (IV) embodiments, **A₆** and **A₇** cannot both be CH.

 In certain formula (V) embodiments, one of **A₆** and **A₇** is CR^b, the other of **A₆** and **A₇** is CH.


10 In other formula (IV) embodiments, **A₆** and **A₇** are each an independently selected CR^b. In other formula (IV) embodiments, **A₆** and **A₇** cannot both be an independently selected CR^b. In certain of these embodiments, when **A₆** and **A₇** are each an independently selected CR^b, then both **R^b** substituents cannot be C₆₋₁₀ aryl (e.g., phenyl) substituted with from 1-5 independently selected **R^c**. As another example, both **R^b** substituents cannot be C₆₋₁₀ aryl (e.g., phenyl) substituted with from 1-3 or 1-2 independently selected **R^c**. For
15 example, both **R^b** substituents cannot be C₆₋₁₀ aryl (e.g., phenyl), substituted with from 1-5 independently halo (e.g., fluoro). As another example, both **R^b** substituents cannot be C₆₋₁₀ aryl (e.g., phenyl), substituted with from 1-3 or 1-2 independently selected halo (e.g., fluoro). For example, both both **R^b** substituents cannot be difluorophenyl, e.g., *o,p*-(difluoro)phenyl.

20

 In some embodiments, ring A is a saturated or unsaturated bicyclic or tricyclic ring that includes from 7-9 (e.g., 7-8, e.g., 7) ring atoms.

25 In certain of these embodiments, (**A**) applies (e.g., three adjacent ring carbon atoms of the divalent group are each independently selected from the group consisting of C, CH, CR^b, CH₂, C(R^b)H, C(R^b)₂ and are fused to a second ring).

 In certain of these embodiments, ring A has the following formula:





, wherein **D** is:

(c) C₃₋₁₀ cycloalkyl optionally substituted with from 1-4 independently selected **R^d**;

or

(d) heterocyclyl including from 4-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(**R^a**), O, and S, wherein the heterocyclyl is optionally substituted with from 1-4 independently selected **R^d**.

As non-limiting examples of the foregoing embodiments, ring A can be:



or


In some embodiments, ring A is a saturated or unsaturated bicyclic or tricyclic ring that includes from 8-10 ring atoms.

In certain of these embodiments, ring A is saturated. In other embodiments, ring A is unsaturated.


In certain of these embodiments, (**A**) applies (e.g., two adjacent ring carbon atoms of the divalent group are each independently selected from the group consisting of C, CH, and, CR^b and are fused to a second ring). In other embodiments, (**B**) applies.

In certain embodiments, ring A is an unsaturated bicyclic or tricyclic ring that includes from 8-10 ring atoms. In certain of these embodiments, (**A**) applies. In certain of these embodiments, ring A is optionally further substituted with 1 oxo.

In certain embodiments, (**A**) applies, ring A is optionally further substituted with 1 oxo, and ring A has formula (VI):



In certain of these embodiments, fused ring B is fused C₆₋₁₀ aryl optionally substituted with from 1-5 independently selected **R^c**. For example, fused ring B can be fused phenyl optionally substituted with from 1-5 independently selected **R^c**. As a further example, ring A can have formula (VI-A):



wherein **R^{c'}** is H or **R^c** (e.g., C₁₋₆ alkyl, e.g., CH₃).


10

In certain of the formula (VI) embodiments, ring B is fused C₁₀ aryl optionally substituted with from 1-5 independently selected **R^c** (e.g., unsubstituted).

In certain of the formula (VI) embodiments, ring B is fused heteroaryl including from 5-10 (e.g., 6) ring atoms, wherein from 1-4 (e.g., 1) ring atoms are each independently selected from the group consisting of N, N(**R^a**), O, and S, wherein the heteroaryl is optionally substituted with from 1-3 independently selected **R^c**.

15

In certain embodiments, ring A is selected from one of the follows:



In certain of the foregoing embodiments, each fused ring B is independently selected from:


- 5 fused heteroaryl including from 5-10 (e.g., 6) ring atoms, wherein from 1-4 (e.g., 1) ring atoms are each independently selected from the group consisting of N, N(**R^a**), O, and S, wherein the heteroaryl is optionally substituted with from 1-3 independently selected **R^c**; and

- 10 fused C₆₋₁₀ (e.g., C₆) aryl optionally substituted with from 1-5 (e.g., from 1-2) independently selected **R^c**.

As a non-limiting example, each fused ring B can be independently a fused C₆₋₁₀ (e.g., C₆) aryl optionally substituted with from 1-5 (e.g., from 1-2) independently selected **R^c**.


- 15 In certain embodiments, ring A is a saturated bicyclic or tricyclic ring that includes from 8-10 ring atoms. In certain of these embodiments, (**A**) applies. In other embodiments, (**B**) applies. In certain of these embodiments, ring A is optionally further substituted with 1 oxo.

- 20 In certain embodiments, (**A**) applies, ring A is optionally further substituted with 1 oxo, and ring A has formula (VI):



In certain of these embodiments, fused ring B is fused C₃₋₁₀ cycloalkyl optionally substituted with from 1-4 independently selected **R^d**. For example, fused ring B can be fused C₃₋₆ cycloalkyl (e.g., C₃₋₄ cycloalkyl) optionally substituted with from 1-4 independently selected **R^d** (e.g., **R^d** can be C₁₋₃ alkyl).

5 In other embodiments, (**B**) applies, ring A is optionally further substituted with 1 oxo, and ring A has formula (VII):



10 In certain of these embodiments, the spiro-fused ring B is spiro-fused C₃₋₁₀ cycloalkyl optionally substituted with from 1-4 independently selected **R^d**. For example, the spiro-fused ring B is spiro-fused C₃₋₆ cycloalkyl (e.g., C₃₋₄ cycloalkyl) optionally substituted with from 1-4 independently selected **R^d** (e.g., **R^d** can be C₁₋₃ alkyl).

Variable L

In some embodiments, **L** has formula (VIII): $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$.

15

In certain embodiments of formula (VIII), **m** is from 2-6 (e.g., **m** can be 2).

In certain embodiments of formula (VIII), **m** is 1.

20 In certain embodiments of formula (VIII), **X¹** is $-N(R')C(O)-$ (e.g., **X¹** can be $-N(H)C(O)-$).

In certain embodiments of formula (VIII), $n + p \geq 2$. For example, $n + p = 2$ (e.g., each of **n** and **p** is 1). As another example, $n + p > 2$ (e.g., $n + p = 3, 4, 5, 6, 7, 8, 9$, or
25 10).

In another embodiment, $n + p < 2$.

In still other embodiments, $n + p = 0$.

5 In certain embodiments of formula (VIII), X^2 is: -O-; -S-; or -S(O)_t-, wherein **t** is 1 or 2. For example, X^2 can be -S-.

In certain embodiments of formula (VIII), X^2 is -C(Q¹)(Q²)-.

10 In certain of these embodiments, each of Q¹ and Q² is independently selected from the group consisting of H and C₁₋₄ alkyl. For example, one of Q¹ and Q² can be H, and the other of Q¹ and Q² can be C₁₋₄ alkyl (e.g., CH₃). For example, Q¹ can be H; and Q² can be C₁₋₄ alkyl. As another example, each of Q¹ and Q² can be H. As a further example, each of Q¹ and Q² can be an independently selected C₁₋₄ alkyl.

15 In other embodiments, Q¹ and Q², together with the carbon atom to which each is attached forms C₃₋₁₀ cycloalkyl that is optionally substituted with from 1-4 independently selected R^d and optionally fused to phenyl. For example, Q¹ and Q², together with the carbon atom to which each is attached forms C₃₋₆ cycloalkyl that is optionally substituted with from 1-4 independently selected R^d and optionally fused to phenyl.

20 In certain of the foregoing embodiments, Q¹ and Q², together with the carbon atom to which each is attached forms C₄₋₆ (e.g., C₄) cycloalkyl that is optionally substituted with from 1-2 independently selected R^d.

In certain embodiments of formula (VIII), X^2 is:

(v) C₆₋₁₀ arylene optionally substituted with from 1-5 independently selected R^c;

25 (vi) heteroarylene including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, N(R^a), O, and S; and which is optionally substituted with from 1-5 independently selected R^c;

(vii) C₃₋₁₀ cycloalkylene optionally substituted with from 1-4 independently selected R^d; or

(viii) heterocycloalkylene including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(R^a), O, and S; and which is optionally substituted with from 1-5 independently selected R^d.

5 For example, X² can be:

(v) C₆₋₁₀ arylene optionally substituted with from 1-5 independently selected R^c; or

(vii) C₃₋₁₀ cycloalkylene optionally substituted with from 1-4 independently selected R^d.


10 As another example, X² can be:

(v) phenylene optionally substituted with from 1-5 (e.g., 1-3, 1-2, 1) independently selected R^c; or

(vii) C₃₋₆ cycloalkylene (e.g., C₃₋₄ cycloalkylene) optionally substituted with from 1-4 independently selected R^d (e.g., R^d can be C₁₋₃ alkyl).

15

In certain embodiments of formula (VIII), X² is (viii) heterocycloalkylene including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(R^a), O, and S; and which is optionally substituted with from 1-5 independently selected R^d.

20 In certain embodiments of formula (VIII), X² is (viii) heterocycloalkylene including from 4-6 (e.g., 4) ring atoms, wherein from 1-3 (e.g., 1) ring atoms are each independently selected from the group consisting of N(R^a), O, and S; and which is optionally substituted with from 1-5 independently selected R^d (e.g., X² can be ).

25

In some embodiments, L has formula (IX): L has formula (IX): -C(O)-(CH₂)_n-X³-(CH₂)_p-. In certain of these embodiments, n + p ≥ 2. For example, n + p = 2 (e.g., each of n and p is 1). As another example, n + p > 2. In certain of these embodiments, X³ is -S-.

Non-Limiting L Combinations

[1] In certain embodiments of formula (VIII):

- 5 **m** is from 2-6;
n + p $\geq$ 2; and
X² is: -O-; -S-; or -S(O)_t-.

In certain of these embodiments, **m** is 2.

- 10 In certain of these embodiments, **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-).

In certain of these embodiments, **n + p** > 2.

In certain of these embodiments, **n + p** = 2 (e.g., each of **n** and **p** is 1).

In certain of these embodiments **X²** is -S-.

- 15 In certain of these embodiments, **m** is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), and **n + p** > 2.

In certain of these embodiments, **m** is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), and **n + p** > 2, and **X²** is -S-.

- 20 In certain of these embodiments, **m** is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), and **n + p** = 2 (e.g., each of **n** and **p** is 1).

In certain of these embodiments, **m** is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), and **n + p** = 2 (e.g., each of **n** and **p** is 1), and **X²** is -S-.

For example, **L** can be -CH₂CH₂NHC(O)CH₂SCH₂-.

- 25 [2] In certain embodiments of formula (VIII):

m is from 2-6;

n + p < 2; and

X² is:

- 30 (i) -C(Q¹)(Q²)-, wherein each of **Q¹** and **Q²** is an independently selected C₁₋₄ alkyl;
 or **Q¹** and **Q²**, together with the carbon atom to which each is attached forms C₃₋₁₀

cycloalkyl that is optionally substituted with from 1-4 independently selected R^d and optionally fused to phenyl.;

(v) C_{6-10} arylene optionally substituted with from 1-5 independently selected R^c ;

(vi) heteroarylene including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, $N(R^a)$, O, and S; and which is optionally substituted with from 1-5 independently selected R^c ;

(vii) C_{3-10} cycloalkylene optionally substituted with from 1-4 independently selected R^d ; or

(viii) heterocycloalkylene including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of $N(R^a)$, O, and S; and which is optionally substituted with from 1-5 independently selected R^d .

In certain of these embodiments, m is 2.

In certain of these embodiments, X^1 is $-N(R^7)C(O)-$ (e.g., $-N(H)C(O)-$).

In certain of these embodiments, $n + p = 0$.

In certain of these embodiments, X^2 is $-C(Q^1)(Q^2)-$.

In certain of these embodiments, each of Q^1 and Q^2 is H.

In certain of these embodiments, Q^1 is C_{1-4} alkyl.

In certain of these embodiments, Q^2 is C_{1-4} alkyl.


In certain of these embodiments, each of Q^1 and Q^2 is an independently selected C_{1-4} alkyl (e.g., CH_3).

In certain of these embodiments, Q^1 and Q^2 , together with the carbon atom to which each is attached forms C_{3-6} cycloalkyl that is optionally substituted with from 1-4 independently selected R^d and optionally fused to phenyl.

In certain of these embodiments, X^2 is:

(v) C_{6-10} arylene optionally substituted with from 1-5 independently selected R^c ; or

(vii) C_{3-10} cycloalkylene optionally substituted with from 1-4 independently selected R^d .

In certain of these embodiments, X^2 is (viii) heterocycloalkylene including from 4-6 (e.g., 4) ring atoms, wherein from 1-3 (e.g., 1) ring atoms are each independently selected from the group consisting of N(R^a), O, and S; and which is optionally substituted with from 1-5 independently selected R^d (e.g., X^2 can be ).

5

In certain of these embodiments, m is 2-6 (e.g., 2), X^1 is $-N(R')C(O)-$ (e.g., $-N(H)C(O)-$), and $n + p = 0$.

In certain of these embodiments, m is 2-6 (e.g., 2), X^1 is $-N(R')C(O)-$ (e.g., $-N(H)C(O)-$), $n + p = 0$, X^2 is $-C(Q^1)(Q^2)-$, and Q^1 and Q^2 , together with the carbon atom to which each is attached forms C_{3-6} cycloalkyl that is optionally substituted with from 1-4 independently selected R^d and optionally fused to phenyl.

In certain of these embodiments, m is 2-6 (e.g., 2), X^1 is $-N(R')C(O)-$ (e.g., $-N(H)C(O)-$), $n + p = 0$, X^2 is $-C(Q^1)(Q^2)-$, and Q^1 and Q^2 is an independently selected C_{1-4} alkyl (e.g., CH_3).

In certain of these embodiments, m is 2-6 (e.g., 2), X^1 is $-N(R')C(O)-$ (e.g., $-N(H)C(O)-$), $n + p = 0$, and X^2 is: (v) C_{6-10} arylene (e.g., phenylene) optionally substituted with from 1-5 independently selected R^c ; or (vii) C_{3-10} cycloalkylene optionally substituted with from 1-4 independently selected R^d .

[3] In certain embodiments of formula (IX): $n + p = 2$ (e.g., each of n and p is 1), and X^3 is $-S-$.

[4] In certain embodiments of formula (VIII):

m is 1;

$n + p \leq 2$; and

X^2 is: $-O-$; $-S-$; $-S(O)_t-$, or $C(Q^1)(Q^2)$.

In certain of these embodiments, $n + p = 2$.

In certain of these embodiments, X^2 is $-S-$.

In certain of these embodiments, $n + p < 2$ (e.g., $n + p = 0$; or $n + p = 1$).

In certain of these foregoing embodiments, X^2 is $C(Q^1)(Q^2)$.

In certain of these embodiments, each of Q^1 and Q^2 is H.

5 In certain of these embodiments, each of Q^1 and Q^2 is C_{1-4} alkyl.

In certain of these embodiments, Q^1 is H; and Q^2 is C_{1-4} alkyl.

Variables R^1 , R^2 , $R^{2'}$, and R^4

10 In some embodiments, R^1 is H. In some embodiments, R^2 is H. In some embodiments, R^4 is H.

In some embodiments, two of R^1 , R^2 , and R^4 are H.

In some embodiments, each of R^1 , R^2 , and R^4 is H.

In some embodiments, R^2 is unsubstituted C_{1-3} alkyl (e.g., methyl).

15 In some embodiments, R^1 and R^4 is H.

In some embodiments, $R^{2'}$ is as defined according to (AA).

In certain embodiments, a' is 1.

In certain of these embodiments, each of R^{3a} and R^{3b} is H.

20 In certain of these embodiments, each of R^{3a} and R^{3b} is C_{1-3} alkyl (e.g., methyl).


In other embodiments, a' is 0.

In some embodiments, R^3 is $-C(O)OH$. In other embodiments, R^3 is a carboxylic acid isostere. Non-limiting examples of carboxylic acid isosteres include noncarbon acyclic acids such as phosphonic/phosphinic and sulfonic/sulfinic acids and sulfonamides; modified carbon-based acids such as hydroxamic acids, hydroxamic esters, acylureas, acyl sulfonamides, and sulfonyl ureas; optionally substituted heteroaryl and heterocyclyl-based isosteres, such as those based on optionally substituted tetrazole, oxadiazol-5(4H)-thione, thiadiazol-5(4H)-one, oxathiadiazole and oxidized forms thereof, isoxazole, thiazolidinedione, oxazolidinedione, tetramic acid, and derivatives thereof; and optionally substituted cycloalkyl and aryl-based isosteres, such as those based on optionally

25

30

substituted cyclopentane-1,3-dione, phenol and squaric acid and derivatives thereof (e.g., tetrazolyl or amide). In certain embodiments, R^3 is an amide. In certain embodiments, R^3 is an optionally substituted tetrazolyl (e.g., unsubstituted tetrazolyl). In certain embodiments, R^3 is an optionally substituted isoxazolyl (e.g., isoxazolyl substituted with



In some embodiments, a is 1-5 (e.g., 1-4, 1-3, 1-2). In some embodiments, a is 0. In some embodiments, a is 0, 1, or 2. In certain embodiments, a is 1. In other embodiments, a is 2. In still other embodiments, a is 0. In some embodiments, a is 0, 1, 2, or 3 (e.g., $a = 0$; or $a = 1$; or $a = 2$).

10

Variables W, W', and R⁵

W is a peptide having the formula $W'-R^5$, wherein **W'** is a sequence of from 5-60 amino acids, and R^5 is a C-terminal amino acid, amino acid ester, or amino acid amide that is optionally substituted with from 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group). As used herein, "peptide" refers to a chain of amino acid monomers (sometimes termed "residues") linked by peptide (amide) bonds (or an isosteric replacement thereof), which have an N-terminal ($N-R^4$ in formulae (IAA), (IA), or (I)) and a C-terminal amino acid residue (R^5) at each of the ends of the peptide. The term peptide also includes modified peptides, including, e.g., any one or more of the modifications described herein.

15

20

Constituent Amino Acids and Modifications Thereof

In some embodiments, **W** includes one or more naturally occurring amino acids found, e.g., in polypeptides and/or proteins produced by living organisms, such as Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M), Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q), Asp (D), Glu (E), Lys (K), Arg (R), and His (H).

25

In some embodiments, **W** includes one or more independently selected modifications that occur present in so-called modified peptides. Such modifications include, but not limited to: (i) the incorporation of lactam-bridge; (ii) head-to-tail cyclization; (iii) one or more alternative or non-naturally occurring (D or L) amino acids, such as synthetic non-native amino acids, substituted amino acids, and D-amino acids; (iv) peptide bond replacements; (v) targeting groups; and the like. In certain embodiments, **W** includes one modification in either the **W'** or **R⁵** component. In other embodiments, **W** includes more than one independently selected modification (e.g., 2 independently selected modifications, 3 independently selected modifications, 4 independently selected modifications, 5 independently selected modifications, 6 independently selected modifications, 7 independently selected modifications, 8 independently selected modifications, 9 independently selected modifications, or 10 independently selected modifications that occur in the **W'** and/or **R⁵** component (e.g., in the **W'** component only; or in the **R⁵** component only; or in both the **W'** and **R⁵** components).

Non-limiting examples of alternative or non-naturally amino acids include, D-amino acids; beta-amino acids; homocysteine, phosphoserine, phosphothreonine, phosphotyrosine, hydroxyproline, gamma-carboxyglutamate; hippuric acid, octahydroindole-2-carboxylic acid, statine, 1,2,3,4,-tetrahydroisoquinoline-3-carboxylic acid, penicillamine (3-mercapto-D-valine), ornithine, citruline, alpha-methyl-alanine, para-benzoylphenylalanine, para-amino phenylalanine, p-fluorophenylalanine, phenylglycine, propargylglycine, sarcosine, and tert-butylglycine), diaminobutyric acid, 7-hydroxy-tetrahydroisoquinoline carboxylic acid, naphthylalanine, biphenylalanine, cyclohexylalanine, amino-isobutyric acid, norvaline, norleucine, tert-leucine, tetrahydroisoquinoline carboxylic acid, pipecolic acid, phenylglycine, homophenylalanine, cyclohexylglycine, dehydroleucine, 2,2-diethylglycine, 1-amino-1-cyclopentanecarboxylic acid, 1-amino-1-cyclohexanecarboxylic acid, amino-benzoic acid, amino-naphthoic acid, gamma-aminobutyric acid, difluorophenylalanine, nipecotic acid, alpha-amino butyric acid, thienyl-alanine, t-butylglycine, trifluorovaline; hexafluoroleucine; fluorinated analogs; azide-modified amino acids; alkyne-modified


amino acids; cyano-modified amino acids; and derivatives thereof (each which can be, where appropriate can each independently be D or L amino acids).

Non-limiting examples of peptide bond replacements include urea, thiourea, carbamate, sulfonyl urea, trifluoroethylamine, ortho-(aminoalkyl)-phenylacetic acid, para-
 5 (aminoalkyl)-phenylacetic acid, meta-(aminoalkyl)-phenylacetic acid, thioamide, tetrazole, boronic ester, olefinic group, and derivatives thereof.

Other non-limiting examples of modifications and/or moieties include PEGylation; glycosylation; HESylation; ELPylation; lipidation; acetylation; amidation; end-capping
 10 modifications (e.g., amidation at the C-terminus, introduction of C-terminal alcohol, aldehyde, ester, and thioester moieties); cyano groups; phosphorylation; cyclization, conjugation with targeting moieties and/or agents that increase retention in the body (e.g., agents such as cellulose, fatty acids, polyethylene glycol (PEG) or combinations thereof); incorporation of retro-inverso peptide motif (ie., a peptide with a reversal of the direction
 15 of the peptide bond on at least one position);

In certain embodiments, **W** includes only naturally occurring amino acids. In other
 20 embodiments, **W** includes only alternative or non-naturally occurring amino acids. In still other embodiments, **W** includes one or more naturally occurring amino acids and one or more alternative or non-naturally occurring amino acids. In certain of the foregoing embodiments, **W** includes only L amino acids; or **W** includes both D and L amino acids; or **W** includes only D amino acids. While not wishing to be bound by theory, it is believed that the incorporation of D amino acids can confer enhanced *in vivo* or intracellular stability to the compounds described herein.

In some embodiments, **W** includes amino acid residues each of Formula **XAA**:



XAA

wherein each of **R^{aa1}** and **R^{aa2}** is independently selected from:

(a) H;

- (b) C₁₋₆ alkyl, which is optionally substituted with from 1-3 **R^{ba}**;
- (c) (C₀₋₃ alkylene)-C₃₋₁₀ cycloalkyl, which is optionally substituted with from 1-4 **R^{ba}**;
- (d) (C₀₋₃ alkylene)-heterocyclyl, wherein the heterocyclyl includes from 3-10 ring atoms, wherein from 1-3 ring atoms are heteroatoms, each independently selected from the group consisting of N(**R^{da}**), O, and S, and wherein one or more of the heterocyclyl ring carbon atoms are optionally substituted with from 1-4 independently selected **R^{ba}**;
- (e) (C₀₋₃ alkylene)-C₆₋₁₀ aryl, which is optionally substituted with from 1-4 **R^{ca}**;
- (f) (C₀₋₃ alkylene)-heteroaryl, wherein the heteroaryl includes from 5-10 ring atoms, wherein from 1-4 ring atoms are heteroatoms, each independently selected from the group consisting of N, N(**R^{da}**), O, and S, and wherein one or more of the heteroaryl ring carbon atoms are optionally substituted with from 1-4 independently selected **R^{ca}**;

OR

- (g) **R^{aa1}** and **R^{da}**, in the -C(=O)C**R^{aa1}**(**R^{aa2}**)N(**R^{da}**)- group, combine to form a ring including from 5-8 ring atoms, wherein the ring includes: (a) from 1-6 ring carbon atoms (in addition to C**R^{aa1}**(**R^{aa2}**)), each of which is substituted with from 1-2 substituents independently selected from H and C₁₋₃ alkyl; and (b) from 0-3 ring heteroatoms (in addition to the nitrogen atom attached to **R^{da}**), which are each independently selected from the group consisting of N(**R^{da}**), O, and S;

each occurrence of **R^{ba}** is selected from the group consisting of -C(=O)(OH); -C(=O)(C₂₋₂₀ alkyl); -C(=O)NR'**R''**; -NHC(=NR')NR'**R''**; -C(=O)O(C₂₋₂₀ alkyl); -S(O)₀₋₂(C₁₋₆ alkyl); oxo; F; C₁₋₁₀ alkoxy; C₁₋₁₀ haloalkoxy; azido; -N(**R^{ga}**)(**R^{ha}**);

each occurrence of **R^{ca}** is independently selected from the group consisting of: -OH; -SH; -F; -Cl; -Br; -NR'**R''**; C₁₋₄ alkyl; C₁₋₄ haloalkyl; C₁₋₄ alkoxy; C₁₋₄ haloalkoxy; -C(=O)O(C₁₋₄ alkyl); -C(=O)(C₁₋₄ alkyl); -C(=O)OH; -CON(R')(R''); -S(O)₁₋₂(NR'**R''**); -S(O)₀₋₂(C₁₋₄ alkyl); cyano; -NR'C(=NR')NR'**R''**; C₆₋₁₀ aryl optionally substituted with 1-4 substituents

independently selected from halo, C₁₋₄ alkyl, and C₁₋₄ haloalkyl; and C₃₋₆ cycloalkyl optionally substituted with from 1-4 independently selected C₁₋₄ alkyl;

5 each occurrence of **R^{da}** is independently selected from the group consisting of: H, C₁₋₆ alkyl; C₃₋₆ cycloalkyl; -C(O)(C₁₋₄ alkyl); -C(O)O(C₁₋₄ alkyl); -CON(R')(R''); -S(O)₁₋₂(NR'R''); -S(O)₁₋₂(C₁₋₄ alkyl); -OH; and C₁₋₄ alkoxy; or **R^{aa1}** and **R^{da}**, in the -C(=O)**CR^{aa1}**(**R^{aa2}**)N(**R^{da}**)- group, combine to form a ring including from 5-8 ring atoms as defined above;

10 each occurrence of **R^{ga}** and **R^{ha}** is independently selected from the group consisting of: H; C₁₋₄ alkyl; -C(=O)O(C₂₋₂₀ alkyl); and -S(O)₁₋₂(C₁₋₆ alkyl); and

each occurrence of **R'** and **R''** is independently selected from the group consisting of: H and C₁₋₄ alkyl; or **R'** and **R''** together with the nitrogen atom to which each is attached forms a ring including from 3-8 ring atoms, wherein the ring includes: (a) from 1-7 ring carbon atoms, each of which is substituted with from 1-2 substituents independently selected from H and C₁₋₃ alkyl; and (b) from 0-3 ring heteroatoms (in addition to the nitrogen atom attached to **R'** and **R''**), which are each independently selected from the group consisting of N(H), O, and S;

20

or a C-terminal amino acid or an amino acid ester or an amino acid amide thereof.

In some embodiments, **W** includes 25-45 amino acid residues of Formula **XAA**, wherein **R^{aa2}** is H; or a C-terminal amino acid or an amino acid ester or an amino acid amide thereof.

25

In certain of these embodiments, **R^{aa1}** is selected from the group consisting of:

- H;

- C₁-C₆ alkyl optionally substituted with 1-2 substituents selected from -NH₂, -OH, -SH, -SMe, -NH(C=NH)NH₂, CO₂H, and CO₂NH₂;
- (C₁-C₆ alkylene)-phenyl, optionally substituted with 1-2 -OH;
- (C₁-C₆ alkylene)-indolyl; and
- (C₁-C₆ alkylene)-imidazolyl; or
- **R^{aa1}** and **R^{da}**, in the -CH(**R^{aa1}**)N(**R^{da}**)- group, combine to form a pyrrolidine ring.

As non-limiting examples of the foregoing, **W** can include from 25-45 naturally occurring amino acids found, e.g., in polypeptides and/or proteins produced by living organisms, such as Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M), Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q), Asp (D), Glu (E), Lys (K), Arg (R), and His (H); or amino acid ester or amino acid amide thereof.


In certain embodiments, **W** includes from 1-2 (e.g., 1) amino acid residue of Formula **XAA**, wherein **R^{aa2}** is H; **R^{aa1}** is: C₁₋₆ alkyl, which is substituted with from 1-2 (e.g., 1) **R^{ba}**, and

each occurrence of **R^{ba}** is independently selected from:

-N(**R^{ga}**)(**R^{ha}**);


or a C-terminal amino acid or an amino acid ester or an amino acid amide thereof.

As non-limiting examples of the foregoing, **W** can include an amino acid residue selected from:



or a C-terminal amino acid or an amino acid ester or an amino acid amide thereof.

In certain embodiments, **W** includes from 1-2 (e.g., 1) amino acid residue of Formula **XAA**, wherein **R^{aa2}** is C₁₋₃ alkyl (e.g., methyl); and **R^{aa1}** is other than H; or a C-terminal amino acid or an amino acid ester or an amino acid amide thereof.



Non-limiting examples include:  ; or a C-terminal amino acid or an amino acid ester or an amino acid amide thereof.

5

Variable W'

In some embodiments, **W'** is a sequence of from 20-60 (e.g., 20-55, 20-50, 20-45, 20-40, 20-30, 20-35) amino acids.

In some embodiments, **W'** is a sequence of from 30-60 (e.g., 30-55, 30-50, 30-45, 30-40) amino acids. In certain embodiments, **W'** is a sequence of from 25-45 (e.g., 30-45) amino acids. In certain embodiments, **W'** is a sequence of from 30-50 amino acids. For example, **W'** can be a sequence of from 30-45 amino acids or from 30-40 amino acids. In certain embodiments, **W'** can be a sequence of 34, 35, 36, 37, 38, or 39 amino acids; e.g., 36 or 37 amino acids; e.g., 36 amino acids. In certain embodiments, **W'** can be a sequence of 25-28 amino acids; e.g., 26 or 27 amino acids.


15

Variable R⁵

In some embodiments, **R⁵** is a C-terminal amino acid amide that is optionally substituted with from 1-2 modifying groups. In other embodiments, **R⁵** is a C-terminal amino acid that is optionally substituted with from 1-2 modifying groups.

20

In certain embodiments, **R⁵** is a C-terminal lysyl residue, e.g., a lysyl amide residue that is optionally substituted with from 1-2 modifying groups. For example, **R⁵** can be a C-terminal *L*-lysyl amide residue that is optionally substituted with from 1-2 modifying groups. In certain embodiments, **R⁵** has formula (XI):




wherein R^* is H or a modifying group. In certain of these embodiments, formula (XI) is L. In other embodiments, formula (XI) is D.


5 In certain embodiments, R^* is H.

In certain embodiments, the modifying group (e.g., R^*) is an acyl group. For example, the acyl group can be a C_{2-30} (e.g., C_{2-20} , C_{2-10} , C_{2-6}) acyl group that is optionally substituted with from 1-2 independently selected R^f . Each occurrence of R^f is selected from the group consisting of $-C(=O)(OH)$; $-C(=O)(C_{2-20} \text{ alkyl})$; $-C(=O)O(C_{2-20} \text{ alkyl})$; and $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$; oxo; F; C_{1-10} alkoxy; C_{1-10} haloalkoxy; and $-N(R^g)(R^h)$. Each occurrence of R^g and R^h is independently selected from the group consisting of H; C_{1-4} alkyl; $-C(=O)(C_{2-20} \text{ alkyl})$; $-C(=O)O(C_{2-20} \text{ alkyl})$; and $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$.

In certain embodiments, the modifying group (e.g., R^*) is a C_{2-30} (e.g., C_{2-20} , C_{2-10} , C_{2-6}) acyl group that is substituted with 1-2 (e.g., 2) independently selected R^f . In certain embodiments, each occurrence of R^f can independently selected from the group consisting of $-C(=O)(OH)$ and $-N(R^g)(R^h)$; e.g., in which one of R^g and R^h is independently selected from the group consisting of $-C(=O)(C_{2-20} \text{ alkyl})$; $-C(=O)O(C_{2-20} \text{ alkyl})$; and $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$, e.g., $-C(=O)(C_{2-20} \text{ alkyl})$. By way of example, the modifying group (e.g., R^*) can be:



As an additional example, R^* can be:



5


In some embodiments, R^5 is a C-terminal amino acid that is optionally substituted with from 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group).

10

In certain embodiments, R^5 is a C-terminal lysine that is optionally substituted with from 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group). For example, R^5 can be a C-terminal *L*-lysine that is optionally substituted with from 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group).

15

In certain embodiments, R^5 has formula (XI-OH):




wherein R^* is H or a modifying group (e.g., an acyl group and a PEG group). In certain of these embodiments, formula (XI-OH) is L. In other embodiments, formula (XI-OH) is D.

In certain embodiments of formula (XI) and (XI-OH), R^* is H.


In certain embodiments, the modifying group (e.g., R^*) is an acyl group. For example, the acyl group can be a C_{2-30} (e.g., C_{2-20} , C_{2-10} , C_{2-6}) acyl group that is optionally substituted with from 1-2 independently selected R^f . Each occurrence of R^f is selected from the group consisting of $-C(=O)(OH)$; $-C(=O)(C_{2-20} \text{ alkyl})$; $-C(=O)O(C_{2-20} \text{ alkyl})$; and $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$; oxo; F; C_{1-10} alkoxy; C_{1-10} haloalkoxy; and $-N(R^g)(R^h)$. Each occurrence of R^g and R^h is independently selected from the group consisting of H; C_{1-4} alkyl; $-C(=O)(C_{2-20} \text{ alkyl})$; $-C(=O)O(C_{2-20} \text{ alkyl})$; and $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$.

In certain embodiments, the modifying group (e.g., R^*) is a C_{2-30} (e.g., C_{2-20} , C_{2-10} , C_{2-6}) acyl group that is substituted with 1-2 (e.g., 2) independently selected R^f . In certain embodiments, each occurrence of R^f can independently selected from the group consisting of $-C(=O)(OH)$ and $-N(R^g)(R^h)$; e.g., in which one of R^g and R^h is independently selected from the group consisting of $-C(=O)(C_{2-20} \text{ alkyl})$; $-C(=O)O(C_{2-20} \text{ alkyl})$; and $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$.

alkyl), e.g., $-C(=O)(C_{2-20} \text{ alkyl})$. By way of example, the modifying group (e.g., R^*) can be:



As an additional example, R^* can be:



5

or

Other non-limiting, representative examples of acyl modifying groups are delineated, e.g., in Table 2.

10 In other embodiments, the modifying group is PEG. As used herein the general term “polyethylene glycol” or “PEG”, refers to mixtures of condensation polymers of ethylene oxide and water, in a branched or straight chain, represented by the general formula $H(OCH_2CH_2)_nOH$, wherein n is at least 9. Absent any further characterization, the term is intended to include polymers of ethylene glycol with an average total molecular weight selected from the range of 5,000 to 40,000 Daltons. “Polyethylene glycol” or “PEG”
 15 is used in combination with a numeric suffix to indicate the approximate average molecular weight thereof. For example, PEG-5,000 refers to polyethylene glycol having a total molecular weight average of about 5,000. As used herein the term “PEGylated” or like terms refers to a compound that has been modified from its native state by linking a PEG

chain to the peptide. A “PEGylated peptide” is a peptide that has a PEG chain covalently attached to the peptide itself.

5 In certain embodiments, **R**⁵ is a C-terminal amino acid selected from serine, glycine, and arginine.

In certain embodiments, **R**⁵ is a C-terminal amino acid amide selected from serinyl amide, glycyl amide, and arginanyl amide.

In certain embodiments, **R**⁵ is a C-terminal glycyl residue (e.g., C-terminal glycine or C-terminal glycyl amide).

10 In certain embodiments, **R**⁵ is a C-terminal arginanyl residue (e.g., C-terminal arginine or C-terminal arginanyl amide).

In certain embodiments, **R**⁵ is a C-terminal serinyl residue (e.g., C-terminal serine or C-terminal serinyl amide).

15 *Non-Limiting Examples of W*

In some embodiments, the amino acid sequence present in **W** is, or includes, the sequence that is present in native GLP-1-OH or GLP-1-NH₂. In other embodiments, the amino acid sequence present in **W** is, or includes, the sequence that is present in native GIP. In still other embodiments, the amino acid sequence present in **W** is, or includes, a hybrid sequence having one or more fragments (e.g., functional fragments) present in native GLP-1-OH or GLP-1-NH₂ and one or more fragments (e.g., functional fragments) present in native GIP. This disclosure further contemplates variations of the foregoing embodiments, e.g., **W** is, or includes, a conservatively substituted variation of the foregoing, meaning that one or more amino acid residues of an original peptide are replaced by different residues, and that the conservatively substituted peptide retains a desired biological activity. Examples of conservative substitutions include substitution of amino acids that tend not to alter the secondary and/or tertiary structure of the compounds described herein, substitutions that do not change the overall or local hydrophobic character, substitutions that do not change the overall or local charge, substitutions by residues of equivalent side chain size, or substitutions by side chains with similar reactive groups.

20
25
30

A given amino acid can be replaced by a residue having similar physiochemical characteristics, e.g., substituting one aliphatic residue for another (such as Ile, Val, Leu, or Ala for one another), or substitution of one polar residue for another (such as between Lys and Arg; Glu and Asp; or Gln and Asn). Other such conservative substitutions, e.g.,
5 substitutions of entire regions having similar hydrophobicity characteristics or substitutions of residues with similar side chain volume are also within the scope of this disclosure.

Amino acids can be grouped according to similarities in the properties of their side chains (in A. L. Lehninger, in Biochemistry, second ed., pp. 73-75, Worth Publishers, New
10 York (1975)): (1) non-polar: Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M); (2) uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q); (3) acidic: Asp (D), Glu (E); (4) basic: Lys (K), Arg (R), His (H). Alternatively, naturally occurring residues can be divided into groups based on common side-chain properties: (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile, Phe, Trp; (2) neutral
15 hydrophilic: Cys, Ser, Thr, Asn, Gln, Ala, Tyr, His, Pro, Gly; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe, Pro, His, or hydroxyproline. Non-conservative substitutions will entail exchanging a member of one of these classes for another class.

In certain embodiments, conservative substitutions for use in the variants described
20 herein are as follows: Ala into Gly or into Ser; Arg into Lys; Asn into Gln or into His; Asp into Glu or into Asn; Cys into Ser; Gln into Asn; Glu into Asp; Gly into Ala or into Pro; His into Asn or into Gln; Ile into Leu or into Val; Leu into Ile or into Val; Lys into Arg, into Gln or into Glu; Met into Leu, into Tyr or into Ile; Phe into Met, into Leu or into Tyr; Ser into Thr; Thr into Ser; Trp into Tyr or into Phe; Tyr into Phe or into Trp; and/or Phe
25 into Val, into Tyr, into Ile or into Leu. In general, conservative substitutions encompass residue exchanges with those of similar physicochemical properties (i.e. substitution of a hydrophobic residue for another hydrophobic amino acid).


In still other embodiments, the amino acid sequence present in **W** is, or includes,
30 or is based upon a sequence that is present in a peptide having at least 0.01% of the GLP-

1 receptor activation activity of the native GLP-1, such as at least 0.1%, 0.2%, 0.5%, 0.8%, 1%, 3%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% of the GLP-1 receptor activation activity of the native GLP-1-OH or GLP-1-NH₂ and/or at least 0.01% of the GIP receptor activation activity of GIP, such as at least 0.1%, 0.2%, 0.5%, 0.8%,
 5 1%, 3%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% of the GIP receptor activation activity of the native GIP.

As used herein the term “native GLP-1” refers to a peptide comprising the sequence of human GLP-1 (7-36, or 7-37), and term “native GIP” refers to a peptide comprising the sequence of human GIP (1-42). As used herein, a general reference to “GLP-1” or “GIP”
 10 in the absence of any further designation is intended to mean native GLP-1 or native GIP, respectively.


In some embodiments, **W** has formula (X): -GTF-W''-R⁵, wherein **W''** is a sequence of 30-40 (e.g., 31-36, 33) amino acids.

15 In certain embodiments, **W** has formula (XII):



wherein **W''** is a sequence of 30-40 (e.g., 31-35, e.g., 33) amino acids, and R* is H
 20 or a modifying group (e.g., an acyl group and a PEG group as described herein).

In certain embodiments, **W** has formula (XII-OH):



wherein **W''** is a sequence of 30-40 (e.g., 31-35, e.g., 33) amino acids, and **R*** is H
 5 or a modifying group (e.g., an acyl group and a PEG group as described herein).

In some embodiments, **W** has formula (XIII):

-GTF-**W'''**-GPSSGAPPPS-**R**⁵ (SEQ ID NO: 1); wherein **W'''** is a sequence of 20-
 10 30 (e.g., 21-25, e.g., 23) amino acids.

In some embodiments, **W** has formula (XIV-AA):

GT(**Xaa3**)(**Xaa4**)SD(**Xaa7**)S(**Xaa9**)(**Xaa10**)(**Xaa11**)(**Xaa12**)(**Xaa13**)(**Xaa14**)(**Xaa15**)(**Xaa16**)(**Xaa17**)(**Xaa18**)(**Xaa19**)(**Xaa20**)(**Xaa21**)WL(**Xaa24**)(**Xaa25**)(**Xaa26**)GP
 15 SSGAPPP(**Xaa36**)-**R**⁵ (SEQ ID NO: 2A which is listed as SEQ ID NO: 35 in sequence
 listing);

wherein:

Xaa3 is F;

Xaa4 is T or I (e.g., T);

20 **Xaa7** is Y, V, L, or K* (e.g., Y);

Xaa9 is I or S (e.g., I);

- Xaa10** is Y, Y*, Q, A, or (Aib) (e.g., Y);
Xaa11 is L, M, or L* (e.g., L);
Xaa12 is D or E (e.g., D);
Xaa13 is K, G, R, or E (e.g., K);
5 **Xaa14** is Q or I (e.g., Q);
Xaa15 is A, H, or R (e.g., A);
Xaa16 is A, Q, or V (e.g., A);
Xaa17 is A, (Aib), K*, K, or Q (e.g., (Aib));
Xaa18 is A, D, E, (Aib), or L (e.g., A, D, E, or L (e.g., E));
10 **Xaa19** is F, or A (e.g., F);
Xaa20 is V or I (e.g., V);
Xaa21 is N, A, Q, K*, or E (e.g., N);
Xaa24 is I, L or V (e.g., L);
Xaa25 is A, K, or I (e.g., A);
15 **Xaa26** is Q-R, G-R-G-K*, Q, or G (e.g., G); and
Xaa36 is S or absent (e.g., S).

In some embodiments (e.g., when **W** has formula (XIV-AA)), **W** has formula (XIV):

20 GTF(**Xaa4**)SD(**Xaa7**)S(**Xaa9**)(**Xaa10**)(**Xaa11**)(**Xaa12**)(**Xaa13**)QA(**Xaa16**)(**Xaa17**)(**Xaa18**)F-(**Xaa20**)(**Xaa21**)WL(**Xaa24**)(**Xaa25**)GGPSSGAPPPS-R⁵ (SEQ ID NO: 2);

wherein:

- Xaa4** is T or I (e.g., T);
Xaa7 is Y, V, or L (e.g., Y);
25 **Xaa9** is I or S (e.g., I);
Xaa10 is Y, Q, or A (e.g., Y);
Xaa11 is L, M, or L* (e.g., L);
Xaa12 is D or E (e.g., D);
Xaa13 is K, G, or E (e.g., K);
30 **Xaa16** is A or V (e.g., A);

Xaa17 is (Aib) or K (e.g., (Aib));

Xaa18 is E or L (e.g., E);

Xaa20 is V or I (e.g., V);

Xaa21 is N, A, or E (e.g., N);

5 **Xaa24** is L or V (e.g., L); and

Xaa25 is A or K (e.g., A).

In certain embodiments, **W** has formula (XIV-A):

10 GTF(**Xaa4**)SD(**Xaa7**)S(**Xaa9**)(**Xaa10**)(**Xaa11**)(**Xaa12**)(**Xaa13**)QA(**Xaa16**)(Aib)
-(**Xaa18**)F(**Xaa20**)(**Xaa21**)WL(**Xaa24**)(**Xaa25**)GGPSSGAPPPS-R⁵ (SEQ ID NO: 3),
wherein each of the “Xaa” variables is as defined in conjunction with Formula (XIV). In
certain of these embodiments, R⁵ can be as defined anywhere herein (e.g., can have formula
(XI); e.g., D or L formula (XI), and R* can be as defined anywhere herein).

15 In certain embodiments, **W** has formula (XIV-B):

GTFTSDYSIYLDKQAA(Aib)EFVNWLLAGGPSSGAPPPS-R⁵ (SEQ ID NO:
4). In certain of these embodiments, R⁵ can be as defined anywhere herein (e.g., can have
formula (XI); e.g., D or L formula (XI), and R* can be as defined anywhere herein).

20


As used herein “(Aib)” refers to 2-aminoisobutyric acid (also known as α -aminoisobutyric acid or α -methylalanine or 2-methylalanine).

25 As used herein, Y* refers to 2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid
(e.g., (S)- 2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid). As used herein, L*
refers to 2-amino-2-methylpentanoic acid (e.g., (S)-2-amino-2-methylpentanoic acid).

or a C-terminal amino acid or an amino acid ester or an amino acid amide thereof.

As used herein K* is a lysine residue substituted with a modifying group, or a C-terminal amino acid or an amino acid ester or amino acid amide thereof.

Non-limiting examples of **K*** can include an amino acid residue selected from:







or a C-terminal amino acid or an amino acid ester or an amino acid amide thereof.

In some embodiments, **W** is represented by formula (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-B), (XV), or any of SEQ ID 1-34.




For example, **W** can have any of the sequences delineated in Table 2.




Table 2.









SEQ ID NO:	Sequence
5	GTFTSDYSIYLDKQAA(Aib)EFVNWLLAGGPSSGAPPPSK—NH ₂
6	GTFTSDYSIYLDKQAA(Aib)EFVNWLLAGGPSSGAPPPSK* K* =
7	GTFTSDYSIYLDKQAA(Aib)EFVNWLLAGGPSSGAPPPSK* K* =
8	GTFTSDYSIYLDKQAA(Aib)EFVNWLLAGGPSSGAPPPSK*



	 K* =
9	GTFTSDYSIYLDKQAA(Aib)EFVNWLLAGGPSSGAPPPSK*,  K* =
10	GTFTSDVSSYLEGQAAKEFIAWLVKGGPSSGAPPPSK*—NH₂,  K* =
11	GTFTSDYSIAMDKIRQQDFVNWLLAQRGPSGAPPPSK*—NH₂,  K* =
12	GTFTSDLSIYLDKQAA(Aib)EFVNWLLAGGPSSGAPPPSK—NH₂
13	GTFTSDYSIYLDKQAA(Aib)EFVNWLLAGGPSSGAPPPSK—NH₂
14	GTFTSDYSIYLDKQAV(Aib)EFVNWLLAGGPSSGAPPPSK—NH₂

15	GTFTSDYSIYLDKQAA(Aib)FVNWLLAGGPSSGAPPPSK—NH ₂
16	GTFTSDYSIYLDKQAA(Aib)EFVNWLLAGGPSSGAPPPSK—NH ₂
17	GTFTSDYSIYLDKQAA(Aib)EFVWLLAGGPSSGAPPPSK—NH ₂
18	GTFTSDYSIYLDKQAA(Aib)EFVNWLLAGGPSSGAPPPSK—NH ₂
19	GTFTSDYSIQNDKQAA(Aib)EFVNWLLAGGPSSGAPPPSK*—NH ₂ K* =
20	GTFTSDYSIAMDKQAA(Aib)EFVNWLLAGGPSSGAPPPSK*—NH ₂ K* =
21	GTFTSDYSIYL*DKQAA(Aib)EFVNWLLAGGPSSGAPPPSK*—NH ₂ K* = L* =

22	~~GTFTSDYSIYLDKQAA(Aib)EFVNWLLAGGPSSGAPPPS-NH₂~~
23	~~R-N-EGTFTSDYSIYLDKQAA(Aib)EFVNWLLAGGPSSGAPPPSK*-NH₂~~ Sequence Ga 
24	~~R-N-EGTFTSDYSIYLDKQAA(Aib)EFVK*WLLAGGPSSGAPPPSK-NH₂~~ Sequence Pa 
25	~~R-N-EGTFTSDYSIYLDKQAA(Aib)EFVNWLLAGRGK*GPSSGAPPPS-NH₂~~ Sequence Qa 

26	R-N-EGTFTSDYSIYLDKQAA~~K~~*EFVNWLLAGGPSSGAPPPSK-NH₂ Sequence Ra 
27	R-N-EGTFTSD~~K~~*SIYLDKQAA(Aib)EFVNWLLAGGPSSGAPPPSK-NH₂ Sequence Sa 
28	GTFTSDYSIYLDKQAA(Aib)EFVNWLLAGGPSSGAPPPSK*-NH₂ 

29	GTFTSDYSI^{Y*}LDKQAA(Aib)EFVNWLLAGGPSSGAPPPSK*—NH₂ $K^* =$  $Y^* =$ 
30	GTFTSDYSIYLDKQAV(Aib)EFVNWLLAGGPSSGAPPPSK*—NH₂  $= K^*$ 
31	GTFTSDYSIYLDKQAA(Aib)EFV~~X~~*WLLAGGPSSGAPPPSK—NH₂  $= K^*$ 
32	GTFTSDYSIYLDKQAA(Aib)EFVNWLLAG~~R~~GK*GPSSGAPPPS—NH₂  $= K^*$ 

33	GTFTSDYSIYLDKQAA~~W~~EFVNWLLAGGPSSGAPPPSK—NH₂ 
34	GTFTSD~~W~~SIYLDKQAA(Aib)EFVNWLLAGGPSSGAPPPSK—NH₂ 

In some embodiments, **W** is represented by any one of SEQ ID 1-34 (e.g., SEQ. ID 5-27; e.g., SEQ ID 5-29; (e.g., SEQ ID 6); e.g., SEQ ID 28-29; e.g., SEQ ID 30-34).

In some embodiments, **W** is represented by any one of SEQ ID 1-27 (e.g., SEQ. ID 5-27; e.g., SEQ ID 6).

In some embodiments, **W** is represented by any one of SEQ ID 28-29 (e.g., 28, 29).

In certain embodiments, **W** has the sequence of SEQ ID 6.

10 **Non-Limiting Combinations of Formulae (IAA), (IA), and (I)**

[1] In some embodiments, the compound has formula (I-A), (I-AA, or (I-AB), ring A is a saturated or unsaturated monocyclic ring that includes from 3-8 (e.g., 4-8, 4-7, 5-6) ring atoms, and **L** has formula (VIII): $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$. In certain embodiments, one, two, or three of **R¹**, **R²**, and **R⁴** are H. In certain embodiments, **R³** is -C(O)OH. In certain embodiments, **a** is 0, 1, or 2 (e.g., 1). In certain embodiments, each of **R¹**, **R²**, and **R⁴** is H, **a** is 0, 1, or 2 (e.g., 1), and **R³** is -C(O)OH.

[1A] In some embodiments, the compound has formula (IA-A), (IA-AA), or (IA-AB), ring A is a saturated or unsaturated monocyclic ring that includes from 3-8 (e.g., 4-8, 4-7, 5-6) ring atoms, and **L** has formula (VIII): $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$. In certain embodiments, one, two, or three of **R**¹, **R**², and **R**⁴ are H. In certain embodiments, **R**³ is -C(O)OH. In certain embodiments, **a** is 0, 1, or 2 (e.g., 1). In certain embodiments, each of **R**¹, **R**², and **R**⁴ is H, **a** is 0, 1, or 2 (e.g., 1), and **R**³ is -C(O)OH. In certain embodiments, **a**^{*} is 1; each of **R**^{3a} and **R**^{3b} is H.

[2] In some embodiments, the compound has formula (I-A), (I-AA), or (I-AB), (I-A), (I-AA), or (I-AB), ring A is a saturated monocyclic ring that includes from 3-8 (e.g., 4-8, 4-7, 5-6) ring atoms, and **L** has formula (VIII): $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$. In certain embodiments, one, two, or three of **R**¹, **R**², and **R**⁴ are H. In certain embodiments, **R**³ is -C(O)OH. In certain embodiments, **a** is 0, 1, or 2 (e.g., 1). In certain embodiments, each of **R**¹, **R**², and **R**⁴ is H, **a** is 0, 1, or 2 (e.g., 1), and **R**³ is -C(O)OH.

[2A] In some embodiments, the compound has formula (IA-A), (IA-AA), or (IA-AB), (IA-B), (IA-BA, or (IA-BB), ring A is a saturated monocyclic ring that includes from 3-8 (e.g., 4-8, 4-7, 5-6) ring atoms, and **L** has formula (VIII): $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$. In certain embodiments, one, two, or three of **R**¹, **R**², and **R**⁴ are H. In certain embodiments, **R**³ is -C(O)OH. In certain embodiments, **a** is 0, 1, or 2 (e.g., 1). In certain embodiments, each of **R**¹, **R**², and **R**⁴ is H, **a** is 0, 1, or 2 (e.g., 1), and **R**³ is -C(O)OH. In certain embodiments, **a**^{*} is 1; each of **R**^{3a} and **R**^{3b} is H.

[3] In some embodiments, the compound has formula (I-A), (I-AA), or (I-AB), ring A is a saturated, monocyclic, 6-membered ring having formula (III) (i.e., **A**¹ is not a bond), and **L** has formula (VIII): $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$. In certain embodiments, one, two, or three of **R**¹, **R**², and **R**⁴ are H. In certain embodiments, **R**³ is -C(O)OH. In certain embodiments, **a** is 0, 1, or 2 (e.g., 1). In certain embodiments, each of **R**¹, **R**², and **R**⁴ is H, **a** is 0, 1, or 2 (e.g., 1), and **R**³ is -C(O)OH.

[3A] In some embodiments, the compound has formula (IA-A), (IA-AA), or (IA-AB), ring A is a saturated, monocyclic, 6-membered ring having formula (III) (i.e., A^1 is not a bond), and **L** has formula (VIII): $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$. In certain embodiments, one, two, or three of R^1 , R^2 , and R^4 are H. In certain embodiments, R^3 is -C(O)OH. In certain embodiments, **a** is 0, 1, or 2 (e.g., 1). In certain embodiments, each of R^1 , R^2 , and R^4 is H, **a** is 0, 1, or 2 (e.g., 1), and R^3 is -C(O)OH. In certain embodiments, a' is 1; each of R^{3a} and R^{3b} is H.

[4] In some embodiments, the compound has formula (I-A), (I-AA), or (I-AB), ring A is a saturated, monocyclic, 5-membered ring having formula (III-A) (i.e., A^1 in formula (III) is a bond), and **L** has formula (VIII): $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$. In certain embodiments, one, two, or three of R^1 , R^2 , and R^4 are H. In certain embodiments, R^3 is -C(O)OH. In certain embodiments, **a** is 0, 1, or 2 (e.g., 1). In certain embodiments, each of R^1 , R^2 , and R^4 is H, **a** is 0, 1, or 2 (e.g., 1), and R^3 is -C(O)OH.

[4A] In some embodiments, the compound has formula (IA-A), (IA-AA), or (IA-AB), ring A is a saturated, monocyclic, 5-membered ring having formula (III-A) (i.e., A^1 in formula (III) is a bond), and **L** has formula (VIII): $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$. In certain embodiments, one, two, or three of R^1 , R^2 , and R^4 are H. In certain embodiments, R^3 is -C(O)OH. In certain embodiments, **a** is 0, 1, or 2 (e.g., 1). In certain embodiments, each of R^1 , R^2 , and R^4 is H, **a** is 0, 1, or 2 (e.g., 1), and R^3 is -C(O)OH. In certain embodiments, a' is 1; each of R^{3a} and R^{3b} is H.

[5] In some embodiments, the compound has formula (I-A), (I-AA), or (I-AB), ring A is a saturated or unsaturated bicyclic or tricyclic ring that includes from 6-14 (e.g., 8-10) ring atoms, and **L** has formula (VIII): $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$. In certain embodiments, one, two, or three of R^1 , R^2 , and R^4 are H. In certain embodiments, R^3 is -

C(O)OH. In certain embodiments, **a** is 0, 1, or 2 (e.g., 1). In certain embodiments, each of **R**¹, **R**², and **R**⁴ is H, **a** is 0, 1, or 2 (e.g., 1), and **R**³ is -C(O)OH.

5 **[5A]** In some embodiments, the compound has formula (IA-A), (IA-AA), or (IA-AB), ring A is a saturated or unsaturated bicyclic or tricyclic ring that includes from 6-14 (e.g., 8-10) ring atoms, and **L** has formula (VIII): -(CH₂)_m-**X**¹-(CH₂)_n-**X**²-(CH₂)_p-. In certain embodiments, one, two, or three of **R**¹, **R**², and **R**⁴ are H. In certain embodiments, **R**³ is -C(O)OH. In certain embodiments, **a** is 0, 1, or 2 (e.g., 1). In certain embodiments,
10 each of **R**¹, **R**², and **R**⁴ is H, **a** is 0, 1, or 2 (e.g., 1), and **R**³ is -C(O)OH. In certain embodiments, **a**' is 1; each of **R**^{3a} and **R**^{3b} is H.

[6] In some embodiments, the compound has formula (I-A), (I-AA), or (I-AB), ring A is a saturated or unsaturated monocyclic ring that includes from 3-8 (e.g., 4-8, 4-7,
15 5-6) ring atoms, **L** has formula (VIII): -(CH₂)_m-**X**¹-(CH₂)_n-**X**²-(CH₂)_p-, and **W** is represented by formula (X), (XII), (XIII), (XIV), (XIV-A), (XIV-B), or any of SEQ ID 1-27 (e.g., SEQ ID 5-27, e.g., SEQ ID 6). In certain embodiments, one, two, or three of **R**¹, **R**², and **R**⁴ are H. In certain embodiments, **R**³ is -C(O)OH. In certain embodiments, **a** is 0, 1, or 2 (e.g., 1). In certain embodiments, **R**⁵ has formula (XI). In certain embodiments,
20 each of **R**¹, **R**², and **R**⁴ is H, **a** is 0, 1, or 2 (e.g., 1), **R**³ is -C(O)OH, and **R**⁵ has formula (XI).

[6A] In some embodiments, the compound has formula (IA-A), (IA-AA), or (IA-AB), ring A is a saturated or unsaturated monocyclic ring that includes from 3-8 (e.g., 4-8,
25 4-7, 5-6) ring atoms, **L** has formula (VIII): -(CH₂)_m-**X**¹-(CH₂)_n-**X**²-(CH₂)_p-, and **W** is represented by formula (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-B), (XV), or any of SEQ ID 1-34 (e.g., SEQ ID 5-27; e.g., SEQ ID 5-29; (e.g., SEQ ID 6); e.g., SEQ ID 28-29; e.g., SEQ ID 30-34). In certain embodiments, one, two, or three of **R**¹, **R**², and **R**⁴ are H. In certain embodiments, **R**³ is -C(O)OH. In certain embodiments, **a** is 0, 1, or 2
30 (e.g., 1). In certain embodiments, **R**⁵ has formula (XI). In certain embodiments, each of

R^1 , R^2 , and R^4 is H, a is 0, 1, or 2 (e.g., 1), R^3 is $-C(O)OH$, and R^5 has formula (XI). In certain embodiments, a' is 1; each of R^{3a} and R^{3b} is H.

[7] In some embodiments, the compound has formula (I-A), (I-AA), or (I-AB),
 5 ring A is a saturated monocyclic ring that includes from 3-8 (e.g., 4-8, 4-7, 5-6) ring atoms,
 L has formula (VIII): $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$, and W is represented by (X), (XII),
 (XIII), (XIV), (XIV-A), (XIV-B), or any of SEQ ID 1-27 (e.g., SEQ ID 5-27, e.g., SEQ ID
 6). In certain embodiments, one, two, or three of R^1 , R^2 , and R^4 are H. In certain
 embodiments, R^3 is $-C(O)OH$. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain
 10 embodiments, R^5 has formula (XI). In certain embodiments, each of R^1 , R^2 , and R^4 is H,
 a is 0, 1, or 2 (e.g., 1), R^3 is $-C(O)OH$, and R^5 has formula (XI).

[7A] In some embodiments, the compound has formula (I-A), (I-AA), or (I-AB),
 ring A is a saturated monocyclic ring that includes from 3-8 (e.g., 4-8, 4-7, 5-6) ring atoms,
 15 L has formula (VIII): $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$, and W is represented by formula
 (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-B), (XV), or any of SEQ ID 1-34
 (e.g., SEQ. ID 5-27; e.g., SEQ ID 5-29; (e.g., SEQ ID 6); e.g., SEQ ID 28-29; e.g., SEQ
 ID 30-34). In certain embodiments, one, two, or three of R^1 , R^2 , and R^4 are H. In certain
 embodiments, R^3 is $-C(O)OH$. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain
 20 embodiments, R^5 has formula (XI). In certain embodiments, each of R^1 , R^2 , and R^4 is H,
 a is 0, 1, or 2 (e.g., 1), R^3 is $-C(O)OH$, and R^5 has formula (XI). In certain embodiments,
 a' is 1; each of R^{3a} and R^{3b} is H.

[8] In some embodiments, the compound has formula (I-A), (I-AA), or (I-AB),
 25 ring A is a saturated, monocyclic, 6-membered ring having formula (III) (i.e., A^1 is not a
 bond), L has formula (VIII): $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$, and W is represented by
 formula (X), (XII), (XIII), (XIV), (XIV-A), (XIV-B), or any of SEQ ID 1-27 (e.g., SEQ
 ID 5-27, e.g., SEQ ID 6). In certain embodiments, one, two, or three of R^1 , R^2 , and R^4 are
 30 H. In certain embodiments, R^3 is $-C(O)OH$. In certain embodiments, a is 0, 1, or 2 (e.g.,

1). In certain embodiments, R^5 has formula (XI). In certain embodiments, each of R^1 , R^2 , and R^4 is H, a is 0, 1, or 2 (e.g., 1), R^3 is $-C(O)OH$, and R^5 has formula (XI).

[8A] In some embodiments, the compound has formula (IA-A), (IA-AA), or (IA-AB), ring A is a saturated, monocyclic, 6-membered ring having formula (III) (i.e., A^1 is not a bond), L has formula (VIII): $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$, and W is represented by formula (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-B), (XV), or any of SEQ ID 1-34 (e.g., SEQ. ID 5-27; e.g., SEQ ID 5-29; (e.g., SEQ ID 6); e.g., SEQ ID 28-29; e.g., SEQ ID 30-34). In certain embodiments, one, two, or three of R^1 , R^2 , and R^4 are H. In certain embodiments, R^3 is $-C(O)OH$. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R^5 has formula (XI). In certain embodiments, each of R^1 , R^2 , and R^4 is H, a is 0, 1, or 2 (e.g., 1), R^3 is $-C(O)OH$, and R^5 has formula (XI). In certain embodiments, a' is 1; each of R^{3a} and R^{3b} is H.

[9] In some embodiments, the compound has formula (I-A), (I-AA), or (I-AB), ring A is a saturated, monocyclic, 5-membered ring having formula (III-A) (i.e., A^1 in formula (III) is a bond), L has formula (VIII): $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$, and W is represented by formula (X), (XII), (XIII), (XIV), (XIV-A), (XIV-B), or any of SEQ ID 1-27 (e.g., SEQ ID 5-27, e.g., SEQ ID 6). In certain embodiments, one, two, or three of R^1 , R^2 , and R^4 are H. In certain embodiments, R^3 is $-C(O)OH$. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R^5 has formula (XI). In certain embodiments, each of R^1 , R^2 , and R^4 is H, a is 0, 1, or 2 (e.g., 1), R^3 is $-C(O)OH$, and R^5 has formula (XI).

[9A] In some embodiments, the compound has formula (IA-A), (IA-AA), or (IA-AB), ring A is a saturated, monocyclic, 5-membered ring having formula (III-A) (i.e., A^1 in formula (III) is a bond), L has formula (VIII): $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$, and W is represented by formula (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-B), (XV), or any of SEQ ID 1-34 (e.g., SEQ. ID 5-27; e.g., SEQ ID 5-29; (e.g., SEQ ID 6); e.g., SEQ

ID 28-29; e.g., SEQ ID 30-34). In certain embodiments, one, two, or three of $\mathbf{R}^1$, $\mathbf{R}^2$, and $\mathbf{R}^4$ are H. In certain embodiments, $\mathbf{R}^3$ is -C(O)OH. In certain embodiments, $\mathbf{a}$ is 0, 1, or 2 (e.g., 1). In certain embodiments, $\mathbf{R}^5$ has formula (XI). In certain embodiments, each of $\mathbf{R}^1$, $\mathbf{R}^2$, and $\mathbf{R}^4$ is H, $\mathbf{a}$ is 0, 1, or 2 (e.g., 1), $\mathbf{R}^3$ is -C(O)OH, and $\mathbf{R}^5$ has formula (XI). In
 5 certain embodiments, $\mathbf{a}^*$ is 1; each of $\mathbf{R}^{3a}$ and $\mathbf{R}^{3b}$ is H.

[10] In some embodiments, the compound has formula (I-A), (I-AA), or (I-AB), ring A is a saturated or unsaturated bicyclic or tricyclic ring that includes from 6-14 (e.g.,
 10 8-10) ring atoms, $\mathbf{L}$ has formula (VIII): $-(\text{CH}_2)_m\text{-X}^1\text{-(CH}_2)_n\text{-X}^2\text{-(CH}_2)_p\text{-}$, and $\mathbf{W}$ is represented by formula (X), (XII), (XIII), (XIV), (XIV-A), (XIV-B), or any of SEQ ID 1-27 (e.g., SEQ ID 5-27, e.g., SEQ ID 6). In certain embodiments, one, two, or three of $\mathbf{R}^1$, $\mathbf{R}^2$, and $\mathbf{R}^4$ are H. In certain embodiments, $\mathbf{R}^3$ is -C(O)OH. In certain embodiments, $\mathbf{a}$ is 0, 1, or 2 (e.g., 1). In certain embodiments, $\mathbf{R}^5$ has formula (XI). In certain embodiments,
 15 each of $\mathbf{R}^1$, $\mathbf{R}^2$, and $\mathbf{R}^4$ is H, $\mathbf{a}$ is 0, 1, or 2 (e.g., 1), $\mathbf{R}^3$ is -C(O)OH, and $\mathbf{R}^5$ has formula (XI).

[10A] In some embodiments, the compound has formula (IA-A), (IA-AA), or (IA-AB), ring A is a saturated or unsaturated bicyclic or tricyclic ring that includes from 6-14
 20 (e.g., 8-10) ring atoms, $\mathbf{L}$ has formula (VIII): $-(\text{CH}_2)_m\text{-X}^1\text{-(CH}_2)_n\text{-X}^2\text{-(CH}_2)_p\text{-}$, and $\mathbf{W}$ is represented by formula (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-B), (XV), or any of SEQ ID 1-34 (e.g., SEQ. ID 5-27; e.g., SEQ ID 5-29; (e.g., SEQ ID 6); e.g., SEQ ID 28-29; e.g., SEQ ID 30-34). In certain embodiments, one, two, or three of $\mathbf{R}^1$, $\mathbf{R}^2$, and $\mathbf{R}^4$ are H. In certain embodiments, $\mathbf{R}^3$ is -C(O)OH. In certain embodiments, $\mathbf{a}$ is 0, 1, or 2
 25 (e.g., 1). In certain embodiments, $\mathbf{R}^5$ has formula (XI). In certain embodiments, each of $\mathbf{R}^1$, $\mathbf{R}^2$, and $\mathbf{R}^4$ is H, $\mathbf{a}$ is 0, 1, or 2 (e.g., 1), $\mathbf{R}^3$ is -C(O)OH, and $\mathbf{R}^5$ has formula (XI). In certain embodiments, $\mathbf{a}^*$ is 1; each of $\mathbf{R}^{3a}$ and $\mathbf{R}^{3b}$ is H.

[11] In some embodiments:
 30 the compound has formula (I-A), (I-AA), or (I-AB);

ring A is a saturated monocyclic ring that includes from 3-8 (e.g., 4-8, 4-7, 5-6) ring atoms;

L has formula (VIII): $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$,

W is represented by formula (X), (XII), (XIII), (XIV), (XIV-A), (XIV-B), or any of SEQ ID 1-27 (e.g., SEQ ID 5-27, e.g., SEQ ID 6); and

m is 2-6 (e.g., 2), **X¹** is $-N(R')C(O)-$ (e.g., $-N(H)C(O)-$), and **n + p** = 2 (e.g., each of **n** and **p** is 1), and **X²** is $-S-$; or

m is 2-6 (e.g., 2), **X¹** is $-N(R')C(O)-$ (e.g., $-N(H)C(O)-$), **n + p** = 0, **X²** is $-C(Q^1)(Q^2)-$, and **Q¹** and **Q²**, together with the carbon atom to which each is attached forms C₃₋₆ cycloalkyl that is optionally substituted with from 1-4 independently selected **R^d** and optionally fused to phenyl; or

m is 2-6 (e.g., 2), **X¹** is $-N(R')C(O)-$ (e.g., $-N(H)C(O)-$), **n + p** = 0, **X²** is $-C(Q^1)(Q^2)-$, and **Q¹** and **Q²** is an independently selected C₁₋₄ alkyl (e.g., CH₃); or

m is 2-6 (e.g., 2), **X¹** is $-N(R')C(O)-$ (e.g., $-N(H)C(O)-$), **n + p** = 0, and **X²** is: (v) C₆₋₁₀ arylene (e.g., phenylene) optionally substituted with from 1-5 independently selected **R^c**; or (vii) C₃₋₁₀ cycloalkylene optionally substituted with from 1-4 independently selected **R^d**.

In certain embodiments, one, two, or three of **R¹**, **R²**, and **R⁴** are H. In certain embodiments, **R³** is $-C(O)OH$. In certain embodiments, **a** is 0, 1, or 2 (e.g., 1). In certain embodiments, **R⁵** has formula (XI). In certain embodiments, each of **R¹**, **R²**, and **R⁴** is H, **a** is 0, 1, or 2 (e.g., 1), **R³** is $-C(O)OH$, and **R⁵** has formula (XI).

In certain of these embodiments, **m** is 2-6 (e.g., 2), **X¹** is $-N(R')C(O)-$ (e.g., $-N(H)C(O)-$), and **n + p** = 2 (e.g., each of **n** and **p** is 1), and **X²** is $-S-$. For example, **L** can be $-CH_2CH_2NHC(O)CH_2SCH_2-$.

In certain of these embodiments, any one of SEQ ID 5-27 (e.g., SEQ ID 6) represents **W**.

[11A] In some embodiments:

the compound has formula (IA-A), (IA-AA), or (IA-AB);

ring A is a saturated monocyclic ring that includes from 3-8 (e.g., 4-8, 4-7, 5-6) ring atoms;

L has formula (VIII): $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$, and

W is represented by formula (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-B), (XV), or any of SEQ ID 1-34 (e.g., SEQ. ID 5-27; e.g., SEQ ID 5-29; (e.g., SEQ ID 6); e.g., SEQ ID 28-29; e.g., SEQ ID 30-34).

In certain embodiments, **m** is 2-6 (e.g., 2), **X¹** is $-N(R')C(O)-$ (e.g., $-N(H)C(O)-$), and **n + p** = 2 (e.g., each of **n** and **p** is 1), and **X²** is $-S-$; or

m is 2-6 (e.g., 2), **X¹** is $-N(R')C(O)-$ (e.g., $-N(H)C(O)-$), **n + p** = 0, **X²** is $-C(Q^1)(Q^2)-$, and **Q¹** and **Q²**, together with the carbon atom to which each is attached forms C₃₋₆ cycloalkyl that is optionally substituted with from 1-4 independently selected **R^d** and optionally fused to phenyl; or

m is 2-6 (e.g., 2), **X¹** is $-N(R')C(O)-$ (e.g., $-N(H)C(O)-$), **n + p** = 0, **X²** is $-C(Q^1)(Q^2)-$, and **Q¹** and **Q²** is an independently selected C₁₋₄ alkyl (e.g., CH₃); or

m is 2-6 (e.g., 2), **X¹** is $-N(R')C(O)-$ (e.g., $-N(H)C(O)-$), **n + p** = 0, and **X²** is: (v) C₆₋₁₀ arylene (e.g., phenylene) optionally substituted with from 1-5 independently selected **R^c**; or (vii) C₃₋₁₀ cycloalkylene optionally substituted with from 1-4 independently selected **R^d**.

In certain embodiments, **m** is 2-6 (e.g., 2), **X¹** is $-N(R')C(O)-$ (e.g., $-N(H)C(O)-$), **n + p** = 0, and **X²** is: heterocycloalkylene including from 4-6 (e.g., 4) ring atoms, wherein from 1-3 (e.g., 1) ring atoms are each independently selected from the group consisting of N(**R^a**), O, and S; and which is optionally substituted with from 1-5 independently selected **R^d** (e.g., **X²** can be .

In certain embodiments, one, two, or three of **R¹**, **R²**, and **R⁴** are H. In certain embodiments, **R³** is $-C(O)OH$. In certain embodiments, **a** is 0, 1, or 2 (e.g., 1). In certain embodiments, **R⁵** has formula (XI). In certain embodiments, each of **R¹**, **R²**, and **R⁴** is H, **a** is 0, 1, or 2 (e.g., 1), **R³** is $-C(O)OH$, and **R⁵** has formula (XI). In certain embodiments, **a'** is 1; each of **R^{3a}** and **R^{3b}** is H.

In certain of these embodiments, **m** is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), and **n + p = 2** (e.g., each of **n** and **p** is 1), and **X²** is -S-. For example, **L** can be -CH₂CH₂NHC(O)CH₂SCH₂-.

5 In certain of these embodiments, any one of SEQ ID 5-34 (e.g., SEQ ID 6) represents **W**.

[12] In some embodiments:

the compound has formula (I-A), (I-AA), or (I-AB);

10 ring A is a saturated, monocyclic, 6-membered ring having formula (III) (i.e., **A¹** is not a bond);

L has formula (VIII): -(CH₂)_m-**X¹**-(CH₂)_n-**X²**-(CH₂)_p-;

W is represented by formula (X), (XII), (XIII), (XIV), (XIV-A), (XIV-B), or any of SEQ ID 1-27 (e.g., SEQ ID 5-27, e.g., SEQ ID 6); and

15 **m** is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), and **n + p = 2** (e.g., each of **n** and **p** is 1), and **X²** is -S-; or

m is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), **n + p = 0**, **X²** is -C(Q¹)(Q²)-, and **Q¹** and **Q²**, together with the carbon atom to which each is attached forms C₃₋₆ cycloalkyl that is optionally substituted with from 1-4 independently selected **R^d** and optionally fused to phenyl; or

m is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), **n + p = 0**, **X²** is -C(Q¹)(Q²)-, and **Q¹** and **Q²** is an independently selected C₁₋₄ alkyl (e.g., CH₃); or

m is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), **n + p = 0**, and **X²** is: (v) C₆₋₁₀ arylene (e.g., phenylene) optionally substituted with from 1-5 independently selected **R^c**; or (vii) C₃₋₁₀ cycloalkylene optionally substituted with from 1-4 independently selected **R^d**.

In certain embodiments, one, two, or three of **R¹**, **R²**, and **R⁴** are H. In certain embodiments, **R³** is -C(O)OH. In certain embodiments, **a** is 0, 1, or 2 (e.g., 1). In certain

embodiments, R^5 has formula (XI). In certain embodiments, each of R^1 , R^2 , and R^4 is H, a is 0, 1, or 2 (e.g., 1), R^3 is $-C(O)OH$, and R^5 has formula (XI).

In certain of these embodiments, m is 2-6 (e.g., 2), X^1 is $-N(R')C(O)-$ (e.g., $-N(H)C(O)-$), and $n + p = 2$ (e.g., each of n and p is 1), and X^2 is $-S-$. For example, L can be $-CH_2CH_2NHC(O)CH_2SCH_2-$.

In certain of these embodiments, any one of SEQ ID 5-27 (e.g., SEQ ID 6) represents W .

In certain formula (III), 6-membered ring embodiments, A_1 , A_2 , A_3 and A_4 are each independently selected from the group consisting of CH_2 , CHR^b , or $C(R^b)_2$.

In certain formula (III), 6-membered ring embodiments, one or two (e.g., one) of A_1 , A_2 , A_3 and A_4 are independently selected from the group consisting of CHR^b and $C(R^b)_2$, and the others are CH_2 .

In certain formula (III), 6-membered ring embodiments, A_1 , A_2 , A_3 and A_4 are each CH_2 .

In certain formula (III), 6-membered ring embodiments, A_1 , A_2 and A_4 are each independently selected from the group consisting of CH_2 , CHR^b , and $C(R^b)_2$; and A_3 is O; S; SO_2 ; or $N(R^a)$. In certain of these embodiments, one or two (e.g., one) of A_2 and A_4 are independently selected from the group consisting of CHR^b and $C(R^b)_2$, and the other (where applicable) is CH_2 . In other embodiments, A_2 and A_3 are both CH_2 . In certain of these embodiments, A_1 is CH_2 . In certain of these embodiments, A_3 is $N(R^a)$ (e.g., A_3 can be NH). In other embodiments, A_3 is O. In still other embodiments, A_3 is SO_2 .

In certain formula (III), 6-membered ring embodiments, A_1 , A_2 and A_3 are each independently selected from the group consisting of CH_2 , CHR^b , and $C(R^b)_2$; and A_4 is O; S; or $N(R^a)$. In certain of these embodiments, one or two (e.g., one) of A_2 and A_4 are independently selected from the group consisting of CHR^b and $C(R^b)_2$, and the other (where applicable) is CH_2 . In other embodiments, A_2 and A_3 are both CH_2 . In certain of these embodiments, A_1 is CH_2 . In certain of these embodiments, A_4 is $N(R^a)$ (e.g., A_4 can be NH). In other embodiments, A_4 is O.

In certain formula (III), 6-membered ring embodiments, A_1 is $C(O)$; and A_2 , A_3 and A_4 are each independently selected from the group consisting of CH_2 , CHR^b , or $C(R^b)_2$. In

certain of these embodiments, one or two (e.g., one) of **A**₂, **A**₃ and **A**₄ are independently selected from the group consisting of CHR^b and C(R^b)₂, and the other(s) is/are CH₂.

In certain formula (III), 6-membered ring embodiments, **A**₁ is C(O); and **A**₂, **A**₃ and **A**₄ are each CH₂.

5 In certain formula (III), 6-membered ring embodiments, **A**₁ is C(O); **A**₂ and **A**₄ are each independently selected from the group consisting of CH₂, CHR^b, and C(R^b)₂; and **A**₃ is O; S; SO₂; or N(R^a). In certain of these embodiments, one or two (e.g., one) of **A**₂ and **A**₄ are independently selected from the group consisting of CHR^b and C(R^b)₂, and the other (where applicable) is CH₂. In other embodiments, **A**₂ and **A**₄ are both CH₂. In certain of
10 these embodiments, **A**₃ is N(R^a) (e.g., **A**₃ can be NH). In other embodiments, **A**₃ is O. In still other embodiments, **A**₃ is SO₂.

In certain formula (III), 6-membered ring embodiments, **A**₁ is C(O); **A**₂ and **A**₃ are each independently selected from the group consisting of CH₂, CHR^b, and C(R^b)₂; and **A**₄ is O; S; or N(R^a). In certain of these embodiments, one or two (e.g., one) of **A**₂ and **A**₃ are
15 independently selected from the group consisting of CHR^b and C(R^b)₂, and the other (where applicable) is CH₂. In other embodiments, **A**₂ and **A**₃ are both CH₂. In certain of these embodiments, **A**₄ is N(R^a) (e.g., **A**₄ can be NH). In other embodiments, **A**₄ is O. In certain formula (III), 6-membered ring embodiments, **A**₁, **A**₂, **A**₃ and **A**₄ are each independently selected from the group consisting of CH₂, CHR^b, or C(R^b)₂.

20

[12A] In some embodiments:

the compound has formula (IA-A), (IA-AA), or (IA-AB);

ring A is a saturated, monocyclic, 6-membered ring having formula (III) (i.e., **A**¹ is not a bond);

25 **L** has formula (VIII): -(CH₂)_m-X¹-(CH₂)_n-X²-(CH₂)_p-; and

W is represented by formula (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-B), (XV), or any of SEQ ID 1-34 (e.g., SEQ. ID 5-27; e.g., SEQ ID 5-29; (e.g., SEQ ID 6); e.g., SEQ ID 28-29; e.g., SEQ ID 30-34).

In certain embodiments, **m** is 2-6 (e.g., 2), **X**¹ is -N(R')C(O)- (e.g., -N(H)C(O)-),
30 and **n** + **p** = 2 (e.g., each of **n** and **p** is 1), and **X**² is -S-; or

m is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), **n + p = 0**, **X²** is -C(Q¹)(Q²)-, and **Q¹** and **Q²**, together with the carbon atom to which each is attached forms C₃₋₆ cycloalkyl that is optionally substituted with from 1-4 independently selected **R^d** and optionally fused to phenyl; or

5 **m** is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), **n + p = 0**, **X²** is -C(Q¹)(Q²)-, and **Q¹** and **Q²** is an independently selected C₁₋₄ alkyl (e.g., CH₃); or

m is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), **n + p = 0**, and **X²** is: (v) C₆₋₁₀ arylene (e.g., phenylene) optionally substituted with from 1-5 independently selected **R^c**; or (vii) C₃₋₁₀ cycloalkylene optionally substituted with from 1-4 independently selected **R^d**.

10 In certain embodiments, **m** is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), **n + p = 0**, and **X²** is: heterocycloalkylene including from 4-6 (e.g., 4) ring atoms, wherein from 1-3 (e.g., 1) ring atoms are each independently selected from the group consisting of N(**R^a**), O, and S; and which is optionally substituted with from 1-5 independently selected

15 **R^d** (e.g., **X²** can be ).

In certain embodiments, one, two, or three of **R¹**, **R²**, and **R⁴** are H. In certain embodiments, **R³** is -C(O)OH. In certain embodiments, **a** is 0, 1, or 2 (e.g., 1). In certain embodiments, **R⁵** has formula (XI). In certain embodiments, each of **R¹**, **R²**, and **R⁴** is H, **a** is 0, 1, or 2 (e.g., 1), **R³** is -C(O)OH, and **R⁵** has formula (XI). In certain embodiments, **a'** is 1; each of **R^{3a}** and **R^{3b}** is H.

20 In certain of these embodiments, **m** is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), and **n + p = 2** (e.g., each of **n** and **p** is 1), and **X²** is -S-. For example, **L** can be -CH₂CH₂NHC(O)CH₂SCH₂-.

25 In certain of these embodiments, any one of SEQ ID 5-34 (e.g., SEQ ID 6) represents **W**.

In certain formula (III), 6-membered ring embodiments, **A₁**, **A₂**, **A₃** and **A₄** are each independently selected from the group consisting of CH₂, CHR^b, or C(R^b)₂.

In certain formula (III), 6-membered ring embodiments, one or two (e.g., one) of **A**₁, **A**₂, **A**₃ and **A**₄ are independently selected from the group consisting of CHR^b and C(R^b)₂, and the others are CH₂.

5 In certain formula (III), 6-membered ring embodiments, **A**₁, **A**₂, **A**₃ and **A**₄ are each CH₂.

In certain formula (III), 6-membered ring embodiments, **A**₁, **A**₂ and **A**₄ are each independently selected from the group consisting of CH₂, CHR^b, and C(R^b)₂; and **A**₃ is O; S; SO₂; or N(R^a). In certain of these embodiments, one or two (e.g., one) of **A**₂ and **A**₄ are independently selected from the group consisting of CHR^b and C(R^b)₂, and the other (where
10 applicable) is CH₂. In other embodiments, **A**₂ and **A**₃ are both CH₂. In certain of these embodiments, **A**₁ is CH₂. In certain of these embodiments, **A**₃ is N(R^a) (e.g., **A**₃ can be NH). In other embodiments, **A**₃ is O. In still other embodiments, **A**₃ is SO₂.

In certain formula (III), 6-membered ring embodiments, **A**₁, **A**₂ and **A**₃ are each independently selected from the group consisting of CH₂, CHR^b, and C(R^b)₂; and **A**₄ is O;
15 S; or N(R^a). In certain of these embodiments, one or two (e.g., one) of **A**₂ and **A**₄ are independently selected from the group consisting of CHR^b and C(R^b)₂, and the other (where applicable) is CH₂. In other embodiments, **A**₂ and **A**₃ are both CH₂. In certain of these embodiments, **A**₁ is CH₂. In certain of these embodiments, **A**₄ is N(R^a) (e.g., **A**₄ can be NH). In other embodiments, **A**₄ is O.

20 In certain formula (III), 6-membered ring embodiments, **A**₁ is C(O); and **A**₂, **A**₃ and **A**₄ are each independently selected from the group consisting of CH₂, CHR^b, or C(R^b)₂. In certain of these embodiments, one or two (e.g., one) of **A**₂, **A**₃ and **A**₄ are independently selected from the group consisting of CHR^b and C(R^b)₂, and the other(s) is/are CH₂.

In certain formula (III), 6-membered ring embodiments, **A**₁ is C(O); and **A**₂, **A**₃ and
25 **A**₄ are each CH₂.

In certain formula (III), 6-membered ring embodiments, **A**₁ is C(O); **A**₂ and **A**₄ are each independently selected from the group consisting of CH₂, CHR^b, and C(R^b)₂; and **A**₃ is O; S; SO₂; or N(R^a). In certain of these embodiments, one or two (e.g., one) of **A**₂ and **A**₄ are independently selected from the group consisting of CHR^b and C(R^b)₂, and the other
30 (where applicable) is CH₂. In other embodiments, **A**₂ and **A**₄ are both CH₂. In certain of

these embodiments, **A₃** is **N(R^a)** (e.g., **A₃** can be NH). In other embodiments, **A₃** is O. In still other embodiments, **A₃** is SO₂.

In certain formula (III), 6-membered ring embodiments, **A₁** is C(O); **A₂** and **A₃** are each independently selected from the group consisting of CH₂, CHR^b, and C(R^b)₂; and **A₄** is O; S; or N(R^a). In certain of these embodiments, one or two (e.g., one) of **A₂** and **A₃** are independently selected from the group consisting of CHR^b and C(R^b)₂, and the other (where applicable) is CH₂. In other embodiments, **A₂** and **A₃** are both CH₂. In certain of these embodiments, **A₄** is N(R^a) (e.g., **A₄** can be NH). In other embodiments, **A₄** is O. In certain formula (III), 6-membered ring embodiments, **A₁**, **A₂**, **A₃** and **A₄** are each independently selected from the group consisting of CH₂, CHR^b, or C(R^b)₂.

[13] In some embodiments:

the compound has formula (IA-A), (IA-AA), or (IA-AB);

ring A is a saturated, monocyclic, 5-membered ring having formula (III-A) (i.e., **A¹** in formula (III) is a bond);

L has formula (VIII): -(CH₂)_m-**X¹**-(CH₂)_n-**X²**-(CH₂)_p-,

W is represented by formula (X), (XII), (XIII), (XIV), (XIV-A), (XIV-B), or any of SEQ ID 1-27 (e.g., SEQ ID 5-27, e.g., SEQ ID 6); and

m is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), and **n + p = 2** (e.g., each of **n** and **p** is 1), and **X²** is -S-; or

m is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), **n + p = 0**, **X²** is -C(Q¹)(Q²)-, and **Q¹** and **Q²**, together with the carbon atom to which each is attached forms C₃₋₆ cycloalkyl that is optionally substituted with from 1-4 independently selected **R^d** and optionally fused to phenyl; or

m is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), **n + p = 0**, **X²** is -C(Q¹)(Q²)-, and **Q¹** and **Q²** is an independently selected C₁₋₄ alkyl (e.g., CH₃); or

m is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), **n + p = 0**, and **X²** is: (v) C₆₋₁₀ arylene (e.g., phenylene) optionally substituted with from 1-5 independently selected

R^c ; or (vii) C_{3-10} cycloalkylene optionally substituted with from 1-4 independently selected R^d .

In certain embodiments, one, two, or three of R^1 , R^2 , and R^4 are H. In certain
 5 embodiments, R^3 is $-C(O)OH$. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain
 embodiments, R^5 has formula (XI). In certain embodiments, each of R^1 , R^2 , and R^4 is H,
 a is 0, 1, or 2 (e.g., 1), R^3 is $-C(O)OH$, and R^5 has formula (XI).

In certain of these embodiments, m is 2-6 (e.g., 2), X^1 is $-N(R')C(O)-$ (e.g., $-$
 $N(H)C(O)-$), and $n + p = 2$ (e.g., each of n and p is 1), and X^2 is $-S-$. For example, L can
 10 be $-CH_2CH_2NHC(O)CH_2SCH_2-$.

In certain of these embodiments, any one of SEQ ID 5-27 (e.g., SEQ ID 6)
 represents W .

[13A] In some embodiments:
 15 the compound has formula (IA-A), (IA-AA), or (IA-AB);
 ring A is a saturated, monocyclic, 5-membered ring having formula (III-A) (i.e., A^1
 in formula (III) is a bond);

L has formula (VIII): $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$, and


W is represented by formula (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-
 20 B), (XV), or any of SEQ ID 1-34 (e.g., SEQ. ID 5-27; e.g., SEQ ID 5-29; (e.g., SEQ ID
 6); e.g., SEQ ID 28-29; e.g., SEQ ID 30-34).

In certain embodiments, m is 2-6 (e.g., 2), X^1 is $-N(R')C(O)-$ (e.g., $-N(H)C(O)-$),
 and $n + p = 2$ (e.g., each of n and p is 1), and X^2 is $-S-$; or

m is 2-6 (e.g., 2), X^1 is $-N(R')C(O)-$ (e.g., $-N(H)C(O)-$), $n + p = 0$, X^2 is $-C(Q^1)(Q^2)-$
 25 , and Q^1 and Q^2 , together with the carbon atom to which each is attached forms C_{3-6}
 cycloalkyl that is optionally substituted with from 1-4 independently selected R^d and
 optionally fused to phenyl; or

m is 2-6 (e.g., 2), X^1 is $-N(R')C(O)-$ (e.g., $-N(H)C(O)-$), $n + p = 0$, X^2 is $-C(Q^1)(Q^2)-$
 , and Q^1 and Q^2 is an independently selected C_{1-4} alkyl (e.g., CH_3); or

m is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), **n + p = 0**, and **X²** is: (v) C₆₋₁₀ arylene (e.g., phenylene) optionally substituted with from 1-5 independently selected **R^c**; or (vii) C₃₋₁₀ cycloalkylene optionally substituted with from 1-4 independently selected **R^d**.

5 In certain embodiments, **m** is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), **n + p = 0**, and **X²** is: heterocycloalkylene including from 4-6 (e.g., 4) ring atoms, wherein from 1-3 (e.g., 1) ring atoms are each independently selected from the group consisting of N(**R^a**), O, and S; and which is optionally substituted with from 1-5 independently selected **R^d** (e.g., **X²** can be ).

10 In certain embodiments, one, two, or three of **R¹**, **R²**, and **R⁴** are H. In certain embodiments, **R³** is -C(O)OH. In certain embodiments, **a** is 0, 1, or 2 (e.g., 1). In certain embodiments, **R⁵** has formula (XI). In certain embodiments, each of **R¹**, **R²**, and **R⁴** is H, **a** is 0, 1, or 2 (e.g., 1), **R³** is -C(O)OH, and **R⁵** has formula (XI). In certain embodiments, **a'** is 1; each of **R^{3a}** and **R^{3b}** is H.

15 In certain of these embodiments, **m** is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), and **n + p = 2** (e.g., each of **n** and **p** is 1), and **X²** is -S-. For example, **L** can be -CH₂CH₂NHC(O)CH₂SCH₂-.

In certain of these embodiments, any one of SEQ ID 5-34 (e.g., SEQ ID 6) represents **W**.

20

Embodiments of combinations [1]-[13] can also include any one or more of the features delineated in the Detailed Descriptions and/or claims.

Embodiments of combinations [1A]-[13A] can also include any one or more of the features delineated in the Detailed Descriptions and/or claims.

25

The skilled artisan will recognize that some chemical structures described herein may be represented on paper by one or more other resonance forms; or may exist in one or more other tautomeric forms, even when kinetically, the artisan recognizes that such tautomeric forms represent only a very small portion of a sample of such compound(s).

Such compounds are contemplated within the scope of this disclosure, though such resonance forms or tautomers are not explicitly represented herein.

Pharmaceutical Compositions and Administration

General

In some embodiments, a chemical entity (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulates (e.g., agonizes or partially agonizes or antagonizes) glucagon-like peptide-1 receptor ("GLP-1R") and/or the gastric inhibitory polypeptide receptor ("GIPR"), is administered as a pharmaceutical composition that includes the chemical entity and one or more pharmaceutically acceptable excipients, and optionally one or more additional therapeutic agents as described herein.

In some embodiments, the chemical entities can be administered in combination with one or more conventional pharmaceutical excipients. Pharmaceutically acceptable excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d- α -tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens, poloxamers or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, tris, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium-chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, and wool fat. Cyclodextrins such as α -, β -, and γ -cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl- β -cyclodextrins, or other solubilized derivatives can also be used to enhance delivery of compounds described herein. Dosage forms or compositions containing a chemical entity as described herein in the range of 0.005% to 100% with the balance made up from non-toxic excipient may be prepared. The contemplated

compositions may contain 0.001%-100% of a chemical entity provided herein, in one embodiment 0.1-95%, in another embodiment 75-85%, in a further embodiment 20-80%. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see *Remington: The Science and Practice of Pharmacy*,
5 22nd Edition (Pharmaceutical Press, London, UK. 2012).

Routes of Administration and Composition Components

In some embodiments, the chemical entities described herein or a pharmaceutical composition thereof can be administered to subject in need thereof by any accepted route
10 of administration. Acceptable routes of administration include, but are not limited to, buccal, cutaneous, endocervical, endosinusial, endotracheal, enteral, epidural, interstitial, intra-abdominal, intra-arterial, intrabronchial, intrabursal, intracerebral, intracisternal, intracoronary, intradermal, intraductal, intraduodenal, intradural, intraepidermal, intraesophageal, intragastric, intragingival, intraileal, intralymphatic, intramedullary,
15 intrameningeal, intramuscular, intraovarian, intraperitoneal, intraprostatic, intrapulmonary, intrasinal, intraspinal, intrasynovial, intratesticular, intrathecal, intratubular, intratumoral, intrauterine, intravascular, intravenous, nasal, nasogastric, oral, parenteral, percutaneous, peridural, rectal, respiratory (inhalation), subcutaneous, sublingual, submucosal, topical, transdermal, transmucosal, transtracheal, ureteral, urethral
20 and vaginal. In certain embodiments, a preferred route of administration is parenteral (e.g., intratumoral).

Compositions can be formulated for parenteral administration, e.g., formulated for injection via the intravenous, intramuscular, sub-cutaneous, or even intraperitoneal routes.
25 Typically, such compositions can be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for use to prepare solutions or suspensions upon the addition of a liquid prior to injection can also be prepared; and the preparations can also be emulsified. The preparation of such formulations will be known to those of skill in the art in light of the present disclosure.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil, or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In general, the form must be sterile and must be fluid to the extent that it may be easily injected. It also should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.

The carrier also can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion, and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques, which yield a powder of the active ingredient, plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Pharmacologically acceptable excipients usable in the rectal composition as a gel, cream, enema, or rectal suppository, include, without limitation, any one or more of cocoa

butter glycerides, synthetic polymers such as polyvinylpyrrolidone, PEG (like PEG ointments), glycerine, glycerinated gelatin, hydrogenated vegetable oils, poloxamers, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol Vaseline, anhydrous lanolin, shark liver oil, sodium saccharinate, menthol, sweet almond oil, sorbitol, sodium benzoate, anoxid SBN, vanilla essential oil, aerosol, parabens in phenoxyethanol, sodium methyl p-oxybenzoate, sodium propyl p-oxybenzoate, diethylamine, carbomers, carbopol, methoxybenzoate, macrogol cetostearyl ether, cocoyl caprylocaprate, isopropyl alcohol, propylene glycol, liquid paraffin, xanthan gum, carboxy-metabisulfite, sodium edetate, sodium benzoate, potassium metabisulfite, grapefruit seed extract, methyl sulfonyl methane (MSM) , lactic acid, glycine, vitamins, such as vitamin A and E and potassium acetate.

In certain embodiments, suppositories can be prepared by mixing the chemical entities described herein with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum and release the active compound. In other embodiments, compositions for rectal administration are in the form of an enema.

In other embodiments, the compounds described herein or a pharmaceutical composition thereof are suitable for local delivery to the digestive or GI tract by way of oral administration (e.g., solid or liquid dosage forms.).

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the chemical entity is mixed with one or more pharmaceutically acceptable excipients, such as sodium citrate or dicalcium phosphate and/or: a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents

such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

In one embodiment, the compositions will take the form of a unit dosage form such as a pill or tablet and thus the composition may contain, along with a chemical entity provided herein, a diluent such as lactose, sucrose, dicalcium phosphate, or the like; a lubricant such as magnesium stearate or the like; and a binder such as starch, gum acacia, polyvinylpyrrolidone, gelatin, cellulose, cellulose derivatives or the like. In another solid dosage form, a powder, granule, solution or suspension (*e.g.*, in propylene carbonate, vegetable oils, PEG's, poloxamer 124 or triglycerides) is encapsulated in a capsule (gelatin or cellulose base capsule). Unit dosage forms in which one or more chemical entities provided herein or additional active agents are physically separated are also contemplated; *e.g.*, capsules with granules (or tablets in a capsule) of each drug; two-layer tablets; two-compartment gel caps, etc. Enteric coated or delayed release oral dosage forms are also contemplated.

Other physiologically acceptable compounds include wetting agents, emulsifying agents, dispersing agents or preservatives that are particularly useful for preventing the growth or action of microorganisms. Various preservatives are well known and include, for example, phenol and ascorbic acid.

In certain embodiments the excipients are sterile and generally free of undesirable matter. These compositions can be sterilized by conventional, well-known sterilization techniques. For various oral dosage form excipients such as tablets and capsules, sterility is not required. The USP/NF standard is usually sufficient.

Ocular compositions can include, without limitation, one or more of any of the following: viscosogens (*e.g.*, Carboxymethylcellulose, Glycerin, Polyvinylpyrrolidone, Polyethylene glycol); Stabilizers (*e.g.*, Pluronic (triblock copolymers), Cyclodextrins);

Preservatives (e.g., Benzalkonium chloride, EDTA, SofZia (boric acid, propylene glycol, sorbitol, and zinc chloride; Alcon Laboratories, Inc.), Purite (stabilized oxychloro complex; Allergan, Inc.)).

Topical compositions can include ointments and creams. Ointments are semisolid preparations that are typically based on petrolatum or other petroleum derivatives. Creams containing the selected active agent are typically viscous liquid or semisolid emulsions, often either oil-in-water or water-in-oil. Cream bases are typically water-washable, and contain an oil phase, an emulsifier and an aqueous phase. The oil phase, also sometimes called the “internal” phase, is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol; the aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant. The emulsifier in a cream formulation is generally a nonionic, anionic, cationic or amphoteric surfactant. As with other carriers or vehicles, an ointment base should be inert, stable, nonirritating and non-sensitizing.

In any of the foregoing embodiments, pharmaceutical compositions described herein can include one or more one or more of the following: lipids, interbilayer crosslinked multilamellar vesicles, biodegradable poly(D,L-lactic-co-glycolic acid) [PLGA]-based or poly anhydride-based nanoparticles or microparticles, and nanoporous particle-supported lipid bilayers.

Dosages

The dosages may be varied depending on the requirement of the patient, the severity of the condition being treating and the particular compound being employed. Proper dosage for a particular situation can be determined by one skilled in the medical arts. In some cases, the total daily dosage may be divided and administered in portions throughout the day or by means providing continuous delivery.

In some embodiments, the compounds described herein are administered at a dosage of from about 0.0002 mg/Kg to about 100 mg/Kg (e.g., from about 0.0002 mg/Kg to about 50 mg/Kg; from about 0.0002 mg/Kg to about 25 mg/Kg; from about 0.0002

mg/Kg to about 10 mg/Kg; from about 0.0002 mg/Kg to about 5 mg/Kg; from about 0.0002 mg/Kg to about 1 mg/Kg; from about 0.0002 mg/Kg to about 0.5 mg/Kg; from about 0.0002 mg/Kg to about 0.1 mg/Kg; from about 0.001 mg/Kg to about 50 mg/Kg; from about 0.001 mg/Kg to about 25 mg/Kg; from about 0.001 mg/Kg to about 10 mg/Kg; from about 0.001 mg/Kg to about 5 mg/Kg; from about 0.001 mg/Kg to about 1 mg/Kg; from about 0.001 mg/Kg to about 0.5 mg/Kg; from about 0.001 mg/Kg to about 0.1 mg/Kg; from about 0.01 mg/Kg to about 50 mg/Kg; from about 0.01 mg/Kg to about 25 mg/Kg; from about 0.01 mg/Kg to about 10 mg/Kg; from about 0.01 mg/Kg to about 5 mg/Kg; from about 0.01 mg/Kg to about 1 mg/Kg; from about 0.01 mg/Kg to about 0.5 mg/Kg; from about 0.01 mg/Kg to about 0.1 mg/Kg; from about 0.1 mg/Kg to about 50 mg/Kg; from about 0.1 mg/Kg to about 25 mg/Kg; from about 0.1 mg/Kg to about 10 mg/Kg; from about 0.1 mg/Kg to about 5 mg/Kg; from about 0.1 mg/Kg to about 1 mg/Kg; from about 0.1 mg/Kg to about 0.5 mg/Kg).

Regimens

The foregoing dosages can be administered on a daily basis (e.g., as a single dose or as two or more divided doses) or non-daily basis (e.g., every other day, every two days, every three days, once weekly, twice weeks, once every two weeks, once a month).

In some embodiments, the period of administration of a compound described herein is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. In a further embodiment, a period of during which administration is stopped is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. In an embodiment, a therapeutic compound is administered to an individual for a period of time followed by a separate period of time. In another embodiment, a therapeutic compound is administered for a first period and a second period following the first period,

with administration stopped during the second period, followed by a third period where administration of the therapeutic compound is started and then a fourth period following the third period where administration is stopped. In an aspect of this embodiment, the period of administration of a therapeutic compound followed by a period where administration is stopped is repeated for a determined or undetermined period of time. In a further embodiment, a period of administration is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. In a further embodiment, a period of during which administration is stopped is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more.

Methods of Treatment

This disclosure features methods for treating a subject (e.g., a human) having a disease, disorder, or condition in which modulation of GLP-1R and/or GIPR activities (e.g., repressed or impaired and/or elevated or unwanted GLP-1R and/or GIPR signaling) is beneficial for the treatment of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In certain embodiments, the methods described herein can include or further include treating one or more conditions associated, co-morbid or sequela with any one or more of the conditions described herein.

In certain embodiments, the chemical entities described herein induce blood glucose reduction (e.g., reduce blood glucose levels), promote insulin synthesis, stimulate insulin secretion, increase the mass of β -cells, modulate gastric acid secretion, modulate gastric emptying, and/or decrease glucagon production. In certain embodiments, the chemical entities described herein stabilize serum glucose and serum insulin levels.

Indications

Obesity

In some embodiments, the condition, disease or disorder is obesity and conditions, diseases or disorders that are associated with obesity. Non-limiting examples of obesity and obesity related conditions include symptomatic obesity, simple obesity, childhood obesity, morbid obesity and abdominal obesity (central obesity characterized by abdominal adiposity). Non-limiting examples of symptomatic obesity include endocrine obesity (e.g., Cushing syndrome, hypothyroidism, insulinoma, obese type II diabetes, pseudohypoparathyroidism, hypogonadism), hypothalamic obesity, hereditary obesity (e.g., Prader-Willi syndrome, Laurence-Moon-Biedl syndrome), and drug-induced obesity (e.g., steroid, phenothiazine, insulin, sulfonylurea agent, or β -blocker-induced obesity).

In some embodiments, the condition, disease or disorder is associated with obesity. Examples of such conditions, disease or disorders include, without limitation, glucose tolerance disorders, diabetes (e.g., type 2 diabetes, obese diabetes), lipid metabolism abnormality, hyperlipidemia, hypertension, cardiac failure, hyperuricemia, gout, fatty liver (including non-alcoholic steatohepatitis (NASH)), coronary heart disease (e.g., myocardial infarction, angina pectoris), cerebral infarction (e.g., brain thrombosis, transient cerebral ischemic attack), bone or articular disease (e.g., knee osteoarthritis, hip osteoarthritis, spondylitis deformans, lumbago), sleep apnea syndrome, obesity hypoventilation syndrome (Pickwickian syndrome), menstrual disorder (e.g., abnormal menstrual cycle, abnormality of menstrual flow and cycle, amenorrhea, abnormal catamenial symptom), visceral obesity syndrome, and metabolic syndrome. In certain embodiments, the chemical entities described herein can be used to treat subjects exhibiting symptoms of both obesity and insulin deficiency.

Diabetes

In some embodiments, the condition, disease or disorder is diabetes. Non-limiting examples of diabetes include type 1 diabetes, type 2 diabetes (e.g., diet-treated type 2-diabetes, sulfonylurea-treated type 2-diabetes, a far-advanced stage type 2-diabetes, long-term insulin-treated type 2-diabetes), diabetes mellitus (e.g., non-insulin-dependent

diabetes mellitus, insulin-dependent diabetes mellitus), gestational diabetes, obese diabetes, autoimmune diabetes, and borderline type diabetes.

In some embodiments, the condition, disease or disorder is associated with diabetes (e.g., a complication of diabetes). Non-limiting examples of disorders associated with diabetes include obesity, obesity-related disorders, metabolic syndrome, neuropathy, nephropathy (e.g., diabetic nephropathy), retinopathy, diabetic cardiomyopathy, cataract, macroangiopathy, osteopenia, hyperosmolar diabetic coma, infectious disease (e.g., respiratory infection, urinary tract infection, gastrointestinal infection, dermal soft tissue infections, inferior limb infection), diabetic gangrene, xerostomia, hypacusis, cerebrovascular disorder, diabetic cachexia, delayed wound healing, diabetic dyslipidemia peripheral blood circulation disorder, cardiovascular risk factors. (e.g., coronary artery disease, peripheral artery disease, cerebrovascular disease, hypertension, and risk factors related to unmanaged cholesterol and/or lipid levels, and/or inflammation), NASH, bone fracture and cognitive dysfunction

Other non-limiting examples of disorders related to diabetes include pre-diabetes, hyperlipidemia (e.g., hypertriglyceridemia, hypercholesterolemia, high LDL-cholesterolemia, low HDL-cholesterolemia, postprandial hyperlipemia), metabolic syndrome (e.g., metabolic disorder where activation of GLP-1R is beneficial, metabolic syndrome X), hypertension, impaired glucose tolerance (IGT), insulin resistance, and sarcopenia.

In some embodiments, the condition, disease or disorder is diabetes and obesity (diabesity). In certain embodiments, the compounds described herein are also useful in improving the therapeutic effectiveness of metformin.

Disorders of Metabolically Important Tissues

In some embodiments, the condition, disease or disorder is a disorder of a metabolically important tissue.

In some embodiments, the condition, disease or disorder is a fatty liver disease. Fatty liver diseases include, but are not limited to, non-alcoholic fatty acid liver disease (NAFLD), steatohepatitis, non-alcoholic steatohepatitis (NASH), fatty liver disease

resulting from hepatitis, fatty liver disease resulting from obesity, fatty liver disease resulting from diabetes, fatty liver disease resulting from insulin resistance, fatty liver disease resulting from hypertriglyceridemia, Abetalipoproteinemia, glycogen storage diseases, Weber-Christian disease, Wolmans disease, acute fatty liver of pregnancy, and lipodystrophy.

Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of disease occurring in the absence of alcohol abuse and is typically characterized by the presence of steatosis (fat in the liver). NAFLD is believed to be linked to a variety of conditions, e.g., metabolic syndrome (including obesity, diabetes and hypertriglyceridemia) and insulin resistance. It can cause liver disease in adults and children and may ultimately lead to cirrhosis (Skelly et al., J Hepatol 2001; 35: 195-9; Chitturi et al., Hepatology 2002; 35(2):373-9). The severity of NAFLD ranges from the relatively benign isolated predominantly macrovesicular steatosis (i.e., nonalcoholic fatty liver or NAFL) to non-alcoholic steatohepatitis (NASH) (Angulo et al., J Gastroenterol Hepatol 2002; 17 Suppl:S186-90). In certain embodiments, the subject is a pediatric subject (e.g., 6-16 years old; or 6-12 years old; or 6-10 years old). In certain embodiments, the subject is an adult subject.

Other non-limiting examples of disorders in metabolically important tissues include joint disorders (e.g., osteoarthritis, secondary osteoarthritis), steatosis (e.g. in the liver); gall stones; gallbladder disorders; gastroesophageal reflux; sleep apnea; hepatitis; fatty liver; bone disorder characterized by altered bone metabolism, such as osteoporosis, including post-menopausal osteoporosis, poor bone strength, osteopenia, Paget's disease, osteolytic metastasis in cancer patients, osteodystrophy in liver disease and the altered bone metabolism caused by renal failure or haemodialysis, bone fracture, bone surgery, aging, pregnancy, protection against bone fractures, and malnutrition polycystic ovary syndrome; renal disease (e.g., chronic renal failure, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end-stage renal disease); muscular dystrophy, angina pectoris, acute or chronic diarrhea, testicular dysfunction, respiratory dysfunction, frailty, sexual dysfunction (e.g., erectile dysfunction) and geriatric syndrome. In certain embodiments, the chemical entities described herein can be used for treating surgical

trauma by improving recovery after surgery and/or by preventing the catabolic reaction caused by surgical trauma.

Cardiovascular Diseases

5 In some embodiments, the condition, disease or disorder is a cardiovascular disease. Non-limiting examples of cardiovascular disease include congestive heart failure, atherosclerosis, arteriosclerosis, coronary heart disease, or peripheral artery disease, stroke, coronary artery disease, congestive heart failure, coronary heart disease, hypertension, cardiac failure, cerebrovascular disorder (e.g., cerebral infarction), vascular dysfunction,
10 myocardial infarction, elevated blood pressure (e.g., 130/85 mm Hg or higher), and prothrombotic state (exemplified by high fibrinogen or plasminogen activator inhibitor in the blood).

Neurological Diseases

15 In some embodiments, the condition, disease or disorder is a neurological disorder (e.g., neurodegenerative disorder) or a psychiatric disorder. Non-limiting examples of neurological disorders include brain insulin resistance, mild cognitive impairment (MCI), Alzheimer's disease (AD), Parkinson's disease (PD), anxiety, dementia (e.g., senile dementia), traumatic brain injury, Huntington's chorea, tardive dyskinesia, hyperkinesia,
20 mania, Morbus Parkinson, steel-Richard syndrome, Down's syndrome, myasthenia gravis, nerve trauma, brain trauma, vascular amyloidosis, cerebral hemorrhage I with amyloidosis, brain inflammation, Friedrich's ataxia, acute confusion disorder, amyotrophic lateral sclerosis (ALS), glaucoma, and apoptosis-mediated degenerative diseases of the central nervous system (e.g., Creutzfeld-Jakob Disease, bovine spongiform encephalopathy (mad
25 cow disease), chronic wasting syndrome). See, e.g., US20060275288A1.

Non-limiting examples of psychiatric disorders include drug dependence/addiction (narcotics and amphetamines and attention deficit/hyperactivity disorder (ADHD)). The chemical entities described herein can be useful in improving behavioral response to addictive drugs, decreasing drug dependence, prevention drug abuse relapse, and relieving

anxiety caused by the absence of a given addictive substance. See, e.g., US20120021979A1.

5 In certain embodiments, the chemical entities described herein are useful in improving learning and memory by enhancing neuronal plasticity and facilitation of cellular differentiation, and also in preserving dopamine neurons and motor function in Morbus Parkinson.

Insulin-Related

10 In some embodiments, the condition, disease or disorder is impaired fasting glucose (IFG), impaired fasting glycemia (IFG), hyperglycemia, insulin resistance (impaired glucose homeostasis), hyperinsulinemia, elevated blood levels of fatty acids or glycerol, a hypoglycemic condition, insulin resistant syndrome, paresthesia caused by hyperinsulinemia, hyperlipidaemia, hypercholesteremia, impaired wound healing, leptin resistance, glucose intolerance, increased fasting glucose, dyslipidemia (e.g.,
15 hyperlipidemia, atherogenic dyslipidemia characterized by high triglycerides and low HDL cholesterol), glucagonoma, hyperuricacidemia, hypoglycemia (e.g., nighttime hypoglycemia), and concomitant comatose endpoint associated with insulin.

In certain embodiments, the chemical entities described herein can reduce or slow down the progression of borderline type, impaired fasting glucose or impaired fasting
20 glycemia into diabetes.

Autoimmune Disorders

In some embodiments, the condition, disease or disorder is an autoimmune disorder. Non-limiting examples of autoimmune disorders include multiple sclerosis,
25 experimental autoimmune encephalomyelitis, autoimmune disorder is associated with immune rejection, graft versus host disease, uveitis, optic neuropathies, optic neuritis, transverse myelitis, inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, myasthenia gravis, and Graves disease. See, e.g., US20120148586A1.

30

Stomach and Intestine-Related Disorders

In some embodiments, the condition, disease or disorder is a stomach or intestine related disorder. Non-limiting examples of these disorders include ulcers of any etiology (e.g. peptic ulcers, Zollinger-Ellison syndrome, drug-induced ulcers, ulcers related to infections or other pathogens), digestion disorders, malabsorption, short bowel syndrome, *cul-de-sac* syndrome, inflammatory bowel diseases (Crohn's disease and ulcerative colitis), celiac sprue, hypogammaglobulinemic sprue, chemotherapy and/or radiation therapy-induced mucositis and diarrhea, gastrointestinal inflammation, short bowel syndrome, colitis ulcerosa, gastric mucosal injury (e.g., gastric mucosal injury caused by aspirin), small intestinal mucosal injury, and cachexia (e.g., cancerous cachexia, tuberculous cachexia, cachexia associated with blood disease, cachexia associated with endocrine disease, cachexia associated with infectious disease, cachexia caused by acquired immunodeficiency syndrome).

Body Weight

In some embodiments, the chemical entities described herein can be used to reduce body weight (e.g., excess body weight), prevent body weight gain, induce weight loss, decrease body fat, or reduce food intake in a subject (e.g., a subject in need thereof). In certain embodiments, the weight increase in a subject may be attributed to excessive ingestion of food or unbalanced diets, or may be weight increase derived from a concomitant drug (e.g., insulin sensitizers having a PPAR γ agonist-like action, such as troglitazone, rosiglitazone, englitazone, ciglitazone, pioglitazone and the like). Alternatively, the weight increase may be weight increase before reaching obesity, or may be weight increase in an obese subject. The weight increase may also be medication-induced weight gain or weight gain subsequent to cessation of smoking.

In some embodiments, the condition, disease or disorder is an eating disorder, such as hyperphagia, binge eating, bulimia, or compulsive eating.

Inflammatory Diseases

In some embodiments, the condition, disease or disorder is an inflammatory disorder. Non-limiting examples of inflammatory disorders include chronic rheumatoid arthritis, spondylitis deformans, arthritis deformans, lumbago, gout, post-operational or post-traumatic inflammation, bloating, neuralgia, laryngopharyngitis, cystitis, pneumonia, pancreatitis, enteritis, inflammatory bowel disease (including inflammatory large bowel disease), inflammation in metabolically important tissues including liver, fat, pancreas, kidney and gut, and a proinflammatory state (e.g., elevated levels of proinflammatory cytokines or markers of inflammation-like C-reactive protein in the blood).

Cancer

In some embodiments, the condition, disease or disorder is cancer. Suitable examples of cancer include breast cancer (e.g., invasive ductal breast cancer, noninvasive ductal breast cancer, inflammatory breast cancer), prostate cancer (e.g., hormone-dependent prostate cancer, hormone-independent prostate cancer), pancreatic cancer (e.g., ductal pancreatic cancer), gastric cancer (e.g., papillary adenocarcinoma, mucous adenocarcinoma, adenosquamous carcinoma), lung cancer (e.g., non-small cell lung cancer, small-cell lung cancer, malignant mesothelioma), colon cancer (e.g., gastrointestinal stromal tumor), rectal cancer (e.g., gastrointestinal stromal tumor), colorectal cancer (e.g., familial colorectal cancer, hereditary non-polyposis colorectal cancer, gastrointestinal stromal tumor), small intestinal cancer (e.g., non-Hodgkin's lymphoma, gastrointestinal stromal tumor), esophageal cancer, duodenal cancer, tongue cancer, pharyngeal cancer (e.g., nasopharyngeal cancer, oropharynx cancer, hypopharyngeal cancer), salivary gland cancer, brain tumor (e.g., pineal astrocytoma, pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma), neurilemmoma, liver cancer (e.g., primary liver cancer, extrahepatic bile duct cancer), renal cancer (e.g., renal cell cancer, transitional cell cancer of the renal pelvis and ureter), bile duct cancer, endometrial cancer, uterine cervical cancer, ovarian cancer (e.g., epithelial ovarian cancer, extragonadal germ cell tumor, ovarian germ cell tumor, ovarian tumor of low malignant potential), bladder cancer, urethral cancer, skin cancer (e.g., intraocular (ocular) melanoma, Merkel cell carcinoma), hemangioma, malignant lymphoma, malignant melanoma, thyroid

cancer (e.g., medullary thyroid cancer), parathyroid cancer, nasal cavity cancer, sinus cancer, bone tumor (e.g., osteosarcoma, Ewing tumor, uterine sarcoma, soft tissue sarcoma), angiofibroma, sarcoma of the retina, penis cancer, testicular tumor, pediatric solid tumor (e.g., Wilms' tumor, childhood kidney tumor), Kaposi's sarcoma, Kaposi's
5 sarcoma caused by AIDS, tumor of maxillary sinus, fibrous histiocytoma, leiomyosarcoma, rhabdomyosarcoma, and leukemia (e.g., acute myeloid leukemia, acute lymphoblastic leukemia).

Combination Therapy

10 This disclosure contemplates both monotherapy regimens as well as combination therapy regimens.

In some embodiments, the methods described herein can further include administering one or more additional therapies (e.g., one or more additional therapeutic agents and/or one or more therapeutic regimens) in combination with administration of the
15 compounds described herein.

In some embodiments, the methods described herein include administering a compound described herein in combination with one or more of a diet therapy (e.g., diet therapy for diabetes), an exercise therapy, blood sugar monitoring, and diet modifications.

In some embodiments, the compound described herein can be administered in
20 combination with one or more of additional therapeutic agents.

Representative additional therapeutic agents include, but are not limited to, anti-obesity agents, therapeutic agents for diabetes, therapeutic agents for diabetic complications, therapeutic agents for hyperlipidemia, antihypertensive agents, diuretics, chemotherapeutics, immunotherapeutics, anti-inflammatory drugs, antithrombotic agents,
25 anti-oxidants, therapeutic agents for osteoporosis, vitamins, antidementia drugs, erectile dysfunction drugs, therapeutic drugs for urinary frequency or urinary incontinence, therapeutic agents for NAFLD, and therapeutic agents for dysuria.

In some embodiments, the one or more additional therapeutic agents include those useful, e.g., as anti-obesity agents. Non-limiting examples include:

- monoamine uptake inhibitors (e.g., tramadol, phentermine, sibutramine, mazindol, fluoxetine, tesofensine);
- serotonin 2C receptor agonists (e.g., lorcaserin);
- serotonin 6 receptor antagonists;
- 5 • histamine H3 receptor modulator;
- GABA modulator (e.g., topiramate), including GABA receptor agonists (e.g., gabapentin, pregabalin);
- neuropeptide Y antagonists (e.g., velneperit);
- cannabinoid receptor antagonists (e.g., rimonabant, taranabant);
- 10 • ghrelin antagonists;
- ghrelin receptor antagonists;
- ghrelin acylation enzyme inhibitors;
- opioid receptor antagonists (e.g., GSK-1521498);
- orexin receptor antagonists;
- 15 • melanocortin 4 receptor agonists;
- 11 β -hydroxysteroid dehydrogenase inhibitors (e.g., AZD-4017, BVT-3498, INCB-13739);
- pancreatic lipase inhibitors (e.g., orlistat, cetilistat);
- β 3 agonists (e.g., N-5984);
- 20 • diacylglycerol acyltransferase 1 (DGAT1) inhibitors;
- acetylCoA carboxylase (ACC) inhibitors;
- stearoyl-CoA desaturated enzyme inhibitors;
- microsomal triglyceride transfer protein inhibitors (e.g., R-256918);
- Na-glucose cotransporter 2 (SGLT-2) inhibitors (e.g., JNJ-28431754, dapagliflozin, AVE2268, TS-033, YM543, TA-7284, ASP1941, remogliflozin);
- 25 • NFK inhibitors (e.g., HE-3286);
- PPAR agonists (e.g., GFT-505, DRF-11605, gemfibrozil and fenofibrate);
- phosphotyrosine phosphatase inhibitors (e.g., sodium vanadate, trodusquemine);

- GPR119 agonists (e.g., PSN-821, MBX-2982, APD597);
 - glucokinase activators (e.g., piragliatin, AZD-1656, AZD6370, TTP-355, compounds described in W0006/112549, W0007/028135, W0008/047821, W0008/050821, W0008/136428 and W0008/156757);
 - 5 • leptin, leptin derivatives (e.g., metreleptin), leptin resistance improving drugs;
 - CNTF (ciliary neurotrophic factor);
 - BDNF (brain-derived neurotrophic factor);
 - cholecystokinin agonists, amylin preparations (e.g., pramlintide, AC-
 - 10 2307);
 - neuropeptide Y agonists (e.g., PYY3-36, derivatives of PYY3-36, obineptide, TM-30339, TM-30335);
 - oxyntomodulin (OXM) preparations;
 - appetite suppressants (e.g. ephedrine);
 - 15 • FGF21 preparations (e.g., animal FGF21 preparations extracted from the pancreas of bovine or swine; human FGF21 preparations genetically synthesized using Escherichia coli or yeast; fragments or derivatives of FGF21); and
 - anorexigenic agents (e.g., P-57).
- 20 In some embodiments, the one or more additional therapeutic agents include those useful, e.g., as anti-diabetic agents. Non-limiting examples include:
- insulin and insulin preparations (e.g., animal insulin preparations extracted from the pancreas of bovine or swine; human insulin preparations genetically synthesized using Escherichia coli or yeast; zinc insulin; protamine zinc insulin;
 - 25 fragment or derivative of insulin (e.g., INS- 1), oral insulin preparation, synthetic human insulin);
 - insulin sensitizers (e.g., pioglitazone or a salt thereof);
 - biguanides (e.g., metformin, buformin or a salt thereof (e.g., hydrochloride, fumarate, succinate));

- glucagon analogs (e.g., any of glucagon analogs described, e.g., in WO 2010/011439);
- agents which antagonize the actions of or reduce secretion of glucagon;
- sulfonylurea agents (e.g., chlorpropamide, tolazamide, gliclazide, glimepiride, tolbutamide, glibenclamide, gliclazide, acetohexamide, glyclopyramide, glybuzole, glyburide);
- thiazolidinedione agents (e.g. rosiglitazone or pioglitazone);
- α -glucosidase inhibitors (e.g., voglibose, acarbose, miglitol, emiglitate);
- insulin secretagogues, such as prandial glucose regulators (sometimes called "short-acting secretagogues"), e.g., meglitinides (e.g. repaglinide and nateglinide);
- cholinesterase inhibitors (e.g., donepezil, galantamine, rivastigmine, tacrine);
- NMDA receptor antagonists;
- dual GLP-1/GIP receptor agonists (e.g., LBT-2000, ZPD1-70);
- GLP-1R agonists (e.g., exenatide, liraglutide, albiglutide, dulaglutide, AVE-0010, S4P and Boc5); and
- dipeptidyl peptidase IV (DPP-4) inhibitors (e.g., vildagliptin, dutogliptin, gemigliptin, alogliptin, saxagliptin, sitagliptin, linagliptin, berberine, adogliptin, BI1356, GRC8200, MP-513, PF-00734200, PHX1149, SK-0403, ALS2-0426, TA-6666, TS-021, KRP-104, trelagliptin).

In some embodiments, the one or more additional therapeutic agents include those useful, e.g., for treating NAFL and NASH. Non-limiting examples include glycyrrhizin, schisandra extract, ascorbic acid, glutathione, silymarin, lipoic acid, and d-alpha-tocopherol, ascorbic acid, glutathione, vitamin B-complex, glitazones/thiazolidinediones (e.g., troglitazone, rosiglitazone, pioglitazone), metformin, cysteamine, sulfonylureas, alpha-glucosidase inhibitors, meglitinides, vitamin E, tetrahydrolipstatin, milk thistle protein, anti-virals, and anti-oxidants.

In some embodiments, the one or more additional therapeutic agents include those useful, e.g., for treating diabetic complications. Non-limiting examples include:

- aldose reductase inhibitors (e.g., tolrestat, epalrestat, zopolrestat, fidarestat, CT-112, ranirestat, lidorestat);
- 5 • neurotrophic factor and increasing agents thereof (e.g., NGF, NT-3, BDNF, neurotrophic production/secretion promoting agents described in WO01/14372 (e.g., 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole), compounds described in WO2004/039365);
- PKC inhibitors (e.g., ruboxistaurin mesylate);
- 10 • AGE inhibitors (e.g., ALT946, N-phenacylthiazolium bromide (ALT766), EXO-226, pyridorin, pyridoxamine);
- serotonin and noradrenalin reuptake inhibitors (e.g., duloxetine);
- sodium channel inhibitors (e.g., lacosamide);
- active oxygen scavengers (e.g., thiocetic acid);
- 15 • cerebral vasodilators (e.g., tiapuride, mexiletine);
- somatostatin receptor agonists (e.g., BIM23190); and
- apoptosis signal regulating kinase-1 (ASK-1) inhibitors.

In some embodiments, the one or more additional therapeutic agents include those useful, e.g., for treating hyperlipidemia. Non-limiting examples include:

- HMG-CoA reductase inhibitors (e.g., pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin, rosuvastatin, pitavastatin or a salt thereof (e.g., sodium salt, calcium salt));
- squalene synthase inhibitors (e.g., compounds described in WO97/10224, 25 e.g., N-[[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-acetic acid);
- fibrate compounds (e.g., bezafibrate, clofibrate, simfibrate, ciprofibrate);
- anion exchange resin (e.g., colestyramine);

- nicotinic acid drugs (e.g., nicomol, niceritrol, niaspan);
- phytosterols (e.g., soysterol, gamma oryzanol (γ -oryzanol));
- cholesterol absorption inhibitors (e.g., zechia);
- CETP inhibitors (e.g., dalcetrapib, anacetrapib); and
- 5 • ω -3 fatty acid preparations (e.g., ω -3-fatty acid ethyl esters 90).

In some embodiments, the one or more additional therapeutic agents include those useful, e.g., as anti-hypertensive agents. Non-limiting examples include:

- angiotensin converting enzyme inhibitors (e.g., captopril, enalapril,
10 delapril);
- angiotensin II antagonists (e.g., candesartan cilexetil, candesartan,
losartan, losartan potassium, eprosartan, valsartan, telmisartan, irbesartan,
tasosartan, olmesartan, olmesartan medoxomil, azilsartan, azilsartan medoxomil);
- calcium antagonists (e.g., manidipine, nifedipine, amlodipine, efonidipine,
15 nicardipine, cilnidipine); and
- β -blockers (e.g., metoprolol, atenolol, propranolol, carvedilol, pindolol).

In some embodiments, the one or more additional therapeutic agents include those useful, e.g., as diuretics. Non-limiting examples include:

- xanthine derivatives (e.g., theobromine sodium salicylate, theobromine
20 calcium salicylate);
- thiazide preparations (e.g., ethiazide, cyclopenthiazide,
trichloromethiazide, hydrochlorothiazide, hydroflumethiazide,
benzylhydrochlorothiazide, penfluthiazide, polythiazide, methyclothiazide);
- 25 • antialdosterone preparations (e.g., spironolactone, triamterene);
- carbonic anhydrase inhibitors (e.g., acetazolamide); and
- chlorobenzenesulfonamide agents (e.g., chlortalidone, mefruside,
indapamide).

In some embodiments, the one or more additional therapeutic agents include those useful, e.g., as immunotherapeutic agents. Non-limiting examples include: microbial or bacterial compounds (e.g., muramyl dipeptide derivative, picibanil); polysaccharides having immunoenhancing activity (e.g., lentinan, sizofiran, krestin); cytokines obtained by
5 genetic engineering approaches (e.g., interferon, interleukin (IL) such as IL-1, IL-2, IL-12); and colony-stimulating factors (e.g., granulocyte colony-stimulating factor, erythropoietin).

In some embodiments, the one or more additional therapeutic agents include those useful, e.g., as anti-thrombotic agents. Non-limiting examples include: heparins (e.g.,
10 heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium); warfarin (e.g., warfarin potassium); anti-thrombin drugs (e.g., aragatroban, dabigatran); FXa inhibitors (e.g., rivaroxaban, apixaban, edoxaban, YM150, compounds described in WO02/06234, WO2004/048363, WO2005/030740, WO2005/058823, and WO2005/113504);
15 thrombolytic agents (e.g., urokinase, tisokinase, alteplase, nateplase, monteplase, pamiteplase); and platelet aggregation inhibitors (e.g., ticlopidine hydrochloride, clopidogrel, prasugrel, E5555, SHC530348, cilostazol, ethyl icosapentate, beraprost sodium, sarpogrelate hydrochloride).

In some embodiments, the one or more additional therapeutic agents include those useful, e.g., for treating osteoporosis. Non-limiting examples include: alfacalcidol, calcitriol, elcatonin, calcitonin salmon, estriol, ipriflavone, pamidronate disodium,
20 alendronate sodium hydrate, incadronate disodium, and risedronate disodium. Suitable examples of vitamins include vitamin B1 and vitamin B12. Suitable examples of erectile dysfunction drugs include apomorphine and sildenafil citrate. Suitable examples of therapeutic agents for urinary frequency or urinary incontinence include flavorxate
25 hydrochloride, oxybutynin hydrochloride and propiverine hydrochloride. Suitable examples of therapeutic agents for dysuria include acetylcholine esterase inhibitors (e.g., distigmine). Suitable examples of anti-inflammatory agents include nonsteroidal anti-inflammatory drugs such as aspirin, acetaminophen, indomethacin.

30 Other additional therapeutic agents include:

- agents that modulate hepatic glucose balance (e.g., fructose 1,6-bisphosphatase inhibitors, glycogen phosphorylase inhibitors, glycogen synthase kinase inhibitors, glucokinase activators);
- agents designed to treat the complications of prolonged hyperglycemia, such as aldose reductase inhibitors (e.g. epalrestat and ranirestat);
- agents used to treat complications related to micro-angiopathies;
- anti-dyslipidemia agents, such as HMG-CoA reductase inhibitors (statins, e.g. rosuvastatin);
- cholesterol-lowering agents;
- bile acid sequestrants (e.g., cholestyramine);
- cholesterol absorption inhibitors (e.g. plant sterols such as phytosterols);
- cholesteryl ester transfer protein (CETP) inhibitors;
- inhibitors of the ileal bile acid transport system (IBAT inhibitors);
- bile acid binding resins;
- nicotinic acid (niacin) and analogues thereof;
- anti-oxidants, such as probucol;
- omega-3 fatty acids;
- antihypertensive agents, including adrenergic receptor antagonists, such as beta blockers (e.g. atenolol), alpha blockers (e.g. doxazosin), and mixed alpha/beta blockers (e.g. labetalol);
- adrenergic receptor agonists, including alpha-2 agonists (e.g. clonidine);
- angiotensin converting enzyme (ACE) inhibitors (e.g. lisinopril);
- calcium channel blockers, such as dihydropyridines (e.g. nifedipine), phenylalkylamines (e.g. verapamil), and benzothiazepines (e.g. diltiazem);
- angiotensin II receptor antagonists (e.g. candesartan);
- aldosterone receptor antagonists (e.g. eplerenone);
- centrally acting adrenergic drugs, such as central alpha agonists (e.g. clonidine);
- diuretic agents (e.g. furosemide);

- haemostasis modulators, including antithrombotics (e.g., activators of fibrinolysis), thrombin antagonists, factor VIIa inhibitors, anticoagulants (e.g., vitamin K antagonists such as warfarin), heparin and low molecular weight analogues thereof, factor Xa inhibitors, and direct thrombin inhibitors (e.g. argatroban);
- antiplatelet agents (e.g., cyclooxygenase inhibitors (e.g. aspirin));
- adenosine diphosphate (ADP) receptor inhibitors (e.g. clopidogrel);
- phosphodiesterase inhibitors (e.g. cilostazol);
- glycoprotein IIB/IIA inhibitors (e.g. tirofiban);
- adenosine reuptake inhibitors (e.g. dipyridamole);
- noradrenergic agents (e.g. phentermine);
- serotonergic agents (e.g. sibutramine);
- diacyl glycerolacyltransferase (DGAT) inhibitors;
- feeding behavior modifying agents;
- pyruvate dehydrogenase kinase (PDK) modulators;
- serotonin receptor modulators;
- monoamine transmission-modulating agents, such as selective serotonin reuptake inhibitors (SSRI) (e.g. fluoxetine), noradrenaline reuptake inhibitors (NARI), noradrenaline-serotonin reuptake inhibitors (SNRI), and monoamine oxidase inhibitors (MAOI) (e.g. toloxatone and amiflamine);
- compounds described in W0007/013694, WO2007/018314, WO2008/093639 and WO2008/099794;
- GPR40 agonists (e.g., fasiglifam or a hydrate thereof, compounds described in WO2004/041266, WO2004/106276, WO2005/063729, WO2005/063725, WO2005/087710, WO2005/095338, WO2007/013689 and WO2008/001931);
- SGLT1 inhibitors;
- adiponectin or agonist thereof;
- IKK inhibitors (e.g., AS-2868);

- somatostatin receptor agonists;
- ACC2 inhibitors;
- cachexia-ameliorating agents, such as a cyclooxygenase inhibitors (e.g., indomethacin), progesterone derivatives (e.g., megestrol acetate), glucocorticoids (e.g., dexamethasone), metoclopramide agents, tetrahydrocannabinol agents, agents for improving fat metabolism (e.g., eicosapentaenoic acid), growth hormones, IGF-1, antibodies against a cachexia-inducing factor TNF- α , LIF, IL-6, and oncostatin M;
- metabolism-modifying proteins or peptides such as glucokinase (GK), glucokinase regulatory protein (GKRP), uncoupling proteins 2 and 3 (UCP2 and UCP3), peroxisome proliferator-activated receptor α (PPAR α);
- MC4r agonists;
- insulin receptor agonist;
- PDE 5 inhibitors;
- glycation inhibitors (e.g., ALT-711);
- nerve regeneration-promoting drugs (e.g., Y-128, VX853, prosaptide);
- antidepressants (e.g., desipramine, amitriptyline, imipramine);
- antiepileptic drugs (e.g., lamotrigine, trileptal, keppra, zonegran, pregabalin, harkoseride, carbamazepine);
- antiarrhythmic drugs (e.g., mexiletine);
- acetylcholine receptor ligands (e.g., ABT-594);
- endothelin receptor antagonists (e.g., ABT-627);
- narcotic analgesics (e.g., morphine);
- $\alpha 2$ receptor agonists (e.g., clonidine);
- local analgesics (e.g., capsaicin);
- antianxiety drugs (e.g., benzothiazepine);
- phosphodiesterase inhibitors (e.g., sildenafil);
- dopamine receptor agonists (e.g., apomorphine);

- cytotoxic antibodies (e.g., T-cell receptor and IL-2 receptor-specific antibodies);
- B cell depleting therapies (e.g., anti-CD20 antibody (e.g., rituxan), i-BLyS antibody);
- 5 • drugs affecting T cell migration (e.g., anti-integrin alpha 4/beta 1 antibody (e.g., tysabri);
- drugs that act on immunophilins (e.g., cyclosporine, tacrolimus, sirolimus, rapamycin);
- interferons (e.g., IFN- β);
- 10 • immunomodulators (e.g., glatiramer);
- TNF-binding proteins (e.g., circulating receptors);
- immunosuppressants (e.g., mycophenolate); and
- metaglidase, AMG-131, balaglitazone, MBX-2044, rivoglitazone, aleglitazar, chiglitazar, lobeglitazone, PLX-204, PN-2034, GFT-505, THR-0921,
- 15 exenatide, exendin-4, memantine, midazolam, ketoconazole, ethyl icosapentate, clonidine, azosemide, isosorbide, ethacrynic acid, piretanide, bumetanide, etoposide.

20 In certain embodiments, the second therapeutic agent or regimen is administered to the subject prior to contacting with or administering the chemical entity (e.g., about one hour prior, or about 6 hours prior, or about 12 hours prior, or about 24 hours prior, or about 48 hours prior, or about 1 week prior, or about 1 month prior).

In other embodiments, the second therapeutic agent or regimen is administered to the subject at about the same time as contacting with or administering the chemical entity.

25 By way of example, the second therapeutic agent or regimen and the chemical entity are provided to the subject simultaneously in the same dosage form. As another example, the second therapeutic agent or regimen and the chemical entity are provided to the subject concurrently in separate dosage forms.

In still other embodiments, the second therapeutic agent or regimen is administered to the subject after contacting with or administering the chemical entity (e.g., about one

hour after, or about 6 hours after, or about 12 hours after, or about 24 hours after, or about 48 hours after, or about 1 week after, or about 1 month after).

Patient Selection

5 In some embodiments, the methods described herein further include the step of identifying a subject (e.g., a patient) in need of such treatment (e.g., by way of biopsy, endoscopy, or other conventional method known in the art).

Compound Preparation and Biological Assays

10 As can be appreciated by the skilled artisan, methods of synthesizing the compounds of the formulae herein will be evident to those of ordinary skill in the art. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic
15 Transformations, VCH Publishers (1989); T. W. Greene and R.G.M. Wuts, Protective Groups in Organic Synthesis, 2d. Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.

20 In some embodiments, intermediates useful for preparing the compounds described herein can be prepared using the chemistries delineated in any one or more of the following schemes and non-limiting examples.

A. Abbreviations:

25 AcOH = Acetic acid

BOP = (Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium
hexafluorophosphate

CDI = 1,1-carbonyldiimidazole

DCC = *N,N'*-dicyclohexylcarbodiimide

30 DCM = Dichloromethane





	DIAD = Diisopropylazodicarboxylate
	DIPEA = <i>N,N</i> -diisopropylethylamine
	DMAP = 4-Dimethylaminopyridine
	DMF = <i>N,N</i> -dimethylformamide
5	DMSO = Dimethylsulfoxide
	EDC = 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
	ESI-MS = Electrospray ionization mass spectrometry
	Et ₂ O = Diethyl ether
	EtOAc = EtOAc
10	EtOH = Ethanol
	HATU = 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate
	HOSu = <i>N</i> -hydroxysuccinimide
	HPLC = High performance liquid chromatography
15	LC-MS = Liquid chromatography-mass spectrometry
	MeCN = Acetonitrile
	MeOH = Methanol
	NMR = Nuclear magnetic resonance
	Proton sponge = 1,8-Bis(dimethylamino)naphthalene
20	TBAB = Tetrabutylammonium bromide
	TBAF = Tetrabutylammonium fluoride
	TBAI = Tetrabutylammonium iodide
	TBSCl = <i>tert</i> -Butyldimethylsilyl chloride
	TEA = Triethylamine
25	TFA = Trifluoroacetic acid
	TFAA = Trifluoroacetic anhydride
	THF = Tetrahydrofuran
	TIS = Triisopropylsilane
	TIPS = Triisopropylsilyl
30	T3P = Propylphosphonic anhydride

TLC = Thin layer chromatography

B. Peptide Sequences of compounds described in this invention (SEQ ID NOS 36-58 disclosed below, respectively, in order of appearance):




Sequence A







Sequence Ba, K* =




Sequence Ca, K* =



Sequence Da, K* =




Sequence E




Sequence F




Sequence G



Sequence H



Sequence I



Sequence J



Sequence K




Sequence La



Sequence Ma



Sequence Na



Sequence O



Sequence Ga



Sequence Pa




Sequence Qa



Sequence Ra




Sequence Sa






Sequence Ta




5




Sequence ACa

In the sequences depicted above with the exception of Sequence Ta, $\text{R}-\underset{\text{H}}{\text{N}}^+$



corresponds to the moiety in any of the formulae described herein (wherein R^1 is H).

10




5 C. Synthesis of Intermediates to Compounds Described in This Invention

General procedure 1 (GP1): Preparation of carboxylic acid building blocks for peptide N-terminal derivatization

To amine or amine salt (1.0 equiv.) in DMF (1-2 mL) was added thiodiglycolic anhydride, 3-methylglutaric anhydride, or 3,3-dimethylglutaric anhydride (1.1-1.2 equiv),
 10 followed by DIPEA (2-5 equiv.). After 0.5-16 hours at ambient temperature, the reaction product was isolated by preparative HPLC (Phenomenex Jupiter 10 μM Proteo 90 Å LC column, 250 x 21.2 mm, with flow rate – 15 mL/min, $\text{H}_2\text{O}/\text{MeCN}$ with 0.1% TFA).


15 **General procedure 2 (GP2): Preparation of bis-(pentafluorophenyl) esters**



Scheme 1

To a slurry of diacid (1.8-3.9 mmol) and triethylamine (2.1-3.0 equiv.) in DCM (5-20 mL) was added pentafluorophenyl trifluoroacetate (2.0-2.1 equiv.). The reaction
 20 mixture was stirred at ambient temperature for 5-18 hours, then concentrated and purified by silica gel chromatography to afford the desired diester.


General procedure 3 (GP3): Preparation of pentafluorophenyl ester building blocks from bis-(pentafluorophenyl)esters (as depicted in Scheme 2)



Scheme 2

To amine (0.1-0.4 mmol) and bis-(pentafluorophenyl)ester (1.0 equiv.) in DMF (1 mL), added DIPEA (3.0 equiv.). After 3 hours at ambient temperature, the reaction mixture was purified by preparative HPLC (Phenomenex Jupiter 10 μ M Proteo 90 Å LC column, 250 x 21.2 mm, with flow rate – 15 mL/min, H₂O/MeCN with 0.1% TFA) to afford the desired substitution product.


Synthesis of I-3 is depicted in Scheme 3:



Scheme 3


To a solution of 1-(2-aminoethyl)pyrrolidin-2-one (103.1 mg, 0.80 mmol) and triethylamine (0.11 mL, 1.0 equiv.) in DCM (2.3 mL) was added chloroacetyl chloride (63.9 μ L, 1.0 equiv.). The reaction mixture was stirred at ambient temperature for 1 hour, then concentrated to a residue which was re-dissolved in DMF (2 mL). Potassium thioacetate (137.7 mg, 1.0 equiv.) was added and the reaction mixture was stirred at ambient temperature for 30 minutes, then concentrated to a residue, which was purified by silica gel chromatography (0–15% MeOH in DCM) to afford I-3. ESI-MS found 245.2, $C_{10}H_{17}N_2O_3S$ (MH^+) requires 245.1.

Synthesis of I-5 is depicted in Scheme 4:




Scheme 4

To a solution of 1-(2-aminoethyl)pyrrolidin-2-one (100.5 mg, 0.44 mmol) and triethylamine (61.8 μ L, 1.0 equiv.) in DCM (1.1 mL) was added chloroacetyl chloride (35.2 μ L, 1.0 equiv.). The reaction mixture was stirred at ambient temperature for 1 hour, then concentrated to a residue which was re-dissolved in DMF (2 mL). Potassium thioacetate (75 mg, 1.0 equiv.) was added and the reaction mixture was stirred at ambient temperature for 30 minutes, then concentrated to a residue, which was purified by silica gel chromatography (0—15% MeOH in DCM) to afford **I-5** (69.3 mg, 51%, 2 steps). ESI-MS found 307.2, $C_{14}H_{15}N_2O_4S$ (MH^+) requires 307.1.


I-6

Prepared according to **GP1**. Yield: 57.8 mg (64%). ESI-MS found 271.2, $C_{11}H_{15}N_2O_4S$ (MH^+) requires 271.1.


I-7

Prepared according to **GP1**. Yield: 28.6 mg (69%). ESI-MS found 339.2, $C_{12}H_{14}F_3N_2O_4S$ (MH^+) requires 339.1.

I-8




Prepared according to **GP1**. Yield: 70.1 mg (100%). ESI-MS found 275.2, $C_{10}H_{15}N_2O_5S$ (MH^+) requires 275.1.


I-9

5


Prepared according to **GP1**. Yield: 188.4 mg (73%). ESI-MS found 292.2, $C_9H_{13}N_2O_5S_2$ (MH^+) requires 292.1.

I-1

10 Prepared according to **GP1**. Yield: 92.7 mg (68%). ESI-MS found 259.3, $C_{10}H_{15}N_2O_4S$ ($M-H^+$) requires 259.1.


I-10

15 Prepared according to **GP1**. Yield: 73 mg. ESI-MS found 300.2, $C_{12}H_{18}N_3O_4S$ (MH^+) requires 300.1.


I-11

Prepared according to **GP1**. Yield: 60.1 mg (87%). ESI-MS found 289.2, $C_{11}H_{17}N_2O_5S$ (MH^+) requires 289.1.

20 **(±)—I-12**




Prepared according to **GP1**. Yield: 68.5 mg (98%). ESI-MS found 289.2, $C_{11}H_{17}N_2O_5S$ (MH^+) requires 289.1.


I-13

Prepared according to **GP1**. Yield: 73.1 mg (95%). ESI-MS found 303.2, $C_{12}H_{19}N_2O_5S$ (MH^+) requires 303.1.

Synthesis of **I-15** is depicted in Scheme 5:




To a solution of amine salt **I-14** (65 mg, 0.33 mmol) and 2,2'-sulfinyldiacetic acid (114 mg, 2.1 equiv.) in DMF (1 mL) was added DIPEA (0.12 mL, 2.1 equiv.) and EDC (67 mg, 1.06 equiv.). The reaction mixture was stirred at ambient temperature for 16 hours. Additional DIPEA (0.06 mL, 1.0 equiv.) was then added. After an additional 24 hours, purification by preparative HPLC ($H_2O/MeCN$ with 0.1% TFA) afforded 106.9 mg (quantitative yield) of **I-15** as a colorless oil. ESI-MS found 306.9, $C_9H_{11}N_2O_6S_2$ ($M-H^+$) requires 307.0.

I-16


Diester **I-16**: Prepared according to **GP2**. Yield: 1.16 g (65%).

I-17



5 Diester **I-17**: Prepared according to **GP2**. Yield: 599 mg (29%)


I-18



Diester **I-18**: Prepared according to **GP2**. Yield: 778 mg (46%)


10

I-19




Diester **I-19**: Prepared according to **GP2**. Yield: 569.8 mg (64%).

15 **I-20**




Diester **I-20**: Prepared according to **GP2**. Yield: 399.3 mg (48%).

I-21


Prepared according to **GP3** from diester **I-16**. Yield: 43.2 mg (50%). ESI-MS found 485.1, $C_{22}H_{18}F_5N_2O_5$ (MH^+) requires 485.1.

5

I-22


Prepared according to **GP3** from diester **I-16**. Yield: 25.8 mg (33%). ESI-MS found 312.1, $C_{12}H_{11}F_5NO_3$ (MH^+) requires 312.1.

10


I-23

Prepared according to **GP3** from diester **I-16**. Yield: 53.4 mg (55%). ESI-MS found 499.1, $C_{23}H_{20}F_5N_2O_5$ (MH^+) requires 499.1.


15

I-24


Prepared according to **GP3** from diester **I-16**. Yield: 56.7 mg (58%). ESI-MS found 471.1, $C_{21}H_{16}F_5N_2O_5$ (MH^+) requires 471.1.

I-25


Prepared according to **GP3** from diester **I-16**. Yield: 28.7 mg (33%). ESI-MS found
5 470.3, $C_{21}H_{17}F_5N_3O_4$ (MH^+) requires 470.1.

I-26


Prepared according to **GP3** from diester **I-16**. Yield: 57.4 mg (86%). ESI-MS found
10 485.3, $C_{22}H_{18}F_5N_2O_5$ (MH^+) requires 485.1.

I-27

Prepared according to **GP3** from diester **I-16**. Yield: 18.1 mg (27%).
15


I-28

Prepared according to **GP3** from diester **I-16**. Yield: 48 mg (33%). ESI-MS found
20 441.1, $C_{16}H_{14}F_5N_2O_5S$ (MH^+) requires 441.1.

I-29


Prepared according to **GP3** from diester **I-18**. Yield: 66.1 mg (59%). ESI-MS found 453.1, $C_{17}H_{14}F_5N_2O_5S$ (MH^+) requires 453.1.

5

I-30


Prepared according to **GP3** from diester **I-17**. Yield: 58.8 mg (48%). ESI-MS found 439.1, $C_{16}H_{12}F_5N_2O_5S$ (MH^+) requires 439.1.

10


I-31

Prepared according to **GP3** from diester **I-16**. Yield: 47.9 mg (61%). ESI-MS found 423.1, $C_{18}H_{20}F_5N_2O_4$ (MH^+) requires 423.1.

15

I-32


Prepared according to **GP3** from diester **I-19**. Yield: 40 mg (30% yield). ESI-MS found 481.2, $C_{19}H_{18}F_5N_2O_5S$ (MH^+) requires 481.1.

I-33

I-33: Prepared according to **GP3** from diester **I-20**. Yield: 8.6 mg (9% yield).

5

Synthesis of **I-34** is depicted in Scheme 6:




Scheme 6

To a slurry of 3-(2-aminoethyl)thiazolidine-2,4-dione hydrochloride (100 mg, 0.51 mmol) and thiodiglycolic anhydride (69 mg, 1.0 equiv.) in DCM (1 mL) was added DIPEA (0.18 mL, 2.0 equiv.). The reaction mixture was stirred at ambient temperature for 2 hours. Pentafluorophenol (98 mg, 1.0 equiv.) was then added, followed by EDC (100 mg, 1.0 equiv.). The reaction mixture was stirred for 16 hours, then concentrated and purified by silica gel chromatography (0-60% EtOAc in Hexanes) to afford 69.1 mg (30% yield) of **I-34** as a white solid. ESI-MS found 459.1. $C_{15}H_{12}F_5N_2O_5S_2$ (MH^+) requires 459.0.

15


Synthesis of **I-35** is depicted in Scheme 7:



Scheme 7

To a slurry of 2-(2-aminoethyl)isoindoline-1,3-dione hydrochloride (200 mg, 0.82 mmol) and thiodiglycolic anhydride (122 mg, 1.05 equiv.) in DCM (5 mL) and DMF (2 mL) was added TEA (0.27 mL, 2.2 equiv.). The reaction mixture was stirred at ambient temperature for 16 hours. Additional thiodiglycolic anhydride (23 mg, 0.2 equiv.) was added for completion of the reaction. The reaction mixture was concentrated and diluted with DCM (30 mL). The organic phase was washed with 1M HCl (30 mL) and the aqueous phase was back-extracted with EtOAc (30 mL). The combined organic extracts were dried (MgSO₄) and concentrated to a residue, which was purified by silica gel chromatography (10:1 DCM/MeOH with 1% AcOH) to afford 400 mg of intermediate acid. This acid was re-dissolved in DCM (5 mL). Pentafluorophenol (215 mg, 1.3 equiv.) was then added, followed by EDC (224 mg, 1.3 equiv.). The reaction mixture was stirred for 1 hour, and additional pentafluorophenol (108 mg, 0.65 equiv.) and EDC (112 mg, 0.65 equiv.) were added. After an additional 30 minutes, the reaction mixture was concentrated and purified by silica gel chromatography (0-100% EtOAc in Hexanes) to afford 250 mg (58% yield, 2 steps) of **I-35** as a white solid. ESI-MS found 489.1. C₂₀H₁₄F₅N₂O₅S (MH⁺) requires 489.1.


Synthesis of I-36 is depicted in Scheme 8:



Scheme 8

Amine salt **I-14** (81 mg, 0.41 mmol) and glutaric anhydride (49 mg, 1.04 equiv.) were suspended in DCM (4 mL), and DIPEA (0.14 mL, 2.0 equiv.) was added. The reaction mixture was stirred at ambient temperature for 15 hours, whereupon pentafluorophenol (80 mg, 1.06 equiv.) and EDC (81 mg, 1.02 equiv.) were added to the homogeneous solution. After an additional 4 hours, the reaction mixture was diluted with DCM (20 mL) and washed with 1M HCl (5 mL) and brine (8 mL). The organic extracts were dried (Na₂SO₄) and concentrated to a residue, which was purified by silica gel chromatography (Hexanes/EtOAc) to afford 105 mg (58% yield) of **I-36** as a white solid. ESI-MS found 441.0. C₁₆H₁₄F₅N₂O₅S (MH⁺) requires 441.1.

Synthesis of **I-37** is depicted in Scheme 9:




Scheme 9

Amine salt **I-14** (69 mg, 0.35 mmol) and succinic anhydride (35 mg, 1.0 equiv.) were suspended in DCM (5 mL), and DIPEA (0.12 mL, 2.0 equiv.) was added. The reaction mixture was stirred at ambient temperature for 16 hours, whereupon pentafluorophenol (80 mg, 1.24 equiv.) and EDC (74 mg, 1.1 equiv.) were added to the homogeneous solution.

After an additional 4 hours, the reaction mixture was diluted with DCM (20 mL) and washed with 1M HCl (5 mL) and brine (8 mL). The organic extracts were dried (Na_2SO_4) and concentrated to a residue, which was purified by silica gel chromatography (Hexanes/EtOAc) to afford 64 mg (43% yield) of **I-37** as a white solid. ESI-MS found 427.0. $\text{C}_{15}\text{H}_{12}\text{F}_5\text{N}_2\text{O}_5\text{S}$ (MH^+) requires 427.1.


Synthesis of **I-38** is depicted in Scheme 10:



Scheme 10

Amine salt **I-14** (73 mg, 0.37 mmol) and diglycolic anhydride (43 mg, 1.0 equiv.) were suspended in DCM (5 mL), and DIPEA (0.14 mL, 2.2 equiv.) was added. The reaction mixture was stirred at ambient temperature for 17 hours, whereupon pentafluorophenol (86 mg, 1.26 equiv.) and EDC (78 mg, 1.1 equiv.) were added to the homogeneous solution. After an additional 6 hours, the reaction mixture was diluted with DCM (20 mL) and washed with 1M HCl (5 mL) and brine (8 mL). The organic extracts were dried (Na_2SO_4) and concentrated to a residue, which was purified by silica gel chromatography (Hexanes/EtOAc) to afford 22 mg (14% yield) of **I-38** as a white solid. ESI-MS found 443.0. $\text{C}_{15}\text{H}_{12}\text{F}_5\text{N}_2\text{O}_6\text{S}$ (MH^+) requires 443.0.


Synthesis of **I-39** is depicted in Scheme 11:



Scheme 11

To a suspension of amine salt **I-14** (99 mg, 0.50 mmol), adipic acid (73.7 mg, 1.0 equiv.) and EDC (98 mg, 1.02 equiv.) in DCM (5 mL) was added DIPEA (0.27 mL, 3.1 equiv.). The reaction mixture was stirred at ambient temperature for 60 hours at which point pentafluorophenol (98 mg, 1.06 equiv.) and additional EDC (102 mg, 1.05 equiv.) were added to the homogeneous solution. After an additional 4.5 hours, the reaction mixture was diluted with DCM (20 mL) and washed with 1M HCl (5 mL) and brine (8 mL). The organic extracts were dried (Na₂SO₄) and concentrated to a residue, which was purified by silica gel chromatography (Hexanes/EtOAc) to afford 90 mg (39% yield) of **I-39** as a white solid. ESI-MS found 455.0. C₁₇H₁₆F₅N₂O₅S (MH⁺) requires 455.1.

Synthesis of **I-40** is depicted in Scheme 12:




Scheme 12

To a slurry of 2-(2-aminoethyl)isoindoline-1,3-dione hydrochloride (74.3 mg, 0.33 mmol) and succinic anhydride (39.4 mg, 1.2 equiv.) in DMF (1.5 mL) was added pyridine (79 μ L, 3.0 equiv.). The reaction mixture was heated to 60 °C for 1 hour at which point

acylation was complete. The reaction mixture was cooled to ambient temperature, and HOSu (75.5 mg, 2.0 equiv.) was added, followed by EDC (125.8 mg, 2.0 equiv.) The reaction mixture was stirred at ambient temperature for 4 hours. The reaction mixture was diluted saturated aqueous NH_4Cl (8 mL) and H_2O (5 mL) and extracted with EtOAc (3 x 5 mL). The organic extracts were combined, dried (MgSO_4), and concentrated to afford a white solid. Silica gel chromatography (EtOAc) afforded 22.9 mg (18% yield) of ester **I-40**.

Synthesis of **I-41** is depicted in Scheme 13:




Scheme 13

To a solution of 2-(2-aminoethyl)isoindoline-1,3-dione hydrochloride (102.2 mg, 0.45 mmol) and glutaric anhydride (61.7 mg, 1.2 equiv.) in DMF (2 mL) was added DIPEA (196 μL , 2.5 equiv.). The reaction mixture was stirred for 22.5 hours at ambient temperature and HOSu (103.8 mg, 2.0 equiv.) was added, followed by EDC (172.8 mg, 2.0 equiv.). The reaction mixture was maintained at ambient temperature for an additional 16 hours, then diluted with H_2O (10 mL) and extracted with EtOAc (3 x 5 mL). The combined organic extracts were dried (MgSO_4) and concentrated to afford a residue, which was purified by silica gel chromatography (EtOAc) to afford 85.8 mg (47% yield, 2 steps) of **I-41** as a white solid. ESI-MS found 402.3. $\text{C}_{19}\text{H}_{20}\text{N}_3\text{O}_7$ (MH^+) requires 402.1.

15

20


Synthesis of **I-42** is depicted in Scheme 14:



Scheme 14

To amine salt **I-14** (63.4 mg, 0.28 mmol) in DMF (1 mL) was added thiodiglycolic anhydride (44.7 mg, 1.2 equiv), followed by DIPEA (123 μ L, 2.5 equiv.). After stirring at ambient temperature for 3 hours, purification by preparative HPLC ($\text{H}_2\text{O}/\text{MeCN}$ with 0.1% TFA) afforded 70.5 mg (78% yield) of carboxylic acid **I-43** as a white solid. Carboxylic acid **I-43** was dissolved in DMF (2 mL), and HOSu (38 mg, 1.5 equiv.) was added, followed by EDC (63.3 mg, 1.5 equiv.). The reaction mixture was stirred at ambient temperature for 18 hours, then subjected to preparative HPLC ($\text{H}_2\text{O}/\text{MeCN}$ with 0.1% TFA) to afford 89.8 mg (98% yield) of ester **I-42** as a white solid. ESI-MS found 418.2. $\text{C}_{15}\text{H}_{20}\text{N}_3\text{O}_7\text{S}_2$ (MH^+) requires 418.1.

Synthesis of **I-44** is depicted in Scheme 15:




Scheme 15

To a slurry of terephthalic acid (216.7 mg, 1.304 mmol) and HOSu (547.9 mg, 2.0 equiv.) in DCM (10 mL) was added pyridine (420 mL, 4.0 equiv.). The reaction mixture was cooled to 0-5 $^{\circ}\text{C}$ and trifluoroacetic anhydride (368 mL, 2.0 equiv.) was added. The reaction mixture was allowed to warm to ambient temperature, stirred for 16 hours, and then concentrated. EtOH (20 mL) was added to the residue and the slurry was filtered and dried to afford the crude bis-*N*-hydroxysuccinimide ester **I-45** (403 mg, 86% yield), which was taken forward without further purification.

To a solution of 3-(2-aminoethyl)thiazolidine-2,4-dione hydrochloride (34.3 mg, 0.174 mmol) in DMF (1 mL) was added diester **I-45** (125.7 mg, 2.0 equiv.) and DIPEA (91 mL, 3.0 equiv.). The reaction mixture was maintained at ambient temperature for 17 hours and then purified by HPLC to afford 54 mg (76% yield) of **I-44**.

5


Synthesis of **I-48** is depicted in Scheme 16:



Scheme 16

I-48: Adipic acid *bis*-*N*-hydroxysuccinimide ester **I-47** was prepared as described for diester **I-45**. Coupling with amine hydrochloride **I-46** as described in the preparation of **I-44** afforded 69.8 mg (69% yield) of **I-48** after purification by preparative HPLC (H₂O/MeCN with 0.1% TFA).

15 Synthesis of **I-51** is depicted in Scheme 17:




Scheme 17

Using a procedure similar to that described for the preparation of **I-42**, amine hydrochloride **I-49** (85 mg, 0.353 mmol) afforded 62.5 mg (38% yield, 2 steps) of **I-51**.

20


Synthesis of I-53 is depicted in Scheme 18:



Scheme 18

To a solution of benzoic acid (66.2 mg, 0.54 mmol) and *tert*-butyl (2-(methylamino)ethyl)carbamate (97.5 mg, 1.03 equiv.) in DMF (3 mL) was added HATU (216.8 mg, 1.05 equiv.) and DIPEA (0.1 mL, 1.06 equiv.). The reaction mixture was stirred at ambient temperature for 16 hours, then diluted with EtOAc (20 mL) and washed with water (10 mL), 1M HCl (10 mL), 1M NaOH (10 mL) and brine (10 mL). The combined organic extracts were dried (Na₂SO₄) and concentrated to afford intermediate amide **I-52** (130.8 mg), which was then dissolved in 4M HCl in dioxane (3 mL). After 1 hour, the reaction mixture was concentrated to afford the deprotected amine as a solid. This amine was suspended in DCM (3 mL) along with thiodiglycolic anhydride (60.4 mg, 0.97 equiv.), and DIPEA (0.17 mL, 2.1 equiv.) was added. The reaction mixture was stirred at ambient temperature for 2.5 hours, at which point HOSu (55.1 mg, 1.02 equiv.) and EDC (90 mg, 1.0 equiv.) were added. After 16 hours, the reaction mixture was diluted with DCM (20 mL) and washed with 1M HCl (2 x 10 mL) and brine (8 mL). The organic extracts were dried (Na₂SO₄) and concentrated to a residue, which was purified by silica gel chromatography (EtOAc) to afford 34.5 mg (18% yield) of **I-53**. ESI-MS found 408.2. C₁₈H₂₂N₃O₆S (MH⁺) requires 408.1.

Synthesis of I-55 is depicted in Scheme 19:




Scheme 19

To a solution of 3,3-dimethyldihydro-2H-pyran-2,6(3H)-dione (98.7 mg, 0.69 mmol) and *tert*-butyl (2-aminoethyl)carbamate hydrochloride (140 mg, 1.02 equiv.) in THF (6 mL) was added TEA (0.2 mL, 2.1 equiv.). The reaction mixture was heated to 60 °C for 48 hours. T3P (50% solution in EtOAc, 0.27 g, 0.6 equiv.) was added, followed by additional THF (3 mL). The reaction mixture was heated to 60 °C for 8 hours, at which time additional T3P (0.47 g, 1.1 equiv.) was added and the reaction mixture was heated to 60 °C for an additional 16 hours. The reaction mixture was diluted with EtOAc (20 mL) and washed with H₂O (2 x 10 mL), saturated aqueous NaHCO₃ (10 mL), 1M HCl (10 mL), and brine (10 mL). The organic extracts were dried (Na₂SO₄) and concentrated to afford a residue, which was purified by silica gel chromatography to afford the glutarimide **I-54** (59 mg, 30% yield).

Glutarimide **I-54** (59 mg, 0.21 mmol) was dissolved in 4M HCl in dioxane (3 mL). After 2 hours, the reaction mixture was concentrated to afford a white solid. This solid and thiodiglycolic anhydride (28.3 mg, 1.03 equiv.) were dissolved in DCM (3 mL), and TEA (90 µL, 3.1 equiv.) was added. After 25 minutes, the reaction mixture was concentrated and purified by preparative HPLC (H₂O/MeCN with 0.1% TFA) to afford 40.5 mg (62% yield) of **I-55**. ESI-MS found 317.2, C₁₃H₂₁N₂O₅S (MH⁺) requires 317.1.


Synthesis of **I-56** is depicted in Scheme 20:



Scheme 20

To a solution of *N*-Fmoc-4-aminobutanoic acid (111.3 mg, 0.34 mmol) in DMF (1 mL) was added HOSu (59.1 mg, 1.5 equiv.) and EDC (98.3 mg, 1.5 equiv.). The reaction mixture was stirred at ambient temperature for 1.5 hours and then purified by preparative HPLC (H₂O/MeCN with 0.1% TFA) to afford 126.2 mg (87% yield) of ester **I-56** as a white solid.


Synthesis of **I-57** is depicted in Scheme 21:



Scheme 21

To a solution of *N*-Fmoc-4-aminopentanoic acid (106.4 mg, 0.31 mmol) in DMF (1 mL) was added HOSu (54.1 mg, 1.5 equiv.) and EDC (90.1 mg, 1.5 equiv.). The reaction mixture was stirred at ambient temperature for 4 hours, then purified by preparative HPLC (H₂O/MeCN with 0.1% TFA) to afford 131.2 mg (96% yield) of ester **I-57** as a white solid.

Synthesis of **I-60** is depicted in Scheme 22:




Scheme 22

To a solution of amine salt **I-14** (202.3 mg, 1.03 mmol) and TEA (0.43 mL, 3.0 equiv.) in DCM (5 mL) was added 2-nitrobenzenesulfonyl chloride (273.6 mg, 1.2 equiv.). The reaction mixture was stirred at ambient temperature for 3 hours, then concentrated and the residue purified by silica gel chromatography (40% EtOAc in hexanes) to afford sulfonamide **I-58** (217.7 mg, 61% yield) as a pale yellow solid.

Sulfonamide **I-58** (79.7 mg, 0.23 mmol) was dissolved in acetone (3 mL). Potassium carbonate (65.5 mg, 2.0 equiv.) was added, followed by methyl iodide (29 μ L, 2.0 equiv.). The reaction mixture was stirred at ambient temperature for 1 hour, then carefully acidified by addition of 1M HCl (5 mL) and extracted with EtOAc (2 x 7 mL).
 5 The combined organic extracts were dried (MgSO_4) and concentrated to a residue, which was purified by preparative TLC (5:1 Toluene/MeCN, 3 elutions) to afford *N*-methylsulfonamide **I-59** (47.7 mg, 58% yield) as a colorless oil.

To *N*-methylsulfonamide **I-59** (47.7 mg, 0.13 mmol) in DMF (1.6 mL) was added 1,10-decanedithiol (41.1 mg, 1.5 equiv.) and cesium carbonate (64.8 mg, 1.5 equiv.). The
 10 reaction mixture was stirred at ambient temperature for 4 hours and then filtered. Thiodiglycolic anhydride (26.3 mg, 1.5 equiv.) was added to the filtrate and the reaction mixture maintained at ambient temperature for 2 hours and then diluted with H_2O (0.5 mL). The slurry was clarified by centrifugation and the supernatant was purified directly by preparative HPLC (H_2O /MeCN with 0.1% TFA) to afford 14.4 mg (35% yield) of **I-60**.
 15 ESI-MS found 307.1, $\text{C}_{10}\text{H}_{15}\text{N}_2\text{O}_5\text{S}_2$ (MH^+) requires 307.0.

Synthesis of **I-61** is depicted in Scheme 23:




Scheme 23

To a solution of beta-alanine-*tert*-butyl ester hydrochloride (221.3 mg, 1.22 mmol) and CDI (197.5 mg, 1.0 equiv.) in DMF (3 mL) was added DIPEA (1.1 mL, 5.0 equiv.). The reaction mixture was stirred for 2 hours, and amine hydrochloride **I-14** (239.5 mg, 1.0 equiv.) was added. The reaction mixture was heated to 40 °C for 18 hours, and then concentrated under reduced pressure. TFA (5 mL) was added to the residue. The reaction
 25 mixture was maintained at ambient temperature for 2 hours, then concentrated under reduced pressure, and purified by preparative HPLC (H_2O /MeCN with 0.1% TFA) to

afford 17 mg (5% yield) of **I-61** as a colorless oil. ESI-MS found 276.3, $C_9H_{14}N_3O_5S$ (MH^+) requires 276.1.


Synthesis of **I-62** is depicted in Scheme 24:



Scheme 24

2-(2-Aminoethyl)isoindoline-1,3-dione hydrochloride (316.1 mg, 1.395 mmol) was dissolved in glacial AcOH (7 mL). Zinc dust (912.2 mg, 10 equiv.) was added, and the reaction mixture was heated to 110 °C for 18.5 hours, filtered hot, and concentrated under reduced pressure to afford the crude reduction product (900 mg). Half of this material was dissolved in MeCN (5 mL). Thiodiglycolic anhydride (120 mg, 0.91 mmol) was added, followed by triethylamine (486 μ L, 5 equiv.). The reaction mixture was stirred at ambient temperature for 16 hours, concentrated, and purified by preparative HPLC ($H_2O/MeCN$ with 0.1% TFA) to afford 20.4mg (10% yield) of **I-62** as a colorless oil. ESI-MS found 309.2, $C_{14}H_{17}N_2O_4S$ (MH^+) requires 309.1.

Synthesis of **I-64** is depicted in Scheme 25:




Scheme 25

To a solution of (1*R*,5*S*)-3-oxabicyclo[3.1.0]hexane-2,4-dione (168.3 mg, 1.50 mmol) in DMF (5 mL) was added *N*-*tert*-butoxycarbonyl ethylenediamine (360.8 mg, 1.5 equiv.). The reaction mixture was stirred at ambient temperature for 30 minutes, and then heated at 120 °C for 4.5 hours. The reaction mixture was then cooled and diluted with

EtOAc (50 mL). The solution was washed with saturated aqueous NH_4Cl (20 mL) and water (3 x 20 mL). The combined washes were back-extracted with EtOAc (30 mL). The combined organic extracts were washed with brine (20 mL), dried (MgSO_4), and concentrated to afford a residue, which was purified by silica gel chromatography (0-60% EtOAc in hexanes) to afford 174.3 mg (46% yield) of carbamate **I-63** as a white solid.

To 34.8 mg (0.137 mmol) of carbamate **I-63** was added TFA (1 mL). The reaction mixture was maintained at ambient temperature for 30 minutes and then concentrated. The residue was re-dissolved in DMF (0.8 mL), and DIPEA (119.2 μL , 5.0 equiv.) was added, followed by thiodiglycolic anhydride (21.7 mg, 1.2 equiv.). The reaction mixture was maintained at ambient temperature for 2 hours and then purified by preparative HPLC ($\text{H}_2\text{O}/\text{MeCN}$ with 0.1% TFA) to afford 31.6 mg (81% yield) of **I-64**. ESI-MS found 287.0, $\text{C}_{11}\text{H}_{15}\text{N}_2\text{O}_5\text{S}$ (MH^+) requires 287.1.

Synthesis of **I-66** is depicted in Scheme 26:




Scheme 26

To a solution of 3-methylglutaric anhydride (247 mg, 1.93 mmol) in DMF (1 mL) was added *N*-benzyloxycarbonyl ethylenediamine (374.4 mg, 1.0 equiv.). The reaction mixture was stirred at ambient temperature for 1.5 hours. AcOH (2 mL) was then added. The reaction mixture was heated to 110 °C for 21.5 hours and then cooled to ambient temperature. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (3 x 5 mL). The combined extracts were dried (MgSO_4) and concentrated to a residue. Purification by silica gel chromatography (0-63% EtOAc in hexanes) afforded carbamate **I-65** (432.8 mg, 74% yield) as a white solid.

A solution of HBr in AcOH (33% v/v, 3 mL) was added to carbamate **I-65** (104 mg, 0.34 mmol). The reaction mixture was sonicated for 5 minutes to solubilize the solids and then maintained at ambient temperature for 45 minutes, after which it was concentrated under reduced pressure. The residue was triturated with Et₂O (10 mL) and the supernatant was discarded. The residue was dissolved in DMF (1.2 mL). DIPEA (179 μL, 3.0 equiv.) was added, followed by thiodiglycolic anhydride (49.7 mg, 1.1 equiv.). The reaction mixture was maintained at ambient temperature for 1.5 hours and then purified by preparative HPLC (H₂O/MeCN with 0.1% TFA) to afford 69 mg (67% yield) of **I-66**. ESI-MS found 303.3, C₁₂H₁₈N₂O₅S (MH⁺) requires 303.1.


Synthesis of (±)-**I-67** is depicted in Scheme 27:



Scheme 27


A solution of 3-phenyldihydrofuran-2,5-dione (71.2 mg, 0.40 mmol) and (2-aminoethyl)carbamate (64.1 mg, 1.0 equiv.) in 1 mL of anhydrous dioxane was stirred over 4 Å molecular sieves for 5.5 hours at ambient temperature. The reaction mixture was filtered and concentrated under reduced pressure. The residue obtained was dissolved in 4N HCl in dioxane (3 mL). After stirring at ambient temperature for 16 hours, the reaction mixture was concentrated under reduced pressure to afford the crude amine hydrochloride. Amine hydrochloride (39 mg, 0.153 mmol) was converted to 17.6 mg of acid **I-67** (33% yield) following **GP1**. ESI-MS: Found 348.9, C₁₆H₁₈N₂O₅S (MH⁺) requires 349.1.

I-68




Prepared according to **GP1**. Yield: 68.1 mg (97%). ESI-MS found 322.2, $C_{14}H_{16}N_3O_4S$ (MH^+) requires 322.1.

5 **I-69**




Prepared according to **GP1**. Yield: 48.1 mg (55%). ESI-MS found 289.2, $C_{15}H_{19}N_2O_4S$ (MH^+) requires 289.1.

10 **I-70**




Prepared according to **GP1**. Yield: 37.7 mg (73%). ESI-MS found 323.2, $C_{12}H_{21}N_2O_4S$ (MH^+) requires 323.1.

15 **I-71**



Prepared according to **GP1**. Yield: 9.9 mg (20%). ESI-MS found 276.1, $C_9H_{14}N_3O_5S$ (MH^+) requires 276.1.


I-72



20

Prepared according to **GP1**. Yield: 60 mg (88%). ESI-MS found 304.2, $C_{11}H_{18}N_3O_5S$ (MH^+) requires 304.1.

Synthesis of ($\pm$)—**I-74** is depicted in Scheme 28:




Scheme 28

To a solution of methyl 2-bromopropanoate (200 μ L, 1.79 mmol) in THF (9 mL) were added thiourea (177 mg, 1.3 equiv.) and sodium acetate (293 mg, 2.0 equiv.). The reaction mixture was heated under reflux for 20 hours. 6N HCl (4 mL) was then added. The reaction mixture was heated under reflux for an additional 16 hours and then allowed to cool to ambient temperature. Water was then added, and the reaction mixture was extracted with EtOAc. The combined organic extracts were washed with brine, dried (sodium sulfate), and concentrated. The residue obtained was subjected to silica gel chromatography (0 to 7% MeOH in DCM) to afford 235 mg of 5-methylthiazolidine-2,4-dione as a clear oil (>95% yield).

To a solution of 5-methylthiazolidine-2,4-dione (112 mg, 0.854 mmol) in DMF (6 mL) at 0 °C was added sodium hydride (41 mg of a 60% dispersion in mineral oil, 1.2 equiv.), and the resulting slurry was stirred for 30 minutes. A solution of *tert*-butyl (2-bromoethyl)carbamate (304 mg, 1.6 equiv.) in DMF (1 mL) was then added and the reaction mixture was allowed to warm to ambient temperature and stirred for two hours. The reaction was quenched with 45 mL of saturated NH_4Cl solution and then extracted three times with EtOAc. The combined organic extracts were washed with brine, dried (Na_2SO_4), and concentrated *in vacuo* to afford a residue, which was purified by silica gel chromatography to afford 202 mg (86% yield) of carbamate **I-73**. Deprotection of carbamate **I-73** in TFA/DCM (1:1 v/v) for 2 hours at ambient temperature was followed by concentration of the reaction mixture *in vacuo* to give a crude trifluoroacetate salt, which

was converted to 99.9 mg of acid **I-74** (44% yield) following **GP1**. ESI-MS: Found 305.1, $C_{10}H_{13}N_2O_5S_2$ ($M-H$)⁻ requires 305.0.


Synthesis of **I-74** is depicted in Scheme 29:



Scheme 29

To a solution of 5,5-dimethylthiazolidine-2,4-dione (163 mg, 1.12 mmol) and *tert*-butyl (2-bromoethyl)carbamate (377 mg, 1.5 equiv.) in 5 mL of anhydrous DMF was added potassium carbonate (309 mg, 2.0 equiv.), and the resulting suspension was stirred for 18 hours at ambient temperature. The reaction mixture was diluted with 50 mL of EtOAc. The organic phase was washed twice with water, brine, dried over sodium sulfate, and concentrated *in vacuo* to afford a residue, which was purified by silica gel chromatography to afford 275 mg (83% yield) of carbamate **I-75**. Deprotection of carbamate **I-73** in TFA/DCM (1:1 v/v) for two hours at ambient temperature was followed by concentration of the reaction mixture *in vacuo* to give a crude trifluoroacetate salt. This amine TFA salt (66 mg, ca. 0.218 mmol) was converted to 36 mg of acid **I-76** (52% yield) following **GP1**. ESI-MS: Found 319.0, $C_{11}H_{15}N_2O_5S_2$ ($M-H$)⁻ requires 319.1.

Synthesis of **I-79** and **I-80** is depicted in Scheme 30:



Scheme 30


I-79: to a solution of (*S*)-3-hydroxypyrrolidinone (488 mg, 4.83 mmol) in DMF (10 mL), was added imidazole (493 mg, 1.5 equiv.), followed by triisopropylsilyl chloride (1.12 g, 1.2 equiv.). The reaction mixture was stirred at ambient temperature. On completion of the reaction, the reaction mixture was diluted with EtOAc (100 mL) and washed with H₂O (5 x 20 mL). The aqueous washes were combined and back-extracted with EtOAc (50 mL). The combined organic extracts were washed with brine (50 mL), dried (MgSO₄) and concentrated to afford a colorless oil. Purification by silica gel chromatography (12 g pre-packed column, eluting with 35-60% EtOAc in Hexanes) afforded 1.23 g (99% yield) of the TIPS-protected alcohol as a colorless oil.

The silyl ether was then dissolved in DMF (7 mL). This solution was added to a suspension of NaH (574 mg of 60% dispersion in mineral oil, 3.0 equiv.) in DMF (15 mL) that had been pre-cooled to 0-5 °C. After 4 minutes, (2-bromoethoxy)(*tert*-butyl)dimethylsilane (1.37 g, 1.2 equiv.) was added. The reaction mixture was allowed to warm to ambient temperature. After 1.5 hours, the reaction mixture was quenched with saturated aqueous NH₄Cl (20 mL), and diluted with brine (100 mL). The aqueous phase was extracted with EtOAc (3 x 70 mL). The combined EtOAc extracts were dried (MgSO₄) and concentrated to afford a colorless oil. Purification by silica gel chromatography (24 g pre-packed column, eluting with 30% EtOAc in Hexanes) afforded 1.38 g (69% yield) of the bis-silyl ether **I-77** as a colorless oil. This bis-silyl ether was dissolved in THF (12 mL). IN HCl (4 mL) was then added. The reaction mixture was stirred at ambient temperature for 2 hours, then diluted with H₂O (100 mL) and extracted with EtOAc (3 x 60 mL). The combined organic extracts were dried (Na₂SO₄) and concentrated to afford a colorless oil. Purification by silica gel chromatography (24 g pre-packed column, eluting with 80-100% EtOAc in Hexanes) afforded 0.85 g (85% yield) of the deprotection product. This deprotected silyl ether was dissolved in THF (20 mL) in the presence of triphenylphosphine (1.11 g, 1.5 equiv.) and phthalimide (622 mg, 1.5 equiv.). The solution was cooled to 0-5 °C, and DIAD (833 µL, 1.5 equiv.) was added. After 1.5 hours, the reaction mixture was concentrated to a yellow oil, which was purified by silica gel chromatography (40 g pre-packed column, eluting with 44% EtOAc in Hexanes) to afford 2.3 g of phthalimide **I-78** (~ 50% pure, with diisopropylhydrazine-1,2-dicarboxylate as impurity).

To a solution of phthalimide **I-78** (254 mg, 0.59 mmol, ~ 50% pure, with diisopropylhydrazine-1,2-dicarboxylate as impurity) in EtOH (3 mL) was added hydrazine hydrate (183 μ L, 10.0 equiv.). The reaction mixture was heated to 80 °C for 20 minutes, cooled and concentrated. The residue was re-suspended in MeOH (5 mL) and filtered. The filtrate was concentrated to a residue and TBAF (1 M in THF, 1.2 mL, 2.0 equiv. based on phthalimide **I-78**) was added. The reaction mixture was stirred at ambient temperature for 19 hours, then concentrated. The residue was re-dissolved in DMF (2 mL) and thiodiglycolic anhydride (78 mg, 1.0 equiv. based on phthalimide **I-78**) was added. After 2 hours, the reaction mixture was subjected to purification by preparative HPLC (H₂O/MeCN with 0.1% TFA) to afford 10.6 mg of the desired carboxylic acid **I-79** as a colorless oil. ESI-MS: Found 277.2, C₁₀H₁₇N₂O₅S (MH⁺) requires 277.1.

I-80: Analogous procedure was used for the preparation of the enantiomer, **I-80**. ESI-MS: Found 277.2, C₁₀H₁₇N₂O₅S (MH⁺) requires 277.1.

Synthesis of I-82 is depicted in Scheme 31:




Scheme 31

A slurry of (3R,5S)-3,5-dimethyldihydro-2H-pyran-2,6(3H)-dione (102.8 mg, 0.723 mmol), benzyl (2-aminoethyl)carbamate hydrochloride (166.8 mg, 1.0 equiv.), T3P (50% w/v solution in DMF, 0.92 mL, 2.0 equiv.) and DIPEA (378 μ L, 3.0 equiv.) in DMF (2 mL) was stirred at ambient temperature for 1 hour, then heated to 80 °C for 2 hours. The reaction mixture was cooled to ambient temperature, diluted with brine (10 mL), and then extracted with EtOAc (3 x 15 mL). The combined organic extracts were dried (MgSO₄) and concentrated to afford an oil, which was purified by silica gel chromatography (12 g pre-packed column, eluting at 51% EtOAc/Hexanes) to afford imide **I-81** (77 mg, 33% yield) as a colorless oil.

To imide **I-81** (77 mg, 0.24 mmol) was added 33% v/v HBr/AcOH (3 mL). The reaction mixture was maintained at ambient temperature for 1 hour and then concentrated. The residue was triturated with Et₂O (10 mL) and the Et₂O was discarded. The remaining residue was dissolved in DMF (1.5 mL). Thiodiglycolic anhydride (32 mg, 1.0 equiv. based on imide **I-81**) was added, followed by DIPEA (126 μ L, 3.0 equiv.). The reaction mixture was maintained at ambient temperature for 20 hours and then purified by preparative HPLC (H₂O/MeCN with 0.1% TFA) to afford 59.4 mg (78% yield) of **I-82** as a colorless oil. ESI-MS: Found 317.3, C₁₃H₂₁N₂O₅S (MH⁺) requires 317.1.

Synthesis of I-85 is depicted in Scheme 32:



Scheme 32


To a slurry of 447.7 mg (5.0 equiv.) of sodium hydride (60% dispersion in mineral oil) in DMF (5 mL) that had been cooled to 0—5 °C was added a solution of 2,2-dimethylpyrrolidinone (253.3 mg, 2.238 mmol) in DMF (7 mL). The reaction mixture was stirred at 0—5 °C for 10 minutes and (2-bromoethoxy)(*tert*-butyl)dimethylsilane (642.5 mg, 1.2 equiv.) was added in one portion. The reaction mixture was stirred for 10 minutes at 0—5 °C, then allowed to warm to ambient temperature. After 18 hours, the reaction mixture was cooled to 0—5 °C, and the reaction was quenched with saturated aqueous NH₄Cl (10 mL). The reaction mixture was diluted with 50% brine (100 mL) and extracted with EtOAc (3 x 50 mL). The organic extracts were combined, dried (Na₂SO₄), and concentrated to afford a colorless oil which was then dissolved in THF (12 mL). Aqueous HCl (1M, 4 mL) was added, and the reaction mixture was stirred at ambient temperature for 5 hours. The reaction was quenched with saturated aqueous NaHCO₃ (10 mL) and

diluted with brine (50 mL), then extracted with EtOAc (3 x 50 mL). The organic extracts were combined, dried (Na₂SO₄) and concentrated to afford a colorless oil, which was purified by silica gel chromatography (Hexanes/Acetone 0—100% gradient) to afford intermediate alcohol **I-83** (183.8 mg, 52% yield over 2 steps) as a colorless oil.

To a solution of alcohol **I-83** (183.8 mg, 1.17 mmol), phthalimide (258 mg, 1.5 equiv.) and triphenylphosphine (460 mg, 1.5 equiv.) in THF (6 mL) that had been cooled to 0—5 °C was added DIAD (0.35 mL, 1.5 equiv.). The reaction mixture was allowed to warm to ambient temperature and concentrated after 2.5 hours. Purification of the resulting residue by silica gel chromatography (EtOAc) afforded phthalimide **I-84** (263.2 mg, 79% yield) as a colorless oil.

To a solution of phthalimide **I-84** (263.2 mg, 0.92 mmol) in MeOH (5 mL) was added hydrazine hydrate (0.29 mL, 10.0 Equiv). The reaction mixture was stirred at ambient temperature for 24 hours and then filtered. The filter cake was washed with MeOH (10 mL). The combined filtrate and wash were concentrated to a residue, which was re-dissolved in DMF (3 mL). Thiodiglycolic anhydride (121.5 mg, 1.0 equiv.) was added and the reaction mixture was stirred at ambient temperature for 4 hours, then purified by preparative HPLC (0—30% MeCN/25 mM NH₄OAc gradient over 35 minutes) to afford 22.8 mg (9% yield, 2 steps) of **I-85** as a colorless oil. ESI-MS: Found 289.2, C₁₂H₂₁N₂O₄S (MH⁺) requires 289.1.

Synthesis of **I-87** is depicted in Scheme 33:




Scheme 33

To a solution of 1-(2-hydroxyethyl)azepan-2-one (97 mg, 0.62 mmol), triphenylphosphine (242.9 mg, 1.5 equiv.), and phthalimide (136.1 mg, 1.5 equiv.) in THF (3 mL) at ambient temperature was added DIAD (0.18 mL, 1.5 equiv.). The reaction

mixture was allowed to warm to ambient temperature and concentrated after 2.5 hours. Purification of the resulting residue by silica gel chromatography (EtOAc) afforded phthalimide **I-86**, which co-eluted with triphenylphosphine oxide. The phthalimide was dissolved in EtOH (10 mL) and hydrazine hydrate (0.19 mL, 10 equiv.) was added. The reaction mixture was heated to 80 °C for 1.5 hours and then cooled to ambient temperature and filtered. The filtrate was concentrated to afford a residue. DMF (3 mL) was added, and the suspension afforded was clarified by centrifugation. Thiodiglycolic anhydride (81.5 mg, 1.0 equiv.) was added to the supernatant and the reaction mixture was maintained at ambient temperature for 24 hours. Purification by preparative HPLC (H₂O/MeCN with 0.1% TFA) to afford 34.1 mg (19% yield, 3 steps) of **I-87** as a colorless oil. ESI-MS: Found 289.2, C₁₂H₂₁N₂O₄S (MH⁺) requires 289.1.

Synthesis of **I-89** and **I-90** is depicted in Scheme 34:



Scheme 34


I-89: a slurry of (*S*)-2-methylglutaric acid (68.5 mg, 0.469 mmol), benzyl (2-aminoethyl)carbamate (91.1 mg, 1.0 equiv.), T3P (50% w/v solution in DMF, 1.5 mL, 5.0 equiv.), and DIPEA (817 μL, 10.0 equiv.) in DMF (3 mL) was stirred at ambient temperature for 63 hours and then heated to 80 °C for 4 hours. The reaction mixture was cooled and diluted with EtOAc (10 mL) and saturated aqueous NaHCO₃ (10 mL). The phases were separated, and the aqueous phase was extracted with EtOAc (2 x 10 mL). The combined organic extracts were dried (MgSO₄) and concentrated to afford a colorless oil, which was purified by silica gel chromatography to afford imide **I-88** (25.8 mg, 18% yield) as a colorless oil.

To imide **I-88** (25.8 mg, 0.085 mmol) was added 33% v/v HBr/AcOH (2 mL). The reaction mixture was maintained at ambient temperature for 1 hour and then concentrated. The residue was triturated with Et₂O (10 mL) and the Et₂O was discarded. The remaining

residue was dissolved in DMF (1 mL). Thiodiglycolic anhydride (13.4 mg, 1.2 equiv. based on imide **I-88**) was added, followed by DIPEA (74 μ L, 5.0 equiv.). The reaction mixture was maintained at ambient temperature for 16 hours and then purified by preparative HPLC (H₂O/MeCN with 0.1% TFA) to afford 20.6 mg (81% yield) of **I-89** as a colorless oil. ESI-MS: Found 303.2, C₁₂H₁₉N₂O₅S (MH⁺) requires 303.1.

I-90: an analogous procedure was used to prepare enantiomeric building block **I-90**. Yield: 43 mg (62%). ESI-MS: Found 303.2, C₁₂H₁₉N₂O₅S (MH⁺) requires 303.1.

Synthesis of **I-92** is depicted in Scheme 35:




Scheme 35

To a solution of anhydride **I-93** (106.8 mg, 0.85 mmol) in DMF (2 mL) was added *tert*-butyl (2-aminoethyl)carbamate (203.5 mg, 1.5 equiv.). The reaction mixture was maintained at ambient temperature for 1.5 hours and then heated to 120 °C for 6 hours and 90 °C for 60 hours. The reaction mixture was cooled, diluted with H₂O (10 mL), and then extracted with EtOAc (3 x 6 mL). The combined organic extracts were dried (MgSO₄) and concentrated to afford a brown solid, which was purified by silica gel chromatography (12 g pre-packed column, 63% EtOAc/Hexanes) to afford imide **I-91** (165.3 mg, 73% yield) as a colorless oil.

To imide **I-91** (43.3 mg (0.161 mmol) was added TFA (2 mL). After 15 minutes at ambient temperature the reaction mixture was concentrated to a residue, which was redissolved in DMF (1 mL). Thiodiglycolic anhydride (23.5 mg, 1.1 equiv. based on imide **I-91**) was added, followed by DIPEA (84 μ L, 3.0 equiv.). The reaction mixture was maintained at ambient temperature for 24 hours and then purified by preparative HPLC (H₂O/MeCN with 0.1% TFA) to afford 42.4 mg (87% yield) of **I-92** as a colorless oil. ESI-MS: Found 301.2, C₁₂H₁₇N₂O₅S (MH⁺) requires 301.1.


Synthesis of **I-94** is depicted in Scheme 36:



Scheme 36

- 5 To a solution of 2-(3-aminopropyl)isoindoline-1,3-dione hydrochloride (49.8 mg, 0.207 mmol), malonic acid (43.1 mg, 2.0 equiv.), and DIPEA (0.11 mL, 3.0 equiv.) in DMF (0.9 mL) was added HATU (157.3 mg, 2.0 equiv.). The reaction mixture was agitated at ambient temperature for 3 hours and then purified by preparative HPLC (H₂O/MeCN with 0.1% TFA) to afford 6.7 mg (11% yield) of **I-94** as a colorless oil. ESI-MS: Found 291.1, 10 C₁₄H₁₅N₂O₅ (MH⁺) requires 291.1.

Synthesis of **I-96** is depicted in Scheme 37:




Scheme 37

- 15 5-methylisobenzofuran-1,3-dione (305 mg, 1.88 mmol) was dissolved in DMF (5 mL). *Tert*-butyl (3-aminopropyl)carbamate hydrochloride (595 mg, 1.5 equiv.) was added, followed by DIPEA (983 μ L, 3.0 equiv.). The reaction mixture was heated to 110 °C for 18 hours. The reaction mixture was then cooled and diluted with EtOAc (50 mL). The EtOAc solution was washed with saturated aq. NH₄Cl (20 mL) and H₂O (3 x 20 mL). The 20 aqueous washes were back-extracted with EtOAc (30 mL). The combined organic extracts were washed with brine (20 mL), dried (MgSO₄), and concentrated to a solid which was 20 purified by silica gel chromatography (39% EtOAc/Hexanes) to afford 481 mg (80% yield) of intermediate carbamate **I-95** as a white solid.

To carbamate **I-95** (40.6 mg, 0.128 mmol) was added TFA (1 mL). After 30 minutes at ambient temperature, the TFA was removed *in vacuo*. Malonic acid (26.5 mg, 2.0 equiv.) was added, followed by DIPEA (67 μ L, 3.0 equiv.) and HATU (97 mg, 2.0 equiv.) The reaction mixture was stirred at ambient temperature for 1 hour, then purified directly by HPLC (H₂O/MeCN with 0.1% TFA) to afford 13.1 mg (34% yield) of **I-96**. ESI-MS found 305.3, C₁₅H₁₇N₂O₅ (MH⁺) requires 305.1.


Synthesis of **I-98** is depicted in Scheme 38:



Scheme 38

Using a procedure similar to that described for the preparation of **I-96**, 295 mg (1.82 mmol) of 5-methylisobenzofuran-1,3-dione afforded 356.7 mg (64% yield) of phthalimide **I-97**. Phthalimide **I-97** (44.2 mg, 0.145 mmol) then afforded 18.5 mg (44% yield, 2 steps) of **I-98**. ESI-MS found 291.2, C₁₄H₁₅N₂O₅ (MH⁺) requires 291.1.

Synthesis of **I-100** is depicted in Scheme 39:




Scheme 39

To (*R*)-2-methylsuccinic acid (174.5 mg, 1.32 mmol) in DMF (2 mL) was added benzyl (2-aminoethyl)carbamate hydrochloride (304.7 mg, 1.0 equiv.), DIPEA (0.69 mL, 3.0 equiv.), and propylphosphonic anhydride (50% in DMF, 2.5 mL, 3.0 equiv.). The reaction mixture was heated to 80 °C for 1.5 hours, then cooled and concentrated. The

resulting residue was purified by silica gel chromatography to afford 48 mg (13%) of the intermediate succinimide **I-99**. HBr (33% solution in AcOH, 2 mL) was added to **I-99**. The reaction mixture was maintained at ambient temperature for 45 minutes, then concentrated under reduced pressure. The residue afforded was triturated with Et₂O (10 mL) and then redissolved in DMF (0.7 mL). DIPEA (86 μ L, 3.0 equiv) was added, followed by thiodiglycolic anhydride (21.8mg, 1.0 equiv.). The reaction mixture was maintained at ambient temperature for 3 hours and then purified by preparative HPLC (0-100% acetonitrile in water with 0.1% TFA) to afford 15.3 mg (32% yield) of **I-100**. ESI-MS found 289.2, C₁₁H₁₇N₂O₅S (MH⁺) requires 289.1.

I-101: an analogous procedure was used to synthesize enantiomeric building block **I-101**. Yield 16.2 mg (6% yield, 3 steps). ESI-MS found 289.2, C₁₁H₁₇N₂O₅S (MH⁺) requires 289.1.

Synthesis of **I-104** is depicted in Scheme 40:




Scheme 40

A solution of *tert*-butyl (2-aminoethyl)carbamate (415 mg, 2.6 mmol) and thiodiglycolic anhydride (376 mg, 1.1 equiv.) in 5 mL of DMF was treated with TEA (1.27 mL, 1.4 equiv.). The reaction mixture was stirred for 3 hours at ambient temperature at which time allyl bromide (336 μ L, 1.5 equiv.) was added and the reaction mixture was stirred for an additional 72 hours. The reaction mixture was then diluted with EtOAc (40 mL). The organic phase was washed with saturated aqueous NaHCO₃, brine, dried (Na₂SO₄), and concentrated *in vacuo*. Purification by flash chromatography (0% to 70% EtOAc in hexanes) afforded 250 mg of **I-102** as a clear oil (75% yield). ESI-MS found 331.2, C₁₄H₂₃N₂O₅S (M—H)[−] requires 331.1

A solution of **I-102** (135 mg, 0.406 mmol) in 1 mL of dioxane was treated with 3 mL of 4N HCl / dioxane and stirred for 2 hours. The reaction mixture was concentrated under reduced pressure and then placed under high vacuum for 8 hours to afford 112 mg of intermediate hydrochloride salt, a portion of which (84.1 mg, 0.313 mmol) was suspended in 5 mL of DCM, treated with DIPEA (223 μ L, 4.0 equiv.) and sonicated for 5 minutes. The resulting suspension was filtered through a plug of cotton, treated with proton sponge (201 mg, 3.0 equiv.), and added to a solution of triphosgene (56 mg, 0.6 equiv.) in 5 mL of DCM at 0 °C under N₂. After stirring for 4 hours at 0—5 °C, the reaction mixture was allowed to warm to ambient temperature, and stirring was continued another 24 hours. The reaction mixture was then diluted with 45 mL of DCM. The organic phase was washed twice with 1M aqueous NaHSO₄, brine, dried over Na₂SO₄ and concentrated *in vacuo*. The resulting residue was purified by preparative HPLC (0-100% acetonitrile in water with 0.1% TFA) to afford 32 mg of **I-103** as a white solid (31% yield). ESI-MS found 259.2, C₁₀H₁₃N₂O₄S (MH⁺) requires 259.1

A solution of **I-103** (42 mg, 0.161 mmol) in 4 mL of DCM was treated with Pd(PPh₃)₄ (46.6 mg, 0.25 equiv.) and phenylsilane (79 μ L, 4.0 equiv.) and the reaction mixture was stirred at ambient temperature for one hour. The reaction mixture was then concentrated *in vacuo* and the residue was suspended in 2.5 mL of 3:1 v/v DMSO / H₂O and filtered to give a clear solution, which was then purified directly by preparative HPLC (0-100% acetonitrile in water with 0.1% TFA) to afford 18.5 mg of **I-104** as a white solid (53% yield). ESI-MS found 217.1, C₇H₉N₂O₄S (MH⁺) requires 217.0.


Synthesis of **I-106** is depicted in Scheme 41:



Scheme 41

A solution of anhydride **I-107** (42 mg, 0.300 mmol) and *tert*-butyl (2-aminoethyl)carbamate (57.6 mg, 1.2 equiv.) in 3 mL of anhydrous dioxane were stirred over 4 Å molecular sieves for 1 hour and then decanted. 4N hydrogen chloride in dioxane (2 mL) was added to the supernatant and the reaction mixture was stirred for 16 hours and then concentrated *in vacuo* to afford the crude hydrochloride salt **I-105**. The crude hydrochloride salt was converted to 27.3 mg of acid **I-106** (29% yield over 3 steps) using **GP1**. ESI-MS found 312.9, C₁₃H₁₈N₂O₅S (MH⁺) requires 313.1.

Synthesis of **I-109** is depicted in Scheme 42:




Scheme 42

To a solution of 3,4-dihydro-1,8-naphthyridin-2(1H)-one (106 mg, 0.714 mmol) in 2.4 mL of anhydrous DMF at 0 °C was added sodium hydride (34.4 mg of a 60% dispersion in mineral oil, 1.2 equiv.), and the resulting suspension was stirred 10 minutes. *Tert*-butyl (2-bromoethyl)carbamate (176 mg, 1.1 equiv.) was added in two portions and the solution was allowed to warm to ambient temperature and stirred for two hours. The reaction was quenched with 25 mL of saturated ammonium chloride solution and then extracted three times with EtOAc. The combined organic extracts were washed with brine, dried over sodium sulfate and concentrated *in vacuo* to afford a residue, which was purified by silica gel chromatography to afford 104 mg (50% yield) of carbamate **I-108**. Carbamate **I-108** (84 mg, 0.287 mmol) was deprotected with TFA/DCM (1:1 v/v) for two hours at ambient temperature. The reaction mixture was concentrated under reduced pressure to afford a crude trifluoroacetate salt, which was dissolved in 1 mL of DMF and 5 mL of DCM and treated with a solution of thiodiglycolic anhydride (37 mg, 1.0 equiv. based on

carbamate **I-108**) and DIPEA (200 μ L, 4.0 equiv.) in 1 mL of DMF. The reaction mixture was stirred for 2 hours. A solution of EDC (72 mg, 1.3 equiv.) and pentafluorophenol (67 mg, 1.3 equiv.) in 1 mL of DMF was then added; stirring was continued for 18 hours. The reaction mixture was then diluted with 50 mL of DCM. the organic phase was washed with 1 N aqueous NaHSO₄ then brine, dried over Na₂SO₄ and concentrated under reduced pressure to afford a residue, which was purified by flash chromatography (0 to 80% ethyl acetate in hexanes) to afford 97 mg of ester **I-109** (69% yield). ESI-MS found 489.9, C₂₀H₁₅F₅N₃O₄S (M—H)[–] requires 490.1.

Synthesis of I-111 is depicted in Scheme 43:




Scheme 43

A solution of 5-nitroisobenzofuran-1,3-dione (295 mg, 1.53 mmol) and *tert*-butyl (2-aminoethyl)carbamate (367 mg, 1.5 equiv.) in 9 mL of anhydrous DMF was stirred for 30 minutes at ambient temperature and then for 2 hours at 120 °C. The reaction mixture was allowed to cool to ambient temperature and diluted with 40 mL of EtOAc. The organic phase was washed with water and brine. The combined organic phase was then dried over sodium sulfate and concentrated under reduced pressure to a residue, which was purified by silica gel chromatography to afford 302 mg (90% yield) of carbamate **I-110**.

Carbamate **I-110** (132 mg, 0.395 mmol) was deprotected with TFA/DCM (1:1 v/v) for two hours at ambient temperature, and the reaction mixture was concentrated under reduced pressure to afford the crude trifluoroacetate salt. The crude trifluoroacetate salt was dissolved in 4 mL of DMF and treated with a solution of thiodiglycolic anhydride

(58.5 mg, 1.1 equiv. based on carbamate **I-110**) and DIPEA (85 μ L, 1.2 equiv.) in 1 mL of DCM. The reaction mixture was stirred for 18 hours and then a solution of EDC (68 mg, 0.8 equiv.) and pentafluorophenol (58 mg, 0.8 equiv.) in 1 mL of DMF was added and stirring was continued for 1 hour. The reaction mixture was then diluted with 30 mL of DCM. The organic phase was washed with 1 N aqueous NaHSO_4 and brine, dried over Na_2SO_4 , and concentrated under reduced pressure to afford a residue which was purified by flash chromatography (0 to 60% ethyl acetate in hexanes) to afford 111 mg of ester **I-111** (46% yield). ESI-MS found 533.8, $\text{C}_{20}\text{H}_{12}\text{F}_5\text{N}_3\text{O}_7\text{S}$ (MH^+) requires 534.0.

Synthesis of I-113 is depicted in Scheme 44:




Scheme 44

A suspension of 4-nitroisobenzofuran-1,3-dione (145 mg, 0.765 mmol) and *tert*-butyl (2-aminoethyl)carbamate (184 mg, 1.5 equiv.) were stirred over 4 Å molecular sieves in a sealed tube at 130 °C for 16 hours. The reaction mixture was filtered, concentrated *in vacuo*, and purified by silica gel chromatography to afford 82 mg (32% yield) of carbamate **I-112** which was deprotected in 1:1 DCM / TFA for two hours at ambient temperature followed by concentration *in vacuo* to give a crude trifluoroacetate salt. The salt was dissolved in 4 mL of DMF and treated with a solution of thiodiglycolic anhydride (32 mg, 0.24 mmol) and DIPEA (48 μ L, 0.27 mmol) in 1 mL of DMF. The reaction mixture was stirred for 2 hours and then a solution of EDC (68 mg, 0.32 mmol) and pentafluorophenol (58 mg, 0.32 mmol) in 1 mL of DMF was added; stirring was continued for one hour. The reaction mixture was then diluted with 30 mL DCM, and the organic phase was washed

with 1 N NaHSO₄ and brine, dried over Na₂SO₄, and concentrated under reduced pressure to afford a residue which was purified by flash chromatography (0 to 60% ethyl acetate in hexanes) to afford 50 mg of **I-113** (39% yield). ESI-MS found 533.8, C₂₀H₁₂F₅N₃O₇S (MH⁺) requires 534.0.

5

Synthesis of **I-115** is depicted in Scheme 45:




Scheme 45

To a solution of thiazolidin-2-one (103 mg, 1.0 mmol) in 2 mL of anhydrous DMF at 0°C was added sodium hydride (48 mg of a 60% dispersion in mineral oil, 1.2 equiv.) and the resulting suspension was stirred for 10 minutes. *Tert*-butyl (2-bromoethyl)carbamate (356 mg, 1.6 equiv.) in 2 mL of anhydrous DMF was added, and the solution was allowed to warm to ambient temperature and stirred for two hours. The reaction was quenched with 45 mL of saturated ammonium chloride solution. The reaction mixture was extracted three times with EtOAc. The combined organic extracts were washed with brine, dried over sodium sulfate, and concentrated *in vacuo* to afford a residue which was purified by silica gel chromatography to afford 125 mg (51% yield) of carbamate **I-114**. **I-114** was deprotected in TFA/DCM (1:1 v/v) for two hours at ambient temperature followed by concentration *in vacuo* to give a crude trifluoroacetate salt, which was converted to 107 mg of acid **I-115** (76% yield) following **GP1**. ESI-MS found 279.1 C₉H₁₄N₂O₄S₂ (MH⁺) requires 279.0.

20


Synthesis of **I-118** is depicted in Scheme 46:



Scheme 46

To 4-aminobutanoic acid (100 mg, 0.97 mmol) in AcOH was added phthalic anhydride (151 mg, 1.05 equiv.) and potassium acetate (286 mg, 3.0 equiv.). The reaction mixture was heated to 100 °C for 16 hours when LC-MS analysis indicated complete formation of phthalimide **I-116**. The reaction mixture was cooled and concentrated. The resulting residue was taken up in EtOAc; the organic extract was washed with 1M HCl, dried, and concentrated to afford the crude phthalimide **I-116** which was re-dissolved in DMF. HATU (400 mg, 1.1 equiv.) was added, followed by DIPEA (607 μ L, 3.5 equiv.) and β -alanine-*tert*-butyl ester hydrochloride (200 mg, 1.1 equiv.) The reaction mixture was stirred at ambient temperature until the reaction was deemed complete by LC-MS. The reaction mixture was concentrated to a residue, which was taken up in EtOAc and the organic extract was washed with 1M HCl, dried and concentrated. The resulting residue was purified by silica gel chromatography to afford 167 mg (48% yield, 2 steps) of phthalimide **I-117**. The *tert*-butyl ester of Phthalimide **I-117** was deprotected to afford **I-118** using TFA prior to coupling to the resin-bound peptide, MS (ESI) m/z calcd for $\text{C}_{15}\text{H}_{15}\text{N}_2\text{O}_5$ $[\text{M}-\text{H}]^-$: 303.1; found 302.9.


Synthesis of **I-120** is depicted in Scheme 47:



Scheme 47

A solution of phthalic anhydride (2.26 g, 20.0 mmol), 3-aminopropanoic acid (1.87 g, 21.0 mmol) and potassium acetate (3.32 g, 1.9 equiv.) in AcOH was stirred 4 hours at 100 °C, cooled to ambient temperature, and concentrated *in vacuo*. The resulting residue was dissolved in EtOAc, washed with 1 N HCl then brine, dried over sodium sulfate, and concentrated *in vacuo* to afford 4.25 g of the crude acid **I-119** (97% yield). A portion of this material (59 mg, ca. 0.270 mmol) was dissolved in DMF and HATU (113 mg, 1.1 equiv.), *tert*-butyl 4-aminobutanoate hydrochloride (58 mg, 1.1 equiv.), and DIPEA (156 μL, 3.5 equiv.) were added. The reaction mixture was stirred at ambient temperature for 18 hours and then concentrated *in vacuo*. The residue was dissolved in EtOAc, and the resulting solution was washed with 1 M HCl, dried over sodium sulfate, and concentrated *in vacuo*. Purification by flash chromatography using hexanes/EtOAc followed by treatment with 1:1 DCM / TFA for 2 hours, concentration *in vacuo* and flash chromatography of the resulting residue with 20% MeOH and 1% AcOH in DCM afforded 39 mg of **I-120** (108 mmol, 40% over two steps).


Synthesis of I-122 is depicted in Scheme 48:



Scheme 48

A solution of 5-methylisobenzofuran-1,3-dione (162 mg, 1.0 mmol), *tert*-butyl (2-aminoethyl)carbamate hydrochloride (207 mg, 1.05 equiv.) and TEA (278 μ L, 2.0 equiv.) in DCM was stirred for 18 hours at ambient temperature. Then 4 Å molecular sieves and DMF were added and the reaction mixture was stirred at 75 °C for 18 hours. The reaction mixture was diluted with EtOAc, filtered, washed with saturated sodium bicarbonate and brine, then dried over sodium sulfate, and concentrated *in vacuo* to afford 300 mg of the intermediate imide **I-121** (99% yield). This material was deprotected by treatment with 4 N HCl in dioxane followed by concentration *in vacuo*. A portion of the crude amine hydrochloride (30 mg, 0.125 mmol) was suspended in DCM and treated with thiodiglycolic anhydride (20 mg, 1.2 equiv.) and DIPEA (48 μ L, 2.2 equiv.). The reaction mixture was stirred for 4 hours, concentrated *in vacuo*, and the residue was dissolved in EtOAc. The solution was washed with 1 M HCl and brine, dried over sodium sulfate, and concentrated *in vacuo* to afford 43 mg of the crude acid. A solution of this material, pentafluorophenol (35 mg, 0.188 mmol) and EDC (36 mg, 0.188 mmol) in DCM was stirred for one hour and then concentrated *in vacuo*. The residue obtained was dissolved in EtOAc, and the solution was washed with 1 M HCl, brine, dried over sodium sulfate and concentrated *in vacuo*. Purification by flash chromatography using EtOAc in hexanes afforded 66 mg of **I-122** (quantitative yield).


Synthesis of I-124 is depicted in Scheme 19:



Scheme 49

A solution of furo[3,4-c]pyridine-1,3-dione (100 mg, 0.671 mmol) and *tert*-butyl (2-aminoethyl)carbamate (112 mg, 1.05 equiv.) in DMF was stirred at 130 °C for 18 hours and then allowed to cool to ambient temperature. The reaction mixture was diluted with EtOAc and washed with 1 M HCl and brine. The combined aqueous washes were back-extracted with EtOAc. The combined organic extracts were dried over sodium sulfate and concentrated *in vacuo*. The resulting crude carbamate **I-123** was stirred in 1:1 DCM / TFA for 2 hours, after which removal of the solvent afforded a primary amine salt, which was suspended in DCM and treated with thiodiglycolic anhydride (98 mg, 1.1 equiv.) and DIPEA (388 μ L, 1.1 equiv.). The reaction mixture was stirred 4 hours. Pentafluorophenol (184 mg, 1.5 equiv.) and EDC (194 mg, 1.5 equiv.) were added; stirring was continued for 2 hours. The reaction mixture was diluted with EtOAc and the solution was washed with 1 M HCl then brine, dried over sodium sulfate and concentrated *in vacuo*. Purification by flash chromatography using EtOAc in hexanes afforded 200 mg of **I-124** (61% yield).

Synthesis of **I-126** is depicted in Scheme 50:



Scheme 50

A solution of 1*H*,3*H*-benzo[*de*]isochromene-1,3-dione (100 mg, 0.505 mmol) and *tert*-butyl (2-aminoethyl)carbamate (85 mg, 1.05 equiv.) in DMF was stirred at 130 °C for

3 hours and allowed to cool to ambient temperature. The reaction mixture was diluted with EtOAc and washed with 1 M HCl and brine. The combined aqueous washes were extracted with EtOAc. The combined organic extracts were dried over sodium sulfate and concentrated *in vacuo*. The resulting crude carbamate **I-125** was stirred in 1:1 DCM / TFA for 2 hours, after which removal of the solvent afforded a primary amine salt. The amine salt was suspended in DCM and treated with thiodiglycolic anhydride (73 mg, 1.1 equiv.) and DIPEA (219 μ L, 2.5 equiv.). The reaction mixture was stirred 4 hours. Pentafluorophenol (139 mg, 1.5 equiv.) and EDC (207mg, 2.0 equiv.) were added; stirring was continued for 2 hours. The reaction mixture was diluted with EtOAc and the solution was washed with 1 M HCl then brine, dried over sodium sulfate and concentrated *in vacuo*. Purification by flash chromatography using EtOAc in hexanes afforded **I-126**.


Synthesis of **I-127** is depicted in Scheme 51:



Scheme 51

A solution of *tert*-butyl (2-aminoethyl)carbamate hydrochloride (207 mg, 1.05 mmol), thiodiglycolic anhydride (132 mg, 0.95 equiv.) and DIPEA (365 μ L, 2.0 equiv.) in DCM was stirred 2 hours, concentrated *in vacuo*. The residue obtained was dissolved in EtOAc. This solution was washed with 1 M HCl and brine, dried over sodium sulfate and concentrated *in vacuo* to afford 366 mg of the crude carbamate, which was deprotected by treatment with 1:1 v/v TFA / DCM to afford the crude amine-TFA salt, **I-127**.


Synthesis of **I-129** is depicted in Scheme 52:



Scheme 52

A solution of amine salt **I-127** (34 mg, 0.111 mmol), (*meso*)-hexahydroisobenzofuran-1,3-dione (21 mg, 1.2 equiv.), and potassium acetate (33 mg, 3.0 equiv.) in AcOH was heated to 100 °C for 18 hours. The resulting mixture was cooled to ambient temperature and concentrated *in vacuo*. The residue was dissolved in EtOAc and washed with 1 M HCl then brine, and the combined aqueous washes were back-extracted with EtOAc. The combined organic extracts were dried over sodium sulfate and concentrated *in vacuo*. The resulting residue was purified by flash chromatography using 15% MeOH in DCM with 1% AcOH to afford 32 mg of intermediate acid **I-128** (88% yield). This material was dissolved in DCM along with pentafluorophenol (18.4 mg, 0.100 mmol) and EDC (19 mg, 0.100 mmol). The resulting reaction mixture was stirred for 2 hours and concentrated *in vacuo*. The residue was dissolved in EtOAc. The resulting solution was washed with 1 M HCl and brine, then dried over sodium sulfate and concentrated *in vacuo*. Purification of the residue by flash chromatography using EtOAc in hexanes afforded 43 mg of **I-129** (78% yield over two steps).


Synthesis of **I-131** is depicted in Scheme 53:



Scheme 53

A solution of amine salt **I-127** (34 mg, 0.111 mmol), furo[3,4-*b*]pyridine-5,7-dione (20 mg, 1.2 equiv.) and potassium acetate (33 mg, 3.0 equiv.) in AcOH was heated to 100 °C for 18 hours then cooled to ambient temperature and concentrated *in vacuo*. The residue was dissolved in EtOAc and the solution was washed with 1 M HCl and then brine. The combined aqueous washes were back-extracted with EtOAc. The combined organic extracts were dried over sodium sulfate and concentrated *in vacuo*. The resulting residue was purified by flash chromatography using 15% MeOH in DCM with 1% AcOH to afford 14 mg of intermediate acid **I-130** (39% yield). This material was dissolved in DCM along with pentafluorophenol (12 mg, 0.065 mmol) and EDC (16 mg, 0.086 mmol). The resulting solution was stirred for 2 hours, concentrated *in vacuo* and the residue was dissolved in EtOAc. The resulting solution was washed with 1 M HCl and brine, then dried over sodium sulfate and concentrated *in vacuo*. Purification of the residue by flash chromatography using EtOAc in hexanes afforded 17 mg of **I-131** (81% yield).

Synthesis of **I-133** is depicted in Scheme 54:




Scheme 54

A solution of amine salt **I-127** (30 mg, 0.098 mmol), 5-chloroisobenzofuran-1,3-dione (21mg, 1.2 equiv.), and potassium acetate (29 mg, 3.0 equiv.) in AcOH was heated to 100 °C for 18 hours then cooled to ambient temperature and concentrated *in vacuo*. The residue was dissolved in EtOAc and the solution was washed with 1 M HCl and then brine. The combined aqueous washes were extracted with EtOAc. The combined organic extracts were dried over sodium sulfate and concentrated *in vacuo*. The resulting residue was purified by flash chromatography using 15% MeOH in DCM with 1% AcOH to afford 29 mg of intermediate acid **I-132** (69%). This material was dissolved in DCM along with

pentafluorophenol (18 mg, 0.100 mmol) and EDC (26 mg, 0.139 mmol). The resulting reaction mixture was stirred for 2 hours and concentrated *in vacuo*; the residue was re-dissolved in EtOAc. The resulting solution was washed with 1 M HCl and brine, dried over sodium sulfate, concentrated *in vacuo*. Purification of the residue by flash chromatography using EtOAc in hexanes afforded 21 mg of **I-133** (60% yield).


Synthesis of **I-135** is depicted in Scheme 55:



Scheme 55

A solution of amine salt **I-127** (23 mg, 0.075 mmol), 4-chloroisobenzofuran-1,3-dione (16 mg, 1.2 equiv.) and potassium acetate (22 mg, 3.0 equiv.) in AcOH was heated to 100 °C for 18 hours, cooled to ambient temperature, and concentrated *in vacuo*. The residue was dissolved in EtOAc and washed with 1 M HCl then brine, and the combined aqueous washes were back-extracted with EtOAc. The combined organic extracts were dried over sodium sulfate and concentrated *in vacuo*. The resulting residue was purified by flash chromatography using 15% MeOH in DCM with 1% AcOH to afford 21 mg of intermediate acid **I-134** (79% yield). This material was dissolved in DCM along with pentafluorophenol (16 mg, 0.089 mmol) and EDC (23 mg, 0.118 mmol). The resulting reaction mixture was stirred for 2 hours and concentrated *in vacuo*. The residue was dissolved in EtOAc. The resulting solution was washed with 1 M HCl and brine, then dried over sodium sulfate and concentrated *in vacuo*. Purification of the residue by flash chromatography using EtOAc in hexanes afforded 20 mg of **I-135** (0.038 mmol, 65% yield).


Synthesis of **I-137** is depicted in Scheme 56:



Scheme 56

A solution of amine salt **I-127** (43 mg, 0.14 mmol), naphtho[2,3-*c*]furan-1,3-dione (33 mg, 1.2 equiv.), and potassium acetate (42 mg, 3.0 equiv.) in AcOH was heated to 100 °C for 18 hours. The reaction mixture was then cooled to ambient temperature and concentrated *in vacuo*. The residue afforded was dissolved in EtOAc, and the solution was washed with 1 M HCl and brine. The combined aqueous washes were back-extracted with EtOAc. The combined organic extracts were dried over sodium sulfate and concentrated *in vacuo*. The resulting residue was purified by flash chromatography using 15% MeOH in DCM with 1% AcOH to afford 20 mg of intermediate acid **I-136** (38% yield). This material was dissolved in DCM along with pentafluorophenol (15 mg, 0.081 mmol) and EDC (16 mg, 0.081 mmol). The resulting reaction mixture was stirred for 2 hours, concentrated *in vacuo* and the residue was re-dissolved in EtOAc. The resulting solution was washed with 1 M HCl and brine, then dried over sodium sulfate and concentrated *in vacuo*. Purification of the residue by flash chromatography using EtOAc in hexanes afforded 31 mg of **I-137** (98% yield).


Synthesis of **I-139** is depicted in Scheme 57:



Scheme 57

A solution of amine salt **I-127** (36 mg, 0.117 mmol), 5-(*tert*-butyl)isobenzofuran-1,3-dione (29 mg, 1.2 equiv.) and potassium acetate (11 mg, 1.0 equiv.) in AcOH was heated to 100 °C for 18 hours. The reaction mixture was then cooled to ambient temperature and concentrated *in vacuo*. The residue was dissolved in EtOAc and the solution was washed with 1 M HCl then brine, and the combined aqueous washes were back-extracted with EtOAc. The combined organic extracts were dried over sodium sulfate and concentrated *in vacuo*. The resulting residue was purified by flash chromatography using 15% MeOH in DCM with 1% AcOH to afford 49 mg of intermediate acid **I-138** containing dicarboxylic acid impurities. This material was dissolved in DCM along with pentafluorophenol (18.4 mg, 0.100 mmol) and EDC (19 mg, 0.100 mmol). The resulting reaction mixture was stirred for 2 hours, concentrated *in vacuo*, and the residue was re-dissolved in EtOAc. The resulting solution was washed with 1 M HCl and brine, dried over sodium sulfate, and concentrated *in vacuo*. Purification of the residue by flash chromatography using EtOAc in hexanes afforded 22 mg of **I-139** (37% yield over two steps).


Synthesis of **I-141** is depicted in Scheme 58:



Scheme 58

To a slurry of 3-(2-aminoethyl)thiazolidine-2,4-dione hydrochloride (43.8 mg, 0.22 mmol) and dicarboxylic acid **I-140** (81.1 mg, 2.0 equiv.) in DMF (1 mL) was added DIPEA (117 μ L, 3.0 equiv.) and HATU (127.2 mg, 1.5 equiv.). The reaction mixture was agitated at ambient temperature for 2.5 hours and then purified directly by preparative HPLC (0-100% acetonitrile in water with 0.1% TFA) to afford 62.1 mg (86% yield) of **I-141** as a white solid. ESI-MS found 325.1, $C_9H_{13}N_2O_7S_2$ (MH^+) requires 325.1.

Synthesis of **I-145** is depicted in Scheme 59:




Scheme 59

To a solution of 3,3-dimethylpiperidin-2-one (240 mg, 1.88 mmol) in DMF (5 mL) at 0 °C under N₂ was added a slurry of NaH (574 mg of 60% dispersion in mineral oil, 3.0 equiv.) in DMF (15 mL). After 20 minutes, (2-bromoethoxy)(*tert*-butyl)dimethylsilane (673 mg, 1.5 equiv.) was added. The reaction mixture was allowed to warm to ambient temperature. After 18 hours, the reaction mixture was quenched with saturated aqueous NH₄Cl (10 mL) and diluted with water (50 mL). The aqueous phase was extracted with EtOAc (3 x 50 mL). The combined EtOAc extracts were dried (Na₂SO₄) and concentrated to afford a colorless oil. Purification by silica gel chromatography (12 g pre-packed column, 0 to 25% EtOAc in Hexanes) afforded 181 mg (34% yield) of the silyl ether **I-142** as a colorless oil. This material (90 mg, 0.315 mmol) was dissolved in THF (3 mL) and treated with 1M TBAF solution in THF (0.95 mL, 3 equiv.) and the resulting solution was stirred at ambient temperature for 2 hours. The reaction mixture was then concentrated under reduced pressure to afford a residue, which was purified by preparative HPLC (H₂O/MeCN with 0.1% TFA) to provide 37.7 mg of alcohol **I-143** (70% yield).

Alcohol **I-143** was dissolved in THF (6 mL) in the presence of triphenylphosphine (85.7 mg, 1.5 equiv.) and phthalimide (48.1 mg, 1.5 equiv.). The solution was cooled to 0—5 °C, and DIAD (64 µL, 1.5 equiv.) was added; the reaction mixture was allowed to warm to ambient temperature. After 1.5 hours, the reaction mixture was concentrated to a yellow oil, which was purified by silica gel chromatography (12 g pre-packed column, eluting with 0 to 35% Acetonitrile in DCM) to afford 42.5 mg of phthalimide **I-144** (65% yield) as a colorless oil.

To a solution of phthalimide **I-144** (42.5 mg, 0.142 mmol) in MeOH (2 mL) was added hydrazine hydrate (44.2 μ L, 10.0 equiv.). The reaction mixture was heated to 45 °C for 2 hours, cooled and concentrated under reduced pressure. The residue was re-dissolved in DMF (2 mL) and thiodiglycolic anhydride (22.5 mg, 1.2 equiv. based on phthalimide **I-144**) was added. After 2 hours, the reaction mixture was subjected to purification by preparative HPLC (H₂O/MeCN with 0.1% TFA) to afford 13.0 mg (30% yield) of the desired carboxylic acid **I-145** as a colorless oil. ESI-MS: Found 301.2, C₁₃H₂₁N₂O₄S (M—H)[–] requires 301.1.


Synthesis of I-146 is depicted in Scheme 60:



Scheme 60

A suspension of 2-(2-oxopiperidin-1-yl)acetic acid (46 mg, 0.292 mmol) and *tert*-butyl 4-aminobutanoate hydrochloride (68 mg, 1.2 equiv.) in 0.5 mL of DCM was treated with DMAP (78 mg, 2.2 equiv.) and then EDC (67 mg, 1.2 equiv.). The mixture was allowed to stir at ambient temperature for 72 hours. The reaction mixture was diluted with 8 mL of DCM, and the organic phase was washed with 1 N NaHSO₃, brine, dried over Na₂SO₄, and concentrated *in vacuo*. The resulting crude ester was dissolved in 1 mL of DCM and treated with 1 mL of TFA, and the resulting solution was concentrated under a stream of nitrogen and held under high vacuum for 2 hours. Half of the crude product was purified by preparative HPLC (H₂O/MeCN with 0.1% TFA) to afford 27.6 mg (78% yield based on 0.146 mmol) of carboxylic acid **I-146**. ESI-MS: Found 243.3, C₁₁H₁₉N₂O₄ (MH⁺) requires 243.3.


Synthesis of I-147 is depicted in Scheme 61:



Scheme 61

A suspension of 3-(2-oxopiperidin-1-yl)propanoic acid (50 mg, 0.292 mmol) and *tert*-butyl 4-aminobutanoate hydrochloride (68 mg, 1.2 equiv.) in 0.5 mL of DCM was treated with DMAP (78 mg, 2.2 equiv.) and then EDC (67 mg, 1.2 equiv.). The mixture was allowed to stir at ambient temperature for 72 hours. The reaction mixture was diluted with 8 mL of DCM, and the organic phase was washed with 1 N NaHSO_3 , brine, dried over Na_2SO_4 and concentrated *in vacuo*. The resulting crude ester was dissolved in 1 mL of DCM and treated with 1 mL of TFA and the resulting solution was concentrated under a stream of nitrogen and held under high vacuum for 2 hours. Half of the crude product was then purified by preparative HPLC ($\text{H}_2\text{O}/\text{MeCN}$ with 0.1% TFA) to afford 32.8 mg (87% yield based on 0.146 mmol) of carboxylic acid I-147. ESI-MS: Found 255.1, $\text{C}_{12}\text{H}_{19}\text{N}_2\text{O}_4$ ($\text{M}-\text{H}$)⁻ requires 255.3.

Synthesis of I-148 is depicted in Scheme 62:




Scheme 62

To a suspension of 1-(2-aminoethyl)piperidin-2-one hydrobromide (71.2 mg, 0.319 mmol), adipic acid (54.0 mg, 1.2 equiv.) and DCC (78.8 mg, 1.2 equiv.) was added TEA (53 μL , 1.2 equiv.). The resulting solution was stirred at ambient temperature for 72 hours, then filtered through celite, and concentrated *in vacuo*. Purification by preparative HPLC

(H₂O/MeCN with 0.1% TFA) afforded 24 mg (23% yield) of carboxylic acid **I-148**. ESI-MS: Found 269.3, C₁₃H₂₁N₂O₄ (M—H)[–] requires 269.3.

Synthesis of **I-150** is depicted in Scheme 63:




5

Scheme 63

To a solution of 4,4-dimethylpiperidine-2,6-dione (28 mg, 0.20 mmol) and *tert*-butyl (2-bromoethyl)carbamate (45 mg, 1.0 equiv.) in 1 mL of anhydrous DMF was added potassium carbonate (41 mg, 1.5 equiv.), and the resulting suspension was stirred for 22 hours at ambient temperature. The reaction mixture was filtered and purified directly by preparative HPLC to afford 23 mg (40% yield) of carbamate **I-149**. Carbamate **I-149** was subjected to deprotection in 2:1 DCM / TFA for 10 minutes at ambient temperature. The reaction mixture was then concentrated *in vacuo* to give a crude trifluoroacetate salt, which was converted to 19 mg (74% yield) of acid **I-150** using **GPI**. ESI-MS found 317.0, C₁₃H₂₀N₂O₅S (MH⁺) requires 317.1.

15

Synthesis of **I-152** is depicted in Scheme 64:




Scheme 64

A solution of *rac*-3-phenyldihydro-2H-pyran-2,6(3H)-dione (38 mg, 0.20 mmol) and *tert*-butyl (2-aminoethyl)carbamate (38 mg, 1.2 equiv.) in 0.6 mL of anhydrous 1,4-dioxane was stirred for 35 minutes at ambient temperature. HCl in 1,4-dioxane (4N, 1.5 mL) was then added and the reaction mixture was stirred for an additional 8 days. The reaction mixture was then concentrated *in vacuo* to give a crude hydrochloride salt, which

20

was converted to 17.5 mg of **I-152** (39% yield overall) following **GP1**. ESI-MS found 365.0, $C_{17}H_{20}N_2O_5S$ (MH^+) requires 365.1.


Synthesis of **I-155** is depicted in Scheme 65:



Scheme 65

Meso-2,3-dimethylsuccinic acid (44 mg, 0.30 mmol) was dissolved in 0.2 mL of TFAA at 0 °C. The solution was allowed to slowly warm to room temperature and stirred for 70 minutes. Concentration of the reaction mixture *in vacuo* gave the crude anhydride **I-153**, which was dissolved in 1 mL of anhydrous 1,4-dioxane and treated with *tert*-butyl (2-aminoethyl)carbamate (58 mg, 1.2 equiv.). The reaction mixture was stirred for 40 minutes at ambient temperature. 4N HCl in 1,4-dioxane (1.5 mL) was then added, and the reaction mixture was stirred for an additional 136 hours and then concentrated *in vacuo* to give a crude hydrochloride salt **I-154** which was converted to 52 mg of carboxylic acid **I-155** (57% yield overall) following **GP1**. ESI-MS found 303.0, $C_{12}H_{18}N_2O_5S$ (MH^+) requires 303.1.

Synthesis of **I-157** is depicted in Scheme 66:




Scheme 66

A solution of 4,5,6,7-tetrahydroisobenzofuran-1,3-dione (46 mg, 0.30 mmol) and *tert*-butyl (2-aminoethyl)carbamate (58 mg, 1.2 equiv.) in 0.8 mL of anhydrous 1,4-dioxane was stirred 50 minutes at ambient temperature. 4N HCl in 1,4-dioxane (1 mL) was then added, and the reaction mixture was stirred for an additional 5 hours and then

concentrated *in vacuo* to give a crude hydrochloride salt **I-156**, which was converted to 55.5 mg of **I-157** (57% yield overall) following **GP1**. ESI-MS found 327.0, C₁₄H₁₈N₂O₅S (MH⁺) requires 327.1.

5 **Synthesis of I-159 is depicted in Scheme 67:**




Scheme 67

A solution of *rac*-3-isopropyl-3-methyldihydrofuran-2,5-dione (47 mg, 0.30 mmol) and *tert*-butyl (2-aminoethyl)carbamate (58 mg, 1.2 equiv.) in 0.8 mL anhydrous 1,4-dioxane was stirred for 15 minutes at ambient temperature. 4N HCl in 1,4-dioxane (0.8 mL) was then added, and the reaction mixture was stirred for an additional 41 hours and then concentrated *in vacuo* to give a crude hydrochloride salt **I-158**, which was converted to 82.0 mg of **I-159** (83% yield overall) following **GP1**. ESI-MS found 331.0, C₁₄H₂₂N₂O₅S (MH⁺) requires 331.1.

15

Synthesis of I-161 is depicted in Scheme 68:




Scheme 68

A solution of 2-oxaspiro[4.4]nonane-1,3-dione (46 mg, 0.30 mmol) and *tert*-butyl (2-aminoethyl)carbamate (58 mg, 1.2 equiv.) in 0.8 mL of anhydrous 1,4-dioxane was stirred for 70 minutes at ambient temperature. 4N HCl in 1,4-dioxane (1 mL) was then added, and the reaction mixture was stirred for an additional 66 hours and then concentrated *in vacuo* to give a crude hydrochloride salt **I-160**, which was converted to 66.0 mg of **I-161** (67% yield overall) following **GP1**. ESI-MS found 329.0, C₁₄H₂₀N₂O₅S (MH⁺) requires 329.1.

25


Synthesis of I-163 is depicted in Scheme 69:



Scheme 69

A solution of 3,3-dimethyldihydrofuran-2,5-dione (38 mg, 0.30 mmol) and *tert*-butyl (2-aminoethyl)carbamate (58 mg, 1.2 equiv.) in 0.8 mL of anhydrous 1,4-dioxane was stirred for 100 minutes at ambient temperature. Then 4N HCl in 1,4-dioxane (0.8 mL) was then added, and the reaction mixture was stirred for an additional 69 hours and then concentrated *in vacuo* to give a crude hydrochloride salt **I-162**, which was converted to 62.5 mg of **I-163** (69% yield overall) following **GP1**. ESI-MS found 303.0, C₁₂H₁₈N₂O₅S (MH⁺) requires 303.1.


Synthesis of I-165 is depicted in Scheme 70:



Scheme 70

A solution of 6,6-dimethyl-3-oxabicyclo[3.1.0]hexane-2,4-dione (70 mg, 0.50 mmol) and *tert*-butyl (2-aminoethyl)carbamate (120 mg, 1.5 equiv.) in 3 mL of anhydrous DMF was stirred for 30 minutes at ambient temperature and then for 91 hours at 120 °C. The reaction mixture was purified directly by preparative HPLC to afford 99 mg (0.35 mmol, 70% yield) of carbamate **I-164**. A portion of the carbamate **I-164** (56 mg, 0.20 mmol) was deprotected in 2:1 v/v DCM/ TFA for twenty minutes at ambient temperature. The reaction mixture was concentrated *in vacuo* to give a crude trifluoroacetate salt, which was converted to 56 mg of **I-165** (89% yield) following **GP1**. ESI-MS found 315.0, C₁₃H₁₈N₂O₅S (MH⁺) requires 315.1.

Synthesis of I-167 is depicted in Scheme 71:




Scheme 71

To 4,6-dimethyl-2H-pyran-2-one (222.8 mg, 1.79 mmol) in MeOH (5 mL) was added *N*-tert-butyloxycarbonyl-1,2-ethanediamine (496 mg, 1.7 equiv.) and TEA (0.75 mL, 3.0 equiv.). The reaction mixture was heated to 60 °C for 48 hours, then to 100 °C for a further 5 hours to ensure completion of the reaction. The reaction mixture was concentrated and purified by silica gel chromatography to afford the intermediate carbamate, **I-166**.

Carbamate **I-166** (33 mg, 0.12 mmol) was treated with TFA for deprotection. After concentration of the reaction mixture, the resulting amine salt was converted to 33.4 mg of **I-167** (90% yield) following **GP1**. ESI-MS found 299.8, C₁₃H₁₉N₂O₄S (MH⁺) requires 299.1.


Synthesis of I-168 is depicted in Scheme 72:



Scheme 72

1-(2-aminoethyl)piperidin-2-one hydrobromide (54.5 mg, 0.24 mmol) was dissolved in DMF (1 mL). DIPEA (128 μL, 3.0 equiv.) was added, followed by succinic anhydride (26.9 mg, 1.1 equiv.). The reaction mixture was agitated at ambient temperature for 3 hours and then directly purified by preparative HPLC (H₂O/MeCN with 0.1% TFA) to afford 48.2 mg (81% yield) of acid **I-168** as a white solid. ESI-MS found 243.3. C₁₁H₁₉N₂O₄ (MH⁺) requires 243.1.


Synthesis of I-169 is depicted in Scheme 73:



Scheme 73

1-(2-aminoethyl)piperidin-2-one hydrobromide (64.9 mg, 0.29 mmol) was dissolved in DMF (1 mL). DIPEA (152 μ L, 3.0 equiv.) was added, followed by glutaric anhydride (36.5 mg, 1.1 equiv.). The reaction mixture was agitated at ambient temperature for 3 hours and then directly purified by preparative HPLC (H₂O/MeCN with 0.1% TFA) to afford 76.8 mg (quantitative yield) of acid **I-169** as a white solid. ESI-MS found 256.1. C₁₂H₂₁N₂O₄ (MH⁺) requires 256.1.


Synthesis of **I-170** is depicted in Scheme 74:



Scheme 74

1-(2-aminoethyl)piperidin-2-one hydrobromide (178.2 mg, 0.8 mmol) was dissolved in DMF (0.9 mL). DIPEA (417 μ L, 3.0 equiv.) was added, followed by 2,2-dimethylsuccinic anhydride (133 mg, 1.3 equiv.). The reaction mixture was agitated at ambient temperature for 12 hours and then directly purified by preparative HPLC (H₂O/MeCN with 0.1% TFA) to afford 51.7 mg (24% yield) of acid **I-170** as a white solid. ESI-MS found 271.2. C₁₃H₂₃N₂O₄ (MH⁺) requires 271.2.


Synthesis of **I-172** is depicted in Scheme 75:



Scheme 75

To a solution of 1-methylimidazolidine-2,4-dione (44 mg, 0.20 mmol) and *tert*-butyl (2-bromoethyl)carbamate (377 mg, 8.4 equiv.) in 1.5 mL of anhydrous DMF was added potassium carbonate (41 mg, 0.30 mmol) and the resulting suspension was stirred for 20 hours at ambient temperature. The reaction mixture was then filtered, and the filtrate was subjected to preparative HPLC to afford 23 mg (0.089 mmol, 45% yield) of carbamate **I-171** which was deprotected in 2:1 v/v DCM / TFA for 15 minutes at ambient temperature. The reaction mixture was concentrated under reduced pressure to give a crude trifluoroacetate salt. A portion of this salt (66 mg, 0.218 mmol) was converted to 9 mg of acid **I-172** using **GP1** (35% yield). ESI-MS found 290.0, C₁₀H₁₅N₃O₅S (MH⁺) requires 290.1.


Synthesis of **I-174** is depicted in Scheme 76:



Scheme 76

To a solution of carboxylic acid **I-173** (125.3 mg, 0.73 mmol) and beta-alanine *tert*-butyl ester hydrochloride (146.3 mg, 1.1 equiv.) in DMF (3 mL) was added DIPEA (382 μ L, 3.0 equiv.), followed by HATU (417.4 mg, 1.5 equiv.). The reaction mixture was stirred at ambient temperature for 16 hours, then diluted with H₂O (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic extracts were washed with brine (30 mL), dried (MgSO₄), and concentrated to afford a brown oil. TFA (5 mL) was added to this oil and the reaction mixture was stirred for 1 hour at ambient temperature. The reaction mixture was then concentrated and purified by preparative HPLC (H₂O/MeCN with 0.1% TFA) to afford **I-174** (153.4 mg, 87% yield over 2 steps) as a colorless oil. ESI-MS found 243.3, C₁₁H₁₉N₂O₄ (MH⁺) requires 243.1.


Synthesis of **I-176** is depicted in Scheme 77:



Scheme 77

Using a procedure similar to that employed for the synthesis of **I-174**, carboxylic acid **I-175** (102.4 mg, 0.65 mmol) afforded 123.5 mg (83% yield, 2 steps) of **I-176** as a white solid. ESI-MS found 229.2, $\text{C}_{10}\text{H}_{17}\text{N}_2\text{O}_4$ (MH^+) requires 229.1.


Synthesis of **I-180** is depicted in Scheme 78:



Scheme 78

To a solution of carboxylic acid **I-177** (79.1 mg, 0.46 mmol) and amine hydrochloride **I-178** (77.5 mg, 1.0 equiv.) in DMF (1 mL) was added DIPEA (241 μL , 3.0 equiv.), followed by HATU (263.5 mg, 1.5 equiv.). The reaction mixture was stirred at ambient temperature for 3 hours, and then purified by preparative HPLC ($\text{H}_2\text{O}/\text{MeCN}$ with 0.1% TFA) to afford the intermediate amide **I-179** (190.2 mg) as a brown oil. This oil was redissolved in MeOH (3 mL). A solution of LiOH (22.1 mg, 2 equiv. based on carboxylic acid **I-177**) in H_2O (1 mL) was added. The reaction mixture was heated to 50 $^\circ\text{C}$ for 18 hours and then concentrated to remove MeOH. HCl (6M) was added to acidify the solution to $\text{pH} < 2$, and the crude material was purified by preparative HPLC ($\text{H}_2\text{O}/\text{MeCN}$ with 0.1% TFA) to afford **I-180** (110.4 mg, 88% yield over 2 steps) as a colorless oil. ESI-MS found 271.2, $\text{C}_{13}\text{H}_{23}\text{N}_2\text{O}_4$ (MH^+) requires 271.2.

5 **Synthesis of I-183 is depicted in Scheme 79:**




Scheme 79

Using a procedure similar to that employed for the synthesis of **I-180**, carboxylic acid **I-177** (77 mg, 0.45 mmol) afforded 62.4 mg (51% yield, 2 steps) of **I-183** as a colorless oil. ESI-MS found 271.2, $C_{13}H_{23}N_2O_4$ (MH^+) requires 271.2.

10

Synthesis of I-184 is depicted in Scheme 80:




Scheme 80

15 To a solution of carboxylic acid **I-175** (72 mg, 0.46 mmol) and glycine *tert*-butyl ester hydrochloride (76.8 mg, 1.0 equiv.) in DMF (1.1 mL) was added DIPEA (240 μ L, 3.0 equiv.), followed by HATU (261.5 mg, 1.5 equiv.). The reaction mixture was stirred at ambient temperature for 21 hours, then diluted with H_2O (1 mL), and purified by preparative HPLC ($H_2O/MeCN$ with 0.1% AcOH) to afford the amide coupling product.


20 TFA (5 mL) was added to this amide, and the reaction mixture was maintained at ambient temperature for 2 hours. The reaction mixture was then concentrated and purified by preparative HPLC ($H_2O/MeCN$ with 0.1% TFA) to afford **I-184** (84 mg, 86% yield over 2 steps) as a colorless oil. ESI-MS found 213.1 $C_9H_{13}N_2O_4$ ($M-H$)⁻ requires 213.1.

25 **Synthesis of I-185 is depicted in Scheme 81:**

**Scheme 81**


Using a procedure similar to that employed for the synthesis of **I-184**, carboxylic acid **I-177** (72.4 mg, 0.42 mmol) afforded 104.1 mg (quant., 2 steps) of **I-185** as a colorless oil. ESI-MS found 229.2 $\text{C}_{10}\text{H}_{17}\text{N}_2\text{O}_4$ (MH^+) requires 229.1.

Synthesis of **I-187** is depicted in Scheme 82:

**Scheme 82**


To a solution of carboxylic acid **I-186** (96.4 mg, 0.51 mmol) and α -aminoisobutyric acid *tert*-butyl ester hydrochloride (119.7 mg, 1.2 equiv.) in DMF (2 mL) was added DIPEA (178 μL , 2.0 equiv.), followed by HATU (290.6 mg, 1.5 equiv.). The reaction mixture was stirred at ambient temperature for 3 hours, then concentrated. TFA (5 mL) was added to the residue. The reaction mixture was stirred at ambient temperature for 1 hour and then concentrated under reduced pressure. The residue was purified by preparative HPLC ($\text{H}_2\text{O}/\text{MeCN}$ with 0.1% TFA) to afford 74 mg (53 % yield, 2 steps) of **I-187** as a white solid. ESI-MS found 273.1, $\text{C}_{10}\text{H}_{13}\text{N}_2\text{O}_5\text{S}$ ($\text{M}-\text{H}$) $^-$ requires 273.1.

Synthesis of **I-188** is depicted in Scheme 83:

**Scheme 83**

To a solution of amine hydrochloride **I-14** (46.8 mg, 0.24 mmol) and fumaric acid (55.2 mg, 2.0 equiv.) in DMF (1.2 mL) was added DIPEA (124 μ L, 3.0 equiv.), followed by HATU (135.7 mg, 1.5 equiv.). The reaction mixture was stirred at ambient temperature for 3.5 hours, then diluted with H₂O (0.3 mL), and purified by preparative HPLC (H₂O/MeCN with 0.1% TFA) to afford 45 mg (73 % yield) of **I-188** as a white solid. ESI-MS found 257.1, C₉H₉N₂O₅S (M-H⁺) requires 257.1.

Synthesis of **I-191** is depicted in Scheme 84:




Scheme 84

To a solution of dicarboxylic acid **I-189** (101.5 mg, 0.65 mmol) and HOSu (149.6 mg, 2.0 equiv.) in DCM (4 mL) was added pyridine (209 μ L, 4.0 equiv.). The solution was cooled to 0-5 °C and TFAA (183 μ L, 2.0 equiv.) was added. The reaction mixture was allowed to warm to ambient temperature, stirred for 16 hours, and then concentrated. EtOH (10 mL) was added and the precipitated solids were collected by filtration and dried *in vacuo* to afford 218 mg of crude diester **I-190**, which was taken forward to the next step without further purification.

To a solution of amine salt **I-14** (42.6 mg, 0.22 mmol) and diester **I-190** (151.7 mg, ca. 2.0 equiv.) in DMF (1.3 mL) was added DIPEA (76 μ L, 2.0 equiv.). The reaction mixture was agitated for 16 hours and then purified by preparative HPLC (H₂O/MeCN with 0.1% TFA) to afford 29 mg (34% yield) of **I-191** as a colorless oil.


Synthesis of **I-194** is depicted in Scheme 85:



Scheme 85

Diester **I-193** and activated ester **I-194** were prepared as described for **I-191**. Yield: 13 mg (10% yield) of **I-194** as a colorless oil.


Synthesis of **I-197** is depicted in Scheme 86:



Scheme 86

Diester **I-196** and activated ester **I-194** were prepared as described for **I-191**. Yield: 33.8 mg (31% yield) of **I-197** as a white solid.

10 Synthesis of **I-200** is depicted in Scheme 87:



Scheme 87

To a solution of thiazolidinedione **I-198** (1.0 g, 8.55 mmol) in anhydrous DMF (10 mL) was added NaH (376.7 mg, 9.41 mmol, 1.1 equiv.), and the reaction mixture was stirred for 30 minutes at ambient temperature. Methyl-7-bromooctanoate (2.09 g, 1.1 equiv.) was added dropwise, and the mixture was stirred at ambient temperature for 16 hours. The reaction was monitored by TLC. The reaction mixture was quenched with H₂O (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic extracts were concentrated and the residue obtained was purified by preparative TLC (Petroleum ether/EtOAc = 1:1) to afford **I-199** (900 mg, 41%) as a white solid.

TLC: (Petroleum ether/EtOAc = 1:1), UV 254 nm

R_f (compound **I-198**) = 0.4

R_f (compound **I-199**) = 0.5

A solution of thiazolidinedione **I-199** (900 mg, 3.47 mmol) in 40% aqueous HBr (10 mL) was refluxed at 110 °C for 4 hours. The reaction was monitored by TLC. Water (10 mL) was added and the reaction mixture was extracted with EtOAc (3 x 40 mL). The combined organic extracts were dried over Na₂SO₄, filtered, concentrated and the residue obtained was purified by preparative TLC (Petroleum ether/EtOAc = 1:1) to afford **I-200** (360 mg, 42%) as a white solid.


TLC: Petroleum ether/EtOAc = 1:1, UV 254 nm

R_f (compound **I-199**) = 0.5

R_f (**I-200**) = 0.1

¹H NMR (400 MHz, *d*₆-DMSO) δ 11.92 (s, 1H), 4.17 (s, 2H), 3.47 (t, *J* = 6.8 Hz, 2H), 2.18 (t, *J* = 7.2 Hz, 2H), 1.57-1.37 (m, 4H), 1.34-1.12 (m, 4H).

Synthesis of **I-202** is depicted in Scheme 88:



Scheme 88

To a solution of thiazolidinedione **I-198** (246 mg, 2.1 mmol) in anhydrous DMF (5 mL) was added NaH (53 mg, 1.1 equiv.) and the reaction mixture was stirred for 30 minutes at ambient temperature. Methyl-8-bromooctanoate (500 mg, 1.0 equiv.) was added dropwise. The mixture was stirred at ambient temperature for 16 hours. The reaction was monitored by TLC. The reaction mixture was quenched with H₂O (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic extracts were dried over Na₂SO₄, concentrated and the residue obtained was purified by preparative TLC (Petroleum ether/EtOAc = 1:1) to afford intermediate ester **I-201** (300 mg, 52%) as a white solid.

TLC: Petroleum ether/EtOAc = 1:1, UV 254 nm

R_f (compound **I-198**) = 0.4

R_f (compound **I-201**) = 0.5

A solution of ester **I-201** (300 mg, 1.1 mmol) in 40% aqueous HBr (5 mL) was refluxed at 110 °C for 4 hours. The reaction was monitored by TLC. Water (20 mL) was added and the reaction mixture was extracted with EtOAc (3 x 20 mL). The combined organic extracts were dried over Na₂SO₄, filtered, and concentrated to a residue, which was purified by preparative TLC (Petroleum Ether/EtOAc = 1:1) to afford **I-202** (144 mg, 51%) as a white solid.


TLC: Petroleum Ether/EtOAc = 1:1, UV 254 nm

R_f (compound **I-202**) = 0.5

R_f (**I-202**) = 0.1

¹H NMR (400 MHz, *d*₆-DMSO) δ 11.96 (s, 1H), 4.17 (s, 2H), 3.46 (t, *J* = 6.8 Hz, 2H), 2.18 (t, *J* = 7.6 Hz, 2H), 1.52-1.43 (m, 4H), .39-1.13 (m, 6H).

Synthesis of **I-204** is depicted in Scheme 89:



Scheme 89

To a solution of thiazolidinedione **I-198** (246 mg, 2.1 mmol) in anhydrous DMF (5 mL) was added NaH (53 mg, 1.1 equiv.) and the mixture was stirred for 30 minutes at ambient temperature. Methyl-9-bromononanoate (500 mg, 0.95 equiv.) was added dropwise and the mixture was stirred at ambient temperature for 4 hours. The reaction was monitored by TLC. The reaction mixture was quenched with H₂O (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic extracts were dried over Na₂SO₄,

concentrated, and the residue obtained was purified by preparative TLC (Petroleum Ether/EtOAc = 1:1) to afford ester **I-203** (287 mg, 48%) as a white solid.

TLC: Petroleum Ether/EtOAc = 1:1, UV 254 nm

R_f (compound **I-198**) = 0.4

5 R_f (ester **I-203**) = 0.5

A solution of ester **I-203** (287 mg, 1.0 mmol) in 40% aqueous HBr (5 mL) was refluxed at 110 °C for 4 hours. The reaction was monitored by TLC. Water (10 mL) was added, and the reaction mixture was extracted with EtOAc (3 x 20 mL). The combined organic extracts were dried over Na₂SO₄, filtered, concentrated, and the residue obtained
10 was purified by preparatory TLC (Petroleum Ether/EtOAc = 1:1) to afford **I-204** (122 mg, 45%) as a white solid.


TLC: Petroleum Ether/EtOAc = 1:1, UV 254 nm

R_f (compound **I-203**) = 0.5

R_f (**I-204**) = 0.1

15 ¹H NMR (400 MHz, DMSO) δ 11.98 (s, 1H), 4.17 (s, 2H), 3.44 (t, J = 6.0 Hz, 2H), 2.48 (t, J = 6.0 Hz, 2H), 1.55-1.36 (m, 4H), 1.32-1.09 (m, 8H).

Synthesis of **I-209** is depicted in Scheme 90:



20

Scheme 90

To a solution of thiazolidinedione **I-198** (1.0 g, 8.55 mmol) in anhydrous DMF (10 mL) was added 60% NaH (376 mg, 1.1 equiv.) and the reaction mixture was stirred at ambient temperature for 1 hour. *Tert*-butyl (3-bromopropyl)carbamate (2.24 g, 1.1 equiv.) was added and the reaction mixture was stirred at ambient temperature for 3 hours. The

reaction was monitored by TLC. The reaction mixture was quenched with H₂O (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic extracts were washed with brine, dried over Na₂SO₄, concentrated, and the residue obtained was purified by preparative TLC (Petroleum Ether/EtOAc = 1:1) to afford carbamate **I-205** (889 mg, 38%) as a light yellow solid.

TLC: Petroleum Ether/EtOAc = 1:1, UV 254 nm

R_f (compound **I-198**) = 0.5

R_f (carbamate **I-205**) = 0.6

To a solution of carbamate **I-205** (500 mg, 1.82 mmol) in DCM (5 mL) was added TFA (0.5 mL). The reaction mixture was stirred at ambient temperature for 1 hour. The reaction was monitored by TLC. The reaction mixture was concentrated under reduced pressure to afford amine **I-206** (315 mg, 99%) as a light yellow solid.

TLC: Petroleum Ether/EtOAc = 1:1, UV 254 nm

R_f (compound **I-205**) = 0.6

R_f (compound amine **I-206**) = 0.1

A solution of amine **I-206** (315 mg, 1.81 mmol), carboxylic acid **I-207** (263 mg, 1.0 equiv.), HATU (688 mg, 1.1 equiv.), and DIPEA (851 mg, 4.0 equiv.) in anhydrous DMF (3 mL) was stirred at ambient temperature for 16 hours. The reaction was monitored by TLC. The reaction mixture was quenched with H₂O (5 mL) and extracted with EtOAc (3 x 5 mL). The combined organic extracts were dried over Na₂SO₄, and concentrated to a residue that was purified by preparative TLC (Petroleum Ether/EtOAc = 1:1) to afford amide **I-208** (250 mg, 48%) as a light yellow solid.

TLC: Petroleum Ether/EtOAc = 1:1, UV 254 nm

R_f (amine **I-206**) = 0.1

R_f (amide **I-208**) = 0.6

To a solution of amide **I-208** (250 mg, 0.79 mmol) in DCM (3 mL) was added TFA (0.3 mL). The mixture was stirred at ambient temperature for 4 hours. The reaction was monitored by TLC. The reaction mixture was concentrated to afford a residue, which was purified by preparative HPLC to yield acid **I-209** (50 mg, 24%) as a white solid.

TLC: Petroleum Ether/EtOAc = 1:1, UV 254 nm


R_f (amide **I-208**) = 0.6

R_f (**I-209**) = 0.1

^1H NMR (400 MHz, DMSO): δ 12.48 (br. s, 1H), 8.06 (s, 1H), 4.16 (s, 2H), 3.49 (t, J = 6.8 Hz, 2H), 3.08 (s, 2H), 3.06-3.00 (m, 2H), 1.65-1.57 (m, 2H).

5

Synthesis of **I-213** is depicted in Scheme 91:



Scheme 91

A solution of thiazolidinedione **I-198** (5.0 g, 42.7 mmol) and KOH (2.63 g, 1.1 equiv.) in EtOH (50 mL) was refluxed for 4 hours. The reaction mixture was concentrated to give the crude potassium salt (6.62 g) as a white solid. To a solution of this salt (6.62 g, 42.7 mmol) in DMF (70 mL) was added K_2CO_3 (25 g, 170.8 mmol, 4.0 equiv.) and methyl-3-bromopropionate (21.4 g, 3.0 equiv.). The reaction mixture was stirred at ambient temperature for 16 hours. The reaction was monitored by TLC and quenched with H_2O (100 mL), then extracted with EtOAc (3 x 80 mL). The combined organic extracts were washed with brine, dried over Na_2SO_4 and concentrated under reduced pressure to a residue, which was purified by flash chromatography on silica (Petroleum Ether/EtOAc = 20:1-5:1) to afford ester **I-210** (2.8 g, 32%) as a light yellow oil.

TLC: Petroleum Ether/EtOAc = 1:1, UV 254 nm

R_f (compound **I-198**) = 0.1

R_f (compound **I-210**) = 0.5

A solution of ester **I-210** (3.16 g, 15.56 mmol) in 45% HBr (25 mL) was refluxed at 110 °C for 4 hours. The reaction was monitored by TLC. Water (25 mL) was added and the reaction mixture was extracted with EtOAc (3 x 20 mL). The combined extracts were washed with brine, dried over Na_2SO_4 , filtered, and concentrated to a residue, which was

purified by preparative TLC (Petroleum Ether/EtOAc = 1:1) to afford carboxylic acid **I-211** (2.73 g, 93%) as a white solid.

TLC: Petroleum Ether/EtOAc = 1:1, UV 254 nm

R_f (ester **I-210**) = 0.5

5 R_f (carboxylic acid **I-211**) = 0.1

A solution of carboxylic acid **I-211** (719 mg, 3.8 mmol), gamma-aminobutyric acid *tert*-butyl ester (550 mg, 3.45 mmol, 1.0 equiv.), BOP (2.52 g, 1.1 equiv.) and DIPEA (2.25 g, 4.0 equiv.) in anhydrous DMF (8 mL) was stirred at ambient temperature for 16 hours. The reaction was monitored by TLC. The reaction mixture was quenched with H₂O (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic extracts were dried
10 over Na₂SO₄, concentrated and the residue obtained was purified by preparative TLC (Petroleum Ether/EtOAc = 1:1) to afford amide **I-212** (600 mg, 52%) as a light yellow solid.

TLC: Petroleum Ether/EtOAc = 1:1, UV 254 nm

15 R_f (carboxylic acid **I-211**) = 0.1

R_f (amide **I-212**) = 0.5

To a solution of amide **I-212** (300 mg, 0.91 mmol) in DCM (3 mL) was added TFA (0.3 mL). The reaction mixture was stirred at ambient temperature for 2 hours. The reaction was monitored by TLC. The reaction mixture was concentrated and the residue obtained
20 was purified by preparative HPLC to afford **I-213** (52 mg, 21%) as a white solid.


TLC: Petroleum Ether/EtOAc = 1:1, UV 254 nm

R_f (carboxylic acid **I-211**) = 0.5

R_f (**I-213**) = 0.1

¹H NMR (400 MHz, DMSO) δ 12.05 (s, 1H), 7.98 (t, *J* = 5.2 Hz, 1H), 4.14 (s, 2H),
25 3.66 (t, *J* = 7.6 Hz, 2H), 3.02-2.96 (m, 2H), 2.31 (t, *J* = 7.2 Hz, 2H), 2.20 (t, *J* = 7.6 Hz, 2H), 1.61-1.53 (m, 2H).

Synthesis of I-217 is depicted in Scheme 92:



Scheme 92

To a solution of thiazolidinedione **I-198** (1.62 g, 13.8 mmol) in anhydrous DMF (15 mL) was added NaH (552 mg, 1.0 equiv.) and the reaction mixture was stirred for 10 min at ambient temperature. Methyl-4-bromobutanoate (2.5 g, 1.0 equiv.) was added dropwise, and the reaction mixture was stirred at ambient temperature for 4 hours. The reaction was monitored by TLC. H₂O (20 mL) was added and the mixture was extracted with EtOAc (3 x 20 mL). The combined organic extracts were washed with 5% HCl solution, dried over Na₂SO₄, and concentrated; the residue obtained was purified by preparative TLC (Petroleum Ether/EtOAc = 2:1) to afford ester **I-214** (1.8 g, 60% yield) as a colorless oil.

TLC: Petroleum Ether/EtOAc = 1:1, UV 254 nm

R_f (compound **I-198**) = 0.2

R_f (ester **I-214**) = 0.5

A solution of ester **I-214** (1.8 g, 8.29 mmol) in 40% HBr (15 mL) was refluxed at 110 °C for 4 hours. The reaction was monitored by TLC. Water (15 mL) was added, and the reaction was extracted with EtOAc (3 x 50 mL). The combined organic extracts were dried over Na₂SO₄, filtered, and concentrated; the residue obtained was purified by preparative TLC (EtOAc) to afford carboxylic acid **I-215** (1.3 g, 77%) as a white solid.

TLC: Petroleum Ether/EtOAc = 2:1, UV 254 nm

R_f (ester **I-214**) = 0.6

R_f (carboxylic acid **I-215**) = 0.3

A solution of carboxylic acid **I-215** (200 mg, 1.0 mmol), DIPEA (387 mg, 3.0 equiv.), β -alanine-*tert*-butyl ester (143 mg, 1.0 equiv.) and HATU (564 mg, 1.5 equiv.) in anhydrous DMF (2 mL) was stirred at ambient temperature for 16 hours. The reaction was monitored by TLC. H₂O (10 mL) was added and the reaction mixture was extracted with

DCM (3 x 10 mL). The combined organic extracts were dried over Na₂SO₄, and concentrated; the residue obtained was purified by preparative TLC (Petroleum Ether/EtOAc = 1:2) to afford amide **I-216** (150 mg, 46%) as a light yellow oil.

TLC: Petroleum Ether/EtOAc = 1:1, UV 254 nm

R_f (carboxylic acid **I-215**) = 0.2


R_f (amide **I-216**) = 0.7

To a solution of amide **I-216** (150 mg, 0.455 mmol) in DCM (2 mL) was added TFA (2 mL). The reaction mixture was stirred at ambient temperature for 2 hours. The reaction was monitored by LC-MS. The reaction mixture was concentrated, and the residue obtained was purified by preparative HPLC to afford **I-217** (30 mg, 24%) as a colorless oil.

LC-MS: 275 (M+1)

¹H NMR (400 MHz, CD₃OD): δ 4.06 (s, 2H), 3.63 (t, *J* = 6.4 Hz, 2H), 3.42-3.38 (m, 2H), 2.50 (t, *J* = 7.6 Hz, 2H), 2.20 (t, *J* = 7.2 Hz, 2H), 1.90-1.85 (m, 2H).

Synthesis of **I-221** is depicted in Scheme 93:



Scheme 93

To a solution of thiazolidinedione **I-198** (2 g, 17.1 mmol) in anhydrous DMF (25 mL) was added NaH (820 mg, 1.2 equiv.), and the reaction mixture was stirred for 10 minutes at ambient temperature. Methyl-5-bromopentanoate (3.66 g, 1.1 equiv.) was added dropwise to the reaction and the mixture was stirred at ambient temperature for 4 hours. The reaction was monitored by TLC. H₂O (40 mL) was added, and the reaction mixture was extracted with EtOAc (3 x 30 mL). The combined organic extracts were washed with 5% HCl solution, dried over MgSO₄, and concentrated. The residue obtained was purified

by preparative TLC (Petroleum Ether/EtOAc = 2:1) to afford ester **I-218** (1.23 g, 31%) as a colorless oil.

TLC: Petroleum Ether/EtOAc = 2:1, UV 254 nm

R_f (compound **I-198**) = 0.2

5 R_f (ester **I-218**) = 0.5

A solution of ester **I-218** (1.23 g, 5.32 mmol) in 40% HBr (12 mL) was refluxed at 110 °C for 4 hours. The reaction was monitored by TLC. Water (12 mL) was added, and the reaction mixture was extracted with EtOAc (3 x 50 mL). The combined organic extracts were dried over MgSO₄, filtered, and concentrated; the residue obtained was purified by
10 preparative TLC (EtOAc) to afford carboxylic acid **I-219** (777 mg, 67%) as a white solid.

TLC: Petroleum Ether/EtOAc = 2:1, UV 254 nm

R_f (ester **I-218**) = 0.6

R_f (carboxylic acid **I-219**) = 0.3

A solution of carboxylic acid **I-219** (200 mg, 0.922 mmol), DIPEA (142 mg, 1.2 equiv.), glycine-*tert*-butyl ester (145 mg, 1.2 equiv.) and HATU (420 mg, 1.2 equiv.) in anhydrous DMF (5 mL) was stirred at ambient temperature for 4 hours. The reaction was monitored by TLC. H₂O (10 mL) was added and the reaction mixture was extracted with DCM (3 x 10 mL). The combined organic extracts were dried over Na₂SO₄, and concentrated. The residue obtained was purified by preparative TLC (Petroleum
15 Ether/EtOAc = 1:2) to give amide **I-220** (200 mg, 66%) as a yellow oil.

TLC: Petroleum Ether/EtOAc = 1:1, UV 254 nm

R_f (carboxylic acid **I-219**) = 0.2


R_f (amide **I-220**) = 0.7

To a solution of amide **I-220** (200 mg, 0.606 mmol) in DCM (2 mL) was added
25 TFA (2 mL). The reaction mixture was stirred at ambient temperature for 2 hours. The reaction was monitored by LC-MS. The reaction mixture was concentrated, and the residue obtained was purified by preparative HPLC to give **I-221** (77 mg, 46%) as a white solid.

LC-MS: 275 (M+1)

¹H NMR (400 MHz, CD₃OD): δ 4.07 (s, 2H), 3.88 (s, 2H), 3.63 (t, J = 6.4 Hz, 2H),
30 2.29 (t, J = 6.4 Hz, 2H), 1.63-1.30 (m, 4H).

The synthesis of compound I-225 involved 4 steps as depicted in the following Scheme 94.



Scheme 94

The chemical structure of the target compound was confirmed by ¹H NMR and LC-MS with the purity > 95% (HPLC 214 & 254 nm).

Step 1: *tert*-butyl (*R*)-(2-(3-hydroxy-2,5-dioxopyrrolidin-1-yl)ethyl)carbamate (I-222)

A mixture of (*R*)-2-hydroxysuccinic acid (cas: 636-61-3, 2 g, 14.92 mmol), *tert*-butyl (2-aminoethyl)carbamate (cas: 57260-73-8, 2 g, 1.0 equiv.) in toluene (25 mL) was refluxed at 130 °C for 2 hours. The reaction mixture was then cooled to ambient temperature and concentrated to give the crude product. The crude product was purified by silica gel chromatography to provide I-222 as a pale yellow oil (0.624 g, 17% yield). MS (ESI, pos. ion) m/z: 281(M+Na).

Step 2: *tert*-butyl (*R*)-(2-(3-methoxy-2,5-dioxopyrrolidin-1-yl)ethyl)carbamate (I-223)

To a solution of *tert*-butyl (*R*)-(2-(3-hydroxy-2,5-dioxopyrrolidin-1-yl)ethyl)carbamate (0.624 g, 2.42 mmol) in anhydrous MeCN (10 mL) at 0-5 °C was added Ag₂O (1.12 g, 2.0 equiv.) under N₂. The reaction mixture was then stirred for 5 minutes and MeI (0.309 g, 0.9 equiv.) was added to the reaction. The reaction mixture was allowed to warm to ambient temperature and stirred for another 10 hours, then filtered. The filtrate was concentrated in vacuo to give the crude product, which was purified by preparative

TLC (Petroleum ether: EtOAc = 1:2) to provide **I-223** as a pale oil (0.2 g, 30% yield). MS (ESI, pos. ion) m/z: 295 (M+Na).

Step 3: **(R)-1-(2-aminoethyl)-3-methoxypyrrolidine-2,5-dione (I-224)**


5 A solution of *tert*-butyl (*R*)-(2-(3-methoxy-2,5-dioxopyrrolidin-1-yl)ethyl)carbamate (200 mg, 0.735 mmol) in TFA/DCM (1:3 v/v, 8 mL) was stirred at 25 °C for 1 hour. When LC-MS analysis indicated that the reaction was complete, the reaction mixture was concentrated under reduced pressure to afford the crude amine TFA salt **I-224** (390 mg) as a pale oil, which was used directly in next step. MS (ESI, pos. ion) m/z: 173(M+1)

10 Step 4: **(R)-2-((2-((2-(3-methoxy-2,5-dioxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (I-225)**

To a solution of (*R*)-1-(2-aminoethyl)-3-methoxypyrrolidine-2,5-dione (390 mg, 1.37 mmol) and thiodiglycolic anhydride (217 mg, 1.2 equiv.) in 5 mL of DCM was added TEA (166 mg, 1.2 equiv.). The reaction mixture was stirred for 2 hours, and then
15 concentrated in vacuo to give the crude product. The crude product was purified by preparative HPLC (Mobile Phase: MeCN/H₂O (0.1%TFA)) to afford **I-225** (130 mg, 19% yield) as a pale oil. MS (ESI, pos. ion) m/z: 305 (M+1). ¹H NMR (400 MHz, DMSO) δ 8.14 (m, 1H), 4.31 (m, 1H), 3.47 – 3.39 (m, 5H), 3.33 (s, 2H), 3.28 – 3.17 (m, 2H), 3.14 (s, 2H), 2.96 (m, 1H), 2.55 (m, 1H).

20

The synthesis of compound **I-229** involved 4 steps as depicted in the following Scheme 95.




Scheme 95

(S)-2-((2-((3-methoxy-2,5-dioxopyrrolidin-1-yl)ethyl)amino)-2-oxoethylthio)acetic acid (I-229)

5 The synthetic route for **I-229** was similar with **I-225** and commenced with (*S*)-2-hydroxysuccinic acid (cas: 97-67-6). **I-229** (pale oil, 120 mg, 15 % yield) was isolated by preparative HPLC (Mobile Phase : MeCN/H₂O (0.1%TFA)). MS (ESI, pos. ion) *m/z*: 305 (M+1). ¹H NMR (400 MHz, CDCl₃) δ 7.41 (s, 1H), 5.68 (s, 1H), 4.28 (m, 1H), 3.71 (m, 2H), 3.60 (s, 3H), 3.56 – 3.50 (m, 2H), 3.33 (m, 4H), 3.05 (m, 1H), 2.70 – 2.62 (m, 1H).

10 **E-149 (from (*R**)-I-234) and E-150 (from (*S**)-I-234):**

The syntheses of both enantiomers of **I-234** involved 5 steps as depicted in Scheme 96:



15

Scheme 96

Step 1: **1-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)-4-methylpyrrolidin-2-one (I-230)**

(2-bromoethoxy)(*tert*-butyl)dimethylsilane (cas: 86864-60-0, 3.18 g, 15 mmol) in 20 mL of THF was added dropwise to an ice-cooled suspension of 4-methylpyrrolidin-2-one (cas: 2996-58-9, 1 g, 1.0 equiv.), NaI (1.5 g, 1.0 equiv.) and NaH (2.4 g, 6.0 equiv.) in THF (50 mL) with stirring under N₂. After 2 hours, the ice bath was removed and the reaction mixture was heated to reflux overnight. The reaction was quenched with H₂O (50 mL). After removal of the solvent under reduced pressure, the residue was partitioned between EtOAc and H₂O. The aqueous layer was extracted with EtOAc (3 x 20 mL). The combined organic extracts were dried over MgSO₄, concentrated and the residue obtained was purified by silica gel chromatography to afford 360 mg (14%) of **I-230** as a pale oil. MS (ESI, pos. ion) m/z: 258 (M+1).

Step 2: **1-(2-hydroxyethyl)-4-methylpyrrolidin-2-one (I-231)**

To 1-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)-methylpyrrolidin-2-one **I-230** (550 mg, 2.14 mmol) in MeOH (5 ml) was added 10 mL of HCl (4 M in MeOH). After 10 min, MeOH was removed under reduced pressure to afford 300 mg of the crude alcohol **I-231** as a light yellow oil, which was taken forward to the next step without purification.

Step 3: **2-(2-(4-methyl-2-oxopyrrolidin-1-yl)ethyl)isoindoline-1,3-dione (I-232)**

To a stirred solution of 1-(2-hydroxyethyl)-4-methylpyrrolidin-2-one **I-231** (96 mg, 0.66 mmol), phthalimide (cas: 85-41-6, 105 mg, 1.0 equiv.) and triphenylphosphine (260 mg, 1.0 equiv.) in anhydrous THF (10 mL) was added a solution of DIAD (400 mg, 3.0 equiv.) in anhydrous THF (2 mL) dropwise at 0 °C. The reaction mixture was allowed to warm to ambient temperature and stirred for 8 hours. The reaction was monitored by LC-MS. Upon completion of the reaction, the reaction mixture was filtered. The filtrate was concentrated, and the resulting residue was purified by silica gel chromatography (10-80% EtOAc in hexanes) to give 145 mg of **I-232** (60% purity) as light oil. MS (ESI, pos. ion) m/z: 273.1 (M+1).

The racemic mixture **I-232** was subjected to chromatographic separation using a chiral column to afford the two enantiomers (CHIRALPAK AD column, (Hexane / EtOH = 50 / 50 (v/v)), but their absolute configuration was not established.

Step 4: 1-(2-(4-methyl-2-oxopyrrolidin-1-yl)ethyl)-4-methylpyrrolidin-2-one (I-233)

5 To a stirred solution of each enantiomer of 2-(2-(4-methyl-2-oxopyrrolidin-1-yl)ethyl)isoindoline-1,3-dione, **I-232** (145 mg, 0.53 mmol) in MeOH (10 mL) was added hydrazine monohydrate (40 mg, 1.5 equiv.). The reaction mixture was stirred at ambient temperature for 18 hours and then filtered. The filtrate was concentrated. The residue was dissolved in DCM, and the precipitate was again filtered off. After concentration of the
10 filtrate, the 72 mg (78%) of crude amine **I-233** was used in the next step without purification. MS (ESI, pos. ion) m/z: 143.1 (M+1).


Step 5: 2-((2-(4-methyl-2-oxopyrrolidin-1-yl)ethyl)amino)-2-oxoethylthio)acetic acid (I-234)

To a stirred solution of each enantiomer of 1-(2-(4-methyl-2-oxopyrrolidin-2-one, **I-233** (144 mg, 1.06 mmol) in DCM (10 mL) at ambient temperature was added
15 thiodiglycolic anhydride (cas: 3261-87-8, 210 mg, 1.6 mmol), and the resulting solution was stirred at ambient temperature for 1 hour. The reaction mixture was concentrated and purified by preparative HPLC to give 150 mg (55%) of **I-234** as a light oil. MS (ESI, pos. ion) m/z: 275.1 (M+1).

20 **(R*)-I-234:** ¹H NMR (400 MHz, CDCl₃) δ 7.30 (s, 1H), 3.71 – 3.61 (m, 1H), 3.58 – 3.39 (m, 4H), 3.36 (s, 2H), 3.20 (d, 2H), 3.10 (dd, 1H), 2.65 (dd, 1H), 2.49 (td, 1H), 2.13 (dd, 1H), 1.14 (s, 3H).

(S*)-I-234: ¹H NMR (400 MHz, CDCl₃) δ 7.35 (s, 1H), 3.71 – 3.61 (m, 1H), 3.58 – 3.39 (m, 4H), 3.36 (s, 2H), 3.20 (d, 2H), 3.10 (dd, 1H), 2.65 (dd, 1H), 2.49 (td, 1H), 2.13
25 (dd, 1H), 1.12 (s, 3H).

The synthesis of I-240 involved 6 steps as depicted in the following Scheme 97.



Scheme 97

5 Step 1: ***tert*-butyl 2-(2-(1,3-dioxoisindolin-2-yl)ethyl)hydrazine-1-carboxylate (I-235)**

To a solution of 2-(2-bromoethyl)isoindoline-1,3-dione (cas: 574-98-1, 20 g, 79 mmol) and *tert*-butyl hydrazinecarboxylate (cas: 870-46-2, 16 g, 1.5 equiv.) in DMF (100 mL) was added K₂CO₃ (28 g, 2 equiv.). The solution was heated to 90°C and stirred for 12 hours. Upon completion of the reaction, the reaction was quenched with water (100 mL) and extracted with EtOAc (3 x 100 mL). After drying with Na₂SO₄, the combined organic extracts were concentrated, and the crude product was purified by silica gel chromatography to provide 5 g of **I-235** as a pale oil (21% yield). MS (ESI, pos. ion) m/z: 328.2 (M+23).

15 Step 2: ***tert*-butyl 2-(2-(1,3-dioxoisindolin-2-yl)ethyl)-3-oxopyrazolidine-1-carboxylate (I-236)**

A solution of *tert*-butyl 2-(2-(1,3-dioxoisindolin-2-yl)ethyl)hydrazine-1-carboxylate (5 g, 16.4 mmol), 3-bromopropanoyl chloride (3.6 g, 1.5 equiv.) and K₂CO₃ (37 g, 2 equiv.) in DMF (80 mL) was heated to 90 °C for 16 hours. Upon completion of the reaction, the reaction was quenched with water (80 mL) and extracted with EtOAc (3 x 80 mL). After drying with Na₂SO₄, the combined organic extracts were concentrated, and the crude product was purified by silica gel chromatography to afford 3.2 g (54% yield) of **I-236** as a pale oil. MS (ESI, pos. ion) m/z: 382.2 (M+23).

Step 3: 2-(2-(5-oxopyrazolidin-1-yl)ethyl)isoindoline-1,3-dione I-237)

A solution of *tert*-butyl 2-(2-(1,3-dioxoisindolin-2-yl)ethyl)-3-oxopyrazolidine-1-carboxylate (3.2 g, 8.9 mmol) in HCl (4M in dioxane, 15 mL) was stirred at ambient temperature for 0.5 hours. Upon completion of the reaction, the reaction mixture was concentrated to afford the crude pyrazolone **I-237** (3.5 g) as a white solid, which was used directly in the next step. MS (ESI, pos. ion) m/z: 260.2(M+1).

Step 4: 2-(2-(2-methyl-5-oxopyrazolidin-1-yl)ethyl)isoindoline-1,3-dione (I-238)

To a solution of 2-(2-(5-oxopyrazolidin-1-yl)ethyl)isoindoline-1,3-dione (3.5 g, ca. 8.9 mmol) and paraformaldehyde (2.7 g, 10 equiv.) in THF was added 2 drops of AcOH. After 1 hour, NaCNBH₃ (cas: 25895-60-7, 2.8 g, 5 equiv.) was added to the reaction mixture at 0 °C. The reaction mixture was stirred for 12 hours, then quenched with water (30 mL), and extracted with DCM: MeOH (10:1) (3 x 40 mL). The combined organic extracts were dried over Na₂SO₄, and concentrated to a residue which was purified by silica gel chromatography to afford **I-238** (0.6 g, 24% yield over 2 steps) as a yellow solid. MS (ESI, pos. ion) m/z: 274.2 (M+1).

Step 5: 2-(2-aminoethyl)-1-methylpyrazolidin-3-one (I-239)

To a solution of 2-(2-(2-methyl-5-oxopyrazolidin-1-yl)ethyl)isoindoline-1,3-dione (600 mg, 2.2 mmol) in MeOH (50 mL) at 0—5 °C was added NH₂NH₂ (85% in H₂O, 1.5 mL, 2.5 equiv.). The reaction mixture was allowed to warm to ambient temperature, stirred for 12 hours, and then filtered. The filtrate was concentrated to afford the crude amine **I-239** (0.4 g) as a pale oil, which was used directly for the next step. MS (ESI, pos. ion) m/z: 144.2(M+23).


Step 6: 2-((2-((2-(2-methyl-5-oxopyrazolidin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (I-240)

A solution of 2-(2-aminoethyl)-1-methylpyrazolidin-3-one (400 mg, 2.8 mmol) and thiodiglycolic anhydride (990 mg, 2.5 equiv.) in 10 mL of DCM was stirred for 0.5 hours and then concentrated *in vacuo* to afford the crude product. Half of this crude product was purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%TFA), gradient: 5-15% MeCN) to afford 56 mg (15% yield) of **I-240** as a white solid. MS (ESI, pos. ion)

m/z: 276.2 (M+1). ¹H NMR (400 MHz, D₂O) δ 3.75-3.70 (m, 2H), 3.38-3.34 (m, 4H), 3.29 (s, 2H), 3.25 (s, 2H), 3.02-2.85 (m, 1H), 2.81-2.77 (m, 3H), 2.55-2.42 (m, 1H).

The synthesis of **I-243** involved 5 steps as depicted in the following Scheme 98.

5



Scheme 98

Step 3: *tert*-butyl 2-(2-aminoethyl)-3-oxopyrazolidine-1-carboxylate (**I-241**)

To a solution of *tert*-butyl 2-(2-(1,3-dioxoisindolin-2-yl)ethyl)-3-oxopyrazolidine-1-carboxylate, **I-236** (2 g, 5.5 mmol) in MeOH (50 mL) at 0–5 °C was added NH₂NH₂ (85% in H₂O, 1 mL, 2.5 equiv.). The reaction mixture was allowed to warm to ambient temperature, stirred for 12 hours, and then filtered. The filtrate was concentrated under reduced pressure to afford the crude amine **I-241** (0.7 g) as a pale oil, which was used directly for next step. MS (ESI, pos. ion) m/z: 252.2(M+23).


Step 4: 2-((2-((2-(2-(*tert*-butoxycarbonyl)-5-oxopyrazolidin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (**I-242**)

A solution of *tert*-butyl 2-(2-aminoethyl)-3-oxopyrazolidine-1-carboxylate **I-241** (700 mg, 3 mmol), thiodiglycolic anhydride (990 mg, 2.5 equiv.), and TEA (0.8 mL, 2 equiv.) in 10 mL of DCM was stirred for 0.5 hours. The reaction mixture was then concentrated *in vacuo* to afford the crude product as a pale oil. Half of this crude product was purified by preparative HPLC to afford 270 mg (49% yield) of **I-242** as a white solid. MS (ESI, pos. ion) m/z: 384.2 (M+23).

Step 5: 2-((2-oxo-2-((2-(5-oxopyrazolidin-1-yl)ethyl)amino)ethyl)thio)acetic acid (**I-243**)

A solution of 2-((2-((2-(2-(*tert*-butoxycarbonyl)-5-oxopyrazolidin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid **I-242** (270 mg, 0.74 mmol) in HCl (4 M in dioxane) (10 mL) was stirred at 20 °C for 0.5 hours. The reaction mixture was then concentrated and the residue obtained was purified by preparative HPLC (MeCN/H₂O with 0.1%TFA), gradient: 10-20% MeCN) to afford 160 mg (81% yield) of **I-243** as a pale oil. MS (ESI, pos. ion) m/z: 262.2 (M+1). ¹H NMR (400 MHz, DMSO) δ 8.19 (s, 1H), 3.39 (dd, 2H), 3.34 (d, 4H), 3.25 (dd, 2H), 3.20 (s, 2H), 2.44 (t, 3H).

The synthesis of **I-248** involved 5 steps as depicted in the following Scheme 99.



Scheme 99

Step 1: 1-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)piperidin-2-one (**I-244**)

To a solution of piperidin-2-one (cas: 675-20-7, 6 g, 60 mmol) in THF (200 mL) at 0—5 °C was added NaH (4.8 g, 2 equiv., 60% dispersion in mineral oil) in portions under N₂. The reaction mixture was stirred for 0.5 hours. (2-bromoethoxy)(*tert*-butyl)dimethylsilane (cas: 86864-60-0, 4.9 g, 1.2 equiv.) was then added and the reaction mixture was heated to reflux for 6 hours. The reaction was then quenched with water (50 mL), and extracted with EtOAc (3 x 80 mL). The combined organic extracts were washed with water (50 mL), brine (50 mL), dried with Na₂SO₄, and concentrated under reduced

pressure to a residue, which was purified by silica gel chromatography to afford **I-244** as a pale oil (2 g, 13% yield). MS (ESI, pos. ion) m/z : 258(M+1).

Step 2: 1-(2-(hydroxyethyl)piperidin-2-one (I-245)

To a solution of 1-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)piperidin-2-one **I-244** (2 g, 7.8 mmol) in MeOH (15 mL) at 0—5 °C was added HCl in MeOH (30% v/v, 10 mL) under N₂. The reaction mixture was stirred for 0.5 hours, then concentrated under reduced pressure to afford the crude alcohol **I-245** as a pale oil (1.2 g), which was used directly for next step. MS (ESI, pos. ion) m/z : 144(M+1).

Step 3: 2-(2-(2-oxopiperidin-1-yl)ethyl)isoindoline-1,3-dione (I-246)

To a solution of 1-(2-(hydroxyethyl)piperidin-2-one **I-245** (1.2 g, 8.4 mmol) in THF (15 mL) at 0—5 °C was added phthalimide (1.85 g, 1.5 equiv.) and PPh₃ (3.9 g, 1.8 equiv.) and the reaction mixture was stirred for 0.5 hours under N₂. DIAD (3.4 g, 2.0 equiv.) was added and the reaction mixture was allowed to warm to ambient temperature and stirred for 2 hours. The reaction mixture was then filtered, and the filtrate was concentrated under reduced pressure to afford a pale oil, which was purified by silica gel chromatography to afford **I-246** (purity: 60%, 0.7 g, 35% yield). MS (ESI, pos. ion) m/z : 273(M+1).

Step 4: 1-(2-(aminoethyl)piperidin-2-one (I-247)


To a solution of 2-(2-(2-oxopiperidin-1-yl)ethyl)isoindoline-1,3-dione **I-246** (0.7 g, 2.6 mmol) in MeOH (10 mL) at 0—5 °C was added NH₂NH₂ (85% in H₂O, 0.2 mL, 1.2 equiv.). The reaction mixture was allowed to warm to ambient temperature and stirred for 12 hours, then filtered, and the filtrate was concentrated under reduced pressure to afford the crude amine **I-247** (0.4 g) as a pale oil, which was used directly for next step. MS (ESI, pos. ion) m/z : 143(M+1).

Step 5: 2-((2-oxo-2-((2-(2-oxopiperidin-1-yl)ethyl)amino)ethyl)thio)acetic acid (I-248)

A solution of 1-(2-(aminoethyl)piperidin-2-one **I-247** (400 mg, 2.8 mmol) and thiodiglycolic anhydride (924 mg, 2.5 equiv.) in 20 mL of DCM was stirred for 0.5 hours, and then concentrated *in vacuo* to give the crude product as a pale oil. The crude product was purified by preparative HPLC (Mobile Phase: MeCN/H₂O (0.1% formic acid), Gradient: 5-15% MeCN) to afford 200 mg of **I-248** (26% yield) as a pale oil. MS (ESI, pos.

ion) m/z: 275.2 (M+1). ^1H NMR (400 MHz, CDCl_3): δ 7.57 (s, 1H), 6.48 (s, 2H), 3.83 – 3.07 (m, 10H), 2.44 (s, 2H), 1.82 (s, 4H).

The synthesis of I-249 involved 1 step as depicted in the following Scheme 100.




Scheme 100

Step 1: 2-((2-((2-cyclopentylethyl)amino)-2-oxoethyl)thio)acetic acid (I-249)

A solution of 2-cyclopentylethan-1-amine (cas: 5763-55-3, 200 mg, 1.8 mmol) and thiodiglycolic anhydride (594 mg, 2.5 equiv.) in 5 mL of DCM was stirred for 0.5 hours, and then concentrated in vacuo to afford a pale oil, which was purified by preparative HPLC (Mobile Phase: MeCN/ H_2O (0.1%TFA), Gradient: 30-40% MeCN) to provide 250 mg (56% yield) of **I-249** as a white solid. MS (ESI, pos. ion) m/z: 246.2 (M+1). ^1H NMR (400 MHz, CDCl_3): δ 6.64 (s, 1H), 3.47 – 3.22 (m, 6H), 1.79 (s, 3H), 1.68 – 1.47 (m, 6H), 1.11 (d, 2H).

The synthesis of compound I-250 involved 1 step as depicted in the following Scheme 101.




Scheme 101

The chemical structure of the target compound was confirmed by ^1H NMR and LC-MS with the purity > 95% (HPLC 214 & 254 nm).

Step1. **2-((2-((2-(1-hydroxycyclopentyl) ethyl)amino)-2-oxoethyl)thio) acetic acid (I-250)**

To a solution of 1-(2-aminoethyl) cyclopentan-1-ol (cas: 859629-83-7, 0.1 g, 0.774 mmol) and thiodiglycolic anhydride (0.102 g, 1.0 equiv.) in DCM (5 mL) was added TEA (93 mg, 1.2 equiv.) and the reaction mixture was stirred for 4 hours at ambient temperature, then concentrated under reduced pressure to afford the crude product. The crude product was purified by preparative HPLC (Mobile Phase: MeCN/H₂O (0.1%TFA)) to afford **I-250** (50 mg, 24 % yield) as a pale oil. MS (ESI, pos. ion) m/z: 262.2 (M+1). ¹H NMR (400 MHz, DMSO): δ 12.63 (s, 1H), 7.97 (s, 1H), 4.09 (m, 1H), 3.35 (s, 2H), 3.20 – 3.12 (m, 4H), 1.75 – 1.35 (m, 10H).

The synthesis of **I-257** involved 7 steps as depicted in the following Scheme 102.



Scheme 102

Step 1: **(R)-4-((tert-butyldimethylsilyl)oxy)pyrrolidin-2-one (I-251)**

To a solution of (R)-4-hydroxypyrrolidin-2-one (cas: 22677-21-0, 2.02 g, 20 mmol) in DMF (10 ml) at 0—5 °C was added *tert*-butylchlorodimethylsilane (3.62 g, 24 mmol, 1.2 equiv.) and imidazole (3.40 g, 50 mmol, 2.5 equiv.). The reaction mixture was allowed to warm to ambient temperature and stirred for 12 hours. Water (50 mL) was then added, and the reaction mixture was stirred for 10 minutes. The white solid that precipitated

was filtered and washed with water (10 mL) and dried under high vacuum to afford **I-251** (4.05 g, 95% yield). MS (ESI, pos. ion) m/z : 216.1(M+1).

Step 2: methyl (*R*)-2-(4-((*tert*-butyldimethylsilyl)oxy)-2-oxopyrrolidin-1-yl)acetate (**I-252**)

5 To a solution of (*R*)-4-((*tert*-butyldimethylsilyl)oxy)pyrrolidin-2-one, **I-251** (3.8 g, 17.37 mmol) in THF (30 mL) was added methyl 2-bromoacetate (cas:96-32-2, 4.03 g, 1.5 equiv.), potassium carbonate (0.84 g, 2.5 equiv.) and TBAB (4.94 g, 0.2 equiv.) under N₂. The reaction mixture was stirred at ambient temperature for 12 hours. The reaction was then quenched with water (10 mL), extracted with EtOAc (3 x 50 mL). The combined
10 organic extracts were then washed with water (20 mL), brine (20 mL), dried (Na₂SO₄), and concentrated under reduced pressure to a residue, which was purified by silica gel chromatography to afford **I-252** (0.71 g, 27% yield) as a pale oil. MS (ESI, pos. ion) m/z : 288.1(M+1).

15 Step 3: (*R*)-4-((*tert*-butyldimethylsilyl)oxy)-1-(2-hydroxyethyl)pyrrolidin-2-one (**I-253**)

To a solution of methyl (*R*)-2-(4-((*tert*-butyldimethylsilyl)oxy)-2-oxopyrrolidin-1-yl)acetate, **I-252** (0.71 g, 2.47 mmol) in *t*-BuOH (10 mL) was added sodium borohydride (0.38 g, 4.0 equiv.) in MeOH (0.5 mL) under N₂. The reaction mixture was stirred for 2
20 hours at 80 °C, then concentrated under reduced pressure to a residue. The residue was diluted with water (2 mL), and extracted with EtOAc (3 x 20 mL). The combined organic extracts were then washed with water (20 mL), brine (20 mL), dried (Na₂SO₄), and concentrated under reduced pressure to a residue, which was purified by silica gel chromatography to afford **I-253** as a pale oil (0.43 g, 69% yield). MS (ESI, pos. ion) m/z :
25 260.2(M+1).

Step 4: (*R*)-2-(2-(4-((*tert*-butyldimethylsilyl)oxy)-2-oxopyrrolidin-1-yl)ethyl)isoindoline-1,3-dione (**I-254**)

To a solution of (*R*)-4-((*tert*-butyldimethylsilyl)oxy)-1-(2-hydroxyethyl)pyrrolidin-2-one, **I-253** (0.43 g, 1.66 mmol) in THF (5 mL) at 0—5 °C
30 was added phthalimide (0.27 g, 1.1 equiv.) and PPh₃ (0.76 g, 1.5 equiv.). The reaction

mixture was stirred for 0.5 hours under N₂, and DIAD (1.01 g, 3.0 equiv.) was added to the solution. The reaction mixture was allowed to warm to ambient temperature and stirred for 12 hours. The resulting mixture was quenched with water (5 mL) and extracted with DCM (3 x 20 mL). The combined organic extracts were washed with water (20 mL), brine (20 mL), dried (Na₂SO₄), and concentrated under reduced pressure to a residue, which was purified by silica gel chromatography to afford **I-254** as a pale oil (0.48 g, 75% yield). MS (ESI, pos. ion) m/z: 389.2(M+1).

Step 5: **(R)-1-(2-aminoethyl)-4-((tert-butyldimethylsilyl)oxy)pyrrolidin-2-one (I-255)**

To a solution of (R)-2-(2-(4-((tert-butyldimethylsilyl)oxy)-2-oxopyrrolidin-1-yl)ethyl)isoindoline-1,3-dione, **I-254** (0.48 g, 1.24 mmol) in MeOH (10 mL) at 0–5 °C was added NH₂NH₂ (85% in H₂O, 0.06 g, 1.2 equiv.). The reaction mixture was allowed to warm to ambient temperature and stirred for 12 hours and then filtered. The filtrate was concentrated under reduced pressure to afford the crude amine, **I-255** (0.3 g) as a pale oil, which was used directly for next step. MS (ESI, pos. ion) m/z: 259.2(M+1).

Step 6: **(R)-2-((2-((2-(4-((tert-butyldimethylsilyl)oxy)-2-oxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-256)**

To a solution of (R)-1-(2-aminoethyl)-4-((tert-butyldimethylsilyl)oxy)pyrrolidin-2-one, **I-255** (0.302 mg, 1.17 mmol) in DCM (10 mL) was added thiodiglycolic anhydride (0.20 mg, 1.52 mmol, 1.3 equiv.). The reaction mixture was stirred for 2 hours at 20 °C and then concentrated under reduced pressure to afford the crude product (0.5 g) as a pale oil. The crude product **I-256** was used directly for the next step. MS (ESI, pos. ion) m/z: 391.2(M+1).


Step 6: **(R)-2-((2-((2-(4-hydroxy-2-oxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-257)**

To a solution of (R)-2-((2-((2-(4-((tert-butyldimethylsilyl)oxy)-2-oxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (0.50 g, 1.28 mmol) in DCM (5 mL) at 0–5 °C was added HCl in EtOAc (2M, 1.5 mL) under N₂. The reaction mixture was stirred for 1 hour. The reaction mixture was then concentrated under reduced pressure to afford the crude product as a pale oil. The crude product was purified by preparative HPLC (Mobile

Phase: MeCN/H₂O with 0.1%TFA), Gradient: 2-8% MeCN) to give 33.3 mg (9% yield) of **I-257** as a pale oil. MS (ESI, pos. ion) *m/z*: 277.1 (M+1). ¹H NMR (400 MHz, CDCl₃) :7.46 (s, 1H), 4.49 – 4.45 (m, 1H), 4.01 (ddd, 1H), 3.80 (ddd, 1H), 3.70 (dt, 2H), 3.39 (s, 2H), 3.35 – 3.28 (m, 1H), 3.20 (q, 2H), 3.08 (d, 1H), 2.81 – 2.74 (m, 1H), 2.57 (s, 1H).

5

The synthesis of **I-264** involved 7 steps as depicted in the following Scheme 103.



Scheme 103

Step 1: *(S)*-4-((*tert*-butyldimethylsilyl)oxy)pyrrolidin-2-one (**I-258**)

To a solution of *(S)*-4-hydroxypyrrolidin-2-one (cas: 68108-18-9, 5.0 g, 49.5 mmol) in DMF (20 mL) at 0—5 °C was added *tert*-butylchlorodimethylsilane (8.9 g, 1.2 equiv.) and imidazole (8.4 g, 2.5 equiv.). The reaction mixture was allowed to warm to ambient temperature and stirred for 12 hours. Water (50 mL) was then added and the reaction mixture was stirred for 10 minutes. The white precipitate that was formed was filtered and washed with water (15 mL) and then dried under high vacuum to afford **I-258** (9.8 g, 92% yield). MS (ESI, pos. ion) *m/z*: 216.1(M+1).

Step 2: methyl (*S*)-2-(4-((*tert*-butyldimethylsilyl)oxy)-2-oxopyrrolidin-1-yl)acetate (**I-259**)

To a solution of (*S*)-4-((*tert*-butyldimethylsilyl)oxy)pyrrolidin-2-one, **I-258** (4.9 g, 22.79 mmol) in THF (40 mL) was added methyl 2-bromoacetate (5.2 g, 1.5 equiv.), potassium carbonate (7.9 g, 2.5 equiv.) and TBAB (1.47 g, 0.2 equiv.) under N₂. The reaction mixture was stirred for 12 hours at 20 °C, quenched with water (10 mL), and extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with water (20 mL), brine (20 mL), dried (Na₂SO₄), and concentrated under reduced pressure to afford a residue, which was purified by silica gel chromatography to afford **I-259** as a pale oil (1.1 g, 29% yield). MS (ESI, pos. ion) m/z: 288.1(M+1).

Step 3: (*S*)-4-((*tert*-butyldimethylsilyl)oxy)-1-(2-hydroxyethyl)pyrrolidin-2-one (**I-260**)

To a solution of methyl (*S*)-2-(4-((*tert*-butyldimethylsilyl)oxy)-2-oxopyrrolidin-1-yl)acetate, **I-259** (1.1 g, 3.8 mmol) in *t*-BuOH (15 mL) was added sodium borohydride (0.58 g, 4.0 equiv.) in MeOH (1 mL) under N₂. The reaction mixture was stirred for 2 hours at 80 °C and then concentrated under reduced pressure to afford a residue. The residue was diluted with water (2 mL) and extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with water (20 mL), brine (20 mL), dried (Na₂SO₄), and concentrated under reduced pressure to afford a residue, which was purified by silica gel chromatography to afford **I-260** as a pale oil (0.82 g, 83% yield). MS (ESI, pos. ion) m/z: 260.2(M+1).

Step 4: (*S*)-2-(2-(4-((*tert*-butyldimethylsilyl)oxy)-2-oxopyrrolidin-1-yl)ethyl)isoindoline-1,3-dione (**I-261**)

To a solution of (*S*)-4-((*tert*-butyldimethylsilyl)oxy)-1-(2-hydroxyethyl)pyrrolidin-2-one, **I-260** (0.82 g, 3.17 mmol) in THF (10 mL) at 0—5 °C was added phthalimide (0.51 g, 1.1 equiv.) and PPh₃ (1.45 g, 1.5 equiv.). The reaction mixture was stirred for 0.5 hours under N₂ and DIAD (1.92 g, 3.0 equiv.) was added to the solution. The reaction mixture was allowed to warm to ambient temperature and stirred for 12 hours. The reaction was quenched with water (5 mL) and extracted with DCM (3 x 50 mL). The

combined organic extracts were washed with water (20 mL), brine (20 mL), dried (Na₂SO₄) and concentrated under reduced pressure to afford a residue, which was purified by silica gel chromatography to afford **I-261** as a pale oil (1.15 g, 94% yield). MS (ESI, pos. ion) m/z: 389.2(M+1).

5 Step 5: **(S)-1-(2-aminoethyl)-4-((tert-butyldimethylsilyl)oxy)pyrrolidin-2-one (I-262)**

To a solution of (S)-2-(2-(4-((tert-butyldimethylsilyl)oxy)-2-oxopyrrolidin-1-yl)ethyl)isoindoline-1,3-dione, **I-261** (1.05 g, 1.24 mmol) in MeOH (10 mL) at 0—5 °C was added NH₂NH₂ (85% in H₂O, 0.12 g, 1.2 equiv.). The reaction mixture was allowed
10 to warm to ambient temperature, stirred for 12 hours, and then filtered. The filtrate was concentrated under reduced pressure to afford the crude amine, **I-262** (0.71 g) as a pale oil, which was used directly for the next step. MS (ESI, pos. ion) m/z: 259.2(M+1).

 Step 6: **(S)-2-((2-((2-(4-((tert-butyldimethylsilyl)oxy)-2-oxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-263)**


15 To a solution of (S)-1-(2-aminoethyl)-4-((tert-butyldimethylsilyl)oxy)pyrrolidin-2-one (0.61 mg, 2.36 mmol) in DCM (10 mL) was added thiodiglycolic anhydride (0.41 mg, 1.3 equiv.) and TEA (0.05 g, 0.2 equiv.). The reaction mixture was stirred for 2 hours at 20 °C and was then concentrated under reduced pressure to give the crude product, **I-263** (0.89 g) as a pale oil. The crude product was used directly for next step. MS (ESI, pos.
20 ion) m/z: 391.2(M+1).

 Step 6: **(S)-2-((2-((2-(4-hydroxy-2-oxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-264)**

To a solution of (S)-2-((2-((2-(4-((tert-butyldimethylsilyl)oxy)-2-oxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid, **I-263** (0.89 g, ca. 2.97 mmol) in DCM (10
25 mL) at 0—5 °C was added HCl in EtOAc (2M, 2.5 mL) under N₂. The reaction mixture was stirred for 1 hour and then concentrated under reduced pressure to afford the crude product as a pale oil. The crude product was purified by preparative HPLC (Mobile Phase: MeCN/H₂O (0.1%TFA), Gradient: 2-8% MeCN) to give 90 mg (11% yield) of **I-264** as a pale oil. MS (ESI, pos. ion) m/z: 277.1 (M+1). ¹H NMR (400 MHz, CDCl₃): 7.40 (s, 1H),

4.44 (dd, 1H), 3.99 (dd, 1H), 3.76 (s, 1H), 3.69 (dt, 2H), 3.37 (s, 2H), 3.33 – 3.26 (m, 1H), 3.19 (q, 2H), 3.06 (d, $J = 14.4$ Hz, 1H), 2.75 (ddd, 1H), 2.52 (d, 1H).

5 The synthesis of compound I-271 involved 7 steps as depicted in the following Scheme 104.



Scheme 104

The chemical structure of the target compound was confirmed by ^1H NMR and LC-MS with the purity > 95% (HPLC 214 & 254 nm).

10 **(R)-2-((2-((2-(2-(hydroxymethyl)-5-oxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-271):**

Step 1. **(R)-5-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidin-2-one (I-265)**

15 To a solution of (R)-5-(hydroxymethyl)pyrrolidin-2-one (cas: 66673-40-3, 2 g, 17.4 mmol) in DCM (15 mL) was added imidazole (2.36 g, 2.0 equiv.) and TBSCl (3.14 g, 1.2 equiv.). The reaction mixture was stirred for 7 hours and was then quenched with water (20 mL). The aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic extracts were washed with water, brine, dried (Na_2SO_4), and concentrated under reduced pressure to afford a residue, which was purified by silica gel chromatography to

provide silyl ether **I-265** (2.9 g, 73% yield) as a pale yellow oil. MS (ESI, pos. ion) *m/z*: 230(*M*+1).

Step 2. **methyl (*R*)-2-(2-(((*tert*-butyldimethylsilyl)oxy)methyl)-5-oxopyrrolidin-1-yl)acetate (**I-266**)**

5 To a solution of (*R*)-5-(((*tert*-butyldimethylsilyl)oxy)methyl)pyrrolidin-2-one, **I-265** (0.4 g, 1.75 mmol) in THF (10 mL) were added methyl 2-bromoacetate (0.4 g, 1.5 equiv.), K₂CO₃ (0.605 g, 2.5 equiv.), and TBAB (0.112 g, 2.0 equiv.). The reaction mixture was then stirred at ambient temperature for 10 hours and then quenched with water (20 mL). The aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic
10 extracts were washed with water, brine, dried (Na₂SO₄), and concentrated under reduced pressure to a residue, which was purified by silica gel chromatography to provide ester **I-266** (100 mg, 19%) as a pale yellow oil. MS (ESI, pos. ion) *m/z*: 302(*M*+1).

Step 3. **(*R*)-5-(((*tert*-butyldimethylsilyl)oxy)methyl)-1-(2-hydroxyethyl)pyrrolidin-2-one (**I-267**)**

15 To a solution of methyl (*R*)-2-(2-(((*tert*-butyldimethylsilyl)oxy)methyl)-5-oxopyrrolidin-1-yl)acetate, **I-266** (0.2 g, 0.66 mmol) in *t*-BuOH (5 mL) and MeOH (0.2 mL) was added NaBH₄ (0.1 g, 4.0 equiv.) in one portion. The reaction mixture was heated to 80 °C for 2 hours and then cooled to ambient temperature and quenched with water (20 mL). The aqueous phase was then extracted with EtOAc (3 x 20 mL). The combined
20 organic extracts were washed with water, brine, dried (Na₂SO₄) and concentrated under reduced pressure to a residue (220 mg), which was used directly for next step. MS (ESI, pos. ion) *m/z*: 274(*M*+1).

Step 4. **(*R*)-2-(2-(2-(((*tert*-butyldimethylsilyl)oxy)methyl)-5-oxopyrrolidin-1-yl)ethyl)isoindoline-1,3-dione (**I-268**)**

25 To a solution of (*R*)-5-(((*tert*-butyldimethylsilyl)oxy)methyl)-1-(2-hydroxyethyl)pyrrolidin-2-one, **I-267** (0.22 g, 0.81 mmol), phthalimide (0.13 g, 1.1 equiv.) and PPh₃ (0.318 g, 1.5 equiv.) in anhydrous THF (5 mL) at 0—5 °C was added DIAD (0.49 g, 3.0 equiv.) under N₂. The reaction mixture was allowed to warm to ambient temperature and stirred for 7 hours and then concentrated under reduced pressure to a residue, which was

and purified by preparative HPLC to afford the imide **I-268** (145 mg, 28% yield). MS (ESI, pos. ion) m/z: 403(M+1).

Step5.

(R)-1-(2-aminoethyl)-5-(((tert-butyl

butyldimethylsilyl)oxy)methyl)pyrrolidin-2-one (I-269)

5 To a solution of (R)-2-(2-(2-(((tert-butyl dimethylsilyl)oxy)methyl)-5-oxopyrrolidin-1-yl)ethyl)isoindoline-1,3-dione, **I-268** (0.345 g, 0.858 mmol) in MeOH (10 mL) was added hydrazine hydrate (85% in H₂O, 0.05 g, 1.5 equiv.). The reaction mixture was stirred for 12 hours at ambient temperature and then filtered. The filtrate was concentrated under reduced pressure to give the crude product, **I-269** (307 mg), which was
10 used directly in next step. MS (ESI, pos. ion) m/z: 273(M+1).


Step6. **(R)-2-((2-((2-(((tert-butyl dimethylsilyl)oxy)methyl)-5-oxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-270)**

To a solution of (R)-1-(2-aminoethyl)-5-(((tert-butyl dimethylsilyl)oxy)methyl)pyrrolidin-2-one, **I-269** (0.307 g, ca. 1.13 mmol) in DCM
15 (5 mL) was added thiodiglycolic anhydride (178 mg, 1.2 equiv.) and TEA (22.8 mg, 0.2 equiv.). The reaction mixture was stirred for 2 hours and then concentrated in vacuo to give crude acid **I-270** as a pale oil (0.5 g). The crude product was used directly for next step. MS (ESI, pos. ion) m/z: 405 (M+1).

Step7. **(R)-2-((2-((2-(hydroxymethyl)-5-oxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (I-271)**
20

To a solution of (R)-2-((2-((2-(((tert-butyl dimethylsilyl)oxy)methyl)-5-oxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid, **I-270** (0.5 g, ca. 1.23 mmol) was added HCl in EtOAc (2M, 5 mL) and the reaction mixture was stirred for 2 hours and then concentrated in vacuo to afford the crude product. The crude product was purified by
25 preparative HPLC (Mobile Phase: MeCN/H₂O (0.1%TFA)) to afford **I-271** (0.1 g, 28% yield). MS (ESI, pos. ion) m/z: 291 (M+1). ¹H NMR (400 MHz, DMSO) δ 12.64 (s, 1H), 8.08 (m, 1H), 4.84 (s, 1H), 3.66 (m, 4.0 Hz, 1H), 3.56 – 3.47 (m, 2H), 3.41 (s, 3H), 3.28 – 3.09 (m, 4H), 3.02 m, 1H), 2.22 (m, 1H), 2.14 (m, 1H), 1.96 (m, 1H), 1.76 (m, 1H).

The synthesis of compound I-278 involved 7 steps as depicted in the following Scheme 105.



5

Scheme 105


The chemical structure of the target compound was confirmed by ^1H NMR and LC-MS with the purity > 95% (HPLC 214 & 254 nm).

(S)-2-((2-((2-(hydroxymethyl)-5-oxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (I-278):

The synthetic route for **I-278** was similar to that for the synthesis of **I-271** and commenced with (S)-5-(hydroxymethyl)pyrrolidin-2-one (cas: 17342-08-4). (S)-2-((2-((2-(hydroxymethyl)-5-oxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid, **I-278** (pale oil, 120 mg, 15% yield) was isolated by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%TFA). MS (ESI, pos. ion) m/z: 291 (M+1). ^1H NMR (400 MHz, DMSO) δ 12.59 (s, 1H), 8.08 (m, 1H), 4.80 (s, 1H), 3.66 (m, 1H), 3.56 – 3.48 (m, 2H), 3.40 (m, 3H), 3.28 – 3.10 (m, 4H), 3.06 – 2.96 (m, 1H), 2.28 – 2.17 (m, 1H), 2.17 – 2.06 (m, 1H), 1.96 (m, 1H), 1.80 – 1.70 (m, 1H).

20

Synthesis of I-279 is depicted in Scheme 106:




Scheme 106

2-((2-oxo-2-((2-(2-oxooxazolidin-3-yl)ethyl)amino)ethyl)thio)acetic acid (I-279)

- 5 To a solution of 3-(2-aminoethyl)oxazolidin-2-one (cas:141778-93-0, 300 mg, 1.8 mmol) in DCM (20 mL) was added thiodiglycolic anhydride (360 mg, 1.5 equiv.) and TEA (90 mg, 0.5 equiv.). The reaction mixture was stirred at ambient temperature for 1 hour and then concentrated in vacuo. The residue obtained was purified by preparative HPLC (Mobile Phase: MeCN/H₂O (0.1%TFA), Gradient: 1-3% MeCN) to afford 87 mg (27%
 10 yield) of **I-279** as a white solid. MS (ESI, pos. ion) m/z: 263.1 (M+1). ¹H NMR (400 MHz, DMSO) δ 12.58 (s, 1H), 8.15 (m, 1H), 4.26 – 4.20 (m, 2H), 3.59 – 3.52 (m, 2H), 3.35 (s, 2H), 3.26 – 3.17 (m, 6H).

The synthesis of compound I-282 involved 3 steps as depicted in the following Scheme 107.




Scheme 107

The chemical structure of the target compound was confirmed by ¹H NMR and LC-MS with the purity > 95% (HPLC 214 & 254 nm).


2-((2-((2-(2,4-dioxooxazolidin-3-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-282):

Step 1: *Tert*-butyl (2-(2,4-dioxooxazolidin-3-yl)ethyl)carbamate (I-280)




To a solution of oxazolidine-2,4-dione (cas: 2346-26-1, 0.1 g, 0.99 mmol) in DMF (5 mL) was added *tert*-butyl (2-bromoethyl) carbamate (cas: 39684-80-5, 0.265 g, 1.2 equiv.) and K₂CO₃ (0.274 g, 2.0 equiv.). The reaction mixture was heated to 70 °C for 2 hours. The reaction mixture was then cooled to ambient temperature, and quenched with water (20 mL). The aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic extracts were washed with water, brine, dried (Na₂SO₄), and concentrated under reduced pressure to afford a residue, which was purified by preparative TLC (Petroleum: EtOAc = 1:1) to provide carbamate **I-280** as a pale yellow oil (0.1 g, 41 % yield). MS (ESI, pos. ion) m/z: 267(M+Na).

Step 2: 3-(2-aminoethyl)oxazolidine-2,4-dione (I-281)



To a solution of *tert*-butyl (2-(2,4-dioxooxazolidin-3-yl)ethyl)carbamate, **I-280** (0.1 g, 0.41 mmol) in DCM (2 ml) that had been pre-cooled to 0-5 °C was added a solution of TFA/DCM (1:1 v/v, 2 mL). The reaction mixture was then stirred at ambient temperature for 2 hours. When LC-MS showed that the reaction went to completion, the reaction solution was concentrated under reduced pressure to give the crude product, **I-281** (pale oil, 176 mg). The crude product was used directly for next step. MS (ESI, pos. ion) m/z: 145(M+1).


Step 3: 2-((2-((2-(2,4-dioxooxazolidin-3-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-282)



To a solution of 3-(2-aminoethyl)oxazolidine-2,4-dione, **I-281** (0.17 g, 1.17 mmol) and thiodiglycolic anhydride (0.087 g, 1.6 equiv. based on carbamate **I-280**) in DCM (5 mL) was added TEA (80 mg, 0.792 mmol). After 4 hours, the reaction mixture was concentrated to give the crude product. The crude product was purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%TFA) to afford **I-282** as a pale oil (50 mg, 2% yield). MS (ESI, pos. ion) m/z: 277.1 (M+1). ¹H NMR (400 MHz, DMSO): δ 8.21 (m, 1H), 4.77 (s, 2H), 3.47 (m, 2H), 3.33 (s, 2H), 3.28 (m, 2H), 3.16 (s, 2H).

5

The synthesis of compound I-289 involved 7 steps as depicted in the following Scheme 108.



10

Scheme 108

The chemical structure of the target compound was confirmed by ¹H NMR and LC-MS with the purity > 95% (HPLC 214 & 254 nm).

Step 1: Methyl-(S)-5-oxotetrahydrofuran-2-carboxylate (I-283)

15

To a solution of (S)-5-oxotetrahydrofuran-2-carboxylic acid (cas: 21461-84-7, 7 g, 53.8 mmol) was added SOCl₂ (17.95 g, 2.8 equiv., 11 mL) and the reaction mixture was refluxed at 80 °C for 4 hours under N₂. The reaction mixture was then allowed to cool to ambient temperature and stirred for 12 hours. The excess SOCl₂ was removed under reduced pressure. The residue was diluted with DCM (70 mL); a solution of MeOH (2.1

mL, 53.8 mmol) and TEA (6.56 g, 64.5 mmol) was added at -20°C . The reaction mixture was warmed to ambient temperature and stirred for 12 hours. The reaction was then quenched with H_2O (40 mL) and extracted with EtOAc (20 mL x 3). The combined organic extracts were dried over MgSO_4 and concentrated under reduced pressure to give the crude product. The crude product was purified by silica gel chromatography (Petroleum ether: EtOAc = 1:1) to afford **I-283** as a pale oil (4.5 g, 58% yield). MS (ESI, pos. ion) m/z : 236(M+1).

Step 2: **Methyl-(S)-5-((2-aminoethyl)amino)-2-hydroxy-5-oxopentanoate (I-284)**

To a solution of methyl (S)-5-oxotetrahydrofuran-2-carboxylate, **I-283** (3 g, 20.83 mmol) in DCM (20 mL) was added *tert*-butyl (2-aminoethyl)carbamate (cas: 57260-73-8, 230 mg). The reaction mixture was then stirred at ambient temperature for 48 hours. When the LC-MS showed the reaction went to completion, the reaction mixture was concentrated under reduced pressure to give the crude product, **I-284**. The crude product (3.5 g, 83% yield) was used directly in next step. MS (ESI, pos. ion) m/z : 205(M+1).

Step 3: **Methyl-(S)-5-((2-((*tert*-butoxycarbonyl)amino)ethyl)amino)-2-((*tert*-butyldimethylsilyl)oxy)-5-oxopentanoate (I-285)**

To a solution of methyl (S)-5-((2-aminoethyl)amino)-2-hydroxy-5-oxopentanoate, **I-284** (3.5 g, 13.98 mmol) in anhydrous DMF (30 mL) was added imidazole (2.38 g, 2.5 equiv.) and TBSCl (3.79 g, 1.8 equiv.). The reaction mixture was stirred at ambient temperature for 3 hours. The reaction was quenched with H_2O (20 mL) and extracted with EtOAc (20 mL x 3). The combined organic extracts were concentrated to afford the crude product. The crude product was purified by silica gel chromatography (Petroleum ether: EtOAc = 1:3) to provide **I-285** as a pale oil (3.6 g, 49% yield). MS (ESI, pos. ion) m/z : 419(M+1).

Step 4: **Methyl (S)-8-((*tert*-butoxycarbonyl)amino)-2-((*tert*-butyldimethylsilyl)oxy)octanoate (I-286)**

A solution of methyl (S)-5-((2-((*tert*-butoxycarbonyl)amino)ethyl)amino)-2-((*tert*-butyldimethylsilyl)oxy)-5-oxopentanoate, **I-285** (2 g, 5.48 mmol) and NaBH_4 (0.373 g, 1.8 equiv.) in THF (anhydrous, 26 mL) was added to a solution of iodine (1.25 g, 0.9 equiv.)

in THF (anhydrous, 10 mL) at -20°C under N_2 . The reaction mixture was gradually warmed to ambient temperature over 8 hours. When the LC-MS showed that the reaction went to completion, the reaction was quenched with H_2O (20 mL) and extracted with EtOAc (30 mL x 3). The combined organic extracts were dried over MgSO_4 and concentrated to give the crude product. The crude product, **I-286** (1.8 g, 93 % yield) was used directly in next step. MS (ESI, pos. ion) m/z : 404(M+1).

Step 5: ***Tert*-butyl (*S*)-(2-(3-((*tert*-butyldimethylsilyl)oxy)-2-oxopiperidin-1-yl)ethyl)carbamate (**I-287**)**

To a solution of methyl (*S*)-8-((*tert*-butoxycarbonyl)amino)-2-((*tert*-butyldimethylsilyl)oxy)octanoate, **I-286** (3.6 g, 8.9 mmol) in DCM (30 mL) was added TEA (0.27 g, 0.3 mmol). The reaction mixture was stirred for 48 hours and was concentrated under reduced pressure to give the crude product. The crude product was purified by silica gel chromatography (Petroleum ether: EtOAc = 3:1) to provide lactam **I-287** as a pale oil (1.2 g, 36% yield). MS (ESI, pos. ion) m/z : 373(M+1), 395(M+Na).

Step 6: ***(S)*-1-(2-aminoethyl)-3-hydroxypiperidin-2-one (**I-288**)**

A solution of *tert*-butyl (*S*)-(2-(3-((*tert*-butyldimethylsilyl)oxy)-2-oxopiperidin-1-yl)ethyl)carbamate, **I-287** (1.2 g, 3.22 mmol) was added to a solution of TFA/DCM (1 mL/3 mL) at 0°C . The reaction mixture was stirred for 2 hours and concentrated under reduced pressure to afford the crude product. The crude product, **I-288** (0.8 g, pale oil) was used directly for next step. MS (ESI, pos. ion) m/z : 159(M+1).


Step 7: ***(S)*-2-((2-((2-(3-hydroxy-2-oxopiperidin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (**I-289**)**

To a solution of (*S*)-1-(2-aminoethyl)-3-hydroxypiperidin-2-one, **I-288** (0.89 g, 5.6 mmol) and thiodiglycolic anhydride (1.11 g, ca. 1.5 equiv.) in 10 mL of DCM was added TEA (0.114 g, 0.2 equiv.). The reaction mixture was stirred for 2 hours and concentrated under reduced pressure to give the crude product. The crude product was purified by preparative HPLC (Mobile Phase: MeCN/ H_2O (0.1% TFA), Gradient: 5-15% MeCN) to give **I-289** (50 mg, 3% yield) as a pale oil. MS (ESI, pos. ion) m/z : 291.1(M+1). ^1H NMR (400 MHz, DMSO) δ 12.63 (s, 1H), 8.11 (m, 1H), 3.84 (m, 1H), 3.45 – 3.37 (m, 2H), 3.35 (s,

2H), 3.30 – 3.24 (m, 2H), 3.24 – 3.19 (m, 3H), 3.18 (s, 2H), 1.99 – 1.89 (m, 1H), 1.81 (m, 1H), 1.70 (m, 1H), 1.64 – 1.52 (m, 1H).

5

The synthesis of **I-296** involved 7 steps as depicted in the following Scheme 109.




Scheme 109

10 **(R)-2-((2-((2-(3-hydroxy-2-oxopiperidin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (I-296)**

The synthetic route for **I-296** was similar to that of **I-288** and commenced with (*R*)-5-oxotetrahydrofuran-2-carboxylic acid (cas: 53558-93-3). **I-296** (pale oil, 39 mg, 3% yield) was isolated by preparative HPLC (Mobile Phase: MeCN/H₂O(0.1%TFA), Gradient: 5-15% MeCN). MS (ESI, pos. ion) *m/z*: 291.1 (M+1). ¹H NMR (400 MHz, DMSO) δ 12.59 (s, 1H), 8.10 (s, 1H), 5.00 (s, 1H), 3.84 (m, 1H), 3.42 (s, 2H), 3.28 (m, 3H), 3.21 (m, 3H), 3.18 (s, 2H), 1.95 (m, 1H), 1.87 – 1.76 (m, 1H), 1.75 – 1.65 (m, 1H), 1.58 (m, 1H).

20 The synthesis of **I-301** involved 5 steps as depicted in the following Scheme 110.



Scheme 110

Step 1: Methyl (2-((*tert*-butoxycarbonyl)amino)ethyl)glycinate (**I-297**)

A solution of *tert*-butyl (2-aminoethyl)carbamate (cas: 57260-73-8, 3.2 g, 20 mmol), methyl 2-bromoacetate (cas: 96-32-2, 3.0 g, 1 equiv.) and TEA (4 mL, 2.9 equiv.) in 100 mL of THF was stirred at ambient temperature for 4 hours. Upon completion of the reaction, the reaction mixture was filtered and the filtrate was concentrated and the crude product, **I-297** (5.3 g) was used in next step directly. MS (ESI, pos. ion) *m/z*: 255.2 (*M*+23).

Step 2: Methyl N-(2-((*tert*-butoxycarbonyl)amino)ethyl)-N-carbamoylglycinate (**I-298**)

A solution of methyl (2-((*tert*-butoxycarbonyl)amino)ethyl)glycinate, **I-297** and trimethylsilyl isocyanate (cas: 1118-02-1, 4.5 mL, 1.7 equiv.) in DCE (50 mL) was heated to 90 °C for 48 hours. LC-MS at this point indicated that the reaction was not complete. The reaction mixture was concentrated, and purified by silica gel chromatography to afford **I-298** as a pale oil (4.2 g, 76 % over 2 steps). MS (ESI, pos. ion) *m/z*: 298.2 (*M*+23).

Step 3: *Tert*-butyl (2-(2,4-dioxoimidazolidin-1-yl)ethyl)carbamate (**I-299**)

Methyl N-(2-((*tert*-butoxycarbonyl)amino)ethyl)-N-carbamoylglycinate, **I-298** (4.2 g, 15 mmol) in toluene (20 mL) was heated to 140 °C under Microwave irradiation for 30 minutes. The reaction mixture was then concentrated and purified by silica gel chromatography to afford **I-299** as a pale oil (1.5 g, 41 % yield). MS (ESI, pos. ion) *m/z*: 266.2 (*M*+23).

Step 4: 1-(2-aminoethyl)imidazolidine-2,4-dione (**I-300**)


A solution of *tert*-butyl (2-(2,4-dioxoimidazolidin-1-yl)ethyl)carbamate, **I-299** (1.2 g, 4.9 mmol) in HCl (4M in dioxane) (18 mL) was stirred at ambient temperature for 2

hours. Upon completion of the reaction, the reaction mixture was concentrated and the crude amine **I-300** was used in the next step directly. MS (ESI, pos. ion) m/z: 144.2 (M+1).

Step 5: 2-((2-((2-(2,4-dioxoimidazolidin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (I-301)

5 A solution of 1-(2-aminoethyl)imidazolidine-2,4-dione, **I-300** (crude, ca. 4.9 mmol) and thiodiglycolic anhydride (1.2 g, 1.8 equiv.) in 30 mL of DCM was stirred for 15 min. Upon completion of the reaction, the reaction mixture was concentrated in vacuo to give the crude product as a pale oil. Half the crude product was purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%TFA), Gradient: 1-3% MeCN) to give 130
10 mg of **I-301** as a white solid (19 % yield). MS (ESI, pos. ion) m/z: 276.2 (M+1). ¹H NMR (400 MHz, DMSO) δ 12.61 (s, 1H), 10.72 (s, 1H), 8.15 (t, 1H), 3.94 (s, 2H), 3.33 (s, 2H), 3.31 – 3.25 (m, 2H), 3.25 – 3.20 (m, 2H), 3.18 (s, 2H).

The synthesis of **I-307** involved 6 steps as depicted in the following Scheme 111.



15

Scheme 111

2-((2-((2-(3-methyl-2,4-dioxoimidazolidin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (I-307):

Steps 1-3 were similar to those used in the preparation of carboxylic acid **I-301**.

Step 4: **Benzyl (2-(3-methyl-2,4-dioxoimidazolidin-1-yl)ethyl)carbamate (I-305)**

To a solution of benzyl (2-(2,4-dioxoimidazolidin-1-yl)ethyl)carbamate, **I-304** (600 mg, 2.17 mmol) in toluene (20 mL) was added *N,N*-dimethylacetamide dimethyl acetal (cas: 18871-66-4, 1.3 mL, 4.0 equiv.) in one portion at 25 °C. The resulting mixture was heated to 130 °C for 2 hours. After cooling to ambient temperature, the reaction mixture was concentrated *in vacuo*. The residue was purified by preparative TLC to give 500 mg (79% yield) of carbamate **I-305** as a pale yellow oil. MS (ESI, pos. ion) *m/z*: 292.1 (M+1).


Step 5: ***Tert*-butyl 1-(((benzyloxy)carbonyl)amino)cyclopropane-1-carboxylate (I-306)**

To a solution of benzyl (2-(3-methyl-2,4-dioxoimidazolidin-1-yl)ethyl)carbamate, **I-305** (500 mg, 1.72 mmol) in 20 mL of THF was added 50 mg of 10% Pd/C. The reaction was stirred at 25 °C for 10 hours under H₂. Upon completion of the reaction, the reaction mixture was filtered and the filtrate was concentrated in *vacuo*. The residue was used in next step directly without purification. MS (ESI, pos. ion) *m/z*: 158.1 (M+1).

Step 6: **2-((2-((2-(3-methyl-2,4-dioxoimidazolidin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (I-307)**

To a solution of *tert*-butyl 1-(((benzyloxy)carbonyl)amino)cyclopropane-1-carboxylate, **I-306** (500 mg, 3.18 mmol) in DCM (20 mL) was added thiodiglycolic anhydride (630 mg, 1.5 equiv.). The reaction mixture was then stirred at 25 °C for 1 hour. Upon completion of the reaction, the solvent was removed in *vacuo*, and the crude product was purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1% TFA), gradient: 1-3% MeCN) to give 250 mg (27% yield) of **I-307** as a pale oil. MS (ESI, pos. ion) *m/z*: 290.1 (M+1). ¹H NMR (400 MHz, DMSO) δ 8.15 (s, 1H), 3.98 (s, 2H), 3.34 (d, 2H), 3.33 (s, 2H), 3.25 (t, 2H), 3.17 (s, 2H), 2.83 (s, 3H).

The synthesis of **I-311** involved 5 steps as depicted in the following Scheme 112.



Scheme 112

2-((2-((2-(2,5-dioxopiperazin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (I-311):

5 Step 2: **Methyl N-(((benzyloxy)carbonyl)glycyl)-N-(2-((tert-butoxycarbonyl)amino) ethyl) glycinate (I-308)**

To a solution of benzyloxycarbonylglycine (3.1 g, 15 mmol, cas: 1138-80-3) in DMF (30 mL) and methyl (2-((tert-butoxycarbonyl)amino)ethyl)glycinate, **I-297** (1.8 g, 7.8 mmol) was added TEA (2.4 g, 24 mmol), EDC (4.6 g, 24 mmol), and then the reaction mixture was stirred at 25 °C for 15 hours. The reaction mixture was then diluted with EtOAc (100 mL) and was sequentially washed with aqueous 5% NaHCO₃ (100 mL × 3), aqueous 5% citric acid solution (100 mL × 3) and brine (100 mL × 3). The EtOAc extracts were dried over anhydrous magnesium sulfate and purified by silica gel column chromatography (3% MeOH/DCM) to give 2.1 g of **I-308** as a pale oil. Yield: 64%. MS (ESI, pos. ion) m/z: 446.1 (M+23).

Step 3: Tert-butyl (2-(2,5-dioxopiperazin-1-yl)ethyl)carbamate(I-309)

To a solution of methyl N-(((benzyloxy)carbonyl)glycyl)-N-(2-((tert-butoxycarbonyl)amino)ethyl)glycinate, **I-308** (2.1 g, 5 mmol) in 30 mL of MeOH was added 500 mg of 10 % Pd/C. The reaction mixture was stirred at ambient temperature for 10 hours under H₂ (1atm). Upon completion of the reaction, Pd/C was filtered and the filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography (3 % MeOH/DCM) to give 800 mg of **I-309** as a pale oil. Yield: 64%. MS (ESI, pos. ion) m/z: 280.1 (M+23).


Step 4: **Benzyl (2-(3-methyl-2,4-dioxoimidazolidin-1-yl)ethyl)carbamate (I-310)**

To a solution of *tert*-butyl (2-(2,5-dioxopiperazin-1-yl)ethyl)carbamate, **I-309** (400 mg, 1.6 mmol) in 15 mL of DCM was added 15mL of 4 M HCl in dioxane. The reaction mixture was stirred at 25 °C for 1 hour. Upon completion of the reaction, the mixture was concentrated under reduced pressure to give 360 mg of crude amine **I-310** as a white solid, which was used in next step. MS (ESI, pos. ion) m/z: 158.1 (M+1).

Step 5: **2-((2-((2-(2,5-dioxopiperazin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (I-311)**

To a solution of benzyl (2-(3-methyl-2,4-dioxoimidazolidin-1-yl)ethyl)carbamate (300 mg, 1.91 mmol) in THF/H₂O (10 mL/1 mL) was added TEA(200 mg, 2 mmol) and thiodiglycolic anhydride (504 mg, 3.82 mmol). The reaction mixture was stirred at 25 °C for 1 hour. Upon completion of the reaction, the solvent was removed under reduced pressure and the resulting residue was purified by preparative HPLC (Mobile Phase:MeCN/H₂O (with 0.1% formic acid) Gradient:2-8% MeCN) to give 65 mg of carboxylic acid **I-311** as a pale oil. Yield: 12 %. MS (ESI, pos. ion) m/z: 290.1 (M+1). ¹H NMR (400 MHz, DMSO) δ 8.12 (dd, J = 12.1, 6.1 Hz, 2H), 3.92 (s, 2H), 3.76 (s, 1H), 3.38 – 3.31 (m, 4H), 3.23 (dd, J = 11.8, 5.9 Hz, 1H).

The synthesis of **I-320** involved 9 steps as depicted in the following Scheme 113.



Scheme 113

2-((2-((4-methyl-2,5-dioxopiperazin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (I-320):

Step 1: 2-((tert-butyldimethylsilyl)oxy)ethan-1-amine (I-312)

To a solution of 2-aminoethan-1-ol (1.2 g, 20 mmol), DMAP (220 mg, 1.8 mmol) and imidazole (2.7 g, 40 mmol) in 30 ml of DCM was added TBSCl (3.1 g, 21 mmol). The resulting mixture was stirred at ambient temperature for 16 hours. Upon completion of the reaction, 50 mL of water was added to the reaction mixture, which was then extracted with DCM (30 mL x 3). The combined organic extracts were dried over Na₂SO₄, then concentrated in vacuo to give 3.1 g of **I-312** as a pale oil. Yield: 89%. MS (ESI, pos. ion) m/z: 176.1 (M+1).

Step 2: Methyl (2-((tert-butyldimethylsilyl)oxy)ethyl)glycidate (I-313)

To a solution of 2-((tert-butyldimethylsilyl)oxy)ethan-1-amine, **I-312** (1.75 g, 10 mmol,) in 30 mL of DCM was added methyl 2-bromoacetate (1.6 g, 1.1 equiv., cas#: 96-32-2) and TEA (2.0 g, 2.0 equiv.). The reaction mixture was stirred at ambient temperature for 10 hours under N₂. Upon completion of the reaction, the solvent was removed in vacuo

and the mixture was purified by column chromatography (5—10% MeOH in DCM) to give 2 g of **I-313** as a yellow oil. Yield: 62%. MS (ESI, pos. ion) m/z: 248.1 (M+1).

Step 3: **Methyl N-(((benzyloxy)carbonyl)glycyl)-N-(2-((tert-butoxycarbonyl)amino) ethyl) glycinate (I-314)**

5 To a solution of benzyloxycarbonylglycine (3.1 g, 15 mmol, cas#: 1138-80-3) and amine **I-313** (1.8 g, 7.28 mmol) in 30 mL of DMF was added TEA (2.4 g, 24 mmol) and the reaction mixture was stirred at 0 °C. To this reaction mixture was added EDC (3.5 g, 18 mmol) and stirring continued at 0 °C for 2 hours, after which the reaction mixture was allowed to warm to ambient temperature and stirred for 15 hours. The reaction mixture was
10 diluted with EtOAc (100 mL) and sequentially washed with aqueous 5% sodium bicarbonate solution (100 mL × 3), aqueous 5% citric acid solution (100 mL × 3), aqueous saturated sodium chloride solution (100 mL × 3). The EtOAc extracts were dried over Na₂SO₄ and purified by silica gel column chromatography (3.8% MeOH/DCM) to give 3 g of amide **I-314** as a yellow oil. Yield: 43%. MS (ESI, pos. ion) m/z: 461.1 (M+23).

15 Step 4: **1-(2-((tert-butyldimethylsilyl)oxy)ethyl)piperazine-2,5-dione (I-315)**

To a solution of methyl N-(((benzyloxy)carbonyl)glycyl)-N-(2-((tert-butoxycarbonyl) amino) ethyl) glycinate, **I-314** (2.1 g, 4.8 mmol) in 30 mL of MeOH was added 500 mg of 10% Pd/C. The reaction mixture was stirred at ambient temperature for 10 hours under H₂ (1 atm). Upon completion of the reaction, Pd/C was filtered and the
20 filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (3% MeOH/DCM) to give 720 mg of diketopiperazine **I-315** as a pale oil. Yield: 55%. MS (ESI, pos. ion) m/z: 273.1 (M+1).

Step 5: **1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-methylpiperazine-2,5-dione (I-316)**

25 To a solution of 1-(2-((tert-butyldimethylsilyl)oxy)ethyl)piperazine-2,5-dione, **I-315** (720 mg, 2.64 mmol) and NaH (500 mg, 8.3 equiv., 60% dispersion in mineral oil) in 20 mL of THF at 0° C was added MeI (1.1 g, 3.0 equiv.). The reaction mixture was stirred at ambient temperature for 1 hour. Upon completion of the reaction, the solvent was removed in vacuo, and the residue obtained was purified by column chromatography

(DCM) to give 680 mg of diketopiperazine **I-316** as a yellow oil, yield: 90%. MS (ESI, pos. ion) m/z: 287.1 (M+1).

Step 6: **1-(2-hydroxyethyl)-4-methylpiperazine-2,5-dione (I-317)**

To a solution of 1-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)-4-methylpiperazine-2,5-dione, **I-316** (800 mg, 2.8 mmol) in DCM (8 mL) cooled in an ice-water bath was added HCl in Dioxane (30% v/v, 8 mL) under N₂. The reaction mixture was stirred for 0.5 hours. Upon completion of the reaction, the reaction mixture was concentrated under reduced pressure to give 608 mg of **I-317** as a pale oil, which was used directly for next step. MS (ESI, pos. ion) m/z: 173.1(M+1).

Step 7: **2-(2-(4-methyl-2,5-dioxopiperazin-1-yl)ethyl)isoindoline-1,3-dione (I-318)**

To a solution of 1-(2-hydroxyethyl)-4-methylpiperazine-2,5-dione, **I-317** (600 mg, 3.8 mmol) in THF (20 mL) was added phthalimide (cas: 85-41-6, 592 mg, 1.05 equiv.) and PPh₃ (1.5 g, 1.5 equiv.). The reaction mixture was stirred for 0.5 h in ice bath under N₂. DIAD (2.3 g, 3.0 equiv.) was added dropwise to the solution. The reaction mixture was allowed to warm to ambient temperature and stirred for 6 hours. Upon completion of the reaction, the reaction mixture was quenched with water (5 mL) and extracted with DCM (3 x 20 mL). The combined organic extracts were washed with water (20 mL), brine (20 mL), and dried over Na₂SO₄, then concentrated and the residue obtained was purified by column chromatography (50-100% EtOAc) to give 480 mg of **I-318** as a yellow solid, yield: 42%. MS (ESI, pos. ion) m/z: 302.1 (M+1).


Step 8: **1-(2-aminoethyl)-4-methylpiperazine-2,5-dione (I-319)**

To a solution of 2-(2-(4-methyl-2,5-dioxopiperazin-1-yl)ethyl)isoindoline-1,3-dione, **I-318** (300 mg, 1 mmol) in MeOH (5 mL) that had been cooled in an ice-water bath was added NH₂NH₂ (85% in H₂O, 300 mg, 5.5 equiv.). The reaction mixture was allowed to warm to ambient temperature and stirred for 12 hours. Upon completion of the reaction, the slurry was filtered and the filtrate was concentrated to afford crude amine **I-319**, which was used directly for the next step (pale oil, 280 mg). MS (ESI, pos. ion) m/z: 172.1(M+1).

Step 9: **2-((2-((2-(4-methyl-2,5-dioxopiperazin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-320)**

A solution of 1-(2-aminoethyl)-4-methylpiperazine-2,5-dione, **I-319** (280 mg, 1.27 mmol) and thiodiglycolic anhydride (300 mg, 1.8 equiv.) in 5 mL of DCM was stirred for 2 hours, and then was concentrated in vacuo to give the crude product as a pale oil. The crude product was purified by preparative HPLC (Mobile Phase: MeCN/H₂O (0.1% formic acid) Gradient: 5—15% MeCN) to give 50 mg of carboxylic acid **I-320** as a white solid, yield: 13%. ¹H NMR (400 MHz, CDCl₃) δ 7.34 (s, 1H), 4.14 (s, 2H), 4.06 (s, 2H), 3.64 (dd, 2H), 3.55 (dd, 2H), 3.36 (s, 2H), 3.25 (s, 2H), 3.00 (s, 3H).

The synthesis of **I-325** involved 5 steps as depicted in the following Scheme 114.



Scheme 114

Step 1: *tert*-butyl 4-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)-3-oxopiperazine-1-carboxylate (**I-321**)

To a solution of *tert*-butyl 3-oxopiperazine-1-carboxylate (cas: 76003-29-7, 2 g, 10 mmol) in DMF (20 mL) that had been pre-cooled in an ice-water bath was added NaH (800 mg, 2.0 equiv.) in portions under N₂. The mixture was stirred for 0.5 hours. (2-bromoethoxy)(*tert*-butyl)dimethylsilane (cas: 86864-60-0, 5.3 mL, 2.5 equiv.) was added to the solution at 0 °C. The reaction mixture was stirred at 25 °C for 12 hours. The reaction mixture was then diluted with water (50 mL) and extracted with EtOAc (3 x 80 mL). The combined organic extracts was then washed with water (50 mL), brine (50 mL), and dried over Na₂SO₄, then concentrated under reduced pressure to a residue. The residue was

purified by silica gel chromatography to afford ketopiperazine **I-321** as a pale oil (1.8 g, 50% yield, pale oil). MS (ESI, pos. ion) m/z: 381 (M+23).

Step 2: ***tert*-butyl 4-(2-(hydroxyethyl)-3-oxopiperazine-1-carboxylate (I-322)**

5 A solution of *tert*-butyl 4-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)-3-oxopiperazine-1-carboxylate, **I-321** (1.8 g, 5 mmol) in AcOH/THF/H₂O (40 mL/13 mL/13 mL) was stirred at 40 °C for 2 hours. Upon completion of the reaction, the solvent was removed under reduced pressure. The crude product was purified by silica gel chromatography to give the alcohol **I-322** (0.95 g, 78%, pale oil). MS (ESI, pos. ion) m/z: 267 (M+23).

10 Step 3: ***tert*-butyl 4-(2-(1,3-dioxoisindolin-2-yl)ethyl)-3-oxopiperazine-1-carboxylate (I-323)**

To a solution of *tert*-butyl 4-(2-hydroxyethyl)-3-oxopiperazine-1-carboxylate, **I-322** (0.82 g, 3.4 mmol) in THF (8 mL) was added phthalimide (cas: 85-41-6, 0.75 g, 1.5 equiv.), PPh₃ (1.6 g, 1.8 equiv.) in sequence at 0 °C under N₂. Then DIAD (1.4 mL, 2.0 equiv.) was added dropwise. The mixture was then stirred at 25 °C for 1.5 hours. After LC-MS showed the reaction went to completion, the mixture solution was filtered. The filtrate was concentrated under reduced pressure to afford the crude product. The crude product was purified by silica gel chromatography to give phthalimide **I-323** as a white solid (purity: 40%, 2.8 g, 88% yield). MS (ESI, pos. ion) m/z: 396(M+23).

Step 4: ***tert*-butyl 4-(2-(aminoethyl)-3-oxopiperazine-1-carboxylate (I-324)**


20 To a solution of *tert*-butyl 4-(2-(1,3-dioxoisindolin-2-yl)ethyl)-3-oxopiperazine-1-carboxylate, **I-323** (0.58 g, ca. 0.77 mmol) in MeOH (8 mL) that had been pre-cooled in an ice-water bath was added NH₂NH₂ (85% in H₂O, 0.1 mL, 2 equiv.). The reaction mixture was allowed to warm to ambient temperature and then stirred for 18 hours. Upon completion of the reaction, the slurry was filtered and the filtrate was concentrated to afford a pale oil. The crude product, **I-324** was used directly for next step. MS (ESI, pos. ion) m/z: 266(M+23).

Step 5: **2-((2-((2-(4-(*tert*-butoxycarbonyl)-2-oxopiperazin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-325)**

30 A solution of *tert*-butyl 4-(2-aminoethyl)-3-oxopiperazine-1-carboxylate, **I-324** (crude product, ca. 0.77 mmol) and 1,4 - thiodiglycolic anhydride (100 mg, 1.0 equiv.) in

THF (5 mL) was stirred for 5 min and concentrated under reduced pressure. The crude product was purified by preparative HPLC (Mobile Phase: MeCN/H₂O (0.1% formic acid), Gradient:20-30% MeCN) to afford carboxylic acid **I-325** as a white solid (54 mg, 19 % yield). MS (ESI, pos. ion) m/z: 398.2 (M+23). ¹H NMR (400 MHz, CDCl₃) δ 4.14 (s, 2H), 3.67 (dd, 4H), 3.59 – 3.50 (m, 2H), 3.44 (d, 2H), 3.35 (s, 2H), 3.27 (s, 2H), 1.47 (s, 9H).

The synthesis of **I-328** involved 3 steps as depicted in the following Scheme 115.



Scheme 115

The chemical structure of the target compound was confirmed by ¹H NMR and LC-MS with the purity > 95% (HPLC 214 & 254 nm).

2-((2-((2-(2,3-dioxopiperazin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-328**):**

Step 1. *tert*-butyl (2-(2,3-dioxopiperazin-1-yl)ethyl)carbamate (**I-326**)

To a solution of *tert*-butyl (2-((2-aminoethyl)amino)ethyl)carbamate (cas: 193206-49-4, 1 g, 5 mmol) in EtOH (50 mL) was added diethyl oxalate (cas: 95-92-1, 0.73 g, 1.0 equiv.). The reaction mixture was heated to reflux for 18 hours, then concentrated under reduced pressure. The residue obtained was purified by silica gel chromatography to provide carbamate **I-326** as a colorless foam. (330 mg, 26% yield). MS (ESI, pos. ion) m/z: 280(M+23).

Step 2. 1-(2-aminoethyl)piperazine-2,3-dione hydrochloride (**I-327**)


To a solution of *tert*-butyl (2-(2,3-dioxopiperazin-1-yl)ethyl)carbamate, **I-326** (280 mg, 1.1 mmol) in DCM (20 ml) was added HCl/MeOH (5 mL). The reaction mixture was then stirred at ambient temperature for 1 hour, then concentrated under reduced pressure to

afford 210 mg of the crude product **I-327**, which was directly used without further purification. MS (ESI, pos. ion) m/z : 158(M+1).

Step 3. 2-((2-((2-(2,3-dioxopiperazin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-328)

5 To a solution of 1-(2-aminoethyl)piperazine-2,3-dione hydrochloride, **I-327** (210 mg, 1.1 mmol) and thiodiglycolic anhydride (cas: 3261-87-8, 144 mg, 1.1 equiv.) in DMF (10 mL) was added TEA (222 mg, 2.2 equiv.). The reaction mixture was stirred at ambient temperature for 2 hours and then was concentrated under reduced pressure to afford the crude product. The crude product was purified by preparative HPLC (Mobile Phase: MeCN/H₂O (with 0.1%TFA)) to give afford acid **I-328** (56 mg, 18% yield) as a white solid). MS (ESI, pos. ion) m/z : 290 (M+1). ¹H NMR (400 MHz, DMSO) δ 8.54 (s, 1H), 8.18 (t, 1H), 3.55 – 3.45 (m, 2H), 3.41 (t, 2H), 3.32 (d, 2H), 3.25 (dd, 2H), 3.18 (s, 2H).

The synthesis of **I-332** involved 4 steps as depicted in the following Scheme 116.



Scheme 116

The chemical structure of the target compound was confirmed by ¹H NMR and LC-MS with the purity > 95% (HPLC 214 & 254 nm).

(S)-2-((2-((2-(2-(hydroxymethyl)-5-oxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-332):

Step 1: 1-Methylpiperazine-2,3-dione (**I-329**)

To a solution of *N*-methylethylene-1,2-diamine (cas: 109-81-9, 1 g, 13.5 mmol) in EtOH (80 mL) was added diethyl oxalate (cas: 95-92-1, 2 g, 5 mmol). The reaction was heated to reflux for 18 hours, then concentrated under reduced pressure. The residue obtained was purified by silica gel chromatography to provide (1.4 g, 80% yield) of **I-329** as a colorless foam. MS ESI, pos. ion) m/z: 129(M+1).

Step 2: ***Tert*-butyl (2-(4-methyl-2,3-dioxopiperazin-1-yl)ethyl)carbamate (I-330)**

To a slurry of 1-methylpiperazine-2,3-dione, **I-329** (1 g, 7.8 mmol), Cs₂CO₃ (12.7 g, 5.0 equiv.) and TBAI(288 mg, 0.1 equiv.) in DMF (50 mL) was added *tert*-butyl (2-bromoethyl)carbamate (3.5 g, 2.0 equiv.). The reaction mixture was heated to 80 °C for 24 hours. The reaction mixture was then concentrated and the residue obtained was purified by silica gel chromatography to provide 1.4 g (67% yield) of carbamate **I-330** as a colorless oil. MS (ESI, pos. ion) m/z: 294(M+23).


Step 3: **1-(2-Aminoethyl)-4-methylpiperazine-2,3-dione hydrochloride (I-331)**

To a solution of *tert*-butyl (2-(4-methyl-2,3-dioxopiperazin-1-yl)ethyl)carbamate, **I-330** (100 mg, 0.37 mmol) in DCM (12 mL) was added HCl/MeOH (2 mL). The reaction was then stirred at ambient temperature for 1 hour. The reaction mixture was then concentrated and the crude product (77 mg, colorless oil) obtained was directly used without purification. MS (ESI, pos. ion) m/z: 172(M+1).

Step 4: **2-(((2-(4-Methyl-2,3-dioxopiperazin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-332)**

To a solution of 1-(2-aminoethyl)-4-methylpiperazine-2,3-dione hydrochloride, **I-331** (77 mg, 0.37 mmol) and thiodiglycolic anhydride (49 mg, 1.0 equiv.) in DCM (10 mL) was added TEA (75 mg, 0.74 mmol). The reaction mixture was stirred at ambient temperature for 1 hour and then was concentrated under reduced pressure to give the crude product. The crude product was purified by preparative HPLC (Mobile Phase: MeCN/H₂O (0.1%TFA)) to afford acid **I-332** (40 mg, 37% yield). MS (ESI, pos. ion) m/z: 304 (M+1). ¹H NMR (400 MHz, DMSO) δ 8.21 (s, 1H), 3.52 (d, *J* = 4.9 Hz, 4H), 3.39 (t, *J* = 5.5 Hz, 2H), 3.31 (s, 2H), 3.26 (d, *J* = 5.5 Hz, 2H), 3.17 (s, 2H), 2.91 (s, 3H).

The synthesis of compound **I-335** involved 3 steps as depicted in the following Scheme 117.



Scheme 117

- 5 The chemical structure of the target compound was confirmed by ¹H NMR and LC-MS with the purity > 95% (HPLC 214 & 254 nm).

Step 1: ***Tert*-butyl (2-((3-chloropropyl)sulfonamido)ethyl)carbamate (I-333)**

A solution of 1-methylpiperazin-2-one (cas: 5625-67-2, 1 g, 9.99 mmol), *tert*-butyl (2-bromoethyl)carbamate (cas: 39684-80-5, 2 g, 0.9 equiv.) in anhydrous DMF (15 mL) was added K₂CO₃ (8.28 g, 6.0 equiv.). The reaction mixture was stirred for 8 hours at ambient temperature. Once LC-MS analysis indicated reaction completion, the reaction was quenched with H₂O (20 mL) and the aqueous phase was extracted with EtOAc (20 mL x 3). The combined organic extracts was concentrated under reduced pressure to give the crude product. The crude product was purified by silica gel chromatography (Petroleum ether: EtOAc = 1:10) to provide carbamate **I-333** as a pale oil (0.65 g, 22%). MS (ESI, pos. ion) m/z: 258(M+1).

Step 2: **4-(2-Aminoethyl)-1-methylpiperazin-2-one (I-334)**


A solution of *tert*-butyl (2-(4-methyl-3-oxopiperazin-1-yl)ethyl)carbamate, **I-333** (0.25 g, 0.97 mmol) in DCM (2 mL) that had been pre-cooled in an ice-water bath was added a solution of TFA/DCM (1:1 v/v, 2 mL). The reaction mixture was then stirred at

ambient temperature for 2 hours. When the LC-MS showed the reaction went to completion, the reaction mixture was concentrated in vacuo to afford the crude amine, **I-334** (pale oil, 200 mg). The crude product was used directly for next step. MS (ESI, pos. ion) m/z: 158(M+1).

5 Step 3: **2-((2-((2-(4-Methyl-3-oxopiperazin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (I-335)**

A solution of 4-(2-aminoethyl)-1-methylpiperazin-2-one, **I-334** (0.2 g, 1.27 mmol) and thiodiglycolic anhydride (0.185 g, 1.1 equiv.) in THF (5 mL) was stirred at ambient temperature for 4 hours, and then the reaction mixture was concentrated to give the crude product. The crude product was purified by preparative HPLC (Mobile Phase: MeCN/H₂O (0.1%TFA)) to afford the acid **I-335** as a pale oil (50 mg, 2% yield). MS (ESI, pos. ion) m/z: 290.1 (M+1). ¹H NMR (400 MHz, DMSO) δ 8.26 (s, 1H), 3.75 (s, 2H), 3.48 (s, 3H), 3.44 – 3.36 (m, 5H), 3.26 (s, 2H), 3.12 (m, 2H), 2.87 (s, 3H).

15 The synthesis of compound **I-338** involved 3 steps as depicted in the following Scheme 118.




Scheme 118

20 **2-((2-oxo-2-((2-(3-oxopiperazin-1-yl)ethyl)amino)ethyl)thio)acetic acid (I-338)**

The synthetic route for **I-338** was similar to that of **I-335** and commenced with piperazin-2-one (cas:5625-67-2). 2-((2-oxo-2-((2-(3-oxopiperazin-1-yl)ethyl)amino)ethyl)thio)acetic acid (pale oil, 50 mg, 15% yield) was isolated by preparative HPLC (Mobile Phase: MeCN/H₂O (with 0.1%TFA)). MS (ESI, pos. ion) m/z: 276.1 (M+1). ¹H NMR (400 MHz, MeOD) δ 3.82 (s, 2H), 3.60 – 3.53 (m, 4H), 3.47 (m, 2H), 3.38 (s, 2H), 3.35 (s, 2H), 3.23 (m, 2H).

The synthesis of **I-343** is depicted in Scheme 119.



Scheme 119

The chemical structure of the target compound was confirmed by ¹H NMR and LC-MS with the purity > 95% (HPLC 214 & 254 nm).

Step 1: **4-(2-(benzyloxy)ethyl)morpholin-3-one (I-339)**

To a solution of morpholin-3-one (cas: 109-11-5, 2 g, 19.8 mmol) in anhydrous DMF (25 mL) was added NaH (60% dispersion in mineral oil, 1.98 g, 2.5 equiv.) at 0 °C under N₂. The reaction mixture was stirred for 30 minutes and then ((2-bromoethoxy)methyl)benzene (cas: 1462-37-9, 1.98 g, 2.5 equiv.) was added to the reaction mixture, which was then allowed to warm to ambient temperature. After 12 hours, analysis by LC-MS indicated completion of the reaction. The reaction mixture was quenched with H₂O (20 mL) and extracted with EtOAc (20 mL x 3). The combined organic extracts were concentrated under reduced pressure to give the crude product, which was purified by silica gel chromatography (Petroleum ether: EtOAc = 1:4) to provide morpholinone **I-339** as a pale oil (2.3 g, 49% yield). MS (ESI, pos. ion) m/z: 236(M+1).

Step 2: **4-(2-hydroxyethyl)morpholin-3-one (I-340)**

To a solution of 4-(2-(benzyloxy)ethyl)morpholin-3-one, **I-339** (2.35 g, 9.79 mmol) in MeOH (10 mL) was added Pd/C (230 mg) quickly under H₂ (1 atm). The reaction mixture was then stirred at ambient temperature for 48 hours, when analysis by LC-MS showed the reaction was complete. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to afford the crude product, **I-340** (pale oil, 1.35 g,

93% yield). The crude product was used directly in next step. MS (ESI, pos. ion) m/z: 146(M+1).

Step 3: 2-(2-(3-oxomorpholino)ethyl)isoindoline-1,3-dione (I-341)

A solution of 4-(2-hydroxyethyl)morpholin-3-one, **I-340** (1.37 g, 9.45 mmol),
5 phthalimide(cas: 85-41-6, 1.53 g, 1.1 equiv.) and PPh₃(3.72 g, 1.5 equiv.) in anhydrous
THF (30 mL) was stirred at 0 °C for 0.5 hours. Then DIAD (5.73 g, 3.0 equiv.) was added
and the reaction mixture was allowed to warm to ambient temperature and stirred for 7
hours. The reaction mixture was concentrated and the residue obtained was purified by
silica gel chromatography (Petroleum ether: EtOAc = 1:5) to provide **I-341** as a pale oil
10 (2.5 g, 50% purity, 50% yield). MS (ESI, pos. ion) m/z: 275(M+1).


Step 4: 4-(2-aminoethyl)morpholin-3-one (I-342)

A solution of 2-(2-(3-oxomorpholino)ethyl)isoindoline-1,3-dione, **I-341** (1.25 g,
4.56 mmol) in MeOH (10 mL) was added hydrazine hydrate (80% aqueous solution, 0.291
g, 1.5 equiv.). The reaction mixture was stirred for 12 hours at ambient temperature, then
15 filtered and the filtrate was then concentrated to give the crude product, **I-342** (1 g), which
was taken forward to the next step without further purification. MS (ESI, pos. ion) m/z:
145(M+1).

Step 5: 2-((2-oxo-2-((2-(3-oxomorpholino)ethyl)amino)ethyl)thio) acetic acid (I-343)

A solution of 4-(2-aminoethyl)morpholin-3-one, **I-342** (1 g, 6.94 mmol) and
20 thiodiglycolic anhydride (cas: 3261-87-8, 1.09 g, 1.2 equiv.) in 10 mL of DCM was stirred
for 2 hours, and then concentrated under reduced pressure to afford a residue, which was
purified by preparative HPLC (Mobile Phase:MeCN/H₂O (with 0.1% Formic Acid),
Gradient:5-15% MeCN) to obtain **I-343** (50 mg, 3% yield) as a pale oil. MS (ESI, pos. ion)
25 m/z: 277(M+1). ¹H NMR (400 MHz, DMSO) δ 12.65 (s, 1H), 8.14 (m, 1H), 4.00 (s, 2H),
3.82 – 3.75 (m, 2H), 3.40 – 3.34 (m, 6H), 3.24 (m, 2H), 3.18 (s, 2H).

The synthesis of I-348 involved 5 steps as depicted in the following Scheme 120.



Scheme 120

Step 1: 4-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)thiomorpholin-3-one (I-344)

To a solution of thiomorpholin-3-one (cas: 20196-21-8, 1.17 g, 10 mmol) in anhydrous DMF (10 mL) was added sodium hydride (cas: 7646-69-7, 1.20 g, 30 mmol, 3.0 equiv.) in ice bath under N₂. After 30 minutes, (2-bromoethoxy)(*tert*-butyl)dimethylsilane (cas: 86864-60-0, 3.59 g, 1.5 equiv.) was added to the solution at 0 °C. The reaction mixture was allowed to warm to ambient temperature and stirred for 5 hours. Once complete, the reaction was quenched with water (5 mL), extracted with EtOAc (3 x 500 mL). The combined organic extracts were then washed with water (50 mL), brine (50 mL), and dried with Na₂SO₄, then concentrated under reduced pressure to a residue, which was purified by silica gel chromatography to afford **I-344** (1.40 g, 54% yield) as a pale yellow oil. MS (ESI, pos. ion) m/z: 276.1(M+1).

Step 2: 4-(2-hydroxyethyl)thiomorpholin-3-one (I-345)

To a solution of 4-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)thiomorpholin-3-one, **I-344** (1.40 g, 5.09 mmol) in DCM (15 mL) that had been pre-cooled in an ice-water bath was added HCl in MeOH (30% v/v, 10 mL) under N₂. The reaction mixture was stirred for 3 hours. Upon completion of the reaction, the resulting solution was concentrated under reduced pressure to a residue. The residue was purified by silica gel chromatography to afford **I-345** (0.71 g, 87% yield) as a pale yellow oil. MS (ESI, pos. ion) m/z: 162.1(M+1).

Step 3: 2-(2-(3-oxothiomorpholino)ethyl)isoindoline-1,3-dione (I-346)

To a solution of 4-(2-hydroxyethyl)thiomorpholin-3-one, **I-345** (0.71 g, 4.41 mmol) in anhydrous THF (10 mL) at 0—5 °C was added phthalimide (cas: 85-41-6, 0.72 g, 1.1 equiv.) and PPh₃ (1.74 g, 1.5 equiv.) under N₂. After 30 minutes, DIAD (2.67 g, 3.0

equiv.) was added. The reaction mixture was allowed to warm to ambient temperature and stirred for 12 hours. Upon completion of the reaction, the reaction mixture was concentrated under reduced pressure to a residue, which was purified by silica gel chromatography to afford imide **I-346** (0.90 g, 70% yield, about 50% purity, contaminated with PPh₃O) as a white solid. MS (ESI, pos. ion) m/z: 291.1(M+1).


Step 4: 4-(2-aminoethyl)thiomorpholin-3-one (I-347)

To a solution of 2-(2-(3-oxothiomorpholino)ethyl)isoindoline-1,3-dione, **I-346** (0.9 g, 1.24 mmol) in MeOH (10 mL) at 0—5 °C was added NH₂NH₂ (85% in H₂O, 0.14 g, 1.2 equiv.). The reaction mixture was allowed to warm to ambient temperature and stirred for 12 hours. Upon completion of the reaction, the reaction mixture was concentrated under reduced pressure. The residue obtained was purified by reversed-phase chromatography to afford the amine **I-347** as a pale oil (0.41 g, 82% yield, about 40% purity). MS (ESI, pos. ion) m/z: 162.1(M+1).

Step 5: 2-((2-oxo-2-((2-(3-oxothiomorpholino)ethyl)amino)ethyl)thio) acetic acid (I-348)

A solution of 4-(2-aminoethyl)thiomorpholin-3-one, **I-347** (0.41 g, 2.56 mmol) and thiodiglycolic anhydride (cas: 3261-87-8, 0.405 g, 3.07 mmol, 1.2 equiv.) in DCM (5 ml) and DMF (2.0 ml) was stirred for 16 hours at 25 °C. Upon completion of the reaction, the mixture was concentrated by vacuum to afford a residue, which was purified by preparative HPLC (Mobile Phase: MeCN/H₂O (0.1%TFA), Gradient: 20-30% MeCN) to obtain 22.8 mg (3% yield) of **I-348** as a pale oil. MS (ESI, pos. ion) m/z: 293.1 (M+1). ¹H NMR (400 MHz, CDCl₃): ¹H NMR (400 MHz, CDCl₃): 7.41 (s, 1H), 3.70 (ddd, 4H), 3.55 (d, 2H), 3.39 (d, 4H), 3.28 (s, 2H), 2.93 – 2.89 (m, 2H).

The synthesis of **I-351** involved 3 steps from the previously described intermediate **I-346** as depicted in the following Scheme 121.



Scheme 121

Step 1: 2-(2-(1,1-dioxido-3-oxothiomorpholino)ethyl)isoindoline-1,3-dione (I-349)

To a solution of 2-(2-(3-oxothiomorpholino)ethyl)isoindoline-1,3-dione, **I-346** (2.3 g, purity 50%, 7.9 mmol) in DCM (10 mL) at 0–5 °C was added *m*-chloroperbenzoic acid (4.08 g, 3.0 equiv.). The mixture was allowed to warm to ambient temperature and stirred for 12 hours. Upon completion of the reaction, the reaction mixture was washed with saturated aqueous Na₂SO₃ (10 mL), saturated aqueous NaHCO₃ (10 mL), brine (10 mL), dried, and concentrated under reduced pressure. The residue was purified by silica gel chromatography to afford sulfone **I-349** as a white solid (0.3 g, 23% yield, about 80% purity). MS (ESI, pos. ion) *m/z*: 323.1(M+1).

Step 2: 4-(2-aminoethyl)thiomorpholin-3-one 1,1-dioxide (I-350)


To a solution of 2-(2-(1,1-dioxido-3-oxothiomorpholino)ethyl)isoindoline-1,3-dione, **I-349** (0.3 g, 0.93 mmol) in MeOH (10 mL) was added hydrazine (85% solution in H₂O, 0.042 g, 1.2 equiv.). The reaction mixture was stirred for 12 hours. Upon completion of the reaction, the reaction mixture was concentrated under reduced pressure to a residue, which was purified by reversed-phase chromatography to afford amine **I-350** (0.1 g, 56% yield, about 80% purity) as a pale oil. MS (ESI, pos. ion) *m/z*: 193.1(M+1).

Step 3: 2-((2-oxo-2-((2-(3-oxothiomorpholino)ethyl)amino)ethyl)thio)acetic acid (I-351)

A solution of 4-(2-aminoethyl)thiomorpholin-3-one 1,1-dioxide, **I-350** (0.1 g, 0.52 mmol) and thiodiglycolic anhydride (cas: 3261-87-8, 0.082 g, 0.62 mmol, 1.2 equiv.) in DMF (4 mL) was stirred for 3 hours at 25 °C. The reaction mixture was then concentrated under reduced pressure to afford a pale oil. The crude product was purified by preparative HPLC (Mobile Phase: MeCN/H₂O (0.1%TFA), Gradient: 1-3% MeCN) to afford 63.4 mg

(38% yield) of acid **I-351** as a pale oil. MS (ESI, pos. ion) m/z : 325.1 (M+1). ^1H NMR (400 MHz, D_2O) δ 4.19 (s, 1H), 3.87 (dd, 1H), 3.59 – 3.53 (m, 2H), 3.41 – 3.37 (m, 1H), 3.32 (s, 2H), 3.25 (s, 2H).

5 **The synthesis of I-356 involved 5 steps as depicted in the following Scheme 122.**



Scheme 122

Step 1: 3-bromopropyl carbonochloridate (I-352)

To a solution of 3-bromopropan-1-ol (cas: 627-18-9, 600 mg, 4.3 mmol) in 15 mL of THF that had been pre-cooled to 0 °C was added TEA (0.9 mL) and a solution of triphosgene (600 mg, 0.5 equiv.) in 5 mL of THF under N_2 . The reaction mixture was monitored by LC-MS (the reaction aliquot was treated with BnNH_2 prior to analysis). After 30 minutes, the reaction mixture was used directly in next step. MS (ESI, pos. ion) m/z : 272.2 (M+1).

15 **Step 2: 3-bromopropyl *tert*-butyl ethane-1,2-diyl dicarbamate (I-353)**

To the reaction mixture from previous step, was added *tert*-butyl (2-aminoethyl)carbamate (1 g, 1.5 equiv.) in one portion. The reaction mixture was stirred at 25 °C for 15 hours. Upon completion of the reaction, the reaction was quenched with water (50 mL), and extracted with EtOAc (3 x 50 mL). The combined organic extracts were concentrated to a residue, which was purified by silica gel chromatography (Petroleum ether: EtOAc= 1:1) to afford 1.2 g (86% yield, 2 steps) of carbamate **I-353** as a white solid. MS (ESI, pos. ion) m/z : 347.2 (M+23).

Step 3: *tert*-butyl (2-(2-oxo-1,3-oxazinan-3-yl)ethyl)carbamate (I-354)

A solution of 3-bromopropyl *tert*-butyl ethane-1,2-diyl dicarbamate, **I-353** (1.1 g, 3.4 mmol), NaH (360 mg, 2.5 equiv., 60% dispersion in mineral oil), NaI (350 mg, 1 equiv.)

in DMF (60 mL) was heated to 80 °C for 2 hours. On completion, the reaction mixture was quenched with water (30 mL) and extracted with EtOAc (3 x 30 mL). The combined organic extracts were concentrated to a residue, which was purified by silica gel chromatography (EtOAc), to afford oxazinone **I-354** (100 mg, 12%) as a pale oil. MS (ESI, pos. ion) m/z: 267.2 (M+23).


Step 4: **3-(2-aminoethyl)-1,3-oxazinan-2-one (I-355)**

A solution of *tert*-butyl (2-(2-oxo-1,3-oxazinan-3-yl)ethyl)carbamate (100 mg, 0.4 mmol) in HCl (2M in EtOAc, 3 mL) was stirred at 25 °C for 2 hours. Upon completion of the reaction, the reaction mixture was concentrated and purified by preparative HPLC (Mobile Phase: MeCN/H₂O (0.1%TFA) to afford amine **I-355** (30 mg, 50% yield) as a pale oil. MS (ESI, pos. ion) m/z: 145.2 (M+1).

Step 5: **2-((2-oxo-2-((2-(2-oxo-1,3-oxazinan-3-yl)ethyl)amino)ethyl)thio) acetic acid (I-356)**

To a stirred solution of 3-(2-aminoethyl)-1,3-oxazinan-2-one, **I-355** (30 mg, 0.2 mmol) in DCM (2 mL), was added thiodiglycolic anhydride (cas:3261-87-8, 27 mg, 1 equiv.), TEA (4 drops) at 25 °C. The reaction mixture was stirred for 2 hours, and then concentrated and purified by preparative HPLC (Mobile Phase: MeCN/H₂O (0.1%TFA), gradient:2-8% MeCN) to afford acid **I-356** (15 mg, 27%) as a pale oil. MS (ESI, pos. ion) m/z: 277.2 (M+1). ¹H NMR (400 MHz, CDCl₃) δ 7.38 (s, 1H), 4.33 – 4.28 (m, 2H), 3.63 – 3.58 (m, 2H), 3.57 – 3.52 (m, 2H), 3.45 (t, 2H), 3.37 (s, 2H), 3.27 (s, 2H), 2.11 – 2.07 (m, 2H).

The synthesis of **I-363** involved 7 steps as depicted in the following Scheme 123.



Scheme 123

2-((2-((2-(3-methyl-2-oxotetrahydropyrimidin-1(2H)-yl)ethyl)amino)-2-oxoethylthio)acetic acid (I-363):

5 Step 1: **1-(2-hydroxyethyl)tetrahydropyrimidin-2(1H)-one (I-357)**

2-((3-aminopropyl)amino)ethan-1-ol (5.9 g, 50 mmol, cas#:4461-39-6) and urea (4.5 g, 1.5 equiv., cas#: 57-13-6) in a sealed tube was heated at 130 °C for 10 hours. After reaction completion, the residue was purified by silica gel column chromatography (20% MeOH in dichloromethane) to afford alcohol **I-357** (1 g, 14% yield) as a white solid. MS (ESI, pos. ion) m/z: 145.1 (M+1).

10 Step 2: **1-(2-((tert-butyldimethylsilyl)oxy)ethyl)tetrahydropyrimidin-2(1H)-one (I-358)**

To a solution of 1-(2-hydroxyethyl)tetrahydropyrimidin-2(1H)-one, **I-357** (2.6 g, 18 mmol), DMAP (220 mg, 0.1 equiv.) and imidazole (2.5 g, 2.0 equiv.) in 30 mL of DCM was added TBSCl (2.7 g, 1.0 equiv.). The reaction mixture was stirred at ambient temperature for 16 hours, then diluted with 50 mL of water and extracted with DCM (30 mL x 3). The combined organic extracts were dried over Na₂SO₄ and concentrated in vacuo to afford 3.1 g (67% yield) of silyl ether **I-358** as a pale oil. MS (ESI, pos. ion) m/z: 259.1 (M+1).

20 Step 3: **1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-methyltetrahydropyrimidin-2(1H)-one (I-359)**

To a solution of 1-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)tetrahydropyrimidin-2(1H)-one, **I-358** (2.1 g, 8 mmol) and NaH (960 mg, 5.0 equiv.) in THF (30 mL) at 0 °C was added MeI (3.4 g, 3.0 equiv.). The reaction mixture was stirred at ambient temperature for 1 hour, then the solvent was removed in vacuo, and the residue obtained was purified by column chromatography (DCM) to afford silyl ether **I-359** (1.1 g, 50% yield) as a white solid. MS (ESI, pos. ion) m/z: 273.1 (M+1).

Step 3: 1-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)-3-methyltetrahydropyrimidin-2(1H)-one (I-360)

To a solution of 1-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)-3-methyltetrahydropyrimidin-2(1H)-one, **I-359** (1.1 g, 4 mmol) in MeOH (10 mL) at 0—5 °C was added HCl in MeOH (30% v/v, 10 mL) under N₂. The reaction mixture was stirred for 0.5 hours, then concentrated under reduced pressure to afford alcohol **I-360** (600 mg, 95% yield) as a pale oil, which was used directly for next step. MS (ESI, pos. ion) m/z: 159.1(M+1).

Step 4: 2-(2-(3-methyl-2-oxotetrahydropyrimidin-1(2H)-yl)ethyl)isoindoline-1,3-dione (I-361)

To a solution of 1-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)-3-methyltetrahydropyrimidin-2(1H)-one, **I-360** (600 mg, 3.8 mmol) in THF (20 mL) at 0—5 °C was added phthalimide (cas: 85-41-6, 592 mg, 1.05 equiv.), PPh₃ (1.5 g, 1.5 equiv) under N₂. After 30 minutes, DIAD (2.3 g, 3.0 equiv.) was added and the reaction mixture was allowed to warm to ambient temperature and stirred for 6 hours. The reaction was then quenched with water (5 mL), and extracted with DCM (3 x 20 mL). The combined organic extracts were washed with water (20 mL), brine (20 mL), and dried with Na₂SO₄, then concentrated under reduced pressure. The residue obtained was purified by column chromatography (50% EtOAc in Petroleum Ether) to afford phthalimide **I-361** (280 mg, 26% yield) as a yellow solid. MS (ESI, pos. ion) m/z: 288.1 (M+1).

Step 5: 1-(2-aminoethyl)-3-methyltetrahydropyrimidin-2(1H)-one (I-362)


To a solution of 2-(2-(3-methyl-2-oxotetrahydropyrimidin-1(2H)-yl)ethyl)isoindoline-1,3-dione, **I-361** (280 mg, 0.98 mmol) in MeOH (5 mL) at 0—5 °C was added NH₂NH₂ (85% solution in H₂O, 200 mg, 5.6 equiv.). The reaction mixture was

allowed to warm to ambient temperature and stirred for 12 hours. The slurry was then filtered, and the filtrate was concentrated to afford the crude amine **I-362** (0.2 g) as a pale oil, which was taken forward to the next step. MS (ESI, pos. ion) m/z: 158.1(M+1).

Step 6: **2-((2-oxo-2-((2-(2-oxotetrahydropyrimidin-1(2H)-yl)ethyl)amino)ethyl)thio) acetic acid (I-363)**

A solution of 1-(2-aminoethyl)-3-methyltetrahydropyrimidin-2(1H)-one, **I-362** (200 mg, 1.27 mmol) and thiodiglycolic anhydride (cas: 3261-87-8, 300 mg, 1.8 equiv.) in 5 mL DCM was stirred for 2 hours, and then concentrated in vacuo to afford the crude product as a pale oil. Purification by preparative HPLC (Mobile Phase: MeCN/H₂O (with 0.1% Formic Acid) Gradient: 5-15% MeCN) afforded **I-363** (50 mg, 14% yield) as a white solid. MS (ESI, pos. ion) m/z: 290.1 (M+1). ¹H NMR (400 MHz, CDCl₃) δ 7.47 (s, 1H), 3.59-3.56 (m, 2H), 3.5-3.42 (m, 2H), 3.36 (s, 2H), 3.36-3.31 (m, 2H), 3.31-3.26 (m, 2H), 3.20 (s, 2H), 2.94 (s, 3H), 2.01-1.96 (m, 2H).

The synthesis of **I-366** involved 3 steps from previously described intermediate **I-357** as depicted in the following Scheme 124.



Scheme 124

2-((2-oxo-2-((2-(2-oxotetrahydropyrimidin-1(2H)-yl)ethyl)amino)ethyl)thio) acetic acid (I-366):

Step 1: **2-(2-(2-oxotetrahydropyrimidin-1(2H)-yl)ethyl)isoindoline-1,3-dione (I-364)**

To a solution of 1-(2-hydroxyethyl)tetrahydropyrimidin-2(1H)-one, **I-357** (1 g, 6.9 mmol) in THF (30 mL) at 0—5 °C was added phthalimide (cas: 85-41-6, 1 g, 1.05 equiv.) and PPh₃ (2.7 g, 1.5 equiv.). After 30 minutes, DIAD (4.2 g, 3.0 equiv.) was added and the reaction mixture was allowed to warm to ambient temperature and stirred for 6 hours. The reaction was then quenched with water (5 mL), extracted with DCM (3 x 20 mL). The combined organic extracts were washed with water (20 mL), brine (20 mL), and dried with Na₂SO₄, then concentrated under reduced pressure. The residue obtained was purified by silica gel column chromatography (50% EtOAc in Petroleum Ether) to afford 800 mg (43% yield) of phthalimide **I-364** as a yellow solid. MS (ESI, pos. ion) m/z: 274.1 (M+1).


Step 2: **1-(2-aminoethyl)-3-methylpyrrolidin-2-one (I-365)**

To a solution of 2-(2-(2-oxotetrahydropyrimidin-1(2H)-yl)ethyl)isoindoline-1,3-dione, **I-364** (0.2 g, 0.7 mmol) in MeOH (5 mL) at 0—5 °C was added NH₂NH₂ (85% in H₂O, 200 mg, 5.5 mmol). The reaction mixture was allowed to warm to ambient temperature and stirred for 7 hours, then filtered, and the filtrate was concentrated to afford crude amine **I-365** (0.12 g) as a pale oil. The crude product was used directly for the next step. MS (ESI, pos. ion) m/z: 145.1(M+1).

Step 3: **2-((2-oxo-2-((2-(2-oxotetrahydropyrimidin-1(2H)-yl)ethyl)amino)ethyl)thio) acetic acid (I-366)**

A solution of 1-(2-aminoethyl)-3-methylpyrrolidin-2-one, **I-365** (120 mg, 0.83 mmol) and thiodiglycolic anhydride (cas: 3261-87-8, 167 mg, 1.5 equiv.) in 5 mL of DCM was stirred for 2 hours, and then concentrated in vacuo to give the crude product as a pale oil. The crude product was purified by preparative HPLC (Mobile Phase: MeCN/H₂O (0.1%TFA), gradient:5-15% MeCN) to afford 80 mg (35% yield) of **I-366** as a white solid. MS (ESI, pos. ion) m/z: 276.2 (M+1). ¹H NMR (400 MHz, CDCl₃) δ 7.54 (s, 1H), 6.71 (s, 1H), 3.59 – 3.52 (m, 2H), 3.51 (d, J = 5.1 Hz, 2H), 3.42 - 3.36 (m, 3H), 3.34 – 3.29 (m, 3H), 1.99 (s, 2H), 1.25 (s, 2H).

The synthesis of compound **I-373** involved 8 steps as depicted in the following Scheme 125.



Scheme 125

The chemical structure of the target compound was confirmed by ¹H NMR and LC-MS with the purity > 95% (HPLC 214 & 254 nm).

5 Step 1: **(R)-1-(2-(benzyloxy)ethyl)-3-((tert-butyldimethylsilyl)oxy)pyrrolidin-2-one (I-367)**

To a solution of (R)-3-((tert-butyldimethylsilyl)oxy)pyrrolidin-2-one, **I-251** (8 g, 37.2 mmol) in anhydrous DMF (80 mL) at 0—5 °C was added NaH (60% dispersion in mineral oil, 3.72 g, 2.5 equiv.) under N₂. The reaction mixture was stirred for 30 minutes
 10 at 0—5 °C and ((2-bromoethoxy)methyl)benzene (cas: 1462-37-9, 11.9 g, 1.5 equiv.) was added. The reaction mixture was allowed to warm to ambient temperature. After 12 hours, LC-MS indicated that the reaction was complete. H₂O (20 mL) was added and the reaction mixture was extracted with EtOAc (20 mL X 3). The combined organic extracts were concentrated under reduced pressure and the crude product was purified by silica gel
 15 chromatography (Petroleum ether: EtOAc = 1:1) to provide **I-367** (5 g, 39% yield) as a pale oil. MS (ESI, pos. ion) m/z: 350(M+1).

Step 2: **(R)-1-(2-(benzyloxy)ethyl)-3-hydroxypyrrolidin-2-one (I-368)**

To a solution of (*R*)-1-(2-(benzyloxy)ethyl)-3-((*tert*-butyldimethylsilyl)oxy)pyrrolidin-2-one, **I-367** (5 g, 14.32 mmol) was added HCl in MeOH (30% v/v, 30 mL) and the reaction mixture was stirred at 0—5 °C for 0.5 hours. Once LC-MS analysis indicated reaction completion, the reaction mixture was concentrated and the crude product was purified by silica gel chromatography (Petroleum ether: EtOAc = 1:10) to afford **I-368** (2.36 g, 70% yield) as a pale oil. MS (ESI, pos. ion) m/z: 236(M+1).

Step 3: (*R*)-1-(2-(benzyloxy)ethyl)-3-methoxypyrrolidin-2-one (**I-369**)

To a solution of (*R*)-1-(2-(benzyloxy)ethyl)-3-hydroxypyrrolidin-2-one, **I-368** (2.36 g, 10.0 mmol) in anhydrous MeCN (30 ml) at 0—5 °C was added Ag₂O (4.65 g, 2.0 equiv.) under N₂. The reaction mixture was then stirred for 5 minutes and CH₃I (1.28 g, 0.9 equiv.) was added. The reaction mixture was allowed to warm to ambient temperature and stirred for 10 hours. When LC-MS analysis indicated that the reaction was complete, the reaction mixture was filtered and the filtrate was concentrated under reduced pressure to afford the crude product, which was purified by silica gel chromatography (Petroleum ether: EtOAc = 1:1) to provide **I-369** (1.7 g, 68%) as a pale oil. MS (ESI, pos. ion) m/z: 250(M+1).

Step 4: (*R*)-1-(2-(hydroxyethyl)-3-methoxypyrrolidin-2-one (**I-370**)

To a solution of (*R*)-1-(2-(benzyloxy)ethyl)-3-methoxypyrrolidin-2-one, **I-369** (1.7 g, 6.82 mmol) in MeOH (10 mL) was added Pd/C (170 mg) quickly under H₂ (1 atm). The reaction mixture was then stirred at ambient temperature for 48 hours. When LC-MS analysis indicated that the reaction was complete, the reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to a residue. The crude product was purified by silica gel chromatography (Petroleum ether: EtOAc = 1:10) to provide **I-370** (0.15g, 14% yield) as a pale oil. MS (ESI, pos. ion) m/z: 160(M+1).

Step 5: (*R*)-2-(2-(3-methoxy-2-oxopyrrolidin-1-yl)ethyl)isoindoline-1,3-dione (**I-371**)

A solution of (*R*)-1-(2-(hydroxyethyl)-3-methoxypyrrolidin-2-one, **I-370** (0.15 g, 0.94 mmol), phthalimide (cas: 85-41-6, 0.148 g, 1.1 equiv.) and PPh₃ (0.369 g, 1.5 equiv.) in anhydrous THF (3 mL) was stirred at 0—5 °C for 0.5 hours. Then DIAD (0.569 g, 3.0

equiv.) was added and the reaction mixture was allowed to warm to ambient temperature and stirred for 7 hours. The reaction mixture was then concentrated to afford the crude product, which was purified by silica gel chromatography (Petroleum ether: EtOAc = 1:10) to provide **I-371** (0.5 g, 50% purity, 50% yield) as a pale oil. MS (ESI, pos. ion) m/z: 275(M+1).


Step 6: **(R)-1-(2-aminoethyl)-3-methoxypyrrolidin-2-one (I-372)**

To a solution of (*R*)-2-(2-(3-methoxy-2-oxopyrrolidin-1-yl)ethyl)isindoline-1,3-dione, **I-371** (0.5 g, 1.74 mmol) in MeOH (5 mL) was added hydrazine hydrate (80% solution, 0.130 g, 1.5 equiv.). The reaction mixture was stirred for 12 hours at ambient temperature, then filtered. The filtrate was concentrated and the crude product, **I-372** (0.5 g) was used directly in the next step. MS (ESI, pos. ion) m/z: 159(M+1).

Step 7: **(R)-2-((2-((2-(3-methoxy-2-oxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-373)**

To a solution of (*R*)-1-(2-aminoethyl)-3-methoxypyrrolidin-2-one, **I-372** (0.5 g, 3.3 mmol) and thiodiglycolic anhydride (cas: 3261-87-8, 0.653 g, 1.5 equiv.) in 5 mL of DCM was added TEA (0.066 g, 0.2 equiv.). The reaction mixture was stirred for 2 hours, and then concentrated under reduced pressure to give the crude product, which was purified by preparative HPLC (Mobile Phase: MeCN/H₂O (0.1% TFA), Gradient: 5-15% MeCN) to afford **I-373** (50 mg, 5% yield) as a pale oil. MS (ESI, pos. ion) m/z: 291.1(M+1). ¹H NMR (400 MHz, DMSO) δ 12.68 (s, 1H), 8.10 (s, 1H), 3.88 (s, 1H), 3.38 (s, 3H), 3.35 (s, 2H), 3.33 – 3.26 (m, 3H), 3.19 (m, 5H), 2.32 – 2.20 (m, 1H), 1.76 (m, 1H).

The synthesis of compound **I-380** involved 8 steps as depicted in the following Scheme 126.




Scheme 126

(S)-2-((2-((2-(3-methoxy-2-oxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (I-380)

- 5 The synthetic route for **I-380** is similar to that of **I-373** and commenced with (S)-3-hydroxypyrrolidin-2-one (cas: 34368-52-0). Carboxylic acid **I-380** (pale oil, 50 mg, 3% yield) was isolated by preparative HPLC (Mobile Phase: MeCN/H₂O (with 0.1% TFA), Gradient: 5-15% MeCN). MS (ESI, pos. ion) m/z: 291.1 (M+1). ¹H NMR (400 MHz, DMSO) δ 8.11 (s, 1H), 3.89 (m, 1H), 3.38 (s, 3H), 3.35 (s, 2H), 3.33 – 3.25 (m, 3H), 3.25 – 3.14 (m, 5H), 2.31 – 2.21 (m, 1H), 1.82 – 1.70 (m, 1H).
- 10

The synthesis of **I-386** involved 6 steps from previously described intermediate **I-259** as depicted in the following Scheme 127.



Scheme 127

Step 1: Methyl (S)-2-(4-hydroxy-2-oxopyrrolidin-1-yl)acetate (**I-381**)

To a solution of methyl (*S*)-2-(4-((*tert*-butyldimethylsilyl)oxy)-2-oxopyrrolidin-1-yl)acetate, **I-259** (2.1 g, 7.32 mmol) in MeOH (15 mL) at 0—5 °C was added HCl in EtOAc (2M, 15 mL) under N₂. The reaction mixture was allowed to warm to ambient temperature and stirred for 4 hours. After reaction completion, ammonium hydroxide (ca. 0.2 mL) was added to adjust the pH to 7, and then the reaction mixture was concentrated under reduced pressure. The residue obtained was purified by silica gel chromatography to afford ester **I-381** (1.3 g, 102% yield) as a pale oil. MS (ESI, pos. ion) *m/z*: 174.1(M+1).

Step 2: Methyl (*S*)-2-(4-methoxy-2-oxopyrrolidin-1-yl)acetate (I-382**)**

To a solution of methyl (*S*)-2-(4-hydroxy-2-oxopyrrolidin-1-yl)acetate, **I-381** (1.3 g, 7.51 mmol) in acetonitrile (15 mL) at 0—5 °C was added silver oxide (cas:260667-12-3, 2.62 g, 1.5 equiv.) and iodomethane (0.96 g, 0.9 equiv.) under N₂. The reaction mixture was allowed to warm to ambient temperature and stirred for 12 hours. Upon completion of the reaction, the reaction mixture was filtered through celite. The filtrate was concentrated under reduced pressure and the residue obtained was purified by silica gel chromatography to afford ester **I-382** (0.48 g, 35% yield) as a pale oil. MS (ESI, pos. ion) *m/z*: 184.1 (M+1).

Step 3: (*S*)-1-(2-hydroxyethyl)-4-methoxypyrrolidin-2-one (I-383**)**

To a solution of methyl (*S*)-2-(4-methoxy-2-oxopyrrolidin-1-yl)acetate, **I-382** (0.25 g, 1.50 mmol) in *t*-BuOH (10 mL) was added sodium borohydride (0.228 g, 4.0 equiv.) in MeOH (0.5 mL) under N₂. The reaction mixture was stirred for 0.5 hours at 85 °C. Upon completion of the reaction, the reaction mixture was concentrated under reduced pressure. The residue afforded was quenched with water (2 mL), and extracted with DCM (3 x 20 mL). The combined organic extracts were then washed with water (20 mL), brine (20 mL), and dried with Na₂SO₄, then concentrated and the residue obtained was purified by silica gel chromatography to afford alcohol **I-383** (0.11 g, 46% yield) as a pale oil. MS (ESI, pos. ion) *m/z*: 160.1(M+1).

Step 4: (*S*)-2-(2-(4-methoxy-2-oxopyrrolidin-1-yl)ethyl)isoindoline-1,3-dione (I-384**)**

To a solution of (*S*)-1-(2-hydroxyethyl)-4-methoxypyrrolidin-2-one, **I-383** (0.31 g, 1.95 mmol) in THF (5 mL) was added phthalimide (0.32 g, 1.1 equiv.), and PPh₃ (0.77 g,

1.5 equiv.). The reaction mixture was stirred for 0.5 h at 0—5 °C under N₂ and DIAD (1.18 g, 3.0 equiv.) was added. The reaction mixture was allowed to warm to ambient temperature and stirred at ambient temperature for 12 hours, then concentrated under reduced pressure. The residue obtained was purified by silica gel chromatography to afford
5 phthalimide **I-384** as a yellow oil (0.40 g, 71% yield). MS (ESI, pos. ion) m/z: 289.1(M+1).

Step 5: **(S)-1-(2-aminoethyl)-4-methoxypyrrolidin-2-one (I-385)**


To a solution of *(S)*-2-(2-(4-methoxy-2-oxopyrrolidin-1-yl)ethyl)isoindoline-1,3-dione, **I-384** (0.40 g, 1.39 mmol) in MeOH (10 mL) at 0—5 °C was added hydrazine (85% in H₂O, 0.06 g, 1.2 equiv.). The reaction mixture was allowed to warm to ambient
10 temperature and stirred for 12 hours, then concentrated under reduced pressure. DCM (10 ml) was added to the residue and the slurry was filtered. The filtrate was concentrated to afford the crude amine **I-385** as a pale oil, 0.18 g, 82% yield), which was used directly in the next step. MS (ESI, pos. ion) m/z: 159.1(M+1).

Step 6: **(S)-2-((2-((2-(4-methoxy-2-oxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-386)**

A solution of *(S)*-1-(2-aminoethyl)-4-methoxypyrrolidin-2-one, **I-385** (0.18 g, 1.13 mmol) and thiodiglycolic anhydride (0.19 g, 1.3 equiv.) in DMF (5 mL) was stirred for 2 hours at 25 °C, then concentrated under reduced pressure to give the crude product as a pale oil. The crude product was purified by preparative HPLC (Mobile Phase:
20 MeCN/H₂O (0.1%TFA), Gradient:1-3% MeCN) to afford 137 mg (42% yield) of **I-386** as a pale oil. MS (ESI, pos. ion) m/z: 291.1 (M+1). ¹H NMR (400 MHz, CDCl₃) δ 7.56 (s, 1H), 4.06 (t, 1H), 3.82 (dd, 1H), 3.68 – 3.59 (m, 2H), 3.46 – 3.36 (m, 5H), 3.32 (s, 3H), 3.27 (s, 2H), 2.72 (dd, 6.7 Hz, 1H), 2.53 (dd, 1.6 Hz, 1H).

25

The synthesis of **I-392** involved 6 steps from previously described intermediate **I-252** as depicted in the following Scheme 128.



Scheme 128

5 Step 1: **Methyl (*R*)-2-(4-hydroxy-2-oxopyrrolidin-1-yl)acetate (**I-387**)**

To a solution of methyl (*R*)-2-(4-((*tert*-butyldimethylsilyl)oxy)-2-oxopyrrolidin-1-yl)acetate, **I-252** (3.7 g, 12.89 mmol) in MeOH (20 mL) at 0—5 °C was added HCl in EtOAc (2M, 20 mL) under N₂. The reaction mixture was stirred for 4 hours. Upon completion of the reaction, ammonium hydroxide (about 0.4 ml) was added to adjust pH
10 7, and then the reaction mixture was concentrated under reduced pressure. The residue obtained was purified by silica gel chromatography to afford alcohol **I-387** as a pale oil (2.1 g, 94% yield). MS (ESI, pos. ion) *m/z*: 174.1(M+1).

Step 2: **Methyl (*R*)-2-(4-methoxy-2-oxopyrrolidin-1-yl)acetate (**I-388**)**

To a solution of methyl (*R*)-2-(4-hydroxy-2-oxopyrrolidin-1-yl)acetate, **I-387** (2.1
15 g, 12.14 mmol) in acetonitrile (20 ml) at 0—5 °C was added silver oxide (4.22 g, 1.5 equiv.) and iodomethane (1.55 g, 0.9 equiv.) under N₂. The reaction mixture was allowed to warm to ambient temperature and stirred for 12 hours, then filtered through celite. The filtrate was concentrated under reduced pressure. The residue obtained was purified by silica gel chromatography to afford ester **I-388** as a pale oil (0.83 g, 37% yield). MS (ESI, pos. ion)
20 *m/z*: 184.1 (M+1).

Step 3: **(*R*)-1-(2-hydroxyethyl)-4-methoxypyrrolidin-2-one (**I-389**)**

To a solution of methyl (*R*)-2-(4-methoxy-2-oxopyrrolidin-1-yl)acetate, **I-388** (1.2 g, 6.42 mmol) in *t*-BuOH (10 mL) was added sodium borohydride (0.73 g, 3.0 equiv.) under N₂. The reaction mixture was stirred for 0.5 hours at 80 °C, then cooled and concentrated under reduced pressure. The residue was quenched with water (2 mL) and extracted with DCM (3 x 20 mL). The combined organic extracts were then washed with water (20 mL), brine (20 mL), and dried with Na₂SO₄, then concentrated and the residue obtained was purified by silica gel chromatography to afford alcohol **I-389** as a pale oil (0.52 g, 51% yield). MS (ESI, pos. ion) *m/z*: 160.1(M+1).

Step 4: (*R*)-2-(2-(4-methoxy-2-oxopyrrolidin-1-yl)ethyl)isoindoline-1,3-dione (**I-390**)

To a solution of (*R*)-1-(2-hydroxyethyl)-4-methoxypyrrolidin-2-one, **I-389** (0.58 g, 3.64 mmol) in THF (6 mL) was added phthalimide (0.59 g, 1.1 equiv.) and PPh₃ (1.43 g, 1.5 equiv.). The reaction mixture was stirred for 0.5 hours in an ice-water bath under N₂. Then DIAD (2.21 g, 3.0 equiv.) was added and the reaction mixture was allowed to warm to ambient temperature and stirred for 12 hours, then concentrated under reduced pressure. The residue obtained was purified by silica gel chromatography to afford phthalimide **I-390** as a yellow oil (0.45 g, 43% yield). MS (ESI, pos. ion) *m/z*: 289.1(M+1).

Step 5: (*R*)-1-(2-aminoethyl)-4-methoxypyrrolidin-2-one (**I-391**)


To a solution of (*S*)-2-(2-(4-methoxy-2-oxopyrrolidin-1-yl)ethyl)isoindoline-1,3-dione, **I-390** (0.45 g, 1.56 mmol) in MeOH (10 mL) at 0—5 °C was added hydrazine (85% in H₂O, 0.07 g, 1.87 mmol, 1.2 equiv.). The reaction mixture was allowed to warm to ambient temperature and stirred for 12 hours, then concentrated. The residue was diluted in DCM (10 mL) and the slurry was filtered. The filtrate was concentrated to afford the crude amine **I-391** as a pale oil (0.21 g, 85% yield, 85% purity), which was used directly in the next step. MS (ESI, pos. ion) *m/z*: 159.1(M+1).

Step 6: (*R*)-2-((2-((2-(4-methoxy-2-oxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (**I-392**)

A solution of (*R*)-1-(2-aminoethyl)-4-methoxypyrrolidin-2-one, **I-391** (0.21 g, 1.33 mmol) and thiodiglycolic anhydride (0.23 g, 1.3 equiv.) in DMF (5 mL) was stirred for 2 hours at 25 °C, then the reaction mixture was concentrated under reduced pressure

and the crude product was purified by preparative HPLC (Mobile Phase: MeCN/H₂O (0.1%TFA), Gradient: 1-3% MeCN) to give 117.5 mg (41% yield) of acid **I-392** as a pale oil. MS (ESI, pos. ion) m/z: 291.1 (M+1). ¹H NMR (400 MHz, CDCl₃) δ 7.52 (s, 1H), 4.04 (t, 1H), 3.78 (dd, 1H), 3.63 – 3.55 (m, 2H), 3.42 – 3.32 (m, 5H), 3.30 (s, 3H), 3.27 (s, 2H), 2.67 (dd, 1H), 2.47 (dd, 1H).

The synthesis of compounds (*S*^{*})-**I-395** and (*R*^{*})-**I-395** involved 4 steps as depicted in Scheme 129 .



Scheme 129

The chemical structure of the target compound was confirmed by ¹H NMR and LC-MS with the purity > 95% (HPLC 214 & 254 nm).

Step 1: *Tert*-butyl (2-(3-ethyl-2,5-dioxopyrrolidin-1-yl)ethyl)carbamate (**I-393**)

A solution of 2-ethylsuccinic acid (cas: 636-48-6, 0.2 g, 1.37 mmol) and *tert*-butyl (2-aminoethyl)carbamate (0.26 g, 1.2 equiv.) in 5 mL of PhCH₃ was heated to reflux for 7 hours. After LC-MS analysis indicated that the reaction was complete, the reaction mixture was concentrated under reduced pressure to give the crude product, which was purified by preparative TLC (EtOAc:Petroleum ether=2:1) to afford imide **I-393** (0.15 g, 41 % yield) a pale oil. MS (ESI, pos. ion) m/z: 293 (M+Na).

Step 2: **1-(2-aminoethyl)-3-ethylpyrrolidine-2,5-dione (I-394)**

A solution of *tert*-butyl (2-(3-ethyl-2,5-dioxopyrrolidin-1-yl)ethyl)carbamate, **I-393** (250 mg, 0.93 mmol) in TFA/DCM (1:3 v/v, 8 mL) was stirred at 25 °C for 1 hour. When LC-MS analysis indicated that the reaction was complete, the reaction mixture was concentrated under reduced pressure to give 1-(2-aminoethyl)-3-ethylpyrrolidine-2,5-dione, **I-394** (500 mg) as a pale oil, which was used directly for next step. MS (ESI, pos. ion) m/z: 171 (M+1).

Step 3: **2-((2-((2-(3-ethyl-2,5-dioxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-395)**

To a solution of (*S*)-1-(2-aminoethyl)-3-hydroxypyrrolidine-2, 5-dione, **I-394** (500 mg, 1.77 mmol) and thiodiglycolic anhydride (257 mg, 1.1 equiv.) in 5 mL DCM was added TEA (257 mg, 1.1 equiv.). The reaction mixture was stirred for 2 hours and was concentrated in vacuo to give the crude product. The crude product was purified by preparative HPLC (Mobile Phase: MeCN/H₂O (0.1% formic acid)) to afford the racemic carboxylic acid **I-395** as a pale oil (220 mg, 41% yield). MS (ESI, pos. ion) m/z: 303.1(M+1).


(*S*)-2-((2-((2-(3-ethyl-2,5-dioxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid ((*S*^{*})-I-395)

(*S*^{*})-I-395 (pale oil, 80 mg, 36% yield) was isolated by chiral separation (Superchiral S-AD (Chiralway), 2cm I.D. * 25 cm Length, 5 μm, CO₂ / EtOH = 70 / 30 (v/v)) from racemic acid **I-395**. MS (ESI, pos. ion) m/z: 303.1(M+1). ¹H NMR (400 MHz, CDCl₃) δ 7.22 (s, 1H), 3.74 – 3.61 (m, 2H), 3.58 – 3.45 (m, 2H), 3.33 (m, 4H), 2.93 – 2.72 (m, 2H), 2.40 (m, 1H), 1.99 – 1.86 (m, 1H), 1.65 – 1.53 (m, 1H), 0.99 (m, 3H).

(*R*)-2-((2-((2-(3-ethyl-2,5-dioxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid ((*R*^{*})-I-395)

(*R*^{*})-I-395 (pale oil, 80 mg, 36% yield) is isolated by chiral separation (Superchiral S-AD (Chiralway), 2cm I.D. * 25 cm Length, 5 μm, CO₂ / EtOH = 70 / 30 (v/v)) from racemic acid **I-395**. MS (ESI, pos. ion) m/z: 303.1(M+1). ¹H NMR (400 MHz, CDCl₃) δ 7.48 (s, 1H), 3.66 (m, 2H), 3.47 (m, 2H), 3.31 (s, 4H), 2.94 – 2.67 (m, 2H), 2.37 (m, 1H), 1.88 (m, 1H), 1.56 (m, 1H), 0.95 (m 3H).

The synthesis of compound I-398 involved 3 steps as depicted in Scheme 130. I-399, the enantiomer of I-398, was made using a similar route.



Scheme 130

Step 1: *Tert*-butyl (*S*)-(2-(3-hydroxy-2,5-dioxopyrrolidin-1-yl)ethyl)carbamate (I-396)

A solution of (*S*)-2-hydroxysuccinic acid (cas: 97-67-6, 2 g, 14.9 mmol) and *tert*-butyl (2-aminoethyl)carbamate (2.88 g, 1.2 equiv.) in 10 mL of toluene was heated to reflux for 7 hours. When LC-MS analysis indicated that the reaction was complete, the reaction mixture was concentrated under reduced pressure to give the crude product, which was purified by silica gel chromatography (EtOAc:Petroleum ether = 2:1) to afford 1.9 g (49% yield) of intermediate *tert*-butyl (*S*)-(2-(3-hydroxy-2,5-dioxopyrrolidin-1-yl)ethyl)carbamate **I-396** as a pale oil. MS (ESI, pos. ion) *m/z*: 281 (M+Na).

Step 2: (*S*)-1-(2-aminoethyl)-3-hydroxypyrrolidine-2, 5- dione (I-397)

A solution of *tert*-butyl (*S*)-(2-(3-hydroxy-2,5-dioxopyrrolidin-1-yl)ethyl)carbamate, **I-396** (300 mg, 1.06 mmol) in TFA/DCM (1:3 v/v, 8 mL) was stirred at 25 °C for 1 hour. When LC-MS analysis indicated that the reaction was complete, the reaction mixture was concentrated under reduced pressure to afford (*S*)-1-(2-aminoethyl)-3-hydroxypyrrolidine-2, 5-dione, **I-397** (400 mg) as a pale oil, which was used directly for next step. MS (ESI, pos. ion) *m/z*: 159 (M+1).


Step 3: (*S*)-2-((2-((3-hydroxy-2,5-dioxopyrrolidin-1-yl)ethyl)amino)-2-oxoethylthio)acetic acid (I-398)

A solution of (*S*)-1-(2-aminoethyl)-3-hydroxypyrrolidine-2, 5-dione, **I-397** (200 mg, 1.3 mmol) and thiodiglycolic anhydride (167 mg, 1.3 mmol) in 5 mL of DCM was added TEA (157 mg, 1.2 equiv.). The reaction mixture was stirred for 2 hours, then concentrated under reduced pressure to give the crude product. The crude product was purified by preparative HPLC to give the carboxylic acid **I-398** (83 mg, 22% yield) as a pale oil. MS (ESI, pos. ion) *m/z*: 291.2 (*M*+1). ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.16-8.13 (m, 1H), 4.48-4.45 (m, 1H), 3.45-3.42 (m, 2H), 3.35 (s, 2H), 3.26-3.17 (m, 2H), 3.14 (s, 2H), 2.98-2.91 (m, 1H), 2.55 (s, 1H), 2.44-2.39 (m, 1H).

R-2-((2-((3-hydroxy-2,5-dioxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-399**)**

I-399 was prepared from (2*R*)-malic acid as a pale oil in 79 % yield. MS (ESI, pos. ion) *m/z*: 291.2 (*M*+1). ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.15-8.12 (m, 1H), 4.47-4.44 (m, 1H), 3.45-3.42 (m, 2H), 3.34 (s, 2H), 3.26-3.16 (m, 2H), 3.14 (s, 2H), 2.97-2.91 (m, 1H), 2.54 (s, 1H), 2.44-2.36 (m, 1H).

The synthesis of racemic compound (±)—**I-403** involved 3 steps as depicted in the following Scheme 131. The intermediate **I-404** was then isolated by chiral separation.




Scheme 131

2-((2-((2-(3,4-dimethyl-2,5-dioxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-404**)**

The synthetic route for **I-404** was similar to that of **I-398** and commenced with (±)-(2R*,3R*)-2,3-dimethylsuccinic acid, (±)—**I-400** (cas: 13545-04-5). **I-404** (pale oil, 30 mg, 15% yield) was isolated by chiral separation (Superchiral S-AD (Chiralway), 2cm I.D. * 25 cm Length, 5 µm, Hexane/EtOH = 60/40 (v/v)) from racemic acid **I-403**. MS (ESI, pos. ion) m/z: 303.1 (M+1). ¹H NMR (400 MHz, CDCl₃): δ 7.34 (s, 1H), 5.6 (s, 1H), 3.67 (m, 2H), 3.5(s, 2H), 3.31 (m, 4H), 2.4 (m, 2H), 1.3 (m, 6H).

The synthesis of (*R**)-**I-409** and (*S**)-**I-409** involved 5 steps as depicted in the following Scheme 132.



Scheme 132

Step 1: 1-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)-3-methylpyrrolidin-2-one (**I-405**)

To a solution of 3-methylpyrrolidin-2-one (cas: 2555-05-7, 0.3 g, 3 mmol) in THF (10 mL) at 0—5 °C was added NaH (0.242 g, 2 equiv.) under N₂. The reaction mixture was stirred for 0.5 hours, then (2-bromoethoxy)(*tert*-butyl)dimethylsilane (cas: 86864-60-0, 0.86 g, 1.2 equiv.) was added. The reaction mixture was allowed to warm to ambient temperature and stirred for 5 hours. The reaction was then quenched with water (5 mL), and extracted with DCM (3 x 20 mL). The combined organic extracts were then washed with water (20 mL), brine (20 mL), dried with Na₂SO₄ and concentrated under reduced pressure. The residue obtained was purified by silica gel chromatography to afford **I-405** (0.25 g, 32% yield) as a pale oil. MS (ESI, pos. ion) m/z: 258(M+1).

Step 2: 1-(2-Hydroxy-ethyl)-3-methyl-pyrrolidin-2-one (I-406)

To a solution of 1-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)-3-methylpyrrolidin-2-one, **I-405** (0.3 g, 3 mmol) in MeOH (10 mL) at 0—5 °C was added HCl in MeOH (30%, 3 mL) under N₂. The mixture was stirred for 0.5 hours. The reaction mixture was then concentrated under reduced pressure to afford the crude alcohol **I-406** as a pale oil (0.25 g), which was used directly in the next step. MS (ESI, pos. ion) m/z: 144(M+1).

Step 3: 2-(2-(3-Methyl-2-oxopyrrolidin-1-yl) ethyl) isoindoline-1,3-dione (I-407)

To a solution of 1-(2-hydroxyethyl)-3-methylpyrrolidin-2-one, **I-406** (0.25 g, 1.75 mmol) in THF (5 mL) was added phthalimide (cas: 85-41-6, 0.25 g, 1.5 equiv.) and PPh₃ (0.68 g, 1.5 equiv.). The reaction mixture was cooled to 0—5 °C and DIAD (1.059 g, 3.0 equiv.) was added. The reaction mixture was allowed to warm to ambient temperature and stirred for 6 hours, then quenched with water (5 mL), and extracted with DCM (3 x 20 mL). The combined organic extracts were then washed with water (20 mL), brine (20 mL), dried with Na₂SO₄ and concentrated under reduced pressure to afford the crude product, **I-407** (purity: 67%, 0.3 g, 48% yield), which was taken to the next step without further purification. MS (ESI, pos. ion) m/z: 273(M+1).

Step 4: 1-(2-aminoethyl)-3-methylpyrrolidin-2-one (I-408)

To a solution of 2-(2-(3-methyl-2-oxopyrrolidin-1-yl)ethyl)isoindoline-1,3-dione, **I-407** (0.3 g, 3 mmol) in MeOH (10 mL) at 0—5 °C was added NH₂NH₂ (85% in H₂O, 1.03 mL, 1.2 equiv.). The reaction mixture was allowed to warm to ambient temperature, stirred for 7 hours, and then filtered. The filtrate was concentrated to afford a pale oil. The crude product, **I-408** (0.35 g) was used directly in the next step. MS (ESI, pos. ion) m/z: 143(M+1).

Step 5: 2-((2-((2-(3-methyl-2-oxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (I-409)


To a solution of 1-(2-aminoethyl)-3-methylpyrrolidin-2-one, **I-408** (350 mg, 1.3 mmol) and thiodiglycolic anhydride (167 mg, 1.0 equiv.) in 5 mL of DCM was added TEA (157 mg, 1.56 mmol). The reaction mixture was stirred for 2 hours and was concentrated in vacuo to give the crude acid, which was purified by preparative HPLC to afford racemic

acid **I-409**. (*R*^{*})-**I-409** (30 mg, 5 %, absolute configuration not known) was isolated by chiral separation (CHIRALPAK AD-H column, Mobile phase: Hexane/EtOH/AcOH = 80/20/0.1(v/v/v)) from racemic **I-409**. MS (ESI, pos. ion) *m/z*: 275.2 (M+1). ¹H NMR (400 MHz, CDCl₃): δ 7.38 (s, 1H), 3.5 (m, 6H), 3.4 (s, 2H), 3.2(s, 2H), 2.6 (m, 1H), 2.3 (m, 1H), 1.6 (m, 1H), 1.1(m, 3H).

2-((2-((2-(3-methyl-2-oxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (*S*^{*})-I-409)

Isolated as a pale oil in 5 % yield by chiral separation (CHIRALPAK AD-H column, Mobile phase: Hexane/EtOH/HOAc = 80/20/0.1(v/v/v)) from racemic **I-409**. The absolute configuration at the stereocenter was not established. MS (ESI, pos. ion) *m/z*: 275.2 (M+1). ¹H NMR (400 MHz, CDCl₃): δ 7.4 (s, 1H), 3.5 (m, 6H), 3.4 (s, 2H), 3.2 (s, 2H), 2.58 (m, 1H), 2.28 (m, 1H), 1.7 (m, 1H), 1.1(m, 3H).

The synthesis of **I-412** involved 3 steps as depicted in the following Scheme 133.



Scheme 133

2-((2-((2-(3,4-dimethyl-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-412**):**

Step 1: *tert*-butyl (2-(3,4-dimethyl-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)carbamate (**I-410**)

A solution of 3,4-dimethylfuran-2,5-dione (cas: 766-39-2, 600 mg, 4.76 mmol) and *tert*-butyl (2-aminoethyl)carbamate (cas: 57260-73-8, 1.1 g, 1.5 equiv.) in toluene (30 mL) was heated to reflux for 2 hours. The reaction mixture was then concentrated and purified by silica gel chromatography (Hexane:EtOAc = 5:1) to afford *tert*-butyl (2-(3,4-dimethyl-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)carbamate, **I-410** as a yellow solid (700 mg, 55 %). MS (ESI, pos. ion) *m/z*: 291.1 (M+23).

Step 2: 1-(2-aminoethyl)-3,4-dimethyl-1H-pyrrole-2,5-dione (**I-411**)

278


To a solution *tert*-butyl (2-(3,4-dimethyl-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)carbamate (700 mg, 2.61 mmol) in DCM (10 mL) was added TFA (2 mL). The reaction mixture was stirred at ambient temperature for 1 hour, then concentrated to afford the crude 1-(2-aminoethyl)-3,4-dimethyl-1H-pyrrole-2,5-dione TFA salt, **I-411** as a brown oil (500 mg, 108 %). MS (ESI, pos. ion) *m/z*: 169.1 (M+1).

Step 3: **2-((2-((3,4-dimethyl-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)amino)-2-oxoethyl) thio) acetic acid (I-412)**

A solution of 1-(2-aminoethyl)-3,4-dimethyl-1H-pyrrole-2,5-dione (0.4 g, 2.38 mmol) and thiodiglycolic anhydride (1.2 g, 4 equiv.) in DCM (5 mL) was stirred at ambient temperature overnight. The reaction was monitored by LC-MS. Upon completion of the reaction, the reaction mixture was concentrated and purified by preparative TLC to afford acid **I-412** (100 mg, 14 %) as a white solid. MS (ESI, pos. ion) *m/z*: 301.1 (M+1). ¹H NMR (400 MHz, CDCl₃): δ 8.28 (s, 1H), 3.70 (m, 2H), 3.50 (m, 2H), 3.39 (s, 2H), 3.36 (s, 1H), 3.32 (s, 2H), 1.96 (s, 6H).

(S*)-I-413 and (R*)-I-413

The synthetic route for **(S*)-I-413** and **(R*)-I-413** was similar to the route for **(R*)-I-234** and **(S*)-I-234**. The synthesis started with 5-methylpyrrolidin-2-one. The final target compounds were purified by preparative HPLC to afford 200 mg (55%) of racemic **I-413** as a pale oil. Preparative chiral separation (CHIRALPAK AD column (Hexane/ EtOH/ AcOH=70 / 30 / 0.1)) of the racemate afforded the two enantiomers.



*Absolute configuration not known


(S*)-I-413

After chiral HPLC purification, 30 mg of **(S*)-I-413** (absolute configuration not determined) was obtained as a yellow oil. MS (ESI, pos. ion) *m/z*: 275.1 (M+1). ¹H NMR (400 MHz, CDCl₃): δ 7.50 (s, 1H), 6.81 (s, 1H), 3.96 - 3.84 (m, 1H), 3.77 - 3.67 (m, 1H), 3.71 - 3.58 (m, 1H), 3.36 (s, 2H), 3.29 - 3.19 (m, 2H), 3.28 - 3.23 (m, 1H), 3.18 - 3.08 (m, 1H), 2.51 - 2.37 (m, 2H), 2.26 - 2.16 (m, 1H), 1.72 - 1.53 (m, 1H), 1.26 - 1.22 (m, 3H).

(*R)-I-413**

After chiral HPLC purification, 41 mg of (*R**)-I-413 (absolute configuration not determined) was obtained as a yellow oil. MS (ESI, pos. ion) *m/z*: 275.1 (M+1). ¹H NMR (400 MHz, CDCl₃): δ 7.39 (s, 1H), 3.96 - 3.88 (m, 1H), 3.88 - 3.79 (m, 1H), 3.73 (s, 1H), 3.36 (s, 2H), 3.29 - 3.19 (m, 3H), 3.15 - 3.07 (m, 1H), 2.47 - 2.37 (m, 2H), 2.27 - 2.19 (m, 1H), 1.67 - 1.56 (m, 1H), 1.26 - 1.24 (m, 3H).

The synthesis of compound I-417 involved 4 steps as depicted in the following Scheme 134.



Scheme 134

The chemical structure of the target compound was confirmed by ¹H NMR and LC-MS with the purity > 95% (HPLC 214 & 254 nm).

(*R*)-2-((2-((2-((3-((*tert*-butoxycarbonyl)amino)-2,5-dioxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-417)

Step 1: *tert*-butyl (2,5-dioxopyrrolidin-3-yl)carbamate (I-414)

To a stirred solution of (*tert*-butoxycarbonyl)-D-asparagine (cas: 75647-01-7, 1.0 g, 4.3 mmol) in DMF (7 mL) was added DCC (0.8 g, 1.0 equiv.) and HOSu (0.5 g, 1.0 equiv.). The reaction mixture was heated to 80 °C for 6 hours and then concentrated under reduced pressure. The residue was dissolved in EtOAc (10 mL) and filtered. The filtrate was washed with water, brine, dried with Na₂SO₄, and then concentrated under reduced

pressure. The resulting residue was purified by column chromatography (EtOAc: Petroleum ether =1:1) to afford imide **I-414** as a pale yellow solid (0.5 g, 53 % yield). MS (ESI, pos. ion) m/z: 237.1 (M+23).

Step 2: ***tert*-butyl (1-(2-(((benzyloxy)carbonyl)amino)ethyl)-2,5-dioxopyrrolidin-3-yl)carbamate (I-415)**

To a solution of *tert*-butyl(2,5-dioxopyrrolidin-3-yl)carbamate, **I-414** (0.5 g, 2.3 mmol) and benzyl (2-bromoethyl)carbamate (cas: 53844-02-3, 890 mg, 1.5 equiv.) in DMF (5 mL) was added potassium carbonate (800 mg, 2.5 equiv.). The reaction mixture was heated to 90 °C for 12 hours. The reaction was then quenched with water (5 mL), and extracted with EtOAc (3 x 20 mL). The combined organic extracts were then washed with water (20 mL), brine (20 mL), dried with Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (EtOAc: Petroleum ether = 1:1) to provide carbamate **I-415** as a pale yellow oil (0.9 g, 100 %). MS (ESI, pos. ion) m/z: 414.1 (M+23).

Step 3: ***tert*-butyl-(1-(2-aminoethyl)-2,5-dioxopyrrolidin-3-yl)carbamate (I-416)**


To a solution of *tert*-butyl (1-(2-(((benzyloxy)carbonyl)amino)ethyl)-2,5-dioxopyrrolidin-3-yl)carbamate, **I-415** (0.9 g, 2.3 mmol) in EtOAc (15 ml), was added 100 mg of Pd/C under H₂ (14 Psi). The reaction mixture was stirred at ambient temperature overnight then filtered, and the filtrate was concentrated to afford the crude *tert*-butyl-(1-(2-aminoethyl)-2,5-dioxopyrrolidin-3-yl)carbamate **I-416** as brown oil (0.5 g, 84 %). MS (ESI, pos. ion) m/z: 280.1 (M+23).

Step 4: **2-((2-((3-((*tert*-butoxycarbonyl)amino)-2,5-dioxopyrrolidin-1-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-417)**

A solution of *tert*-butyl-(1-(2-aminoethyl)-2,5-dioxopyrrolidin-3-yl)carbamate, **I-416** (0.1 g, 0.4 mmol) and thiodiglycolic anhydride (211 mg, 4 equiv.) in DCM (5 mL) was stirred at ambient temperature for 4 hours. The reaction was monitored by LC-MS. Upon completion of the reaction, the reaction mixture was concentrated, and the resulting residue was purified by preparative HPLC to afford **I-417** (racemic) (39 mg, 25 % yield). MS (ESI, pos. ion) m/z: 412.2 (M+23). ¹H NMR (400 MHz, CDCl₃): δ 7.34 (s, 1H), 5.62 (m, 1H),

4.36 (s, 1H), 3.72 (m, 1H), 3.57(m, 1H), 3.45 (m, 3H), 3.31 (1H), 3.05 (m, 1H), 2.80 (s, 2H), 2.01 (s, 2H), 1.44 (s, 9H).

The synthesis of compound **I-421** involved 4 steps as depicted in the following Scheme 135.



Scheme 135

The chemical structure of the target compound was confirmed by ^1H NMR and LC-MS with the purity > 95% (HPLC 214 & 254 nm).

Step 1: ***Tert*-butyl (2-((3-chloropropyl)sulfonamido)ethyl)carbamate (**I-418**)**

A solution of 3-chloropropane-1-sulfonyl chloride (cas: 1633-82-5, 1.22 g, 6.9 mmol) in anhydrous THF (5 mL) was added to a solution of *tert*-butyl (2-aminoethyl)carbamate (1 g, 6.25 mmol) and DIPEA (1.30 mL) in anhydrous THF (62 mL) at 0–5 °C. The reaction mixture was allowed to warm to ambient temperature and stirred for 8 hours. When LC-MS analysis indicated that the reaction was complete, H_2O (20 mL) was added, and the reaction mixture was extracted with EtOAc (20 mL x 3). The combined organic extracts were concentrated under reduced pressure to give the crude product. The crude product was purified by silica gel chromatography (Petroleum ether: EtOAc = 1:2) to provide **I-418** (2.0 g, 96%) as a pale oil. MS (ESI, pos. ion) m/z : 323($\text{M}+\text{Na}$).

Step 2: ***Tert*-butyl (2-(1,1-dioxidoisothiazolidin-2-yl)ethyl)carbamate (**I-419**)**

To a solution of *tert*-butyl (2-aminoethyl)carbamate, **I-418** (2 g, 6.67 mmol) in anhydrous THF (70 mL) at 0–5 °C was added NaH(60% dispersion in mineral oil, 0.4 g, 1.5 equiv.) in portions. The reaction was allowed to warm to ambient temperature and

stirred for 8 hours. When LC-MS analysis indicated that the reaction was complete, H₂O (20 mL) was added and the reaction mixture was extracted with EtOAc (20 mL x 3). The combined organic extracts were concentrated in vacuo to provide the crude product. The crude product was purified by silica gel chromatography (Petroleum Ether: EtOAc = 2:1) to provide **I-419** (0.15 g, 9% yield) as a pale oil. MS (ESI, pos. ion) m/z: 287(M+Na).

Step 3: **2-(2-aminoethyl)isothiazolidine 1,1-dioxide (I-420)**


A solution of *tert*-butyl (2-(1,1-dioxidoisothiazolidin-2-yl)ethyl)carbamate, **I-419** (150 mg, 0.57 mmol) in TFA/DCM (1:3 v/v, 4 mL) was stirred at 25 °C for 2 hours. When LC-MS analysis indicated that the reaction was complete, the reaction mixture was concentrated in vacuo to give the crude amine TFA salt, **I-420** as a pale oil (337 mg), which was used directly in the next step. MS (ESI, pos. ion) m/z: 165(M+1).

Step 4. **2-((2-((2-(1,1-dioxidoisothiazolidin-2-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (I-421)**

To a solution of 2-(2-aminoethyl)isothiazolidine-1,1-dioxide (337 mg, 1.22 mmol) and thiodiglycolic anhydride (193 mg, 1.2 equiv.) in 5 mL of DCM was added TEA (24 mg, 0.244 mmol). The reaction mixture was stirred for 2 hours and then concentrated under reduced pressure to give the crude product. The crude product was purified by preparative HPLC (Mobile Phase: MeCN/H₂O (0.1%TFA), Gradient: 1-5% MeCN) to afford **I-421** as a pale oil (50mg, 14% yield). MS (ESI, pos. ion) m/z: 297.1 (M+1). ¹H NMR (400 MHz, DMSO) δ 12.60 (s, 1H), 8.11 (m, 1H), 3.36 (s, 2H), 3.27 – 3.19 (m, 6H), 3.19 – 3.12 (m, 2H), 2.95 (m, 2H), 2.25 – 2.15 (m, 2H).

I-425:

The synthesis of compound **I-425** involved 4 steps as depicted in the following Scheme 136.




Scheme 136

2-((2-((2-(1,1-dioxido-1,2-thiazinan-2-yl)ethyl)amino)-2-oxoethyl)thio) acetic acid (I-425)

5 The synthetic route for **I-425** was similar to that used for the synthesis of **I-421** and commenced with 4-chlorobutane-1-sulfonyl chloride (cas: 1633-84-7). 2-((2-((2-(1,1-dioxido-1,2-thiazinan-2-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid, **I-425** (pale oil, 50 mg, 15% yield) was isolated by preparative HPLC (Mobile Phase: MeCN/H₂O (with 0.1%TFA), Gradient:10-20% MeCN). MS (ESI, pos. ion) m/z: 311.1 (M+1). ¹H NMR (400
10 MHz, DMSO) δ 12.57 (s, 1H), 8.13 (m, 1H), 3.37 (s, 2H), 3.34 – 3.30 (m, 2H), 3.21 (s, 2H), 3.18 (m, 2H), 3.11 (m, 2H), 3.08 – 3.03 (m, 2H), 2.06 – 1.95 (m, 2H), 1.54 (m, 3.7 Hz, 2H).


Synthesis of I-426 was depicted in Scheme 137:



15

Scheme 137

To a solution of amine salt **I-14** (44.5 mg, 0.226 mmol), 2,2-dimethylmalonic acid (59.8 mg, 2.0 equiv.) and DIPEA (118 μL, 3.0 equiv.) in DMF (1 mL) was added HATU (129.1 mg, 1.5 equiv.). The reaction mixture was maintained at ambient temperature for 2
20 hours and was then purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%TFA) to afford **I-426** (8.6 mg, 14% yield).

D. Examples of Compounds Described in This Invention**General procedure 4 (GP4): Solid phase synthesis of peptides utilizing carboxylic acid building blocks****Example 1: Compound 83****Scheme 138**


E-1 was synthesized as depicted in **Scheme 138**.

To Rink-amide resin **R-1** (0.125 mmol/g, 140.5 mg, 17.6 μ mol) in a 6 mL polypropylene tube with an end-cap was added 20% v/v piperidine/DMF (2 mL). The tube was capped and agitated at ambient temperature for 30 minutes, then drained. The resin was washed with DMF (5 x 3 mL). A solution of carboxylic acid building block **I-1** (36.6 mg, 8.0 equiv.) in DMF (2.8 mL) was added to the resin, followed by DIPEA (61 μ L, 20 equiv.). HATU (80 mg, 12.0 equiv.) was then added and the reaction mixture was agitated at ambient temperature for 18 hours. The reaction mixture was drained and the resin washed with DMF (5 x 3 mL), DCM (5 x 3 mL) and dried *in vacuo* for 30 minutes.

The resin was transferred to a 15 mL Falcon tube and 3 mL of cleavage reagent (95:2.5:2.5 v/v/v TFA/TIS/H₂O) was added. The reaction mixture was agitated at ambient temperature for 1 hour. The resin was filtered and washed with TFA (2 x 3 mL). The combined filtrate and washes were concentrated under reduced pressure to afford a residue, which was triturated with Et₂O (3 mL) to precipitate the peptide. The peptide was re-dissolved in glacial AcOH (2 mL) and purified by preparative HPLC (Phenomenex Jupiter 10 μ M Proteo 90 Å LC column, 250 x 21.2 mm, with flow rate – 15 mL/min, gradient of 0—100% acetonitrile in 25 mM aqueous ammonium acetate over 30 minutes) to afford

25.8 mg of **E-1** as a white solid. ESI-MS (positive ionization) found 1149.7, $[C_{213}H_{325}N_{47}O_{64}S]^{4+}$ calculated 1149.3.

General procedure 5 (GP5): Solid phase synthesis of peptides utilizing pentafluorophenyl or *N*-hydroxysuccinimide ester building blocks



Scheme 139

Example 2: Compound 173


E-2 was synthesized as depicted in **Scheme 139**.

To Rink-amide resin (0.125 mmol/g, 107.8 mg, 13.5 μ mol) in a 6 mL polypropylene tube with an end-cap was added 20% v/v piperidine/DMF (2 mL). The tube was capped, agitated at ambient temperature for 30 minutes, and then drained. The resin was washed with DMF (5 x 3 mL). A solution of pentafluorophenyl ester **I-2** (32.9 mg, 5.0 equiv.) in DMF (1 mL) was added to the resin, followed by DIPEA (24 μ L, 10 equiv.) and the reaction mixture was agitated at ambient temperature for 24 hours. The reaction mixture was drained. The resin was washed with DMF (5 x 3 mL), DCM (5 x 3 mL), and dried *in vacuo* for 30 minutes.

The resin was transferred to a 15 mL falcon tube and 3 mL of cleavage reagent (95:2.5:2.5 v/v/v TFA/TIS/H₂O) was added. The reaction mixture was agitated at ambient temperature for 3 hours. The resin was filtered and washed with TFA (2 x 0.5 mL). The combined filtrate and washes were concentrated under reduced pressure to afford a residue, which was triturated with Et₂O (2 mL) to precipitate the peptide. The peptide was re-dissolved in glacial AcOH (1.2 mL) and purified by preparative HPLC (Phenomenex Jupiter 10 μ M Proteo 90 Å LC column, 250 x 21.2 mm, with flow rate – 15 mL/min, gradient of 0—100% acetonitrile in 25 mM aqueous ammonium acetate over 30 minutes)

to afford 9.4 mg of **E-2** as a white solid. ESI-MS (positive ionization) found 1165.3, $[C_{217}H_{323}N_{47}O_{65}S]^{4+}$ calculated 1164.8.


Example 3: Compound 189



E-3 was synthesized as depicted in **Scheme 140**.

To peptide **I-4** (0.25 mL of a 5 mM stock solution in DMSO, 1.2 μ mol) was added **I-3** (50 μ L of a 50 mM stock solution in DMSO, 2.0 equiv.), followed by 300 mM sodium phosphate buffer, pH 11.5 (50 μ L). The reaction mixture was agitated at ambient temperature for 16 hours and then purified by preparative HPLC ($H_2O/MeCN$ with 0.1% TFA) to afford **E-3** (4.3 mg) as a white solid. ESI-MS found 1374.3, $C_{186}H_{269}N_{46}O_{59}S$ (M—3H) requires 1374.3.

Example 4: Compound 190




E-4 was synthesized as depicted in **Scheme 141**.

To peptide **I-4** (0.25 mL of a 5 mM stock solution in DMSO, 1.2 μ mol) was added **I-5** (50 μ L of a 50 mM stock solution in DMSO, 2.0 equiv.), followed by 500 mM borate buffer, pH 9.5 (25 μ L). The reaction mixture was agitated at ambient temperature for 16 hours and then purified by preparative HPLC ($H_2O/MeCN$ with 0.1% TFA) to afford **E-4**


(1.8 mg) as a white solid. ESI-MS found 1395.0, $C_{190}H_{267}N_{46}O_{60}S$ ($M-3H$) requires 1395.0.

Example 5: Compound 139




E-5 was prepared according to **GP4** using 24 mg of resin (estimated loading 0.18 mmol/g) and **I-6** to afford 2.3 mg of **E-5** as a white solid. ESI-MS found 1058.5, $C_{193}H_{278}N_{46}O_{60}S$ ($M-4H^+$) requires 1058.0.

Example 6: Compound 118




E-6 was prepared according to **GP4** using 30.9 mg of resin (estimated loading 0.15 mmol/g) and **I-6** to afford 0.9 mg of **E-6** as a white solid. ESI-MS found 1063.5, $C_{194}H_{288}N_{46}O_{60}S$ ($M+4H^+$) requires 1063.5.

Example 7: Compound 52



E-7 was prepared according to **GP4** using 43.3 mg of resin (estimated loading 0.125 mmol/g) and **I-6** to afford 2.5 mg of **E-7** as a white solid. ESI-MS found 1152.3, $C_{214}H_{323}N_{47}O_{64}S$ ($M+4H^+$) requires 1151.8.


Example 8: Compound 121



E-8 was prepared according to **GP4** using 30.8 mg of resin (estimated loading 0.18 mmol/g) and **I-7** to afford 2.4 mg of **E-8** as a white solid. ESI-MS found 1077.6, $C_{194}H_{285}FN_{46}O_{60}S$ ($M+4H^+$) requires 1077.0.

5


Example 9: Compound 117



E-9 was prepared according to **GP4** using 30.3 mg of resin (estimated loading 0.18 mmol/g) and **I-8** to afford 3.1 mg of **E-9** as a white solid. ESI-MS found 1061.0, $C_{192}H_{286}N_{46}O_{61}S$ ($M+4H^+$) requires 1061.0.

10


Example 10: Compound 114



E-10 was prepared according to **GP4** using 40.1 mg of resin (estimated loading 0.125 mmol/g) and **I-8** to afford 1.5 mg of **E-10** as a white solid. ESI-MS found 1152.8, $C_{213}H_{323}N_{47}O_{65}S$ ($M+4H^+$) requires 1152.8.


15

Example 11: Compound 53




E-11 was prepared according to **GP4** using 67 mg of resin (estimated loading 0.08 mmol/g) and **I-9** to afford 2.5 mg of **E-11** as a white solid. ESI-MS found 1157.9, $C_{212}H_{321}N_{47}O_{65}S_2$ ($M+4H^+$) requires 1157.3.

5 **Example 12: Compound 56**




E-12 was prepared according to **GP4** using 55.6 mg of resin (estimated loading 0.15 mmol/g) and **I-9** to afford 1.7 mg of **E-12** as a white solid. ESI-MS found 1125.8,
10 $C_{207}H_{313}N_{45}O_{63}S_2$ ($M+4H^+$) requires 1125.3.

Example 13: Compound 60




E-13 was prepared according to **GP4** using 53.3 mg of resin (estimated loading
15 0.18 mmol/g) and **I-9** to afford 5.0 mg of **E-13** as a white solid. ESI-MS found 1125.4, $C_{207}H_{314}N_{46}O_{62}S_2$ ($M+4H^+$) requires 1125.1.

Example 14: Compound 76



20 **E-14** was prepared according to **GP4** using 41.3 mg of resin (estimated loading 0.11 mmol/g) and **I-9** to afford 0.5 mg of **E-14** as a white solid. ESI-MS found 1238.2, $C_{222}H_{348}N_{56}O_{66}S_3$ ($M+4H^+$) requires 1237.6.


Example 15: Compound 73



E-15 was prepared according to **GP4** using 40.4 mg of resin (estimated loading 0.06 mmol/g) and **I-9** to afford 0.8 mg of **E-15** as a white solid. ESI-MS found 1135.3, $C_{206}H_{319}N_{47}O_{64}S_2$ ($M+4H^+$) requires 1134.8.

5


Example 16: Compound 70



E-16 was prepared according to **GP4** using 56.5 mg of resin (estimated loading 0.18 mmol/g) and **I-9** to afford 1.1 mg of **E-16** as a white solid. ESI-MS found 1161.2, $C_{213}H_{323}N_{47}O_{65}S_2$ ($M+4H^+$) requires 1160.8.

10


Example 17: Compound 71



E-17 was prepared according to **GP4** using 68 mg of resin (estimated loading 0.16 mmol/g) and **I-9** to afford 3.3 mg of **E-17** as a white solid. ESI-MS found 1139.3, $C_{205}H_{315}N_{47}O_{64}S_3$ ($M+4H^+$) requires 1138.8.


15

Example 18: Compound 72



E-18 was prepared according to **GP4** using 56.9 mg of resin (estimated loading 0.17 mmol/g) and **I-9** to afford 0.7 mg of **E-18** as a white solid. ESI-MS found 1153.4, $C_{207}H_{318}N_{48}O_{65}S_3$ ($M+4H^+$) requires 1153.1.


5 **Example 19: Compound 137**



E-19 was prepared according to **GP4** using 27.3 mg of resin (estimated loading 0.18 mmol/g) and **I-10** to afford 0.7 mg of **E-19** as a white solid. ESI-MS found 1065.8, $C_{194}H_{281}N_{47}O_{60}S$ ($M-4H$)⁻ requires 1065.3.

10


Example 20: Compound 138



E-20 was prepared according to **GP4** using 29 mg of resin (estimated loading 0.18 mmol/g) and **I-11** to afford 3.0 mg of **E-20** as a white solid. ESI-MS found 1063.0, $C_{193}H_{280}N_{46}O_{61}S$ ($M-4H$)⁻ requires 1062.5.

15


Example 21: Compound 123



E-21 was prepared according to **GP4** using 108.5 mg of resin (estimated loading 0.125 mmol/g) and **I-11** to afford 9.7 mg of **E-21** as a white solid. ESI-MS found 1156.8, $C_{214}H_{325}N_{47}O_{65}S$ ($M+4H^+$) requires 1156.3.

20


Example 22: Compound 120



E-22 was prepared according to **GP4** using 31.5 mg of resin (estimated loading 0.18 mmol/g) and **I-12** to afford 1.8 mg of **E-22** as a white solid. ESI-MS found 1065.1, $C_{193}H_{288}N_{46}O_{61}S$ ($M+4H^+$) requires 1064.5.

5


Example 23: Compound 122



E-23 was prepared according to **GP4** using 29.4 mg of resin (estimated loading 0.18 mmol/g) and **I-13** to afford 4.2 mg of **E-23** as a white solid. ESI-MS found 1068.6, $C_{194}H_{290}N_{46}O_{61}S$ ($M+4H^+$) requires 1068.0.

10


Example 24: Compound 170



E-24 was prepared according to **GP4** using 26.9 mg of resin (estimated loading 0.15 mmol/g) and **I-15** to afford 3.3 mg of **E-24** as a white solid. ESI-MS found 1068.0, $C_{191}H_{276}N_{46}O_{62}S_2$ ($M-4H$)⁻ requires 1067.5.


15

Example 25: Compound 131



E-25 was prepared according to **GP3** using 29.1 mg of resin (estimated loading 0.18 mmol/g) and diester **I-16** to afford 2.1 mg of **E-25** as a white solid. ESI-MS found 1024.0, $C_{187}H_{272}N_{44}O_{60}$ ($M-4H$)⁻ requires 1023.5.


5 **Example 26: Compound 143**



E-26 was prepared according to **GP5** using 28.7 mg of resin (estimated loading 0.18 mmol/g) and **I-21** to afford 3.4 mg of **E-26** as a white solid. ESI-MS found 1070.5, $C_{198}H_{282}N_{46}O_{61}$ ($M-4H$)⁻ requires 1070.0.

10


Example 27: Compound 142



E-27 was prepared according to **GP5** using 24.7 mg of resin (estimated loading 0.18 mmol/g) and **I-22** to afford 2.5 mg of **E-27** as a white solid. ESI-MS found 1027.3, $C_{188}H_{275}N_{45}O_{59}$ ($M-4H$)⁻ requires 1026.8.

15


Example 28: Compound 141



E-28 was prepared according to **GP5** using 26.1 mg of resin (estimated loading 0.18 mmol/g) and **I-23** to afford 1.8 mg of **E-28** as a white solid. ESI-MS found 1074.0, $C_{199}H_{284}N_{46}O_{61}$ ($M-4H$)⁻ requires 1073.5.

20


Example 29: Compound 140



E-29 was prepared according to **GP5** using 23.5 mg of resin (estimated loading 0.18 mmol/g) and **I-24** to afford 0.5 mg of **E-29** as a white solid. ESI-MS found 1067.0, $C_{197}H_{280}N_{46}O_{61}$ ($M-4H$)⁻ requires 1066.5.

5


Example 30: Compound 116



E-30 was prepared according to **GP5** using 24.9 mg of resin (estimated loading 0.18 mmol/g) and **I-25** to afford 1.4 mg of **E-30** as a white solid. ESI-MS found 1068.7, $C_{197}H_{289}N_{47}O_{60}$ ($M+4H$)⁺ requires 1068.3.

10


Example 31: Compound 127



E-31 was prepared according to **GP5** using 28.4 mg of resin (estimated loading 0.18 mmol/g) and **I-26** to afford 2.4 mg of **E-31** as a white solid. ESI-MS found 1070.5, $C_{198}H_{282}N_{46}O_{61}$ ($M-4H$)⁻ requires 1070.0.


15

Example 32: Compound 129




E-32 was prepared according to **GP5** using 26.4 mg of resin (estimated loading 0.18 mmol/g) and **I-27** to afford 5.5 mg of **E-32** as a white solid. ESI-MS found 1074.0, $C_{199}H_{284}N_{46}O_{61}$ ($M-4H$)⁻ requires 1073.5.


20

Example 33: Compound 132


E-33 was prepared according to **GP5** using 27.1 mg of resin (estimated loading 0.2 mmol/g) and **I-28** to afford 3.1 mg of **E-33** as a white solid. ESI-MS found 1070.0, $C_{195}H_{284}N_{46}O_{61}S$ ($M-4H$)⁻ requires 1069.5.

Example 34: Compound 134

E-34 was prepared according to **GP5** using 28 mg of resin (estimated loading 0.18 mmol/g) and **I-29** to afford 3.0 mg of **E-34** as a white solid. ESI-MS found 1062.5, $C_{193}H_{278}N_{46}O_{61}S$ ($M-4H$)⁻ requires 1149.8.


Example 35: Compound 135

E-35 was prepared according to **GP5** using 25.8 mg of resin (estimated loading 0.18 mmol/g) and **I-30** to afford 2.4 mg of **E-35** as a white solid. ESI-MS found 1059.0, $C_{192}H_{276}N_{46}O_{61}S$ ($M-4H$)⁻ requires 1058.5.

Example 36: Compound 19

E-36 was prepared according to **GP5** using 39.7 mg of resin (estimated loading 0.125 mmol/g) and **I-31** to afford 5.9 mg of **E-36** as a white solid. ESI-MS found 1148.9, $C_{215}H_{329}N_{47}O_{64}$ ($M+4H^+$) requires 1148.3.


5 **Example 37: Compound 119**



E-37 was prepared according to **GP5** using 34 mg of resin (estimated loading 0.18 mmol/g) and **I-32** to afford 5.2 mg of **E-37** as a white solid. ESI-MS found 1071.6, $C_{195}H_{290}N_{46}O_{61}S$ ($M+4H^+$) requires 1071.0.

10


Example 38: Compound 124



E-38 was prepared according to **GP5** using 21.6 mg of resin (estimated loading 0.18 mmol/g) and **I-33** to afford 3.5 mg of **E-38** as a white solid. ESI-MS found 1080.0, $C_{198}H_{288}N_{46}O_{61}S$ ($M+4H^+$) requires 1079.5.


15

Example 39: Compound 80




E-39 was prepared according to **GP5** using 51.5 mg of resin (estimated loading 0.14 mmol/g) and **I-9** to afford 0.8 mg of **E-39** as a white solid. ESI-MS found 1164.9, $C_{214}H_{325}N_{47}O_{65}S_2$ ($M+4H^+$) requires 1164.3.


20

Example 40: Compound 196

E-40 was prepared according to **GP5** using 26.2 mg of resin (estimated loading 0.38 mmol/g) and **I-34** to afford 3.3 mg of **E-40** as a white solid. ESI-MS found 1064.0, $C_{191}H_{276}N_{46}O_{61}S_2$ ($M-4H$)⁻ requires 1063.5.


Example 41: Compound 195

E-41 was prepared according to **GP5** using 109.9 mg of resin (estimated loading 0.125 mmol/g) and **I-34** to afford 7.3 mg of **E-41** as a white solid. ESI-MS found 1156.1, $C_{212}H_{313}N_{47}O_{65}S_2$ ($M-4H$) requires 1155.3.

Example 42: Compound 147


Peptide **E-42** was prepared from 39 mg of resin (approximate loading 0.18 mmol/g) using **I-35** and **GP5** to afford **E-42** as a white solid. ESI-MS found 1078.5, $C_{198}H_{282}N_{46}O_{61}S$ ($M-4H$)⁻ requires 1078.0.

Example 43: Compound 145

**E-43**


Peptide **E-43** was prepared from 36 mg of resin (approximate loading 0.18 mmol/g) using **I-35** and **GP5** to afford **E-43** as a white solid. ESI-MS found 1067.5, $C_{197}H_{282}N_{46}O_{59}S$ ($M-4H$)⁻ requires 1067.0.

5

Example 44: Compound 144**E-44**


Peptide **E-44** was prepared from 36 mg of resin (approximate loading 0.18 mmol/g) using **I-35** and **GP5** to afford **E-44** as a white solid. ESI-MS found 1075.0, $C_{197}H_{280}N_{46}O_{61}S$ ($M-4H$)⁻ requires 1074.5.

10

Example 45: Compound 133**E-45**


Peptide **E-45** was prepared from 27.9 mg of resin (approximate loading 0.2 mmol/g) using **I-35** and **GP5** to afford 2.3 mg of **E-45** as a white solid. ESI-MS found 1082.0, $C_{199}H_{284}N_{46}O_{61}S$ ($M-4H$)⁻ requires 1081.5.

15

Example 46: Compound 149**E-46**

Peptide **E-46** was prepared from 32 mg of resin (approximate loading 0.17 mmol/g) using **I-35** and **GP5** to afford 4.7 mg of **E-46** as a white solid. ESI-MS found 1075.3, $C_{197}H_{279}N_{45}O_{62}S$ ($M-4H$)⁻ requires 1074.8.


5 **Example 47: Compound 150**



Peptide **E-47** was prepared from 32.6 mg of resin (approximate loading 0.17 mmol/g) using **I-35** and **GP5** to afford 4.8 mg of **E-47** as a white solid. ESI-MS found 1071.7, $C_{195}H_{273}N_{45}O_{63}S$ ($M-4H$)⁻ requires 1071.2.

10


Example 48: Compound 151



Peptide **E-48** was prepared from 30.2 mg of resin (approximate loading 0.19 mmol/g) using **I-35** and **GP5** to afford 5.4 mg of **E-48** as a white solid. ESI-MS found 1059.0, $C_{193}H_{280}N_{46}O_{60}S$ ($M-4H$)⁻ requires 1058.5.

15


Example 49: Compound 193



E-49 was prepared according to **GP5** using 50 mg of resin (estimated loading 0.18 mmol/g) and **I-36** to afford 7.7 mg of **E-49** as a white solid. ESI-MS found 1059.5, $C_{192}H_{278}N_{46}O_{61}S$ ($M-4H$)⁻ requires 1059.0.

20


Example 50: Compound 155



E-50 was prepared according to **GP5** using 52.9 mg of resin (estimated loading 0.15 mmol/g) and **I-36** to afford **E-50** as a white solid. ESI-MS found 1151.3, $C_{212}H_{323}N_{47}O_{64}S$ ($M-4H$)⁻ requires 1150.8.

5


Example 51: Compound 192



E-51 was prepared according to **GP5** using 50 mg of resin (estimated loading 0.18 mmol/g) and **I-37** to afford 5.9 mg of **E-51** as a white solid. ESI-MS found 1056.0, $C_{191}H_{276}N_{46}O_{61}S$ ($M-4H$)⁻ requires 1055.5.

10


Example 52: Compound 194



E-52 was prepared according to **GP5** using 50 mg of resin (estimated loading 0.18 mmol/g) and **I-38** to afford 3.1 mg of **E-52** as a white solid. ESI-MS found 1060.0, $C_{191}H_{276}N_{46}O_{62}S$ ($M-4H$)⁻ requires 1059.5.


15

Example 53: Compound 191



E-53 was prepared according to **GP5** using 50 mg of resin (estimated loading 0.18 mmol/g) and **I-39** to afford 7.8 mg of **E-53** as a white solid. ESI-MS found 1063.0, $C_{193}H_{280}N_{46}O_{61}S$ ($M-4H$)[−] requires 1062.5.


5 **Example 54: Compound 187**



E-54 was prepared according to **GP5** using 22 mg of resin (estimated loading 0.5 mmol/g) and **I-40** to afford 1.8 mg of **E-54** as a white solid. ESI-MS found 1063.5, $C_{196}H_{278}N_{46}O_{61}$ ($M-4H$)[−] requires 1063.0.

10


Example 55: Compound 188



E-55 was prepared according to **GP5** using 21.3 mg of resin (estimated loading 0.5 mmol/g) and **I-41** to afford 1.0 mg of **E-55** as a white solid. ESI-MS found 1067.0, $C_{197}H_{280}N_{46}O_{61}$ ($M-4H$)[−] requires 1066.5.

15


Example 56: Compound 184



E-56 was prepared according to **GP5** using 13.6 mg of resin (estimated loading 0.5 mmol/g) and **I-42** to afford 0.8 mg of **E-56** as a white solid. ESI-MS found 1071.0, $C_{193}H_{280}N_{46}O_{61}S_2$ ($M-4H$)[−] requires 1070.5.

20


Example 57: Compound 186



E-57 was prepared according to **GP5** using 16.1 mg of resin (estimated loading 0.5 mmol/g) and **I-44** to afford 0.4 mg of **E-57** as a white solid. ESI-MS found 1068.0, $C_{195}H_{276}N_{46}O_{61}S$ ($M-4H$)[−] requires 1067.5.

5


Example 58: Compound 181



E-58 was prepared according to **GP5** using 20.7 mg of resin (estimated loading 0.5 mmol/g) and **I-48** to afford 0.3 mg of **E-58** as a white solid. ESI-MS found 1070.5, $C_{198}H_{282}N_{46}O_{61}$ ($M-4H$)[−] requires 1070.0.

10


Example 59: Compound 180



E-59 was prepared according to **GP5** using 13.6 mg of resin (estimated loading 0.5 mmol/g) and **I-51** to afford 0.6 mg of **E-59** as a white solid. ESI-MS found 1075.0, $C_{197}H_{280}N_{46}O_{61}S$ ($M-4H$)[−] requires 1074.5.


15

Example 60: Compound 169



E-60 was prepared according to **GP5** using 30.5 mg of resin (estimated loading 0.15 mmol/g) and **I-53** to afford 3.6 mg of **E-60** as a white solid. ESI-MS found 1068.5, $C_{196}H_{282}N_{46}O_{60}S$ ($M-4H$)⁻ requires 1068.0.


5 **Example 61: Compound 81**



E-61 was prepared according to **GP4** using 36.9 mg of resin (estimated loading 0.125 mmol/g) and **I-55** to afford 5.1 mg of **E-61** as a white solid. ESI-MS found 1163.8, $C_{216}H_{329}N_{47}O_{65}S$ ($M+4H$)⁺ requires 1163.3.

10


Example 62: Compound 185



E-62 was prepared according to **GP4** using 22 mg of resin (estimated loading 0.5 mmol/g) and commercially available 2-(2,4-dioxothiazolidin-3-yl)acetic acid to afford 0.8 mg of **E-62** as a white solid. ESI-MS found 1034.7, $C_{187}H_{269}N_{45}O_{60}S$ ($M-4H$)⁻ requires 1034.2.

15

Example 63: Compound 178




20

Scheme 142

E-63 was synthesized as depicted in **Scheme 142**.

Resin **R-2** (29.2 mg, approximate loading 0.39 mmol/g, 11.3 μ mol) was treated with 20% piperidine/DMF (3 x 5 min x 1 mL) for Fmoc deprotection. The resin was drained and washed with DMF (5 x 1 mL). A solution of ester **I-56** (23.9 mg, 5.0 equiv.) in DMF (0.6 mL) was added, followed by DIPEA (19.7 μ L, 10.0 equiv.) and the reaction mixture was agitated at ambient temperature for 16 hours. The resin was then drained and washed with DMF (5x) and DCM (5x) and then dried in vacuo. The resin was treated with 20% piperidine/DMF (3 x 5 min x 1 mL) for Fmoc deprotection. The resin was drained and washed with DMF (5 x 1 mL). A solution of 2-(2,4-dioxothiazolidin-3-yl)acetic acid (9.9 mg, 5.0 equiv.) in DMF (0.6 mL) was added, followed by DIPEA (23.6 μ L, 12.0 equiv.) and HATU (34.4 mg, 8.0 equiv.) and the reaction mixture was agitated at ambient temperature for 16 hours. The resin was then drained and washed with DMF (5x) and DCM (5x) and then dried in vacuo. Resin cleavage was performed with TFA/TIPS/H₂O (95:2.5:2.5 v/v/v, 1 mL) at ambient temperature for 1 hour. The reaction mixture was filtered and the resin was washed with TFA (2 x 1 mL). The combined filtrate and washes were concentrated. The residue was triturated with Et₂O (2 mL) and the supernatant was discarded. The residue was dissolved in AcOH (1 mL) and purified by preparative HPLC (25 mM NH₄OAc/MeCN, 0—100% gradient over 30 minutes) to afford 1.6 mg of peptide **E-63** as a white solid. ESI-MS found 1056.0, C₁₉₁H₂₇₆N₄₆O₆₁S (M—4H)[–] requires 1055.5.

Example 64: Compound 177




Scheme 143


E-64 was synthesized as depicted in **Scheme 143**.

Resin **R-2** (36.1 mg, approximate loading 0.39 mmol/g, 14.1 μ mol) was treated with 20% piperidine/DMF (3 x 5 min x 1 mL) for Fmoc deprotection. The resin was drained and washed with DMF (5 x 1 mL). A solution of ester **I-57** (30.7 mg, 5.0 equiv.) in DMF

(0.6 mL) was added, followed by DIPEA (24.5 μ L, 10.0 equiv.) and the reaction mixture was agitated at ambient temperature for 16 hours. The resin was then drained and washed with DMF (5x) and DCM (5x) and then dried in vacuo. The resin was treated with 20% piperidine/DMF (3 x 5 min x 1 mL) for Fmoc deprotection. The resin was drained and washed with DMF (5 x 1 mL). A solution of 2-(2,4-dioxothiazolidin-3-yl)acetic acid (12.3 mg, 5.0 equiv.) in DMF (0.6 mL) was added, followed by DIPEA (29.4 μ L, 12.0 equiv.) and HATU (42.8 mg, 8.0 equiv.) and the reaction mixture was agitated at ambient temperature for 16 hours. The resin was then drained and washed with DMF (5x) and DCM (5x) and then dried in vacuo. Resin cleavage was performed with TFA/TIPS/H₂O (95:2.5:2.5 v/v/v, 1 mL) at ambient temperature for 1 hour. The reaction mixture was filtered and the resin was washed with TFA (2 x 1 mL). The combined filtrate and washes were concentrated. The residue was triturated with Et₂O (2 mL) and the supernatant was discarded. The residue was dissolved in AcOH (1 mL) and purified by preparative HPLC (25 mM NH₄OAc/MeCN, 0—100% gradient over 30 minutes) to afford 1.2 mg of peptide **E-64** as a white solid. ESI-MS found 1059.5, C₁₉₂H₂₇₈N₄₆O₆₁S (M—4H)[–] requires 1059.0.


Example 65: Compound 93

E-65 was prepared according to **GP4** using 49.4 mg of resin (estimated loading 0.125 mmol/g) and **I-60** to afford 5.8 mg of **E-65** as a white solid. ESI-MS found 1161.4, C₂₁₃H₃₂₃N₄₇O₆₅S₂ (M+4H⁺) requires 1160.8.

Example 66: Compound 148

E-66 was prepared according to **GP4** using 28.6 mg of resin (estimated loading 0.18 mmol/g) and **I-61** to afford 2.4 mg of **E-66** as a white solid. ESI-MS found 1059.8, $C_{191}H_{277}N_{47}O_{61}S$ ($M-4H$)⁻ requires 1059.3.


5 **Example 67: Compound 152**



E-67 was prepared according to **GP4** using 26.5 mg of resin (estimated loading 0.18 mmol/g) and **I-62** to afford **E-67** as a white solid. ESI-MS found 1068.0, $C_{196}H_{280}N_{46}O_{60}S$ ($M-4H$)⁻ requires 1067.5.

10


Example 68: Compound 109



E-68 was prepared according to **GP4** using 30.2 mg of resin (estimated loading 0.18 mmol/g) and **I-64** to afford 4.6 mg of **E-68** as a white solid. ESI-MS found 1064.0, $C_{193}H_{286}N_{46}O_{61}S$ ($M+4H$)⁺ requires 1064.0.

15


Example 69: Compound 113



E-69 was prepared according to **GP4** using 27.8 mg of resin (estimated loading 0.18 mmol/g) and **I-66** to afford 2.9 mg of **E-69** as a white solid. ESI-MS found 1067.9, $C_{194}H_{290}N_{46}O_{61}S$ ($M+4H$)⁺ requires 1068.0.

20


Example 70: Compound 105

**E-70**

* mixture of diastereomers

Peptide **E-70** was prepared from 35 mg of resin (approximate loading 0.18 mmol/g) using **I-67** and **GP4** to afford 2.4 mg of **E-70** as a white solid. ESI-MS found 1080.0, $C_{198}H_{290}N_{46}O_{61}S$ ($M+4H^+$) requires 1080.0.


5

Example 71: Compound 99**E-71**

*mixture of diastereomers

Peptide **E-71** was prepared from 35 mg of resin (approximate loading 0.125 mmol/g) using **I-67** and **GP4** to afford 1.5 mg of **E-71** as a white solid. ESI-MS found 1171.9, $C_{219}H_{327}N_{47}O_{65}S$ ($M+4H^+$) requires 1171.8.


10

Example 72: Compound 136**E-72**

E-72 was prepared according to **GP4** using 24.4 mg of resin (estimated loading 0.18 mmol/g) and **I-68** to afford 2.5 mg of **E-72** as a white solid. ESI-MS found 1071.3, $C_{196}H_{279}N_{47}O_{60}S$ ($M-4H$)⁻ requires 1070.8.


15

Example 73: Compound 17**E-73**



E-73 was prepared according to **GP4** using 46.2 mg of resin (estimated loading 0.125 mmol/g) and **I-69** to afford 6.6 mg of **E-73** as a white solid. ESI-MS found 1156.8, $C_{215}H_{329}N_{47}O_{64}S$ ($M+4H^+$) requires 1156.3.


5 **Example 74: Compound 13**



Peptide **E-74** was prepared from 30 mg of resin (approximate loading 0.125 mmol/g) using **I-70** and **GP4** to afford 2.2 mg of **E-74** as a white solid. ESI-MS found 1165.6, $C_{218}H_{327}N_{47}O_{64}S$ ($M+4H^+$) requires 1164.8.

10


Example 75: Compound 84



E-75 was prepared according to **GP4** using 35.8 mg of resin (estimated loading 0.125 mmol/g) and **I-71** to afford 3.2 mg of **E-75** as a white solid. ESI-MS found 1153.5, $C_{212}H_{323}N_{48}O_{65}S$ ($M+4H^+$) requires 1153.1.


15

Example 76: Compound 87




E-76 was prepared according to **GP4** using 34.9 mg of resin (estimated loading 0.125 mmol/g) and **I-72** to afford 3.5 mg of **E-76** as a white solid. ESI-MS found 1160.5, $C_{214}H_{326}N_{48}O_{65}S$ ($M+4H^+$) requires 1160.1.

20


Example 77: Compound 90**E-77**

*mixture of diastereomers

Peptide E-77 was prepared from 37 mg of resin (approximate loading 0.125 mmol/g) using **I-74** and **GP1** to afford 3.1 mg of **E-77** as a white solid. ESI-MS found 1161.4, $C_{213}H_{323}N_{47}O_{65}S_2$ ($M+4H^+$) requires 1160.8.


Example 78: Compound 94**E-78**

Peptide **E-78** was prepared from 30 mg of resin (approximate loading 0.125 mmol/g) using **I-76** and **GP4** to afford 2.2 mg of **E-78** as a white solid. ESI-MS found 1164.9, $C_{214}H_{325}N_{47}O_{65}S_2$ ($M+4H^+$) requires 1164.3.

Example 79: Compound 66**E-79**

E-79 was prepared according to **GP4** using 38.4 mg of resin (estimated loading 0.125 mmol/g) and **I-79** to afford 4.2 mg of **E-79** as a white solid. ESI-MS found 1153.8, $C_{213}H_{325}N_{47}O_{65}S$ ($M+4H^+$) requires 1153.3.


Example 80: Compound 47



E-80 was prepared according to **GP4** using 39.8 mg of resin (estimated loading 0.125 mmol/g) and **I-80** to afford 2.5 mg of **E-80** as a white solid. ESI-MS found 1153.8, $C_{213}H_{325}N_{47}O_{65}S$ ($M+4H^+$) requires 1153.3.

5


Example 81: Compound 88



E-81 was prepared according to **GP4** using 37.6 mg of resin (estimated loading 0.125 mmol/g) and **I-82** to afford 2.1 mg of **E-81** as a white solid. ESI-MS found 1163.8, $C_{216}H_{329}N_{47}O_{65}S$ ($M+4H^+$) requires 1163.3.

10


Example 82: Compound 35



E-82 was prepared according to **GP4** using 49.9 mg of resin (estimated loading 0.125 mmol/g) and **I-85** to afford 6.5 mg of **E-82** as a white solid. ESI-MS found 1156.9, $C_{215}H_{329}N_{47}O_{64}S$ ($M+4H^+$) requires 1156.3.


15

Example 83: Compound 41



E-83 was prepared according to **GP4** using 50.8 mg of resin (estimated loading 0.125 mmol/g) and **I-87** to afford 6.0 mg of **E-83** as a white solid. ESI-MS found 1157.0, $C_{215}H_{329}N_{47}O_{64}S$ ($M+4H^+$) requires 1156.3.


5 **Example 84: Compound 92**



E-84 was prepared according to **GP4** using 39.3 mg of resin (estimated loading 0.125 mmol/g) and **I-89** to afford 2.9 mg of **E-84** as a white solid. ESI-MS found 1160.4, $C_{215}H_{327}N_{47}O_{65}S$ ($M+4H^+$) requires 1159.8.

10


Example 85: Compound 85



E-85 was prepared according to **GP4** using 41.1 mg of resin (estimated loading 0.125 mmol/g) and **I-90** to afford 3.7 mg of **E-85** as a white solid. ESI-MS found 1160.4, $C_{215}H_{327}N_{47}O_{65}S$ ($M+4H^+$) requires 1159.8.

15


Example 86: Compound 97



E-86 was prepared according to **GP4** using 30.9 mg of resin (estimated loading 0.125 mmol/g) and **I-92** to afford 3.1 mg of **E-86** as a white solid. ESI-MS found 1159.7, $C_{215}H_{325}N_{47}O_{65}S$ ($M+4H^+$) requires 1159.3.

20


Example 87: Compound 125



E-87 was prepared according to **GP4** using 21.9 mg of resin (estimated loading 0.18 mmol/g) and **I-94** to afford 2.2 mg of **E-87** as a white solid. ESI-MS found 1063.5, $C_{196}H_{278}N_{46}O_{61}$ ($M-4H$)⁻ requires 1063.0.

5


Example 88: Compound 128



E-88 was prepared according to **GP4** using 31 mg of resin (estimated loading 0.18 mmol/g) and **I-96** to afford 3.4 mg of **E-88** as a white solid. ESI-MS found 1067.0, $C_{197}H_{280}N_{46}O_{61}$ ($M-4H$)⁻ requires 1066.5.

10


Example 89: Compound 126



E-89 was prepared according to **GP4** using 28.1 mg of resin (estimated loading 0.18 mmol/g) and **I-98** to afford 2.5 mg of **E-89** as a white solid. ESI-MS found 1063.5, $C_{196}H_{278}N_{46}O_{61}$ ($M-4H$)⁻ requires 1063.0.


15

Example 90: Compound 91




E-90 was prepared according to **GP4** using 35.5 mg of resin (estimated loading 0.125 mmol/g) and **I-101** to afford 4.8 mg of **E-90** as a white solid. ESI-MS found 1156.8, $C_{214}H_{325}N_{47}O_{65}S$ ($M+4H$)⁺ requires 1156.3.


20

Example 91: Compound 89

E-91 was prepared according to **GP4** using 35.3 mg of resin (estimated loading 0.125 mmol/g) and **I-100** to afford 3.2 mg of **E-91** as a white solid. ESI-MS found 1156.8, $C_{214}H_{325}N_{47}O_{65}S$ ($M+4H^+$) requires 1156.3.


Example 92: Compound 98

Peptide **E-92** was prepared from 35 mg of resin (approximate loading 0.125 mmol/g) using **I-104** and **GP4** to afford 3.7 mg of **E-92** as a white solid. ESI-MS found 1139.3, $C_{210}H_{319}N_{47}O_{64}S$ ($M+4H^+$) requires 1138.8.

Example 93: Compound 103


Peptide **E-93** was prepared from 38 mg of resin (approximate loading 0.125 mmol/g) using **I-106** and **GP4** to afford 2.0 mg of **E-93** as a white solid. ESI-MS found 1162.8, $C_{216}H_{327}N_{47}O_{65}S$ ($M+4H^+$) requires 1162.8.

Example 94: Compound 106



Peptide **E-94** was prepared from 44 mg of resin (approximate loading 0.18 mmol/g) using **I-109** and **GP5** to afford 4.1 mg of **E-94** as a white solid. ESI-MS found 1073.3, $C_{196}H_{289}N_{47}O_{60}S$ ($M+4H^+$) requires 1073.2.


5 **Example 95: Compound 107**



Peptide **E-95** was prepared from 34 mg of resin (approximate loading 0.18 mmol/g) using **I-111** and **GP5** to afford 4.9 mg of **E-95** as a white solid. ESI-MS found 1084.2, $C_{196}H_{285}N_{47}O_{63}S$ ($M+4H^+$) requires 1084.2.

10


Example 96: Compound 108



Peptide **E-96** was prepared from 34 mg of resin (approximate loading 0.18 mmol/g) using **I-113** and **GP5** to afford 4.4 mg of **E-96** as a white solid. ESI-MS found 1084.2, $C_{196}H_{285}N_{47}O_{63}S$ ($M+4H^+$) requires 1084.2.


15

Example 97: Compound 86



Peptide **E-97** was prepared from 35 mg of resin (approximate loading 0.125 mmol/g) using **I-115** and **GP4** to afford 2.5 mg of **E-97** as a white solid. ESI-MS found 1154.4, $C_{212}H_{323}N_{47}O_{64}S_2$ ($M+4H^+$) requires 1153.8.


5 **Example 98: Compound 146**



Peptide **E-98** was prepared from 26 mg of resin (approximate loading 0.18 mmol/g) using **I-118** and **GP4** to afford **E-98** as a white solid. ESI-MS found 1167.0, $C_{197}H_{282}N_{46}O_{59}S$ ($M-4H$)⁻ requires 1167.0.

10


Example 99: Compound 115



Peptide **E-99** was prepared from 108 mg of resin (approximate loading 0.18 mmol/g) using **I-118** and **GP4** to afford 1.0 mg of **E-99** as a white solid. ESI-MS found 1160.3, $C_{218}H_{325}N_{47}O_{65}$ ($M+4H^+$) requires 1160.3.

15

Example 100: Compound 154



To 26 mg of resin (approximate loading 0.18 mmol/g, 4.68 μ mol) in a 3 mL polypropylene tube with an end-cap was added 20% v/v piperidine/DMF (2 mL). The tube was capped, agitated at ambient temperature for 30 minutes, and then drained. The resin


20

The resin was transferred to a 15 mL Falcon tube and 3 mL of cleavage reagent (95:2.5:2.5 v/v/v TFA/TIS/H₂O) was added. The reaction mixture was agitated at ambient temperature for 1 hour. The resin was filtered and washed with TFA (2 x 3 mL). The combined filtrate and washes were concentrated under reduced pressure to afford a residue, which was triturated with Et₂O (3 mL) to precipitate the peptide. The peptide was redissolved in glacial AcOH (2 mL) and purified by preparative HPLC (Phenomenex Jupiter 10 μM Proteo 90 Å LC column, 250 x 21.2 mm, with flow rate – 15 mL/min, gradient of 0—100% acetonitrile in 25 mM aqueous ammonium acetate over 30 minutes) to afford **E-100** as a white solid. ESI-MS found 1169.0, C₁₉₇H₂₈₈N₄₆O₆₁ (M+4H⁺) requires 1168.5.

E-101


Chemical structure of E-101: A 4-substituted phthalimide ring connected via a methylene group to a secondary amide, which is further connected to a 1,3-bis(methylene)thioether chain, ending in a primary amide linked to a peptide sequence labeled "Sequence A".

Example 102: Compound 157




Peptide **E-102** was prepared from 25 mg of resin (approximate loading 0.18 mmol/g) using **I-124** and **GP5** to afford **E-102** as a white solid. ESI-MS found 1073.8, C₁₉₅H₂₈₅N₄₇O₆₁S (M+4H⁺) requires 1073.3.

5 Example 103: Compound 158




Peptide **E-103** was prepared from 25 mg of resin (approximate loading 0.18 mmol/g) using **I-126** and **GP5** to afford **E-103** as a white solid. ESI-MS found 1083.5, $\text{C}_{200}\text{H}_{280}\text{N}_{46}\text{O}_{61}\text{S} (\text{M}-4\text{H})^-$ requires 1084.0.

Example 104: Compound 159




Peptide **E-104** was prepared from 25 mg of resin (approximate loading 0.18 mmol/g) using **I-129** and **GP5** to afford **E-104** as a white solid. ESI-MS found 1073.0, $C_{196}H_{284}N_{46}O_{61}S$ ($M-4H$)[−] requires 1072.5.

Example 105: Compound 160



Peptide **E-105** was prepared from 25 mg of resin (approximate loading 0.18 mmol/g) using **I-131** and **GP5** to afford **E-105** as a white solid. ESI-MS found 1071.8, $C_{195}H_{277}N_{47}O_{61}S$ ($M-4H$)[−] requires 1071.3.


5 **Example 106: Compound 161**



Peptide **E-106** was prepared from 25 mg of resin (approximate loading 0.18 mmol/g) using **I-133** and **GP5** to afford **E-106** as a white solid. ESI-MS found 1080.2, $C_{196}H_{277}N_{46}O_{61}SCl$ ($M-4H$)[−] requires 1079.5.

10


Example 107: Compound 162



Peptide **E-107** was prepared from 25 mg of resin (approximate loading 0.18 mmol/g) using **I-135** and **GP5** to afford **E-107** as a white solid. ESI-MS found 1080.2, $C_{196}H_{277}N_{46}O_{61}SCl$ ($M-4H$)[−] requires 1079.5.


15

Example 108: Compound 163



Peptide **E-108** was prepared from 25 mg of resin (approximate loading 0.18 mmol/g) using **I-137** and **GP5** to afford **E-108** as a white solid. ESI-MS found 1084.0, $C_{200}H_{280}N_{46}O_{61}S$ ($M-4H$)⁻ requires 1083.5.


5 **Example 109: Compound 164**



Peptide **E-109** was prepared from 25 mg of resin (approximate loading 0.18 mmol/g) using **I-139** and **GP5** to afford **E-109** as a white solid. ESI-MS found 1085.5, $C_{200}H_{290}N_{46}O_{61}S$ ($M-4H$)⁻ requires 1085.0.

10


Example 110: Compound 168



E-110 was prepared according to **GP4** using 21.8 mg of resin (estimated loading 0.15 mmol/g) and **I-141** to afford 2.0 mg of **E-110** as a white solid. ESI-MS found 1072.0, $C_{191}H_{276}N_{46}O_{63}S_2$ ($M-4H$)⁻ requires 1071.5.


15

Example 111: Compound 10




Peptide **E-111** was prepared from 30 mg of resin (approximate loading 0.125 mmol/g) using **I-145** and **GP4** to afford 2.2 mg of **E-111** as a white solid. ESI-MS found 1160.3, $C_{216}H_{331}N_{47}O_{64}S$ ($M+4H$)⁺ requires 1159.8.


20

Example 112: Compound 16


Peptide **E-112** was prepared from 33 mg of resin (approximate loading 0.125 mmol/g) using **I-146** and **GP4** to afford 3.7 mg of **E-112** as a white solid. ESI-MS found
5 1145.3, $C_{215}H_{329}N_{47}O_{64}$ ($M+4H^+$) requires 1144.8.

Example 113: Compound 15

Peptide **E-113** was prepared from 33 mg of resin (approximate loading 0.125
10 mmol/g) using **I-147** and **GP4** to afford 3.4 mg of **E-113** as a white solid. ESI-MS found
1148.8, $C_{215}H_{329}N_{47}O_{64}$ ($M+4H^+$) requires 1148.3.

Example 114: Compound 20

Peptide **E-114** was prepared from 45 mg of resin (approximate loading 0.125
15 mmol/g) using **I-148** and **GP4** to afford 5.8 mg of **E-114** as a white solid. ESI-MS found
1152.3, $C_{216}H_{331}N_{47}O_{64}$ ($M+4H^+$) requires 1151.8.


Example 115: Compound 82

20

321

E-115 was prepared according to **GP4** using 45.9 mg of resin (estimated loading 0.125 mmol/g) and **I-150** to afford 6.0 mg of **E-115** as a white solid. ESI-MS found 1163.9, $C_{216}H_{329}N_{47}O_{65}S$ ($M+4H^+$) requires 1163.3.


5 **Example 116: Compound 95**



E-116 was prepared according to **GP4** using 30.5 mg of resin (estimated loading 0.125 mmol/g) and **I-152** to afford 2.4 mg of **E-116** as a white solid. ESI-MS found 1175.9, $C_{220}H_{329}N_{47}O_{65}S$ ($M+4H^+$) requires 1175.3.

10


Example 117: Compound 96



E-117 was prepared according to **GP4** using 34.2 mg of resin (estimated loading 0.125 mmol/g) and **I-155** to afford 2.1 mg of **E-117** as a white solid. ESI-MS found 1160.3, $C_{215}H_{327}N_{47}O_{65}S$ ($M+4H^+$) requires 1159.8.

15


Example 118: Compound 100



E-118 was prepared according to **GP4** using 28 mg of resin (estimated loading 0.125 mmol/g) and **I-157** to afford **E-118** as a white solid. ESI-MS found 1166.4, $C_{217}H_{327}N_{47}O_{65}S$ ($M+4H^+$) requires 1165.8.

20

Example 119: Compound 101




*Mixture of diastereomers

E-119 was prepared according to **GP4** using 29.8 mg of resin (estimated loading 0.125 mmol/g) and **I-159** to afford 3.6 mg of **E-119** as a white solid. ESI-MS found 1167.1, $C_{217}H_{331}N_{47}O_{65}S$ ($M+4H^+$) requires 1166.8.

5


Example 120: Compound 102



E-120 was prepared according to **GP4** using 29.3 mg of resin (estimated loading 0.125 mmol/g) and **I-161** to afford 4.4 mg of **E-120** as a white solid. ESI-MS found 1166.8, $C_{217}H_{329}N_{47}O_{65}S$ ($M+4H^+$) requires 1166.3.

10


Example 121: Compound 104




E-121 was prepared according to **GP4** using 26.2 mg of resin (estimated loading 0.125 mmol/g) and **I-163** to afford 3.2 mg of **E-121** as a white solid. ESI-MS found 1160.3, $C_{215}H_{327}N_{47}O_{65}S$ ($M+4H^+$) requires 1159.8.

15

Example 122: Compound 110



5 Example 123: Compound 111



10


E-124

15

E-125

20


324



E-126 was prepared according to **GP4** using 45.5 mg of resin (estimated loading 0.125 mmol/g) and **I-170** to afford 4.7 mg of **E-126** as a white solid. ESI-MS found 1152.3, $C_{216}H_{331}N_{47}O_{64}$ ($M+4H^+$) requires 1151.8.

5


Example 127: Compound 112



E-127 was prepared according to **GP4** using 36.2 mg of resin (estimated loading 0.18 mmol/g) and **I-172** to afford 2.1 mg of **E-127** as a white solid. ESI-MS found 1064.8, $C_{192}H_{287}N_{47}O_{61}S$ ($M+4H^+$) requires 1064.8.

10


Example 128: Compound 9



E-128 was prepared according to **GP4** using 38.3 mg of resin (estimated loading 0.125 mmol/g) and **I-174** to afford 3.1 mg of **E-128** as a white solid. ESI-MS found 1145.4, $C_{214}H_{327}N_{47}O_{64}$ ($M+4H^+$) requires 1144.8.


15

Example 129: Compound 5



E-129 was prepared according to **GP4** using 40.1 mg of resin (estimated loading 0.125 mmol/g) and **I-176** to afford 5.2 mg of **E-129** as a white solid. ESI-MS found 1141.8, $C_{213}H_{325}N_{47}O_{64}$ ($M+4H^+$) requires 1141.3.


5 **Example 130: Compound 4**



E-130 was prepared according to **GP4** using 40 mg of resin (estimated loading 0.125 mmol/g) and **I-180** to afford 5.2 mg of **E-130** as a white solid. ESI-MS found 1152.4, $C_{216}H_{331}N_{47}O_{64}$ ($M+4H^+$) requires 1151.8.

10


Example 131: Compound 3



E-131 was prepared according to **GP4** using 39.3 mg of resin (estimated loading 0.125 mmol/g) and **I-183** to afford 3.0 mg of **E-131** as a white solid. ESI-MS found 1152.3, $C_{216}H_{331}N_{47}O_{64}$ ($M+4H^+$) requires 1151.8.

15

Example 132: Compound 2




E-132 was prepared according to **GP4** using 39.8 mg of resin (estimated loading 0.125 mmol/g) and **I-184** to afford 5.7 mg of **E-132** as a white solid. ESI-MS found 1138.3, $C_{212}H_{323}N_{47}O_{64}$ ($M+4H^+$) requires 1141.3.



20

E-133

Example 134: Compound 130




Example 135: Compound 167

20 **Example 136: Compound 179**

E-136 was prepared according to **GP5** using 20.9 mg of resin (estimated loading 0.15 mmol/g) and **I-191** to afford 1.6 mg of **E-136** as a white solid. ESI-MS found 1065.5, $C_{194}H_{278}N_{46}O_{61}S$ ($M-4H$)⁻ requires 1065.0.


5 **Example 137: Compound 183**



E-137 was prepared according to **GP5** using 16.6 mg of resin (estimated loading 0.5 mmol/g) and **I-194** to afford 1.3 mg of **E-137** as a white solid. ESI-MS found 1069.5, $C_{195}H_{282}N_{46}O_{61}S$ ($M-4H$)⁻ requires 1069.0.

10


Example 138: Compound 182



E-138 was prepared according to **GP5** using 16.9 mg of resin (estimated loading 0.5 mmol/g) and **I-197** to afford 1.0 mg of **E-138** as a white solid. ESI-MS found 1069.5, $C_{195}H_{282}N_{46}O_{61}S$ ($M-4H$)⁻ requires 1069.0.


15

Example 139: Compound 176




E-139 was prepared according to **GP4** using 22.2 mg of resin (estimated loading 0.15 mmol/g) and **I-200** to afford 0.9 mg of **E-139** as a white solid. ESI-MS found 1052.3, $C_{192}H_{279}N_{45}O_{60}S$ ($M-4H$)⁻ requires 1051.8.


20

Example 140: Compound 175


E-140 was prepared according to **GP4** using 31 mg of resin (estimated loading 0.15 mmol/g) and **I-202** to afford 2.7 mg of **E-140** as a white solid. ESI-MS found 1055.8, $C_{193}H_{281}N_{45}O_{60}S$ ($M-4H$)⁻ requires 1055.3.

Example 141: Compound 174

E-141 was prepared according to **GP4** using 24.7 mg of resin (estimated loading 0.15 mmol/g) and **I-204** to afford 1.6 mg of **E-141** as a white solid. ESI-MS found 1059.3, $C_{194}H_{283}N_{45}O_{60}S$ ($M-4H$)⁻ requires 1058.8.


Example 142: Compound 166

E-142 was prepared according to **GP4** using 20.7 mg of resin (estimated loading 0.15 mmol/g) and **I-209** to afford 2.4 mg of **E-142** as a white solid. ESI-MS found 1056.0, $C_{191}H_{274}N_{46}O_{61}S$ ($M-4H$) requires 1055.5.

Example 143: Compound 165

E-143 was prepared according to **GP4** using 21 mg of resin (estimated loading 0.15 mmol/g) and **I-213** to afford 2.1 mg of **E-143** as a white solid. ESI-MS found 1059.5, $C_{192}H_{278}N_{46}O_{61}S$ ($M-4H$)⁻ requires 1059.0.


5 **Example 144: Compound 51**



E-144 was prepared according to **GP4** using 45.5 mg of resin (estimated loading 0.125 mmol/g) and **I-213** to afford 4.8 mg of **E-144** as a white solid. ESI-MS found 1153.1, $C_{213}H_{323}N_{47}O_{65}S$ ($M+4H$)⁺ requires 1152.8.

10


Example 145: Compound 172



E-145 was prepared according to **GP4** using 23 mg of resin (estimated loading 0.15 mmol/g) and **I-217** to afford 3.0 mg of **E-145** as a white solid. ESI-MS found 1059.5, $C_{192}H_{278}N_{46}O_{61}S$ ($M-4H$)⁻ requires 1059.0.

15


Example 146: Compound 171



E-146 was prepared according to **GP4** using 24.1 mg of resin (estimated loading 0.15 mmol/g) and **I-221** to afford 2.5 mg of **E-146** as a white solid. ESI-MS found 1059.5, $C_{192}H_{278}N_{46}O_{61}S$ ($M-4H$)⁻ requires 1059.0.

20


Example 147: Compound 48



E-147 was prepared according to **GP4** using 42.5 mg of resin (estimated loading 0.125 mmol/g) and **I-225** to afford 1.7 mg of **E-147** as a white solid. ESI-MS found 1160.8, $C_{214}H_{325}N_{47}O_{66}S$ ($M+4H^+$) requires 1160.3.

5


Example 148: Compound 49



E-148 was prepared according to **GP4** using 44.5 mg of resin (estimated loading 0.125 mmol/g) and **I-229** to afford 2.8 mg of **E-148** as a white solid. ESI-MS found 1160.7, $C_{214}H_{325}N_{47}O_{66}S$ ($M+4H^+$) requires 1160.3.

10

Example 149: Compound 28




* Absolute configuration not known

E-149 was prepared according to **GP4** using 38.9 mg of resin (estimated loading 0.125 mmol/g) and **(R*)-I-234** to afford 5.7 mg of **E-149** as a white solid. ESI-MS found 1153.3, $C_{214}H_{327}N_{47}O_{64}S$ ($M+4H^+$) requires 1152.8.

15


Example 150: Compound 64



*Absolute configuration not known

E-150 was prepared according to **GP4** using 39 mg of resin (estimated loading 0.125 mmol/g) and **(S*)-I-234** to afford 4.2 mg of **E-190** as a white solid. ESI-MS found 1153.3, $C_{214}H_{327}N_{47}O_{64}S$ ($M+4H^+$) requires 1152.8.


5 **Example 151: Compound 55**



E-151 was prepared according to **GP4** using 43.4 mg of resin (estimated loading 0.125 mmol/g) and **I-240** to afford 6.0 mg of **E-151** as a white solid. ESI-MS found 1153.6, $C_{213}H_{326}N_{48}O_{64}S$ ($M+4H^+$) requires 1153.1.

10


Example 152: Compound 58



E-152 was prepared according to **GP4** using 37.7 mg of resin (estimated loading 0.125 mmol/g) and **I-243** to afford 1.8 mg of **E-152** as a white solid. ESI-MS found 1150.0, $C_{212}H_{324}N_{48}O_{64}S$ ($M+4H^+$) requires 1149.6.

15


Example 153: Compound 65



E-153 was prepared according to **GP4** using 41 mg of resin (estimated loading 0.125 mmol/g) and **I-248** to afford 4.1 mg of **E-153** as a white solid. ESI-MS found 1153.3, $C_{214}H_{327}N_{47}O_{64}S$ ($M+4H^+$) requires 1152.8.

20


Example 154: Compound 57



E-154 was prepared according to **GP4** using 41.1 mg of resin (estimated loading 0.125 mmol/g) and **I-249** to afford 6.5 mg of **E-154** as a white solid. ESI-MS found 1146.1, $C_{214}H_{328}N_{46}O_{63}S$ ($M+4H^+$) requires 1145.6.

5


Example 155: Compound 54



E-155 was prepared according to **GP4** using 39.8 mg of resin (estimated loading 0.125 mmol/g) and **I-250** to afford 4.7 mg of **E-155** as a white solid. ESI-MS found 1145.6, $C_{214}H_{326}N_{46}O_{63}S$ ($M+4H^+$) requires 1145.

10


Example 156: Compound 50



E-156 was prepared according to **GP4** using 46.9 mg of resin (estimated loading 0.125 mmol/g) and **I-257** to afford 2.7 mg of **E-156** as a white solid. ESI-MS found 1153.8, $C_{213}H_{325}N_{47}O_{65}S$ ($M+4H^+$) requires 1153.3.


15

Example 157: Compound 45




E-157 was prepared according to **GP4** using 45.5 mg of resin (estimated loading 0.125 mmol/g) and **I-264** to afford 7.0 mg of **E-157** as a white solid. ESI-MS found 1153.7, $C_{213}H_{325}N_{47}O_{65}S$ ($M+4H^+$) requires 1153.3.


20

Example 158: Compound 43


E-158 was prepared according to **GP4** using 44.5 mg of resin (estimated loading 0.125 mmol/g) and **I-271** to afford 2.7 mg of **E-158** as a white solid. ESI-MS found 1157.2, $C_{214}H_{327}N_{47}O_{65}S$ ($M+4H^+$) requires 1156.8.

Example 159: Compound 44

E-159 was prepared according to **GP4** using 39.9 mg of resin (estimated loading 0.125 mmol/g) and **I-278** to afford 2.6 mg of **E-159** as a white solid. ESI-MS found 1157.3, $C_{214}H_{327}N_{47}O_{65}S$ ($M+4H^+$) requires 1156.8.


Example 160: Compound 39

E-160 was prepared according to **GP4** using 43.8 mg of resin (estimated loading 0.125 mmol/g) and **I-279** to afford 5.5 mg of **E-160** as a white solid. ESI-MS found 1150.3, $C_{212}H_{323}N_{47}O_{64}S$ ($M+4H^+$) requires 1149.8.

Example 161: Compound 59

E-161 was prepared according to **GP4** using 39.7 mg of resin (estimated loading 0.125 mmol/g) and **I-282** to afford 4.8 mg of **E-161** as a white solid. ESI-MS found 1153.9, $C_{212}H_{321}N_{47}O_{66}S$ ($M+4H^+$) requires 1153.3.


5 **Example 162: Compound 21**



E-162 was prepared according to **GP4** using 40.4 mg of resin (estimated loading 0.125 mmol/g) and **I-289** to afford 5.3 mg of **E-162** as a white solid. ESI-MS found 1157.3, $C_{214}H_{327}N_{47}O_{65}S$ ($M+4H^+$) requires 1156.8.

10


Example 163: Compound 7



E-163 was prepared according to **GP4** using 36.6 mg of resin (estimated loading 0.125 mmol/g) and **I-296** to afford 2.9 mg of **E-163** as a white solid. ESI-MS found 1157.4, $C_{214}H_{327}N_{47}O_{65}S$ ($M+4H^+$) requires 1156.8.

15


Example 164: Compound 34



E-164 was prepared according to **GP4** using 41.3 mg of resin (estimated loading 0.125 mmol/g) and **I-301** to afford 2.0 mg of **E-164** as a white solid. ESI-MS found 1153.7, $C_{212}H_{322}N_{48}O_{65}S$ ($M+4H^+$) requires 1153.1.


20

Example 165: Compound 46




E-165 was prepared according to **GP4** using 38.4 mg of resin (estimated loading 0.125 mmol/g) and **I-307** to afford 5.3 mg of **E-165** as a white solid. ESI-MS found 1157.1, $C_{213}H_{324}N_{48}O_{65}S$ ($M+4H^+$) requires 1156.6.

Example 166: Compound 25




E-166 was prepared according to **GP4** using 34.3 mg of resin (estimated loading 0.125 mmol/g) and **I-311** to afford 3.3 mg of **E-166** as a white solid. ESI-MS found 1157.1, $\text{C}_{213}\text{H}_{324}\text{N}_{48}\text{O}_{65}\text{S} (\text{M}+4\text{H}^+)$ requires 1156.6.

Example 167: Compound 12




E-167 was prepared according to **GP4** using 30 mg of resin (estimated loading 0.125 mmol/g) and **I-320** to afford 4.0 mg of **E-167** as a white solid. ESI-MS found 1160.6, C₂₁₄H₃₂₆N₄₈O₆₅S (M+4H⁺) requires 1160.1.

Example 168: Compound 33



5 Example 169: Compound 24



10


E-170

E-170 was prepared according to **GP4** using 36.3 mg of resin (estimated loading 0.125 mmol/g) and **I-332** to afford 4.4 mg of **E-170** as a white solid. ESI-MS found 1160.7, $C_{214}H_{326}N_{48}O_{65}S$ ($M+4H^+$) requires 1160.1.

[illegible]


E-171 was prepared according to **GP4** using 43.4 mg of resin (estimated loading 0.125 mmol/g) and **I-335** to afford 4.3 mg of **E-171** as a white solid. ESI-MS found 1157.2, $C_{214}H_{328}N_{48}O_{64}S$ ($M+4H^+$) requires 1156.6.

Example 172: Compound 37




E-172 was prepared according to **GP4** using 42.5 mg of resin (estimated loading 0.125 mmol/g) and **I-338** to afford 4.5 mg of **E-172** as a white solid. ESI-MS found 1153.5, $\text{C}_{213}\text{H}_{326}\text{N}_{48}\text{O}_{64}\text{S} (\text{M}+4\text{H}^+)$ requires 1153.1.

Example 173: Compound 32




E-173 was prepared according to **GP4** using 38.5 mg of resin (estimated loading 0.125 mmol/g) and **I-343** to afford 4.5 mg of **E-172** as a white solid. ESI-MS found 1153.9, $C_{213}H_{325}N_{47}O_{65}S$ ($M+4H^+$) requires 1153.3.

Example 174: Compound 36




E-174 was prepared according to **GP4** using 42.4 mg of resin (estimated loading 0.125 mmol/g) and **I-348** to afford 4.5 mg of **E-174** as a white solid. ESI-MS found 1157.9, $C_{213}H_{325}N_{47}O_{64}S_2$ ($M+4H^+$) requires 1157.3.

Example 175: Compound 29



E-175 was prepared according to **GP4** using 45 mg of resin (estimated loading 0.125 mmol/g) and **I-351** to afford 6.5 mg of **E-175** as a white solid. ESI-MS found 1165.8, $C_{213}H_{325}N_{47}O_{66}S_2$ ($M+4H^+$) requires 1165.3.


5 **Example 176: Compound 6**



E-176 was prepared according to **GP4** using 38.5 mg of resin (estimated loading 0.125 mmol/g) and **I-356** to afford 5.1 mg of **E-176** as a white solid. ESI-MS found 1153.9, $C_{213}H_{325}N_{47}O_{65}S$ ($M+4H^+$) requires 1153.3.

10


Example 177: Compound 23



E-177 was prepared according to **GP4** using 39 mg of resin (estimated loading 0.125 mmol/g) and **I-363** to afford 5.2 mg of **E-177** as a white solid. ESI-MS found 1157.2, $C_{214}H_{328}N_{48}O_{64}S$ ($M+4H^+$) requires 1156.6.

15


Example 178: Compound 31



E-178 was prepared according to **GP4** using 38.5 mg of resin (estimated loading 0.125 mmol/g) and **I-366** to afford 4.8 mg of **E-178** as a white solid. ESI-MS found 1153.7, $C_{213}H_{326}N_{48}O_{64}S$ ($M+4H^+$) requires 1153.1.

20

Example 179: Compound 11




E-179

E-179 was prepared according to **GP4** using 30 mg of resin (estimated loading 0.125 mmol/g) and **I-373** to afford 4.1 mg of **E-179** as a white solid. ESI-MS found 1157.3, $C_{214}H_{327}N_{47}O_{65}S$ ($M+4H^+$) requires 1156.8.

5


Example 180: Compound 14



E-180

Peptide **E-180** was prepared from 30 mg of resin (approximate loading 0.125 mmol/g) using **I-380** and **GP4** to afford 2.3 mg of **E-180** as a white solid. ESI-MS found 1157.4, C₂₁₄H₃₂₇N₄₇O₆₅S (M+4H⁺) requires 1156.8.


Example 181: Compound 22



E-181

E-181 was prepared according to **GP4** using 40.3 mg of resin (estimated loading 0.125 mmol/g) and **I-386** to afford 5.5 mg of **E-181** as a white solid. ESI-MS found 1157.3, $\text{C}_{214}\text{H}_{327}\text{N}_{47}\text{O}_{65}\text{S} (\text{M}+4\text{H}^+)$ requires 1156.8.


Example 182: Compound 8



E-182

E-182 was prepared according to **GP4** using 41 mg of resin (estimated loading 0.125 mmol/g) and **I-392** to afford 5.1 mg of **E-182** as a white solid. ESI-MS found 1157.3, $C_{214}H_{327}N_{47}O_{65}S$ ($M+4H^+$) requires 1156.8.


5 **Example 183: Compound 62**



E-183 was prepared according to **GP4** using 40.8 mg of resin (estimated loading 0.125 mmol/g) and **(S*)-I-395** to afford 4.5 mg of **E-183** as a white solid. ESI-MS found 1160.3, $C_{215}H_{327}N_{47}O_{65}S$ ($M+4H^+$) requires 1159.8.

10


Example 184: Compound 61



E-184 was prepared according to **GP4** using 38 mg of resin (estimated loading 0.125 mmol/g) and **(R*)-I-395** to afford 3.0 mg of **E-184** as a white solid. ESI-MS found 1160.3, $C_{215}H_{327}N_{47}O_{65}S$ ($M+4H^+$) requires 1159.8.

15


Example 185: Compound 78



E-185 was prepared according to **GP4** using 34 mg of resin (estimated loading 0.125 mmol/g) and **I-398** to afford 2.5 mg of **E-185** as a white solid. ESI-MS found 1157.2, $C_{213}H_{323}N_{47}O_{66}S$ ($M+4H^+$) requires 1156.8.


20

Example 186: Compound 79



E-186 was prepared according to **GP4** using 35.3 mg of resin (estimated loading 0.125 mmol/g) and **I-399** to afford 1.3 mg of **E-186** as a white solid. ESI-MS found 1157.3, $C_{213}H_{323}N_{47}O_{66}S$ ($M+4H^+$) requires 1156.8.


5 **Example 187: Compound 63**



*Absolute configuration not known

E-187 was prepared according to **GP4** using 39 mg of resin (estimated loading 0.125 mmol/g) and **I-404** to afford 3.0 mg of **E-187** as a white solid. ESI-MS found 1160.3, $C_{215}H_{327}N_{47}O_{65}S$ ($M+4H^+$) requires 1159.8.

10



*Absolute configuration not determined

Example 188: Compound 69


E-188 was prepared according to **GP4** using 45.9 mg of resin (estimated loading 0.125 mmol/g) and **(R*)-I-409** to afford 4 mg of **E-188** as a white solid. ESI-MS found 1153.3, $C_{214}H_{327}N_{47}O_{64}S$ ($M+4H^+$) requires 1152.8.

15


Example 189: Compound 68

E-189 was prepared according to **GP4** using 43.8 mg of resin (estimated loading 0.125 mmol/g) and **(S*)-I-409** to afford 4.3 mg of **E-189** as a white solid. ESI-MS found 1153.3, $C_{214}H_{327}N_{47}O_{64}S$ ($M+4H^+$) requires 1152.8.

20

Example 190: Compound 77

E-190 was prepared according to **GP4** using 36.6 mg of resin (estimated loading 0.125 mmol/g) and **I-412** to afford 0.5 mg of **E-190** as a white solid. ESI-MS found 1159.7, $C_{215}H_{325}N_{47}O_{65}S$ ($M+4H^+$) requires 1159.3.




*Absolute configuration not determined

Example 191: Compound 75

E-191 was prepared according to **GP4** using 30.2 mg of resin (estimated loading 0.125 mmol/g) and **(S*)-I-413** to afford 2.9 mg of **E-191** as a white solid. ESI-MS found 1153.4, $C_{214}H_{327}N_{47}O_{64}S$ ($M+4H^+$) requires 1152.8.


Example 192: Compound 74

E-192 was prepared according to **GP4** using 31.1 mg of resin (estimated loading 0.125 mmol/g) and **(R*)-I-413** to afford 3.3 mg of **E-192** as a white solid. ESI-MS found 1153.4, $C_{214}H_{327}N_{47}O_{64}S$ ($M+4H^+$) requires 1152.8.

Example 193: Compound 67

E-193 was prepared according to **GP4** using 41.4 mg of resin (estimated loading 0.125 mmol/g) and **I-417** to afford 4.1 mg of **E-193** as a white solid. ESI-MS found 1157.1, $C_{213}H_{324}N_{48}O_{65}S$ ($M+4H^+$) requires 1156.6.


5 **Example 194: Compound 42**



E-194 was prepared according to **GP4** using 42.1 mg of resin (estimated loading 0.125 mmol/g) and **I-421** to afford 5.4 mg of **E-194** as a white solid. ESI-MS found 1158.8, $C_{212}H_{325}N_{47}O_{65}S_2$ ($M+4H^+$) requires 1158.3.

10


Example 195: Compound 40



E-195 was prepared according to **GP4** using 50.9 mg of resin (estimated loading 0.125 mmol/g) and **I-425** to afford 5.8 mg of **E-195** as a white solid. ESI-MS found 1162.3, $C_{213}H_{327}N_{47}O_{65}S_2$ ($M+4H^+$) requires 1161.8.

15

Example 196: Compound 153




Peptide **E-196** was prepared from 24.9 mg of resin (approximate loading 0.18 mmol/g) using **I-426** and **GP4** to afford 2.7 mg of **E-196** as a white solid. ESI-MS found 1059.4989, $C_{192}H_{278}SN_{46}O_{61}$ ($M-4H$)⁻ requires 1059.0.

20

C2. Synthesis of Additional Intermediates to Compounds Described in This Invention

The synthesis of carboxylic acid **I-430** is depicted in **Scheme 138**:



5


Scheme 138

To a solution of amine salt **I-427** (165.8 mg, 0.743 mmol), carboxylic acid **I-428** (119 mg, 1.0 equiv.) and DIPEA (388 μL , 3.0 equiv.) in DMF (2 mL) at ambient temperature was added HATU (423.8 mg, 1.5 equiv.). The reaction mixture was maintained at ambient temperature for 23 hours and was then purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%TFA) to afford ester **I-429** as a colorless oil (180.7 mg, 86% yield).

To a solution of ester **I-429** (90.3 mg, 0.318 mmol) in MeOH (3 mL) and H₂O (1 mL) was added lithium hydroxide (15.2 mg, 2.0 equiv.). The reaction mixture was heated to 60 °C for 23 hours, acidified with 6 N HCl to pH <2, and then purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%TFA) to afford acid **I-430** as a white solid (26.1 mg, 30% yield). ESI-MS found 271.3, C₁₃H₂₃N₂O₄ (M+4H)⁴⁺ requires 271.3.


15

The syntheses of compounds **I-439** & **I-443** involved 8 steps as depicted in the following **Scheme 139**.




Scheme 139

Step 1. 5-((2-(((benzyloxy)carbonyl)amino)ethyl)amino)-3-((tert-butylidimethylsilyl)oxy)-5-oxopentanoic acid (I-432)




A solution of 4-((tert-butylidimethylsilyl)oxy)dihydro-2H-pyran-2,6(3H)-dione **I-431** (cas: 91424-40-7, 5.0 g, 20.5 mmol), benzyl (2-aminoethyl)carbamate (cas: 72080-83-2, 3.97 g, 20.5 mmol) and TEA (6.2 g, 61.5 mmol) in anhydrous THF (150 mL) was stirred at 25 °C for 16 hours. The reaction mixture was concentrated to afford the crude 5-((2-(((benzyloxy)carbonyl)amino)ethyl)amino)-3-((tert-butylidimethylsilyl)oxy)-5-oxopentanoic acid **I-432** (8.9 g), which was taken on to the next reaction without further purification. MS (ESI, positiveion) m/z: 439.2(M+1).

Step 2. methyl 5-((2-(((benzyloxy)carbonyl)amino)ethyl)amino)-3-((tert-butylidimethylsilyl)oxy)-5-oxopentanoate (I-433)




To a mixture of acid **I-432** (5 g, 11.4 mmol) and K_2CO_3 (2.4 g, 17.1 mmol) in anhydrous DMF (30 mL) was added MeI (1.95 g, 13.7 mmol) at 25 °C under N_2 . The reaction mixture was heated to 50 °C for 5 hours, then concentrated and dissolved in EtOAc (150 mL). The organic phase was washed with water (50 mL x 3), dried and concentrated to afford the crude product, which was purified by silica gel chromatography (Petroleum ether: EtOAc = 3:1 to 1:1) to provide a pale oil (4.5 g, 87 % yield). MS (ESI, positiveion) m/z: 453.2(M+1).

Step 3. methyl 5-((2-(((benzyloxy)carbonyl)amino)ethyl)amino)-3-((tert-butyldimethylsilyl)oxy) pentanoate (**I-434**)



To a solution of ester **I-433** (2 g, 4.4 mmol) in anhydrous THF (200 mL) was added BH_3 -THF(1 M, 22 mL, 22 mmol) at 0 °C. The reaction mixture was heated to 80 °C for 2 hours and cooled to 0 °C, then quenched by adding 1 mL of concentrated HCl. The reaction mixture was concentrated and dissolved in EtOAc (150 mL). The organic phase was washed with water (50 mL x 3), dried and concentrated to afford the crude amine **I-434** (2.5 g), which was taken to the next reaction without further purification. MS (ESI, positiveion) m/z: 439.2(M+1).


Step 4. Benzyl (2-(4-((tert-butyldimethylsilyl)oxy)-2-oxopiperidin-1-yl)ethyl)carbamate (**I-435**)



A solution of amine **I-434** (2.5 g, 5.7 mmol) and TEA (2.89 g, 28.5 mmol) in anhydrous toluene (150 ml) was heated to 50 °C for 16 hours. The reaction mixture was concentrated and purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%TFA) to afford a brown oil (430 mg, 19 % yield). MS (ESI, positiveion) m/z: 407.2(M+1).


- 5 Step 5. **Chiral SFC separation** [5.0 cm I.D. × 25 cm L CHIRALCEL OZ column at 35 °C, flow rate 60 mL/min with Hexane/IPA=80/20(V/V)] afforded enantiomers **I-436** and **I-440**.

Step 6. **(R or S)-1-(2-aminoethyl)-4-((tert-butyldimethylsilyl)oxy)piperidin-2-one (peak1)(I-437 or I-441)**



- To a solution of benzyl (R or S)-2-(4-((tert-butyldimethylsilyl)oxy)-2-oxopiperidin-1-yl)ethyl)carbamate **I-436** (150 mg, 6.82 mmol) in THF (10 ml) was added Pd/C (170 mg) quickly under H₂. The reaction was then stirred at ambient temperature for 16 hours, when analysis by LC-MS indicated reaction completion. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to afford crude amine **I-437** (105 mg), which was taken to the next reaction without further purification. MS (ESI, positiveion) m/z: 273.2 (M+1).
- 15


Step 7. **(R or S)-2-(2-(3-methoxy-2-oxopyrrolidin-1-yl)ethyl)isoindoline-1,3-dione (I-438 or I-442)**



A solution of (R or S)-1-(2-hydroxyethyl)-3-methoxypyrrolidin-2-one (**I-437**) (100 mg, 0.94 mmol) and thiodiglycolic anhydride(cas: 3261-87-8, 240 mg, 1.84 mmol) in anhydrous THF (5 mL) was stirred at 25 °C for 16 hours. The reaction mixture was

concentrated to afford crude acid **I-438** (340 mg), which was taken to the next reaction without further purification. MS (ESI, positiveion) m/z: 405.1 (M+1).

Step 8. **(R or S)-2-((2-((2-(4-hydroxy-2-oxopiperidin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (I-439)**




To a solution of crude acid **I-438** (340 mg) in THF (10 mL) was added HCl/EtOAc (5 M, 2 mL) at 0 °C. The reaction mixture was stirred for 12 hours at ambient temperature, then concentrated to afford a residue, which was purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%TFA) to afford acid **I-439** as a pale oil (22 mg, 9% yield). MS (ESI, positiveion) m/z: 291.2(M+1). ¹H NMR (400 MHz, D₂O) δ 4.05-4.03 (m, 1 H), 3.44-3.24 (m, 6 H), 3.22 (s, 2 H), 3.17 (s, 2 H), 2.55-2.50 (m, 1 H), 2.20 - 2.15 (m, 1 H), 1.91-1.87 (m, 1 H), 1.73-1.68 (m, 1 H).

10


A similar sequence of steps with carbamate **I-441** afforded acid **I-443** (40 mg, 16% yield) as a pale oil.

15 The syntheses of intermediates **I-451** and **I-454** involved 8 steps as depicted in the following **Scheme 140**.




Scheme 140

Step 1. ((2-iodoethoxy)methyl)benzene (I-444)



- 5 A mixture of ((2-bromoethoxy)methyl)benzene (cas: 1462-37-9, 10 g, 46.7 mmol) and sodium iodide (10.5 g, 1.5 equiv.) in acetone (250 mL) was heated to reflux for 16 hours. The reaction mixture was concentrated, and the residue was dissolved into EtOAc (200 mL) and diluted with water (100 mL). The organic layer was washed with brine (50 mL x 3), dried over anhydrous Na₂SO₄ and concentrated to afford the crude product, which was
- 10 purified by silica gel chromatography (Petroleum ether: EtOAc= 20:1) to afford iodide **I-444** as a brown liquid (7 g, yield: 60%).


Step 2. 1-(2-(benzyloxy)ethyl)piperidin-2-one (I-445)



- A solution of 2-piperidone (cas: 675-20-7, 2 g, 20.2 mmol) in anhydrous THF (50 mL) was added NaH (60% in mineral oil, 1.2 g, 30.3 mmol) at 0 °C, then iodide **I-444** (10.6 g,
- 15


40.4 mmol). The reaction mixture was heated at 80 °C for 16 hours, then quenched by adding 100 mL of saturated aqueous NH₄Cl at 0 °C. The aqueous phase was extracted with EtOAc (50 mL x 3). The organic extracts were combined, dried and concentrated afford the crude product, which was purified by silica gel chromatography (DCM:MeOH=20:1) to afford amide **I-445** (1.2 g, yield: 25 %) as a pale oil. MS (ESI, positiveion) m/z: 234.2 (M+1).

Step 3. 1-(2-(benzyloxy)ethyl)-3-methylpiperidin-2-one (**I-446**)




To a solution of amide **I-445** (500 mg, 2.14 mmol) in anhydrous THF (20 mL) was added LDA (2 M, 1.6 mL, 3.2 mmol) at -78 °C under N₂. The reaction mixture was stirred for 30 minutes at the same temperature and MeI (914 mg, 6.44 mmol) was added. After 1 hour, LC-MS analysis indicated reaction completion. The reaction mixture was quenched with H₂O (20 mL) and extracted with EtOAc (20 mL x 3). The combined organic extracts was concentrated to obtain crude product, which was purified by silica gel chromatography (DCM: MeOH =20:1) to provide lactam **I-446** as a brown oil (380 mg, 72% yield). MS (ESI, positiveion) m/z: 248.2 (M+1).

Step 4. 1-(2-hydroxyethyl)-3-methylpiperidin-2-one (**I-447**)



To a solution of lactam **I-446** (5 g, 20.24 mmol) and acetic acid (0.5 mL) in MeOH (150 mL) was added 10%Pd(OH)₂ (300 mg) under H₂. The reaction mixture was heated to 50 °C under H₂ (3 atm) for 2 days. The reaction mixture was filtered, and the filtrate was concentrated to afford the crude product (3.2 g), which was taken to the next reaction without further purification. MS (ESI, positiveion) m/z: 158.2 (M+1).


Step 5. 2-(2-(3-methyl-2-oxopiperidin-1-yl)ethyl)isoindoline-1,3-dione (**I-448**)



A solution of lactam **I-447** (200 mg, 1.27 mmol), phthalimide (374 mg, 2.54 mmol) and P(n-Bu)₃ (514 mg, 2.54 mmol) in anhydrous THF (10 mL) was stirred at 0 °C for 0.5 hours. Then DIAD (514 mg, 2.54 mmol) was added to the reaction dropwise and the reaction mixture was stirred for 18 hours at ambient temperature. The reaction mixture was concentrated to get crude product, which was purified by silica gel chromatography (Petroleum ether: EtOAc = 1:1) to provide imide **I-448** as a pale oil (180 mg, 49% yield). MS (ESI, positive ion) m/z: 287.2 (M+1).


Step 6. Phthalimide **I-448** was subjected to chiral SFC to separate the racemate into its constituent enantiomers. Separation was accomplished using a Superchiral S-AD (Chiralway) column (2.1 cm I.D. × 25 cm L, 5 μm at 35 °C, flow rate 10 mL/min with Hexane/EtOH = 55/45 (v/v), 30 mg injection) affording 137 mg of each enantiomer (**I-449** and **I-452**) from 400 mg of racemate.

Step 7. (**R** or **S**)-2-(2-(3-methoxy-2-oxopyrrolidin-1-yl)ethyl)isoindoline-1,3-dione (**I-450**)



To a solution of **I-449** (150 mg, 0.52 mmol) in MeOH (10 mL) was added Hydrazine hydrate (cas: 7803-57-8, 80%, 0.3 mL) at 0 °C. The reaction mixture was stirred for 12 hours at ambient temperature, then filtered and the filtrate was concentrated. The residue afforded (210 mg) was used directly in the next step. MS (ESI, positive ion) m/z: 157.2 (M+1).


Step 8. (**R** or **S**)-2-((2-((2-(3-methyl-2-oxopiperidin-1-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (**I-451**)



A solution of (R or S)-1-(2-aminoethyl)-3-methylpiperidin-2-one, **I-450** (210 mg, 1.36 mmol) and thiodiglycolic anhydride (533 mg, 4.08 mmol) in 5 mL of DCM was stirred at 25 °C for 16 hours. The reaction mixture was concentrated to afford the crude product, which was purified by preparative HPLC (Mobile Phase: MeCN/H₂O (with 0.1% TFA)) to afford acid **I-451** (40 mg, 11 % yield) as a pale oil. MS (ESI, positive ion) m/z: 289.2 (M+1). ¹H NMR (400 MHz, D₂O) δ 3.43-3.39 (m, 2 H), 3.36-3.28 (m, 6 H), 3.24 (s, 2 H), 2.36-2.31 (m, 1 H), 1.80-1.70 (m, 2 H), 1.66-1.58 (m, 1 H), 1.46-1.39 (m, 1 H), 1.08-1.06 (d, 3 H).

A similar sequence of steps from phthalimide **I-452** afforded acid **I-454** (43 mg, 12% yield) as a pale oil.

The synthesis of intermediate **I-458** is depicted in Scheme 141:




Scheme 141

To a solution of amine salt **I-456** (57.3 mg, 0.315 mmol), carboxylic acid **I-455** (49.5 mg, 1.0 equiv.) and DIPEA (165 μL, 3.0 equiv.) in DMF (1 mL) at ambient temperature was added HATU (179.7 mg, 1.5 equiv.). The reaction mixture was maintained at ambient temperature for 2 hours and was then purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1% AcOH) to afford ester **I-457** as a colorless oil (75.3 mg, 84% yield). To ester **I-457** (75.3 mg, 0.265 mmol) was added TFA (4 mL). The reaction mixture was maintained at ambient temperature for 4 hours, then concentrated. The residue afforded

was purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%TFA) to afford acid **I-458** as a white solid (42.3 mg, 70% yield). ESI-MS found 227.1. C₁₀H₁₅N₂O₄ (M-H)⁻ requires 227.1.

The synthesis of intermediate **I-461** is depicted in Scheme 142:

5




Scheme 142

To a solution of amine salt **I-456** (57.1 mg, 0.314 mmol), carboxylic acid **I-455** (53.8 mg, 1.0 equiv.) and DIPEA (164 μ L, 3.0 equiv.) in DMF (1 mL) at ambient temperature was added HATU (179.3 mg, 1.5 equiv.). The reaction mixture was maintained at ambient temperature for 3 hours and was then purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%AcOH) to afford ester **I-460** as a colorless oil (81.1 mg, 87% yield).

To ester **I-460** (81.1 mg, 0.272 mmol) was added TFA (4 mL). The reaction mixture was maintained at ambient temperature for 4 hours, then concentrated. The residue afforded was purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%TFA) to afford acid **I-461** as a white solid (73.8 mg, quantitative yield). ESI-MS found 243.3. C₁₁H₁₉N₂O₄ (M+H)⁺ requires 243.1.

The synthesis of intermediate **I-464** is depicted in Scheme 143:




Scheme 143

To a solution of amine salt **I-462** (96.6 mg, 0.493 mmol), carboxylic acid **I-455** (77.5 mg, 1.0 equiv.) and DIPEA (258 μ L, 3.0 equiv.) in DMF (1 mL) at ambient temperature was added HATU (281.4 mg, 1.5 equiv.). The reaction mixture was maintained at ambient temperature for 16 hours and was then purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%AcOH) to afford ester **I-463** as a white solid (127.6 mg, 87% yield).

To ester **I-463** (127.6 mg, 0.428 mmol) was added TFA (4 mL). The reaction mixture was maintained at ambient temperature for 4 hours, then concentrated. The residue afforded acid **I-464** as a white solid (115.7 mg, quantitative yield). ESI-MS found 243.3. C₁₁H₁₉N₂O₄ (M+H)⁺ requires 243.1.

The synthesis of intermediate **I-466** is depicted in Scheme 144:




Scheme 144

To a solution of amine salt **I-462** (93.1 mg, 0.476 mmol), carboxylic acid **I-459** (81.4 mg, 1.0 equiv.) and DIPEA (249 μ L, 3.0 equiv.) in DMF (2 mL) at ambient temperature was added HATU (271.2 mg, 1.5 equiv.). The reaction mixture was maintained at ambient

temperature for 3 hours and was then purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%AcOH) to afford ester **I-465** as a colorless oil (133 mg, 90% yield).

To ester **I-465** (133 mg, 0.426 mmol) was added TFA (4 mL). The reaction mixture was maintained at ambient temperature for 4 hours, then concentrated. The residue afforded
5 was purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%TFA) to afford acid **I-466** as a white solid (108.4 mg, >99% yield). ESI-MS found 257.3. C₁₂H₂₁N₂O₄ (M+H)⁺ requires 257.1.

The synthesis of intermediate **I-469** is depicted in Scheme 145:




10

Scheme 145

To a solution of amine salt **I-467** (80.1 mg, 0.441 mmol), carboxylic acid **I-455** (69.3 mg, 1.0 equiv.) and DIPEA (231 μL, 3.0 equiv.) in DMF (2 mL) at ambient temperature was added HATU (251.6 mg, 1.5 equiv.). The reaction mixture was maintained at ambient
15 temperature for 16 hours and was then purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%AcOH) to afford ester **I-468** as a colorless oil (112.4 mg, 90% yield).

To ester **I-468** (112.4 mg, 0.395 mmol) was added TFA (4 mL). The reaction mixture was maintained at ambient temperature for 4 hours, then concentrated. The residue afforded
20 was purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%TFA) to afford acid **I-469** as a white solid (79.1 mg, 88% yield). ESI-MS found 229.2. C₁₀H₁₇N₂O₄ (M+H)⁺ requires 229.1.

The synthesis of intermediate **I-471** is depicted in Scheme 146:




Scheme 146

To a solution of amine salt **I-467** (87.9 mg, 0.484 mmol), carboxylic acid **I-459** (82.8 mg, 1.0 equiv.) and DIPEA (253 μ L, 3.0 equiv.) in DMF (2 mL) at ambient temperature was added HATU (275.8 mg, 1.5 equiv.). The reaction mixture was maintained at ambient temperature for 16 hours and was then purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1% AcOH) to afford ester **I-470** as a colorless oil (131.9 mg, 91% yield).

To ester **I-470** (131.9 mg, 0.442 mmol) was added TFA (4 mL). The reaction mixture was maintained at ambient temperature for 4 hours, then concentrated. The residue afforded was purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1% TFA) to afford acid **I-471** as a white solid (102.2 mg, 95% yield). ESI-MS found 243.3. C₁₁H₁₉N₂O₄ (M+H)⁺ requires 243.1.

The synthesis of intermediate **I-474** is depicted in Scheme 147:




Scheme 147

To a solution of amine salt **I-472** (79.1 mg, 0.436 mmol), carboxylic acid **I-455** (68.4 mg, 1.0 equiv.) and DIPEA (228 μ L, 3.0 equiv.) in DMF (2 mL) at ambient temperature was added HATU (248.4 mg, 1.5 equiv.). The reaction mixture was maintained at ambient

temperature for 16 hours and was then purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%AcOH) to afford ester **I-473** as a colorless oil (105.9 mg, 86% yield).

To ester **I-473** (105.9 mg, 0.372 mmol) was added TFA (4 mL). The reaction mixture was maintained at ambient temperature for 4 hours, then concentrated. The residue afforded
 5 was purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%TFA) to afford acid **I-474** as a white solid (100.5 mg, quantitative yield). ESI-MS found 229.2. C₁₀H₁₇N₂O₄ (M+H)⁺ requires 229.1.

The synthesis of intermediate **I-476** is depicted in Scheme 148:




10

Scheme 148

To a solution of amine salt **I-472** (74.4 mg, 0.41 mmol), carboxylic acid **I-459** (70.1 mg, 1.0 equiv.) and DIPEA (214 μ L, 3.0 equiv.) in DMF (2 mL) at ambient temperature was added HATU (233.6 mg, 1.5 equiv.). The reaction mixture was maintained at ambient temperature for 16 hours and was then purified by preparative HPLC (Mobile Phase:
 15 MeCN/H₂O with 0.1%AcOH) to afford ester **I-475** as a colorless oil (104.3 mg, 85% yield).

To ester **I-475** (104.3 mg, 0.35 mmol) was added TFA (4 mL). The reaction mixture was maintained at ambient temperature for 4 hours, then concentrated. The residue afforded was purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%TFA) to afford acid **I-476** as a white solid (96.6 mg, quantitative yield). ESI-MS found 243.2. C₁₁H₁₉N₂O₄
 20 (M+H)⁺ requires 243.1.

The synthesis of intermediate **I-478** is depicted in Scheme 149:




Scheme 149


To a solution of 2,5-dioxopyrrolidin-1-yl (tert-butoxycarbonyl)glycinate (50 mg, 0.183 mmol) in 1 mL of anhydrous DCM was added piperidine (0.2 mL, 5 equiv.). The reaction mixture was stirred at room temperature for 18 hours, then diluted with 5 mL of DCM, washed with 1N HCl (5 mL), saturated aqueous NaHCO₃ (5 mL) and brine (5 mL). The organic extracts were dried (Na₂SO₄) and concentrated to afford a residue, which was purified by silica gel chromatography to afford the amide **I-477** (35 mg, 81% yield).

Amide **I-477** (35 mg, 0.15 mmol) was dissolved in 1:1 DCM/TFA (3 mL). After 1 hour at room temperature, the reaction mixture was concentrated and held under high vacuum for 1 hour. The resulting oil and thiodiglycolic anhydride (21.5 mg, 1.1 equiv.) were dissolved in DCM (3 mL), and TEA (65 μ L, 2.5 equiv.) was added. After 25 minutes, the reaction mixture was concentrated and purified by preparative HPLC (H₂O/MeCN with 0.1% TFA) to afford 14.6 mg (5% yield) of acid **I-478**. ESI-MS found 275.1, C₁₁H₁₉N₂O₄S (MH⁺) requires 275.1.


The synthesis of intermediate **I-486** is depicted in Scheme 150:



Scheme 150


Step 1: *Tert*-butyl (2-(3-methyl-2-oxopyridin-1(2H)-yl)ethyl)carbamate (**I-484**)

A solution of 3-methylpyridin-2(1H)-one, **I-483** (cas: 1003-56-1, 3.0 g, 27.52 mmol, 1.0 equiv.), KI (0.913 g, 5.50 mmol, 0.2 equiv.), NaH (60%, 1.321 g, 33.02 mmol, 1.2 equiv.),
 5 in DMF (20 mL) was stirred under nitrogen at 0 °C for 1 hour. Then the reaction mixture was added to a solution of *tert*-butyl (2-bromoethyl)carbamate (cas: 39684-80-5, 9.205 g, 41.28 mmol, 1.5 equiv.) in DMF (20 mL) dropwise. The reaction mixture was stirred at 0 °C for other 1 hour and then 25 °C for another 48 hours. LCMS analysis showed ~50% conversion. Then H₂O (50 mL) was added and the mixture was extracted with EtOAc (100
 10 mL x 3). The organic phase was dried and purified by silica gel chromatography (20%-50% EtOAc with Petroleum ether) to afford the product *tert*-butyl (2-(3-methyl-2-oxopyridin-1(2H)-yl)ethyl)carbamate **I-484** (1.2 g, 17% yield, 95% purity) as white solid, MS (ESI, positive ion) m/z: 253 (M+1) and byproduct: *tert*-butyl (2-((3-methylpyridin-2-yl)oxy)ethyl)carbamate (0.2 g, 3% yield, 95% purity), MS (ESI, positive ion) m/z:
 15 253.1(M+1).

Step 2: 1-(2-aminoethyl)-3-methylpyridin-2(1H)-one (**I-485**)


To the solution of *tert*-butyl (2-(3-methyl-2-oxopyridin-1(2H)-yl)ethyl)carbamate **I-484** (1.2 g, 4.76 mmol, 1.0 equiv.) in DCM (20 mL) was added TFA (10 mL). The solution was
 20 stirred for 2 h at 25 °C. After completion, the mixture was concentrated and the remained TFA was removed by centrifugation to give light yellow oil (0.7 g, TFA salt, 97% yield, 60% purity by LCMS). MS (ESI, positive ion) m/z: 153.1(M+1).

Step 3: 2-((2-((3-methyl-2-oxopyridin-1(2H)-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (**I-486**)




A solution of 1-(2-aminoethyl)-3-methylpyridin-2(1H)-one (0.7 g, 4.61 mmol, 1.0 equiv.), TEA (1.397 g, 13.83 mmol, 3.0 equiv.), thiodiglycolic anhydride (0.913 g, 6.92 mmol, 1.5 equiv.) in DCM (10 mL) was stirred for 36 hours at 25 °C. After completion, the reaction mixture was concentrated. The residue was purified by Preparative HPLC (Mobile Phase: ACN-H₂O) to afford **I-486** (119.7 mg, 9% yield, 99.2% purity) as a white solid. MS (ESI, positive ion) *m/z*: 285.1(M+1). ¹H NMR (400 MHz, D₂O) δ 7.41 – 7.36 (m, 1H), 7.32 (dd, 1H), 6.31 (t, 1H), 4.07 – 4.01 (m, 2H), 3.54 – 3.48 (m, 2H), 3.17 (d, 4H), 1.99 (s, 3H).

The synthesis of intermediate **I-490** is depicted in Scheme 151:



Scheme 151


Step 1: *tert*-butyl (2-(6-methyl-2-oxopyridin-1(2H)-yl)ethyl)carbamate (**I-488**)



To a solution of 6-methylpyridin-2(1H)-one **I-487** (cas: 3279-76-3, 5.0 g, 45.87 mmol, 1.0 equiv.), Cs₂CO₃ (29.91 g, 91.74 mmol, 2.0 equiv.) in anhydrous DMF (40 mL) was added *tert*-butyl (2-bromoethyl)carbamate (cas: 39684-80-5, 15.34 g, 68.81 mmol, 1.5 equiv.). The reaction mixture was stirred at 90 °C for 4 hours. After completion, the reaction mixture was purified by reversed flash column (Mobile Phase: MeCN-H₂O, Gradient: 20-30% H₂O) to afford *tert*-butyl (2-(6-methyl-2-oxopyridin-1(2H)-yl)ethyl)carbamate, **I-488**

(3.0 g, 26% yield, 95% purity) as a white solid, MS (ESI, positive ion) m/z : 253.1 (M+1) and byproduct: *tert*-butyl (2-((6-methylpyridin-2-yl)oxy)ethyl)carbamate (7.0 g, 61% yield, 95% purity) as a white solid, MS (ESI, positive ion) m/z : 253.1 (M+1).

Step 2: 1-(2-aminoethyl)-6-methylpyridin-2(1H)-one (**I-489**)




5

To a solution of *tert*-butyl (2-(6-methyl-2-oxopyridin-1(2H)-yl)ethyl)carbamate, **I-488** (1.5 g, 5.95 mmol, 1.0 equiv.) in DCM (20 mL) was added TFA (10 mL). The reaction mixture was stirred for 2 hours at 25 °C. After completion, the reaction mixture was concentrated and the remained TFA was removed by centrifugation to give amine **I-489** as a light yellow oil (0.9 g, TFA salt, 101% yield, 90% purity). MS (ESI, positive ion) m/z : 153.1(M+1).

10

Step 3: 2-((2-((2-(6-methyl-2-oxopyridin-1(2H)-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid

(**I-490**)




15

The solution of 1-(2-aminoethyl)-6-methylpyridin-2(1H)-one, **I-489** (0.9 g, 5.92 mmol, 1.0 equiv.), TEA (1.79 g, 17.76 mmol, 3.0 equiv.), thiodiglycolic anhydride (1.172 g, 8.88 mmol, 1.5 equiv.) in DCM (10 mL) was stirred for 24 hours at 25 °C. After completion, the reaction mixture was concentrated. The residue was purified by preparative HPLC (Mobile Phase: ACN-H₂O, Gradient: 5-10% MeCN) to afford carboxylic acid **I-490** (119 mg, 7% yield, 99.6% purity) as a light yellow solid. MS (ESI, positive ion) m/z : 285.1(M+1). ¹H NMR (400 MHz, D₂O) δ 7.39 (dd, 1H), 6.34 (dd, 2H), 4.13 (t, 2H), 3.50 (t, 2H), 3.20 (s, 2H), 3.17 (s, 2H), 2.35 (s, 3H).


20

The synthesis of carboxylic acid **I-494** involved 3 steps as depicted in the following Scheme 152:




Scheme 152

5 Step 1: *Tert*-butyl (2-(4-methyl-2-oxopyridin-1(2H)-yl)ethyl)carbamate (**I-492**)




A solution of 4-methylpyridin-2(1H)-one, **I-491** (cas: 13466-41-6, 5.0 g, 45.87 mmol, 1.0 equiv.), KI (1.522 g, 9.17 mmol, 0.2 equiv.), NaH (60%, 2.20 g, 55.04 mmol, 1.2 equiv.) in DMF (20 ml) was stirred under nitrogen at 0 °C for 1 hour. Then the mixture was added to a solution of *tert*-butyl (2-bromoethyl)carbamate (cas: 39684-80-5, 15.34 g, 68.80 mmol, 1.5 equiv.) in DMF (30 mL) dropwise. The reaction mixture was stirred at 0 °C for 1 hour and then 25 °C for other 12 hours. LCMS showed ~50% conversion, at which point H₂O (50 mL) was added and the reaction mixture was extracted with EtOAc (100 mL x 3). The organic phase was dried and purified by flash (20%-50% EtOAc with Petroleum ether) to afford *tert*-butyl (2-(4-methyl-2-oxopyridin-1(2H)-yl)ethyl)carbamate, **I-492** (1.3 g, 11% yield, 95% purity) as a white solid, MS (ESI, positive ion) *m/z*: 253(M+1) and by product: *tert*-butyl (2-((4-methylpyridin-2-yl)oxy)ethyl)carbamate (0.2 g, 2% yield, 95% purity), MS (ESI, positive ion) *m/z*: 253(M+1).

Step 2: 1-(2-aminoethyl)-4-methylpyridin-2(1H)-one (**I-493**)




To a solution of *tert*-butyl (2-(4-methyl-2-oxopyridin-1(2H)-yl)ethyl)carbamate, **I-492** (1.3 g, 5.16 mmol, 1.0 equiv.) in DCM (20 mL) was added TFA (10 mL). The solution was stirred for 2 hours at 25 °C. After completion, the reaction mixture was concentrated and the remained TFA was removed by centrifugation to afford amine **I-493** as a light yellow oil (0.8 g, TFA salt, 102% yield, 90% purity by LCMS). MS (ESI, positive ion) *m/z*: 153.1(*M*+1).

Step 3: 2-((2-((2-(4-methyl-2-oxopyridin-1(2H)-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (I-494)




The solution of 1-(2-aminoethyl)-4-methylpyridin-2(1H)-one, **I-493** (0.8 g, 5.26 mmol, 1.0 equiv.), TEA (1.593 g, 15.78 mmol, 3.0 equiv.), thiodiglycolic anhydride (1.041 g, 7.89 mmol, 1.5 equiv.) in DCM (10 mL) was stirred for 12 hours at 40 °C. After completion, the reaction mixture was concentrated. The residue was purified by preparative HPLC (Mobile Phase: ACN-H₂O, Gradient: 5-10% MeCN) to afford **I-494** (114.2 mg, 8% yield, 99.6% purity) as a white solid. MS (ESI, positive ion) *m/z*: 285.1(*M*+1). ¹H NMR (400 MHz, D₂O) δ 7.36 (d, 1H), 6.36 (s, 1H), 6.31 (dd, 1H), 4.03 – 3.97 (m, 2H), 3.52 – 3.47 (m, 2H), 3.20 (s, 2H), 3.16 (s, 2H), 2.14 (s, 3H).

The synthesis of carboxylic acid **I-498** involved 3 steps as depicted in the following Scheme 153.




Scheme 153

Step 1: **Tert-butyl (2-(5-methyl-2-oxopyridin-1(2H)-yl)ethyl)carbamate (I-496)**




- 5 A solution of 5-methylpyridin-2(1H)-one, **I-495** (cas: 1003-68-5, 5.0 g, 45.87 mmol, 1.0 equiv.), KI (1.522 g, 9.17 mmol, 0.2 equiv.), and NaH (60%, 2.20 g, 55.04 mmol, 1.2 equiv.) in DMF (20 ml) was stirred under nitrogen at 0 °C for 1 hour. Then the reaction mixture was added to a solution of *tert*-butyl (2-bromoethyl)carbamate (cas: 39684-80-5, 15.34 g, 68.80 mmol, 1.5 equiv.) in DMF (30 mL) dropwise. The reaction mixture was
- 10 stirred at 0 °C for 1 hour and then 25 °C for 12 hours. LCMS analysis showed ~50% conversion, at which point H₂O (50 mL) was added and the reaction mixture was extracted with EtOAc (100 mL x 3). The organic phase was dried and purified by silica gel chromatography (20%-50% EtOAc with Petroleum ether) to give the product *tert*-butyl (2-(5-methyl-2-oxopyridin-1(2H)-yl)ethyl)carbamate, **I-496** (1.7 g, 15% yield, 95% purity) as
- 15 a white solid, MS (ESI, positive ion) *m/z*: 253(M+1) and byproduct: *tert*-butyl (2-((5-methylpyridin-2-yl)oxy)ethyl)carbamate (0.4 g, 3% yield, 95% purity), MS (ESI, positive ion) *m/z*: 253(M+1).

Step 2: **1-(2-aminoethyl)-5-methylpyridin-2(1H)-one (I-497)**




To a solution of *tert*-butyl (2-(4-methyl-2-oxopyridin-1(2H)-yl)ethyl)carbamate, **I-496** (1.7 g, 6.74 mmol, 1.0 equiv.) in DCM (20 mL) was added TFA (10 mL) and the reaction mixture was stirred for 2 hours at 25 °C. After completion, the reaction mixture was concentrated and the remaining TFA was removed by centrifugation to give the amine **I-497** as a light yellow oil (1.0 g, TFA salt, 103% yield, 90% purity by LCMS). MS (ESI, positive ion) m/z: 153.1(M+1).

Step 3: 2-((2-((2-(5-methyl-2-oxopyridin-1(2H)-yl)ethyl)amino)-2-oxoethyl)thio)acetic acid (**I-498**)



A solution of 1-(2-aminoethyl)-5-methylpyridin-2(1H)-one, **I-497** (1.0 g, 6.58 mmol, 1.0 equiv.), TEA (1.994 g, 19.74 mmol, 3.0 equiv.), and thiodiglycolic anhydride (1.303 g, 9.87 mmol, 1.5 equiv.) was stirred in DCM (10 mL) for 12 hours at 40 °C. After completion, the reaction mixture was concentrated. The residue was purified by preparative HPLC (Mobile Phase: ACN-H₂O, Gradient: 5-10% MeCN) to give **I-498** (106 mg, 7% yield) as a white solid. MS (ESI, positive ion) m/z: 285.1(M+1). ¹H NMR (400 MHz, D₂O) δ 7.44 (dd, 1H), 7.30 (s, 1H), 6.47 (d, 1H), 4.05 – 3.98 (m, 2H), 3.56 – 3.49 (m, 2H), 3.21 (s, 2H), 3.17 (s, 2H), 2.01 (s, 3H).

The synthesis of intermediate **I-505** is depicted in Scheme 155:




Scheme 155

To a solution of amine hydrochloride **I-427** (144 mg, 0.645 mmol) and DIPEA (225 μ L, 2.0 equiv.) in DCM (5 mL) that had been cooled in an ice-water bath was added acid chloride **I-503** (88.1 mg, 1.0 equiv.). The reaction mixture was gradually allowed to warm to ambient temperature and after 3 hours was concentrated to a residue that was purified by preparative HPLC (MeCN/H₂O with 0.1% TFA) to afford ester **I-504** (163.8 mg, >99% yield) as a colorless oil.

To a solution of ester **I-504** (78 mg, 0.322 mmol) in MeOH (3 mL) and H₂O (1 mL) was added lithium hydroxide (23.1 mg, 3.0 equiv.). The reaction mixture was stirred for 2 hours at ambient temperature at which point analysis by LC-MS indicated that the reaction was complete. The reaction mixture was concentrated and diluted with H₂O (1 mL), then acidified to pH~1 with 2N HCl. The solution was subjected to purification by preparative HPLC (MeCN/H₂O with 0.1% TFA) to afford carboxylic acid **I-505** (56.5 mg, 82% yield) as a white solid. ESI-MS found 215.3, C₉H₁₅N₂O₄ (MH⁺) requires 215.1.

The synthesis of intermediate **I-507** is depicted in Scheme 156:




Scheme 156

Amine **I-506** (84.2 mg, 0.584 mmol) was treated with Glutaric anhydride (66.6 mg, 1.0 equiv.) in DMF (1.1 mL). After 1.5 hours the reaction mixture was subjected to purification by preparative HPLC (MeCN/H₂O with 0.1% TFA) to afford carboxylic acid

I-507 (40 mg, 27% yield) as a colorless oil. ESI-MS found 259.2, $C_{11}H_{19}N_2O_5$ (MH^+) requires 259.1.


The synthesis of intermediate **I-508** is depicted in Scheme 157:



Scheme 157

Amine **I-506** (96 mg, 0.666 mmol) was treated with 2,2-dimethylsuccinic anhydride (96 mg, 1.1 equiv.) in DMF (1 mL). After 16 hours the reaction mixture was subjected to purification by preparative HPLC (MeCN/H₂O with 0.1% TFA) to afford carboxylic acid **I-508** (24.8 mg, 14% yield) as a colorless oil.

The synthesis of intermediate **I-510** is depicted in Scheme 158:




Scheme 158

To a solution of amine **I-506** (169.5 mg, 1.174 mmol) and DIPEA (614 μ L, 3.0 equiv.) in DCM (5 mL) that had been cooled in an ice-water bath was added acid chloride **I-500** (209.3 mg, 1.0 equiv.). The reaction mixture was allowed to warm to ambient temperature and after 1.5 hours was concentrated to a residue to afford crude ester **I-509** as a colorless oil, which was redissolved in MeOH (3 mL). A solution of lithium hydroxide (84.4 mg, 3.0 equiv.) in H₂O (1 mL) was added. The reaction mixture was stirred for 17 hours at ambient temperature. The reaction mixture was concentrated and 1M NaHSO₄ and 6N HCl was added to afford a solution of pH $\sim$ 1.5. Purification by preparative HPLC (MeCN/H₂O

with 0.1% TFA) afforded carboxylic acid **I-510** (125.3 mg, 41% yield) as a colorless oil. ESI-MS found 259.2, $C_{11}H_{19}N_2O_5$ (MH^+) requires 259.1.

The synthesis of intermediate **I-513** is depicted in Scheme 159:




5

Scheme 159

To a solution of amine dihydrochloride **I-511** (138.5 mg, 0.656 mmol) and DIPEA (343 μ L, 3.0 equiv.) in DCM (4 mL) that had been cooled in an ice-water bath was added acid chloride **I-500** (117.2 mg, 1.0 equiv.). The reaction mixture was allowed to warm to ambient temperature and after 1.5 hours was deemed complete by LC-MS analysis. The reaction mixture was concentrated to a residue to afford crude ester **I-512** as a colorless oil, which was redissolved in MeOH (2 mL). A solution of lithium hydroxide (47.2 mg mg, 3.0 equiv.) in H_2O (1 mL) was added. The reaction mixture was stirred for 17 hours at ambient temperature. Additional LiOH (47.2 mg mg, 3.0 equiv.) in H_2O (1 mL) was added and stirring was continued for 2 more hours. The reaction mixture was concentrated and 6N HCl was added to afford a solution of pH $\sim$ 1.5. Purification by preparative HPLC (MeCN/ H_2O with 0.1% TFA) afforded carboxylic acid **I-513** (136 mg, 82% yield). ESI-MS found 253.2, $C_{12}H_{17}N_2O_4$ (MH^+) requires 253.1.

15

The synthesis of intermediate **I-516** is depicted in Scheme 160:




369

SUBSTITUTE SHEET (RULE 26)


Scheme 160

To a solution of amine salt **I-427** (62.8 mg, 0.281 mmol), carboxylic acid **I-514** (52.4 mg, 1.0 equiv.) and DIPEA (147 μ L, 3.0 equiv.) in DMF (1 mL) at ambient temperature was added PyAOP (190.7 mg, 1.3 equiv.). The reaction mixture was maintained at ambient temperature for 17 hours and was then purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%TFA) to afford ester **I-515** as a colorless oil (68.7 mg, 79% yield).

To a solution of ester **I-515** (68.7 mg, 0.221 mmol) in MeOH (2 mL) and H₂O (1 mL) was added lithium hydroxide (15.9 mg, 3.0 equiv.). The reaction mixture was stirred at ambient temperature for 3 hours, then acidified with 6 N HCl to pH <2, then purified by preparative HPLC (Mobile Phase: MeCN/H₂O with 0.1%TFA) to afford acid **I-516** as a white solid (33.9 mg, 54% yield). ESI-MS found 283.3, C₁₄H₂₃N₂O₄ (M+4H)⁴⁺ requires 283.2.

I-517


Prepared according to **GP1**. Yield: 32.5 mg (74%). ESI-MS found 323.1, C₁₅H₁₉N₂O₄S (MH⁺) requires 323.1.

I-518

Prepared according to **GP1**. Yield: 18 mg (39%). ESI-MS found 323.3, C₁₅H₁₉N₂O₄S (MH⁺) requires 323.1.

Synthesis of intermediate I-552:


The synthesis of **I-552** involved 5 steps as depicted in the following Scheme 161.



Scheme 161


Summary

The chemical structure of the target compound was confirmed by ^1H NMR and LC-MS with the purity > 90% (HPLC 214 & 254 nm).

Step 1: (1*S*,4*R*)-2-(2-hydroxyethyl)-2-azabicyclo[2.2.1]hept-5-en-3-one(I-548)

To a solution of (1*S*,4*R*)-2-azabicyclo[2.2.1]hept-5-en-3-one, **I-547** (2.18 g, 20.0 mmol, CAS:13031-83-8) in anhydrous THF (30 mL) was added LDA (10 mL, 2M in THF, 1.0 equiv.) at 0 °C.


The mixture was stirred at 0 °C for 0.5 hours and oxirane (20 mL, 20.0 equiv.) was added. The reaction mixture was allowed to warm to 20 °C and maintained at that temperature for another 16 hours. After the reaction was deemed complete, the pH of the reaction mixture was adjusted to 6 with 1N HCl. The reaction mixture was concentrated to a volume of approximately 5 mL and purified by reversed phase column chromatography (C_{18} column, 20-35 μm , 100 Å, 80 g, 0.1% v/v Formic acid in MeCN/ H_2O) to afford the alcohol **I-548** (1.3 g, 43% yield). MS (ESI, pos. ion) m/z : 154.1, (MH^+).

Step 2: 2-((1*S*,4*R*)-3-oxo-2-azabicyclo[2.2.1]hept-5-en-2-yl)ethyl methanesulfonate (I-549)

To a solution of methyl (1*S*,4*R*)-2-(2-hydroxyethyl)-2-azabicyclo[2.2.1]hept-5-en-3-one, **I-548** (1.3 g, 8.50 mmol) and TEA


(2.5 g, 3.0 equiv.) in anhydrous THF (20 mL) was added MsCl (1.46 g, 1.5 equiv.). The reaction mixture was stirred at 20 °C for 16 hours, then diluted with water (50 mL), and extracted with EtOAc (50 mL). The organic extract was dried over sodium sulfate, and concentrated to afford the crude mesylate **I-549** as a yellow oil (1.8 g, 92% yield), which was used for the next step.. MS (ESI, pos. ion) m/z: 232.0, (MH⁺).

Step 3: **(1*S*,4*R*)-2-(2-aminoethyl)-2-azabicyclo[2.2.1]hept-5-en-3-one(I-550)**




To a solution of crude 2-((1*S*,4*R*)-3-oxo-2-azabicyclo[2.2.1]hept-5-en-2-yl)ethyl methanesulfonate, **I-549** (1.8 g, 7.79 mmol) in EtOH (20 mL) was added concentrated aqueous NH₃ (25-28% solution, 5 mL). The mixture was stirred at 100 °C for 0.5 hours. After completion, the reaction mixture was concentrated to ca. 5 mL and purified by reversed phase column chromatography (0.1% Formic acid in MeCN/H₂O) to afford the desired amine **I-550** as a colorless syrup (550 mg, 47% yield). MS (ESI, pos. ion) m/z: 153.1, (MH⁺).

Step 4: **(1*R*,4*S*)-2-(2-aminoethyl)-2-azabicyclo[2.2.1]heptan-3-one(I-551)**



A slurry of (1*S*,4*R*)-2-(2-aminoethyl)-2-azabicyclo[2.2.1]hept-5-en-3-one, **I-550** (200 mg, 1.32 mmol) and Pd/C (10%, 100 mg) in EtOH (6 mL) was stirred under H₂ (1 atm) at 20 °C for 16 hours. The reaction mixture was then filtered, and the filtrate was concentrated to afford the desired amine **I-551** as a colorless syrup (200 mg, 98% yield). MS (ESI, pos. ion) m/z: 155.1, (MH⁺).

Step 5: **2-((2-oxo-2-((2-((1*R*,4*S*)-3-oxo-2-azabicyclo[2.2.1]heptan-2-yl)ethyl)amino)ethyl)thio)acetic acid (I-552)**



To a solution of (1*R*,4*S*)-2-(2-aminoethyl)-2-azabicyclo[2.2.1]heptan-3-one (200 mg, 1.30 mmol) in DMF (3 mL) was added thiodiglycolic anhydride (343 mg, 2.0 equiv.), and the reaction mixture was stirred at 40 °C for 16 hours, then purified by reversed phase column chromatography (0.1% Formic acid in MeCN/H₂O) to afford acid **I-552** as a colorless syrup (160 mg, 42% yield). MS (ESI, pos. ion) m/z: 287.1, (MH⁺). ¹H NMR (400 MHz, D₂O) δ 4.04(s,1H),3.42-3.54 (m,2H),3.31-3.38 (m,5H),3.03-3.09


(m, 1H), 2.80-2.81(m, 1H), 1.90-1.98(m, 1H), 1.80-1.86 (m, 2H), 1.59-1.65(m, 1H), 1.39-1.46(m, 2H).

Synthesis of intermediate I-557:

The synthesis of intermediate **I-557** involved 4 steps as described in the following Scheme

5

162.




Scheme 162

Summary

The chemical structure of the target compound was confirmed by ¹H NMR and LC-MS with the purity > 95% (HPLC 214 & 254 nm).

10

Step 1: (1*R*,4*S*)-2-(2-hydroxyethyl)-2-azabicyclo[2.2.1]hept-5-en-3-one (**I-554**)




15

To a solution of (1*R*,4*S*)-2-azabicyclo[2.2.1]hept-5-en-3-one (3 g, CAS: 79200-56-9, 27.5 mmol) in THF (50 mL) was added LDA (2M in THF, 13.8 mL, 1.0 equiv.) at 25 °C. The reaction mixture was stirred for 1 h at 25 °C and then oxirane (cas: 75-21-8, 20 mL, 17.6 g, 0.4 mol, 14.5 equiv.) was added. The reaction mixture was stirred at 25 °C for 48 hours. When the reaction was deemed complete by LC-MS analysis, the pH of the reaction mixture was adjusted to 6-7 with HCl (1M). The reaction mixture was concentrated to a residue, which was purified by reversed phase column chromatography (0.1% Formic acid in MeCN/H₂O) to afford (1*R*,4*S*)-2-(2-hydroxyethyl)-2-azabicyclo [2.2.1]hept-5-en-3-one, **I-554** (2.8 g, 67% yield) as a yellow oil. MS (ESI, pos. ion) found *m/z*: 154.1 (MH⁺).


20

Step 2: 2-((1*R*,4*S*)-3-oxo-2-azabicyclo[2.2.1]hept-5-en-2-yl)ethyl methanesulfonate(**I-555**)




To a solution of (1*R*,4*S*)-2-(2-hydroxyethyl)-2-azabicyclo[2.2.1]hept-5-en-3-one (2.8 g, 18.3 mmol) in THF (50 mL) was added TEA (5.5 g, 3.0 equiv.) and MsCl (2.08 g, 1.0 equiv.) at 25 °C. The reaction mixture was stirred at 25 °C for 2 hours. When the reaction was deemed complete by LC-MS analysis, the reaction mixture was diluted with water (50 mL), and extracted with EtOAc (50 mL). The organic extract was washed with water (2 x 40 mL), brine (2 x 30 mL) and dried over anhydrous Na₂SO₄, then concentrated to afford the crude mesylate **I-555** (3.0 g, 71% yield) as a yellow solid, which was used for next step without further purification. MS (ESI, neg. ion) *m/z*: 232.0 (M+1).

Step 3: (1*R*,4*S*)-2-(2-aminoethyl)-2-azabicyclo[2.2.1]hept-5-en-3-one (**I-556**).



To a solution of crude mesylate **I-555** (3.0 g, 12.9 mmol) in EtOH (20 mL) was added concentrated aqueous ammonia (25-28% solution, 5 mL), and the reaction mixture was stirred at 100 °C for 1 hour, then concentrated to ca. 5 mL and purified by reversed phase column chromatography (0.1% Formic acid in MeCN/H₂O) to afford the desired amine **I-556** (1.8 g, 95% yield) as a colorless syrup. MS (ESI, pos. ion) *m/z*: 153.1, (MH⁺).


Step 4: 2-((2-oxo-2-((2-((1*R*,4*S*)-3-oxo-2-azabicyclo[2.2.1]hept-5-en-2-yl)ethyl)amino)ethyl)thio)acetic acid. (**I-557**).




To a solution of (1*R*,4*S*)-2-(2-aminoethyl)-2-azabicyclo[2.2.1]hept-5-en-3-one (1.4 g, 9.1 mmol) in DMF (3 mL) was added thiodiglycolic anhydride (2.4 g, 2.0 equiv.), and the reaction mixture was stirred at 40 °C for 12 hours. The reaction mixture was purified by Preparatory HPLC (0.1% Formic acid in MeCN/H₂O) to afford carboxylic acid **I-557** (33.1 mg, 1% yield) as a white solid. MS (ESI, pos. ion) *m/z*: 285.1, (MH⁺). ¹H NMR (400 MHz, D₂O) δ 6.18-6.24 (m, 1H), 6.01-6.05 (m, 1H), 5.59-5.61 (m, 0.5H), 5.25-5.27 (m, 0.5H), 4.17-4.24 (m, 0.5H), 3.89-3.95 (m, 0.5H), 3.56-3.82 (m, 4H), 3.37-3.54 (m, 4H), 2.44-2.61 (m, 2H).

Synthesis of intermediate I-559:

The synthesis of intermediate **I-559** from previously described intermediate **I-556** involved 2 steps as depicted in the following Scheme 163.


**Scheme 163****Summary**

The chemical structure of the target compound was confirmed by ^1H NMR and LC-MS with the purity > 90% (HPLC 214 & 254 nm).

Step 1: (1*S*,4*R*)-2-(2-aminoethyl)-2-azabicyclo[2.2.1]heptan-3-one, I-558

A solution of amine **I-556** (1.0 g, 6.6 mmol) and 10% Pd/C (300 mg) in EtOH (10 mL) was stirred under H_2 (1 atm) at 20 °C for 16 hours.

The reaction mixture was then filtered, and the filtrate was concentrated to afford the amine **I-558** (1.0 g, 98% yield) as a colorless syrup. MS (ESI, pos. ion) m/z : 155.1($M+1$).


Step 2: 2-((2-oxo-2-((1*S*,4*R*)-3-oxo-2-azabicyclo[2.2.1]heptan-2-yl)ethyl)amino)ethyl)thio)acetic acid (I-559).

To a solution of amine **I-558** (1.0 g, 6.6 mmol) in DMF (10 mL) was added thiodiglycolic anhydride (1.7 g, 2.0 equiv.). The reaction mixture was stirred at

40 °C for 36 hours, then purified directly by Preparative HPLC (0.1% TFA in MeCN/ H_2O) to afford carboxylic acid **I-559** (46.1 mg, 3% yield) as a colorless syrup. MS (ESI, pos. ion) m/z : 287.1, (MH^+). ^1H NMR (400 MHz, D_2O) δ 4.06 (s, 1H), 3.46-3.54 (m, 2H), 3.31-3.38 (m, 5H), 3.05-3.11 (m, 1H), 2.82 (s, 1H), 1.94-1.99 (m, 1H), 1.81-1.88 (m, 2H), 1.59-1.65 (m, 1H), 1.34-1.48 (m, 2H).

Synthesis of intermediate I-571:


The synthesis of **I-571** involved 9 steps as described in the following Scheme 164.



Scheme 164


Summary

- 5 The chemical structure of the target compound was confirmed by ^1H NMR and LC-MS with the purity > 95% (HPLC 214 & 254 nm).

Step 1: **1-(chloromethyl)-2,4-dimethoxybenzene. (I-561)**


- To a solution of (2,4-dimethoxyphenyl)methanol, **I-560** (10 g, 59.5 mmol) in Et₂O (100 mL) was added pyridine (4.65 g, 1.0 equiv.), and SOCl₂ (7.02 g, 1.0 equiv.) at 0 °C. The reaction mixture was stirred at 0 °C for 2 hours, then poured into ice water (120 mL) and the layers were separated. The aqueous layer was extracted with diethyl ether (2×60 mL) and the combined organic extracts were washed with ice water (60 mL) and a solution of 5:1 saturated aqueous sodium chloride: saturated aqueous sodium bicarbonate (2×60 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to ~50 mL of solution. The crude solution was used directly in next step.
- 15

Step 2: **Methyl 3-((3,4-dimethylbenzyl)oxy)isoxazole-5-carboxylate (I-563) .**




To a solution of 1-(chloromethyl)-2,4-dimethoxybenzene, **I-561** (20 g, 107 mmol, 5.0 equiv.) in acetone (200 mL) was added methyl 3-hydroxyisoxazole-5-carboxylate, **I-562** (3 g, 21.5 mmol) and K_2CO_3 (8.9 g, 3.0 equiv.). The reaction mixture was stirred at 70 °C for 19 hours. When the reaction was deemed complete by LC-MS analysis, the reaction mixture was concentrated under reduced pressure. The crude product was purified by column chromatography (silica gel, Petroleum/EtOAc=1:1) to afford methyl 3-((3,4-dimethylbenzyl)oxy)isoxazole-5-carboxylate, **I-563** (2.0 g, 32% yield, as a yellow oil).

Step 3: **(3-((3,4-dimethylbenzyl)oxy)isoxazol-5-yl)methanol. (I-564)** .




To a solution of methyl 3-[(3,4-dimethylphenyl)methoxy]-1,2-oxazole-5-carboxylate, **I-563** (1.1 g, 4.2 mmol) in EtOH (10 mL) was added $NaBH_4$ (245 mg, 1.5 equiv.) at 0 °C. The reaction mixture was allowed to warm to 25 °C and stirred for 2 hours. After completion, the reaction mixture was quenched with H_2O (5 mL), and extracted with DCM (20 mL). The organic extract was dried (Na_2SO_4), concentrated under reduced pressure and the residue obtained was purified by silica gel chromatography (Petroleum ether: EtOAc = 1:1) to afford (3-((3,4-dimethylbenzyl)oxy)isoxazol-5-yl)methanol, **I-564** (0.9 g, quantitative yield) as a yellow oil. MS (ESI, pos. ion) m/z: 288.1 (M+Na).

Step 4: **(3-((3,4-dimethylbenzyl)oxy)isoxazol-5-yl)methyl methanesulfonate. (I-565)** .




To a solution of {3-[(3,4-dimethylphenyl)methoxy]-1,2-oxazol-5-yl}methanol, **I-564** (300 mg, 1.287 mmol) in DCM (5 mL) was added $MsCl$ (440 mg, 3.0 equiv.) and TEA (258 mg, 2.0 equiv.) at 0 °C. The reaction mixture was allowed to warm to 25 °C and stirred for 2 hours. After completion, the reaction mixture was quenched with H_2O (15 mL), and extracted with DCM (50 mL). The organic extract was dried (Na_2SO_4), concentrated under reduced pressure and the residue obtained was purified by silica gel chromatography (Petroleum ether: EtOAc=2:1) to afford (3-((3,4-dimethylbenzyl)oxy)isoxazol-5-yl)methyl methane sulfonate, **I-565** (300 mg, 77% yield) as a yellow oil. MS (ESI, pos.ion) m/z: 366.0 (M+ Na).

Step 5: **5-(bromomethyl)-3-((3,4-dimethylbenzyl)oxy)isoxazole. (I-566)** .




To a solution of {3-[(3,4-dimethylphenyl)methoxy]-1,2-oxazol-5-yl}methyl methane sulfonate, **I-565** (2.9 g, 9.3 mmol) in acetone (50 mL) was added LiBr (2.4 g, 3.0 equiv.). The reaction mixture was stirred at 60 °C for 3 hours. When the reaction was deemed complete by LC-MS analysis, the reaction mixture was concentrated under reduced pressure to a residue, which was purified by silica gel column chromatography (DCM: MeOH= 20:1) to afford 5-(bromomethyl)-3-((3,4-dimethylbenzyl)oxy)isoxazole, **I-566** (2.5 g, 90% yield) as a yellow oil. MS (ESI, pos. ion) m/z: 350.0 (M+Na).

Step 6: **3-((3,4-dimethylbenzyl)oxy)-5-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)isoxazole. (I-568)** .



To a solution of (3R)-3-isopropyl-2,5-dimethoxy-3,6-dihydropyrazine, **I-567** (46 mg, CAS:109838-95-9, 0.25 mmol) in THF (5 mL) was added *n*-BuLi (2.5M in hexane, 0.1 ml, 1.0 equiv.) at -78 °C under N₂. After 30 minutes, 5-(bromomethyl)-3-[(3,4-dimethylphenyl)methoxy]-1,2-oxazole, **I-566** (50 mg, 0.7 equiv.) was added. The flask was evacuated and purged again with nitrogen. The resulting mixture was slowly warmed to room temperature over 18 hours. When the reaction was deemed complete by LC-MS analysis, the reaction mixture was quenched with water (2 mL) and extracted with EtOAc (2 × 10 mL). The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (Petroleum:EtOAc = 2:1) to afford 3-((3,4-dimethylbenzyl)oxy)-5-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)isoxazole, **I-568** (20 mg, 30% yield) as a yellow oil. MS (ESI, pos. ion) m/z: 432.2 (MH⁺).

Step 7: **Methyl (S)-2-amino-3-(3-((2,4-dimethoxybenzyl)oxy)isoxazol-5-yl)propanoate (I-569)** .




5

A mixture of (2*S*,5*R*)-2-({3-[(3,4-dimethylphenyl)methoxy]-1,2-oxazol-5-yl}methyl)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine, **I-568** (30 mg, 0.05 mmol) in 1*N* HCl (1 mL) and MeCN (5 mL) was stirred under 30 °C for 3 hours. The solvent

was then removed under reduced pressure to afford the crude methyl (*S*)-2-amino-3-((2,4-dimethoxybenzyl)oxy)isoxazol-5-ylpropanoate, **I-569** (20 mg, 86% yield) as a yellow oil, which was used in the next step without any purification. MS (ESI, pos. ion) *m/z*: 337.1(MH⁺).

10 Step 8: (*S*)-2-amino-3-((2,4-dimethoxybenzyl)oxy)isoxazol-5-ylpropanoic acid. (**I-570**)




15

To a stirred solution of methyl (*S*)-2-amino-3-{3-[(2,4-dimethoxyphenyl)methoxy]-1,2-oxazol-5-yl}propanoate, **I-569** (1.2 g, 3.57 mmol) in MeOH (20 mL) was added LiOH (246 mg, 3.0 equiv.) in H₂O (20 mL) at 0 °C. The reaction mixture was allowed to warm

to room temperature over 2 hours. The reaction mixture was then concentrated to a residue, which was purified by reverse phase HPLC (MeCN/H₂O with 0.5% formic acid) to afford (*S*)-2-amino-3-((2,4-dimethoxybenzyl)oxy)isoxazol-5-ylpropanoic acid, **I-570** (300 mg, 25% yield) as a yellow solid. MS (ESI, pos. ion) *m/z*: 323.1 (MH⁺).

20

Step 8: (*S*)-2-amino-3-((2,4-dimethoxybenzyl)oxy)isoxazol-5-ylpropanoic acid (**I-571**).



25

To a solution of (*S*)-2-amino-3-{3-[(2,4-dimethoxyphenyl)methoxy]-1,2-oxazol-5-yl}propanoic acid, **I-570** (300 mg, 0.93 mmol) in dioxane (10 mL) and H₂O (10 mL) was added Fmoc-OSu (340 mg, 1.3 equiv.) and Na₂CO₃ (197 mg, 2.0 equiv.). The mixture was stirred for 2 hours at 20 °C. When the reaction was deemed

complete by LC-MS analysis, the pH of the reaction mixture was adjusted to 2 using 1*N* HCl. The reaction mixture was then extracted with DCM (30 mL), and the organic extract


30

was dried (Na₂SO₄) and concentrated under reduced pressure. The residue obtained was purified by preparatory TLC (DCM:MeOH=10:1) to afford the desired carboxylic acid, **I-571** (200 mg, 40% yield) as a white solid. MS (ESI, pos. ion) m/z: 545.2 (MH⁺).

¹H NMR (400 MHz, DMSO-*d*₆) δ = 7.89 (d, J=7.5, 2H), 7.65 (d, J=4.5, 2H), 7.41 (t, J=7.4, 2H), 7.37 – 7.23 (m, 2H), 6.97 (d, J=8.4, 1H), 6.53 (d, J=2.1, 1H), 6.41 (dd, J=8.3, 2.3, 1H), 5.56 (s, 1H), 4.76 (s, 2H), 4.21 (dd, J=15.1, 8.1, 3H), 3.86 (s, 1H), 3.74 (s, 3H), 3.69 (s, 3H), 2.96 (d, J=11.9, 1H), 2.84 (d, J=6.9, 1H).


D2. Additional Examples of Compounds Described in This Invention

Example 197: Compound 197




Peptide **E-197** was prepared from 31.7 mg of the corresponding sequence immobilized on Rink amide resin (estimated loading 0.19 mmol/g) using **I-34** and **GP5** to afford 1.0 mg of **E-197** as a white solid. ESI-MS found 1160.8, C₂₁₄H₃₂₇S₂N₄₇O₆₄ (M+4H)⁴⁺ requires 1160.8.

Example 198: Compound 198




Peptide **E-198** was prepared from 64.4 mg of the corresponding sequence immobilized on Rink amide resin (estimated loading 0.11 mmol/g) using **I-9** and **GP4** to afford 3.2 mg of **E-198** as a white solid. ESI-MS found 1613.4, C₂₂₀H₃₃₅S₂N₅₂O₆₇ (M+3H)³⁺ requires 1613.8.

Example 199: Compound 199




Peptide **E-199** was prepared from 138.8 mg of the corresponding sequence immobilized on chlorotrityl resin (estimated loading 0.18 mmol/g) using **I-9** and **GP4** to afford 6.5 mg of **E-199** as a white solid. ESI-MS found 1542.9, $C_{212}H_{319}S_2N_{46}O_{66}$ ($M+3H$)³⁺ requires 1543.1.

Example 200: Compound 200




Peptide **E-200** was prepared from 158 mg of the corresponding sequence immobilized on Rink amide resin (estimated loading 0.16 mmol/g) using **I-9** and **GP4** to afford 12 mg of **E-200** as a white solid. ESI-MS found 1556.2, $C_{214}H_{325}S_2N_{48}O_{65}$ ($M+3H$)³⁺ requires 1557.1.

Example 201: Compound 201




Peptide **E-201** was prepared from 184 mg of the corresponding sequence immobilized on Rink amide resin (estimated loading 0.16 mmol/g) using **I-9** and **GP4** to afford 14 mg of **E-201** as a white solid. ESI-MS found 1532.4, $C_{209}H_{323}S_2N_{48}O_{64}$ ($M+3H$)³⁺ requires 1531.1.

Example 202: Compound 202




Peptide **E-202** was prepared from 30 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-443** (*absolute configuration arbitrarily assigned) and **GP4** to afford 1.9 mg of **E-202** as a white solid. ESI-MS found 1157.3, $C_{214}H_{327}SN_{47}O_{65}$ ($M+4H$)⁴⁺ requires 1156.8.

Example 203: Compound 203




Peptide **E-203** was prepared from 30 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-439** (*absolute configuration arbitrarily assigned) and **GP4** to afford 1.2 mg of **E-203** as a white solid. ESI-MS found 1157.2, $C_{214}H_{327}SN_{47}O_{65}$ ($M+4H$)⁴⁺ requires 1156.8.

Example 204: Compound 204




Peptide **E-204** was prepared from 39.6 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-430** and **GP4** to afford 3.2 mg of **E-204** as a white solid. ESI-MS found 1152.3, $C_{216}H_{331}N_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1151.8.

Example 205: Compound 208




Peptide **E-205** was prepared from 46.6 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-451** and **GP4** to afford 6.4 mg of **E-205** as a white solid. ESI-MS found 1156.9, $C_{215}H_{329}SN_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1156.3.

Example 206: Compound 207




Peptide **E-206** was prepared from 44.4 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-454** and **GP4** to afford 5.9 mg of **E-206** as a white solid. ESI-MS found 1156.9, $C_{215}H_{329}SN_{47}O_{64} (M+4H)^{4+}$ requires 1156.3.

5 Example 207: Compound 205




Peptide **E-207** was prepared from 37 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-458** and **GP4** to afford 4.8 mg of **E-207** as a white solid. ESI-MS found 1141.8, $C_{213}H_{325}N_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1141.3.

10 **Example 208: Compound 206**




Peptide **E-208** was prepared from 40.4 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-461** and **GP4** to afford 7 mg of **E-208** as a white solid. ESI-MS found 1145.3, $C_{214}H_{327}N_{47}O_{64} (M+4H)^{4+}$ requires 1144.8.


15 **Example 209: Compound 209**




Peptide **E-209** was prepared from 44.2 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-464** and **GP4** to afford 2.2 mg of **E-209** as a white solid. ESI-MS found 1145.3, $C_{214}H_{327}N_{47}O_{64} (M+4H)^{4+}$ requires 1144.8.

Example 210: Compound 210


Peptide **E-210** was prepared from 43.2 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-466** and **GP4** to afford 1.5 mg of **E-210** as a white solid. ESI-MS found 1148.9,
5 $C_{215}H_{329}N_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1148.3.

Example 211: Compound 211

Peptide **E-211** was prepared from 48.2 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-469** and **GP4** to afford 1.5 mg of **E-211** as a white solid. ESI-MS found 1141.8,
10 $C_{213}H_{325}N_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1141.3.


Example 212: Compound 212

Peptide **E-212** was prepared from 44.2 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-471** and **GP4** to afford 3.8 mg of **E-212** as a white solid. ESI-MS found 1145.3,
15 $C_{214}H_{327}N_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1144.8.

Example 213: Compound 213

Peptide **E-213** was prepared from 44.1 mg of resin **R-1** (estimated loading 0.18 mmol/g) using **I-474** and **GP4** to afford 4.3 mg of **E-213** as a white solid. ESI-MS found 1141.9, $C_{213}H_{325}N_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1141.3.

Example 214: Compound 214




5

Peptide **E-214** was prepared from 45.9 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-476** and **GP4** to afford 3.0 mg of **E-214** as a white solid. ESI-MS found 1145.4, $C_{214}H_{327}N_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1144.8.

Example 215: Compound 217

10 The synthesis of example **E-215** is depicted in Scheme 167:




Scheme 167

15 To Rink amide resin **R-3** (0.17 mmol/g, 60 mg, 0.01 mmol) in a 3 mL polypropylene tube with an end-cap was added 20% v/v piperidine/DMF (2 mL). The tube was capped, agitated at ambient temperature for 20 minutes, and then drained. The resin was washed with DMF (5 x 3 mL). A solution of carboxylic acid **I-519** (25.2 mg, 6.0 equiv.) in DMF

(1.2 mL) was added, followed by DIPEA (27 μ L, 15.0 equiv.) and HATU (34.9 mg, 9.0 equiv.). The reaction mixture was agitated at ambient temperature for 5 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL).

20% v/v piperidine/DMF (2 mL) was added to the resin. The tube was capped, agitated at ambient temperature for 20 minutes, and then drained. The resin was washed with DMF (5 x 3 mL). A solution of carboxylic acid **I-248** (16.7 mg, 6.0 equiv.) in DMF (1.2 mL) was added, followed by DIPEA (27 μ L, 15.0 equiv.) and HATU (34.9 mg, 9.0 equiv.). The reaction mixture was agitated at ambient temperature for 16 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL). The peptide was cleaved from the resin using 1 mL of cleavage reagent (88:2:5:5 v/v/v/v TFA/TIS/PhOH/H₂O) for 1 hour. The resin was filtered and washed with TFA (2 x 0.5 mL). The combined filtrate and washes were concentrated under reduced pressure to afford a residue, which was triturated with Et₂O (2 mL) to precipitate the peptide. The peptide was re-dissolved in glacial AcOH (1.2 mL) and purified by preparative HPLC (Phenomenex Jupiter 10 μ M Proteo 90 Å LC column, 250 x 21.2 mm, with flow rate – 15 mL/min, gradient of 0—100% acetonitrile in 25 mM aqueous ammonium acetate over 30 minutes) to afford 2.7 mg of **E-215** as a white solid. ESI-MS found 1149.8, C₂₁₃H₃₂₅N₄₇O₆₄ (M+4H)⁴⁺ requires 1149.3.


Example 216: Compound 226



Peptide **E-216** was prepared from 50 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-478** and **GP4** to afford 4.2 mg of **E-216** as a white solid. ESI-MS found 1153.4, C₂₁₄H₃₂₇N₄₇O₆₄ (M+4H)⁴⁺ requires 1152.8.

Example 217: Compound 219

The synthesis of example **E-217** is depicted in Scheme 168:




Scheme 168

- To Rink amide resin **R-3** (0.17 mmol/g, 62.5 mg, 0.011 mmol) in a 3 mL polypropylene tube with an end-cap was added 20% v/v piperidine/DMF (2 mL). The tube was capped, agitated at ambient temperature for 20 minutes, and then drained. The resin was washed with DMF (5 x 3 mL). A solution of carboxylic acid **I-520** (28 mg, 6.0 equiv.) in DMF (1.2 mL) was added, followed by DIPEA (28 μ L, 15.0 equiv.) and HATU (36.3 mg, 9.0 equiv.). The reaction mixture was agitated at ambient temperature for 4 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL).
- 20% v/v piperidine/DMF (2 mL) was added to the resin. The tube was capped, agitated at ambient temperature for 20 minutes, and then drained. The resin was washed with DMF (5 x 3 mL). A solution of carboxylic acid **I-248** (17.5 mg, 6.0 equiv.) in DMF (1.2 mL) was added, followed by DIPEA (28 μ L, 15.0 equiv.) and HATU (36.3 mg, 9.0 equiv.). The reaction mixture was agitated at ambient temperature for 5 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL). The peptide was cleaved from the resin using 1 mL of cleavage reagent (88:2:5:5 v/v/v/v TFA/TIS/PhOH/H₂O) for 1 hour. The resin was filtered and washed with TFA (2 x 0.5 mL). The combined filtrate and washes were concentrated under reduced pressure to afford a residue, which was triturated with Et₂O (2 mL) to precipitate the peptide. The peptide was re-dissolved in glacial AcOH (1.2 mL) and purified by preparative HPLC (Phenomenex Jupiter 10 μ M Proteo 90 Å LC column, 250 x 21.2 mm, with flow rate – 15

mL/min, gradient of 0—100% acetonitrile in 25 mM aqueous ammonium acetate over 30 minutes) to afford 2.5 mg of **E-217** as a white solid. ESI-MS found 1156.8, $C_{215}H_{329}SN_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1156.3.

Example 218: Compound 223

- 5 The synthesis of example **E-218** is depicted in Scheme 169:




Scheme 169

- To Rink amide resin **R-3** (0.17 mmol/g, 61.4 mg, 0.01 mmol) in a 3 mL polypropylene tube with an end-cap was added 20% v/v piperidine/DMF (2 mL). The tube was capped, agitated at ambient temperature for 20 minutes, and then drained. The resin was washed with DMF (5 x 3 mL). A solution of carboxylic acid **I-521** (23.8 mg, 6.0 equiv.) in DMF (1.2 mL) was added, followed by DIPEA (27 μ L, 15.0 equiv.) and HATU (35.6 mg, 9.0 equiv.). The reaction mixture was agitated at ambient temperature for 4 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL).
- 20% v/v piperidine/DMF (2 mL) was added to the resin. The tube was capped, agitated at ambient temperature for 20 minutes, and then drained. The resin was washed with DMF (5 x 3 mL). A solution of carboxylic acid **I-248** (17.2 mg, 6.0 equiv.) in DMF (1.2 mL) was added, followed by DIPEA (27 μ L, 15.0 equiv.) and HATU (35.6 mg, 9.0 equiv.). The reaction mixture was agitated at ambient temperature for 5 hours, then drained and the resin

was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL). The peptide was cleaved from the resin using 1 mL of cleavage reagent (88:2:5:5 v/v/v/v TFA/TIS/PhOH/H₂O) for 1 hour. The resin was filtered and washed with TFA (2 x 0.5 mL). The combined filtrate and washes were concentrated under reduced pressure to afford a residue, which was triturated with Et₂O (2 mL) to precipitate the peptide. The peptide was re-dissolved in glacial AcOH (1.2 mL) and purified by preparative HPLC (Phenomenex Jupiter 10 μM Proteo 90 Å LC column, 250 x 21.2 mm, with flow rate – 15 mL/min, gradient of 0—100% acetonitrile in 25 mM aqueous ammonium acetate over 30 minutes) to afford 1.7 mg of **E-218** as a white solid. ESI-MS found 1155.8, C₂₁₃H₃₂₅SN₅₁O₆₂ (M+4H)⁴⁺ requires 1155.3.

Example 219: Compound 218

The synthesis of example **E-219** is depicted in Scheme 170:




Scheme 170

Fmoc cleavage from Rink amide resin **R-3** (0.17 mmol/g, 66.7 mg, 0.011 mmol) was performed as described in **example 218**. A solution of Fmoc-D-Asp(OtBu)-OH (28 mg, 6.0 equiv.) in DMF (1.2 mL) was added, followed by DIPEA (30 μL, 15.0 equiv.) and HATU (38.8 mg, 9.0 equiv.). The reaction mixture was agitated at ambient temperature for 4 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3

- mL). After further Fmoc cleavage, A solution of carboxylic acid **I-248** (18.7 mg, 6.0 equiv.) in DMF (1.2 mL) was added, followed by DIPEA (28 μ L, 15.0 equiv.) and HATU (38.8 mg, 9.0 equiv.). The reaction mixture was agitated at ambient temperature for 5 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL).
- 5 The peptide was cleaved from the resin and purified as described in **example 218** to afford 4.3 mg of **E-219** as a white solid. ESI-MS found 1149.8, $C_{213}H_{325}SN_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1149.3.

Example 220: Compound 221

The synthesis of example **E-220** is depicted in Scheme 171:



10


Scheme 171

- Fmoc cleavage from Rink amide resin **R-3** (0.17 mmol/g, 65.5 mg, 0.011 mmol) was performed as described in **example 218**. A solution of carboxylic acid **I-522** (42.5 mg, 6.0 equiv.) in DMF (1.2 mL) was added, followed by DIPEA (29 μ L, 15.0 equiv.) and HATU (38 mg, 9.0 equiv.). The reaction mixture was agitated at ambient temperature for 4 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL). After further Fmoc cleavage, a solution of carboxylic acid **I-248** (18.3 mg, 6.0 equiv.) in DMF
- 15

(1.2 mL) was added, followed by DIPEA (29 μ L, 15.0 equiv.) and HATU (38 mg, 9.0 equiv.). The reaction mixture was agitated at ambient temperature for 5 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL). The peptide was cleaved from the resin and purified as described in **example 218** to afford 2.0 mg of **E-220** as a white solid. ESI-MS found 1159.3, $C_{214}H_{327}SN_{51}O_{62}$ ($M+4H$)⁴⁺ requires 1158.8.

Example 221: Compound 222

The synthesis of example **E-221** is depicted in Scheme 172:




Scheme 172

Fmoc cleavage from Rink amide resin **R-3** (0.17 mmol/g, 64.8 mg, 0.011 mmol) was performed as described in **example 218**. A solution of carboxylic acid **I-523** (26 mg, 6.0 equiv.) in DMF (1.2 mL) was added, followed by DIPEA (29 μ L, 15.0 equiv.) and HATU (37.6 mg, 9.0 equiv.). The reaction mixture was agitated at ambient temperature for 4 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL). After further Fmoc cleavage, a solution of carboxylic acid **I-248** (18.1 mg, 6.0 equiv.) in DMF (1.2 mL) was added, followed by DIPEA (29 μ L, 15.0 equiv.) and HATU (37.6 mg, 9.0 equiv.). The reaction mixture was agitated at ambient temperature for 5 hours, then

drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL). The peptide was cleaved from the resin and purified as described in **example 218** to afford 1.4 mg of **E-221** as a white solid. ESI-MS found 1159.4, $C_{214}H_{327}SN_{51}O_{62}$ ($M+4H$)⁴⁺ requires 1158.8.

Example 222: Compound 224

- 5 The synthesis of example **E-222** is depicted in Scheme 173:




Scheme 173

- 10 Fmoc cleavage from Rink amide resin **R-3** (0.17 mmol/g, 62.8 mg, 0.011 mmol) was performed as described in **example 218**. A solution of carboxylic acid **I-524** (24.3 mg, 6.0 equiv.) in DMF (1.2 mL) was added, followed by DIPEA (29 μ L, 15.0 equiv.) and HATU (36.6 mg, 9.0 equiv.). The reaction mixture was agitated at ambient temperature for 4 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x
- 15 3 mL). After further Fmoc cleavage, a solution of carboxylic acid **I-248** (17.6 mg, 6.0 equiv.) in DMF (1.2 mL) was added, followed by DIPEA (29 μ L, 15.0 equiv.) and HATU (36.6 mg, 9.0 equiv.). The reaction mixture was agitated at ambient temperature

for 5 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL). The peptide was cleaved from the resin and purified as described in **example 218** to afford 2.5 mg of **E-222** as a white solid. ESI-MS found 1155.9, $C_{213}H_{325}SN_{51}O_{62}$ ($M+4H$)⁴⁺ requires 1155.3.


5 **Example 228: Compound 232**



Peptide **E-228** was prepared from 44.5 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-486** and **GP4** to afford 4.8 mg of **E-228** as a white solid. ESI-MS found 1155.8, $C_{215}H_{325}SN_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1155.3.

10 **Example 229: Compound 233**

The synthesis of example **E-229** is depicted in Scheme 179:



Scheme 179


15 Fmoc cleavage from Rink amide resin **R-1** (estimated loading 0.125 mmol/g, 121.6 mg, 0.015 mmol) was performed as described in **example 218**. A solution of Fmoc-β-Ala-OH (28.4 mg, 6.0 equiv.) in DMF (3 mL) was added, followed by DIPEA (40 μL, 15.0 equiv.) and HATU (52 mg, 9.0 equiv.). The reaction mixture was agitated at ambient temperature

for 2 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL) and dried *in vacuo* to afford resin **R-4**.

Resin **R-4** (49.3 mg, estimated loading 0.125 mmol/g, 6.2 μ mol) was subjected to Fmoc cleavage as described above, and a solution of carboxylic acid **I-528** (6 mg, 6.0 equiv.) in DMF (1.2 mL) was added, followed by DIPEA (16 μ L, 15.0 equiv.) and HATU (21 mg, 9.0 equiv.). The reaction mixture was agitated at ambient temperature for 16 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL) and dried *in vacuo*. The peptide was cleaved from the resin and purified as described in **example 218** to afford 5.6 mg of Peptide **E-229** as a white solid. ESI-MS found 1142.3, $C_{212}H_{323}N_{47}O_{65}$ ($M+4H$)⁴⁺ requires 1141.8.

Example 230: Compound 234


The synthesis of example **E-230** is depicted in Scheme 180:



Scheme 180

Resin **R-4** (52.2 mg, estimated loading 0.125 mmol/g, 6.5 μ mol) was subjected to Fmoc cleavage as described in **example 218**, and a solution of carboxylic acid **I-529** (6 mg, 6.0 equiv.) in DMF (1.2 mL) was added, followed by DIPEA (17 μ L, 15.0 equiv.) and HATU (22 mg, 9.0 equiv.). The reaction mixture was agitated at ambient temperature for 16 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL) and dried *in vacuo*. The peptide was cleaved from the resin and purified as described in **example 218** to afford 4.3 mg of **E-230** as a white solid. ESI-MS found 1140.8, $C_{213}H_{321}N_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1140.3.


Example 234: Compound 238



Peptide **E-234** was prepared from 46.2 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-498** and **GP4** to afford 6.1 mg of **E-234** as a white solid. ESI-MS found 1155.8, $C_{215}H_{325}SN_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1155.3.

5 Example 235: Compound 239

The synthesis of example **E-235** is depicted in Scheme 184:




Scheme 184

Fmoc deprotection of resin **R-1** (111.9 mg, estimated loading 0.125 mmol/g, 0.014 mmol) was carried out as described in **example 218**, then a solution of thiodiglycolic anhydride (14.8 mg, 8.0 equiv.) in DMF (1.2 mL) was added and the reaction mixture was agitated for 6 hours at ambient temperature. The solution was drained and the resin was washed with DMF (5x) and DCM (5x) and dried *in vacuo* to afford resin **R-5**.

To resin **R-5** (40.5 mg, estimated loading 0.125 mmol/g, 5.1 μ mol) was added a solution of amine hydrochloride **I-532** (7.8 mg, 8.0 equiv.) and DIPEA (18 μ L, 20.0 equiv.) in DMF (1.2 mL), followed by HATU (15.4 mg, 8.0 equiv.). The reaction mixture was agitated at ambient temperature for 5 hours, then the solution was drained and the resin was washed with DMF (5x) and DCM (5x) and dried *in vacuo*. The peptide was cleaved from resin and purified as described in **example 218** to afford 1.7 mg of peptide **E-235** as a white solid. ESI-MS found 1156.0, $C_{213}H_{322}SN_{48}O_{65}$ ($M+4H$)⁴⁺ requires 1156.1.


Example 236: Compound 240



Peptide **E-236** was prepared from 42.2 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-490** and **GP4** to afford 2.7 mg of **E-236** as a white solid. ESI-MS found 1155.3, $C_{215}H_{325}SN_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1155.3.


5 **Example 237: Compound 241**

The synthesis of example **E-237** is depicted in Scheme 185:




To resin **R-5** (41.3 mg, estimated loading 0.125 mmol/g, 5.2 μ mol) was added a solution of amine hydrochloride **I-533** (7.9 mg, 8.0 equiv.) and DIPEA (18 μ L, 20.0 equiv.) in DMF (1.2 mL), followed by HATU (15.7 mg, 8.0 equiv.). The reaction mixture was agitated at ambient temperature for 3.5 hours, then the solution was drained and the resin was washed with DMF (5x) and DCM (5x) and dried *in vacuo*. The peptide was cleaved from resin and purified as described in **example 218** to afford 2.3 mg of peptide **E-237** as a white solid. ESI-MS found 1156.0, $C_{213}H_{322}SN_{48}O_{65}$ ($M+4H$)⁴⁺ requires 1156.1.


15 **Example 239: Compound 215**




Peptide **E-239** was prepared from 49.5 mg of resin (estimated loading 0.125 mmol/g) using **I-505** and **GP4** to afford 5.3 mg of **E-239** as a white solid. ESI-MS found 1137.7, $C_{212}H_{323}N_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1137.8.

Example 240: Compound 243


Peptide **E-240** was prepared from 47.1 mg of resin (estimated loading 0.125 mmol/g) using **I-507** and **GP4** to afford 5.0 mg of **E-240** as a white solid. ESI-MS found 1148.7, $C_{214}H_{327}N_{47}O_{65}$ ($M+4H$)⁴⁺ requires 1148.8.

Example 241: Compound 244

Peptide **E-241** was prepared from 53.3 mg of resin (estimated loading 0.125 mmol/g) using **I-508** and **GP4** to afford 3.7 mg of **E-241** as a white solid. ESI-MS found 1152.3, $C_{215}H_{329}N_{47}O_{65}$ ($M+4H$)⁴⁺ requires 1152.3.


Example 244: Compound 247

Peptide **E-244** was prepared from 47.8 mg of resin (estimated loading 0.125 mmol/g) using **I-122** and **GP5** to afford 7.0 mg of **E-244** as a white solid. ESI-MS found 1168.2, $C_{218}H_{325}SN_{47}O_{65}$ ($M+4H$)⁴⁺ requires 1168.3

Example 245: Compound 248

Peptide **E-245** was prepared from 44.3 mg of resin (estimated loading 0.125 mmol/g) using **I-126** and **GP5** to afford 3.3 mg of **E-245** as a white solid. ESI-MS found 1177.3, $C_{221}H_{325}SN_{47}O_{65}$ ($M+4H$)⁴⁺ requires 1177.3.

Example 246: Compound 249




E-246

5

Peptide **E-246** was prepared from 21.2 mg of resin (estimated loading 0.125 mmol/g) using **I-137** and **GP5** to afford 1.5 mg of **E-246** as a white solid. ESI-MS found 1177.3, $C_{221}H_{325}SN_{47}O_{65}$ ($M+4H$)⁴⁺ requires 1177.3.

Example 251: Compound 220

10 The synthesis of example **E-251** is depicted in Scheme 190:




Scheme 190

Fmoc cleavage from Rink amide resin **R-3** (0.18 mmol/g, 51.5 mg, 0.009 mmol) was performed as described in **example 218**. A solution of carboxylic acid **I-538** (24.4 mg, 6.0 equiv., *absolute configuration not established) in 20% Collidine/DMF (1.5 mL) was added, followed by HATU (19.4 mg, 5.5 equiv.). The reaction mixture was agitated at ambient temperature for 16 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL). After further Fmoc cleavage, a solution of carboxylic acid **I-248** (15.3 mg, 6.0 equiv.) in 20% Collidine/DMF (1.5 mL) was added, followed by HATU (19.4 mg, 5.5 equiv.). The reaction mixture was agitated at ambient temperature for 16 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL). The peptide was cleaved from the resin and purified as described in **example 218** to afford 3.6 mg of **E-251** as a white solid. ESI-MS found 1156.8, $C_{215}H_{329}SN_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1156.3.


Example 252: Compound 254

The synthesis of example **E-252** is depicted in Scheme 191:




Scheme 191


Fmoc cleavage from resin **R-1** (estimated loading 0.125 mmol/g, 42 mg, 5.3 μ mol) was performed as described in **example 218**. A solution of carboxylic acid **I-513** (8 mg, 6.0 equiv.) in DMF (1.3 mL) was then added to the resin, followed by DIPEA (14 μ L, 15.0 equiv.) and PyAOP (19.2 mg, 7.0 equiv.). The reaction mixture was agitated at ambient temperature for 20 hours and then the resin was drained and washed with DMF (5x), DCM (5x) and dried *in vacuo*. Cleavage of the peptide from resin and purification was performed as described for **example 218** to afford 4.0 mg of **E-252** as a white solid. ESI-MS found 1147.8, $C_{215}H_{325}N_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1147.3.

Example 255: Compound 257

Peptide **E-255** was prepared from 49.7 mg of resin (estimated loading 0.125 mmol/g) using **I-510** as described for **example 252** (coupling time: 5 hours) to afford 5.7 mg of **E-255** as a white solid. ESI-MS found 1149.4, $C_{214}H_{327}N_{47}O_{65}$ ($M+4H$)⁴⁺ requires 1148.8.


Example 258: Compound 260**Scheme 195**

Fmoc cleavage from resin **R-1** (estimated loading 0.125 mmol/g, 46.2 mg, 5.8 μ mol) was performed as described in **example 218**. A solution of carboxylic acid **I-517** (11.2 mg, 6.0 equiv.) in DMF (1.3 mL) was then added to the resin, followed by DIPEA (15 μ L, 15.0 equiv.) and HATU (12.1 mg, 5.5 equiv.). The reaction mixture was agitated at ambient temperature for 2 hours and then the resin was drained and washed with DMF (5x), DCM (5x) and dried *in vacuo*. Cleavage of the peptide from resin and purification was performed as described for **example 218** to afford 3.9 mg of **E-258** as a white solid. ESI-MS found 1165.4, $C_{218}H_{327}SN_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1164.8.

Example 262: Compound 264**Scheme 199**

Resin **R-4** (39.3 mg, estimated loading 0.125 mmol/g, 4.9 μ mol) was subjected to Fmoc cleavage as described in **example 218**, and a solution of carboxylic acid **I-541** (4.2 mg, 6.0 equiv.) in 20% Collidine/DMF (1.3 mL) was added, followed by HATU (10.3 mg, 5.5 equiv.). The reaction mixture was agitated at ambient temperature for 5 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL) and dried *in vacuo*. The peptide was cleaved from the resin and purified as described in **example 218** to afford 6.5 mg of **E-262** as a white solid. ESI-MS found 1138.4, $C_{212}H_{323}N_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1137.8.


Example 263: Compound 265



Scheme 200

Resin **R-4** (40.7 mg, estimated loading 0.125 mmol/g, 5.1 μ mol) was subjected to Fmoc cleavage as described in **example 218**, and a solution of carboxylic acid **I-542** (9.2 mg, 11.5 equiv.) in 20% Collidine/DMF (1.3 mL) was added, followed by HATU (10.3 mg, 5.5 equiv.). The reaction mixture was agitated at ambient temperature for 19 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL) and dried *in vacuo*. The peptide was cleaved from the resin and purified as described in **example 218** to afford 5.0 mg of **E-263** as a white solid. ESI-MS found 1141.8, $C_{213}H_{325}N_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1141.3.


Example 264: Compound 266



Scheme 201

Resin **R-4** (43 mg, estimated loading 0.125 mmol/g, 5.4 μ mol) was subjected to Fmoc cleavage as described in **example 218**, and a solution of carboxylic acid **I-543** (8.2 mg, 8.9 equiv.) in 20% Collidine/DMF (1.3 mL) was added, followed by HATU (11.2 mg, 5.5 equiv.). The reaction mixture was agitated at ambient temperature for 19 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL) and dried *in vacuo*. The peptide was cleaved from the resin and purified as described in **example 218** to afford 4.3 mg of **E-264** as a white solid. ESI-MS found 1145.3, $C_{214}H_{327}N_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1144.8.


Example 265: Compound 267



Scheme 202


Resin **R-4** (36.6 mg, estimated loading 0.125 mmol/g, 4.6 μ mol) was subjected to Fmoc cleavage as described in **example 218**, and a solution of carboxylic acid **I-544** (7.3 mg, 8.6 equiv.) in 20% Collidine/DMF (1.3 mL) was added, followed by HATU (9.6 mg, 5.5 equiv.). The reaction mixture was agitated at ambient temperature for 19 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL) and dried *in vacuo*. The peptide was cleaved from the resin and purified as described in **example 218** to afford 4.4 mg of **E-265** as a white solid. ESI-MS found 1148.9, $C_{215}H_{329}N_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1148.3.

Example 268: Compound 270



Peptide **E-268** was prepared from 55.1 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-518** as described in **example 252** to afford 5.7 mg of **E-268** as a white solid. ESI-MS found 1165.4, $C_{218}H_{327}SN_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1164.8.


Example 283: Compound 225



5


Peptide **E-283** was prepared from 102 mg of the corresponding sequence immobilized on Rink amide resin (estimated loading 0.19 mmol/g) using **I-248** and **GP4** to afford 6.6 mg of **E-283** as a white solid. ESI-MS found 1156.8, $C_{215}H_{329}SN_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1156.3.

10 **Example 284: Compound 285**




Peptide **E-284** was prepared from 50.2 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-494** and **GP4** to afford 5.1 mg of **E-284** as a white solid. ESI-MS found 1155.8, $C_{215}H_{325}SN_{47}O_{64}$ ($M+4H$)⁴⁺ requires 1155.3.

15 **Example 288: Compound 289**




Peptide **E-288** was prepared from 72.4 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-552** as described in **example 254** to afford 7.5 mg of **E-288** as a white solid. ESI-MS found 1156.4, $C_{215}H_{327}N_{47}O_{64}S$ ($M+4H$)⁴⁺ requires 1155.8.

20 **Example 289: Compound 290**



Peptide **E-289** was prepared from 65.4 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-557** as described in **example 254** to afford 9.3 mg of **E-289** as a white solid. ESI-MS found 1155.8, C₂₁₅H₃₂₅N₄₇O₆₄S (M+4H)⁴⁺ requires 1155.3.


5 Example 290: Compound 291



Peptide **E-290** was prepared from 70.7 mg of resin **R-1** (estimated loading 0.125 mmol/g) using **I-559** as described in **example 254** to afford 4.8 mg of **E-290** as a white solid. ESI-MS found 1156.4, C₂₁₅H₃₂₇N₄₇O₆₄S (M+4H)⁴⁺ requires 1155.8.

10 **Example 291: Compound 292**

The synthesis of example **E-291** is depicted in Scheme 208:



Scheme 208

Fmoc cleavage from Rink amide resin **R-3** (0.19 mmol/g, 79.1 mg, 0.015 mmol) was performed as described in **example 218**. A solution of carboxylic acid **I-571** (49 mg, 6.0 equiv.) in 20% Collidine/DMF (1.5 mL) was added, followed by HATU (31.4 mg, 5.5 equiv.). The reaction mixture was agitated at ambient temperature for 14.5 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL). After further Fmoc cleavage, a solution of carboxylic acid **I-248** (24.7 mg, 6.0 equiv.) in 20% Collidine/DMF (1.5 mL) was added, followed by HATU (31.4 mg, 5.5 equiv.). The reaction mixture was agitated at ambient temperature for 6.5 hours, then drained and the resin was washed with DMF (5 x 3 mL) and DCM (5 x 3 mL). The peptide was cleaved from the resin and purified as described in **example 218** to afford 5.3 mg of **E-291** as a white solid. ESI-MS found 1159.4, $C_{215}H_{326}SN_{48}O_{64}$ ($M+4H$)⁴⁺ requires 1159.1.

E. Biological Assays

a) HitHunter cAMP Assay

Suspension cells were harvested and resuspended in 1X HBSS (+10mM HEPES, 625μM IBMX, 0.2%BSA) according to the following procedure: 5uL of 2X cell suspension + 1X antibody were added to each well, where the optimal cell density was 10,000 cells per well in a low volume 384-well plate. Agonist serial dilutions in a separate

384 well dilution plate in a 22-point series of 2X dilutions of agonist in DMSO were performed as follows. 80 μ L of the highest concentration of Agonist/DMSO was added to well No. 1. 40 μ L was removed from well No. 1 and added it to well No. 2, followed by gentle mixing. 40 μ L was removed from well No. 2 and added it to well No. 3, followed by gentle mixing. This process was repeated until well No. 22. Additional serial dilutions for additional agonists were set up in a similar manner. 50nL of each 2X agonist serial dilution was added in duplicate to the designated agonist rows of the assay plate using the Labcyte ECHO. Assay plate was incubated for 30 minutes at room temperature. Following agonist incubation, 5 μ L of cAMP Antibody Reagent was added to all wells. A stock of cAMP Working Detection Solution in a separate 15 ml polypropylene tube was prepared by mixing 19 parts of cAMP Lysis Buffer, 5 parts of Substrate Reagent 1, 1 part Substrate Reagent 2, and 25 parts of cAMP Solution D. 5 μ L of cAMP Working Detection Solution was added to all wells of the assay plate [Note: *Do not* pipette up and down in the vial to mix or vortex plates]. Plates were spun down briefly. Assay plate was incubated for 1 hour at room temperature in the dark for the immunocompetition reaction to occur. 5 μ L of cAMP Solution A was added to all wells of the assay plate [Note: *Do not* pipette up and down in the vial to mix or vortex plates]. Plates were spun down briefly. Assay plate was incubated O/N at room temperature in the dark. Samples were read on Tecan i-control plate reader using luminescence mode with 300ms integration time. Data analysis was performed using GraphPad Prism. Results of the HitHunter cAMP assay are presented in **Table 3** and **Table 3A**.

Note:

- In table 3 “+++++” denotes $EC_{50} < 0.1$ nM; “++++” denotes 0.1 nM $\leq EC_{50} < 1$ nM; “+++” denotes 1 nM $\leq EC_{50} < 10$ nM; “++” denotes 10 nM $\leq EC_{50} < 100$ nM; “+” denotes 100 nM $\leq EC_{50} \leq 1000$ nM; and “-” denotes $EC_{50} > 1000$ nM.
- In table 3A, for GLP-1R data: “+++++” denotes $EC_{50} < 0.1$ nM; “++++” denotes 0.1 nM $\leq EC_{50} < 1$ nM; “+++” denotes 1 nM $\leq EC_{50} < 10$ nM; “++” denotes 10 nM $\leq EC_{50} < 100$ nM; “+” denotes 100 nM $\leq EC_{50} \leq 1000$ nM; and “-” denotes $EC_{50} > 1000$ nM.

- In table 3A, for GIP-R data: “+++++” denotes $EC_{50} < 0.1 \text{ nM}$; “++++” denotes $0.1 \text{ nM} \leq EC_{50} < 1 \text{ nM}$; “+++” denotes $1 \text{ nM} \leq EC_{50} < 10 \text{ nM}$; “++” denotes $10 \text{ nM} \leq EC_{50} < 100 \text{ nM}$ or $E_{\text{max}} < 30\%$; “+” denotes $100 \text{ nM} \leq EC_{50} \leq 1000 \text{ nM}$ or $E_{\text{max}} < 20\%$; and “-” denotes $EC_{50} > 1000 \text{ nM}$ or $E_{\text{max}} < 10\%$.

5

Table 3

Compound #	$EC_{50}(E_{\text{max}})$ GLP-1R/nM	$EC_{50}(E_{\text{max}})$ GIP-R/nM	Compound #	$EC_{50}(E_{\text{max}})$ GLP-1R/nM	$EC_{50}(E_{\text{max}})$ GIP-R/nM
1	++++ (97)	+++ (23)	99	+++ (102)	- (11 at 1 μM)
2	+++++ (99)	+++ (46)	100	++ (95)	+++ (100)
3	++++ (96)	-	101	++ (92)	-
4	+++++ (100)	+++ (23)	102	+++ (104)	++ (34)
5	+++++ (95)	+++ (74)	103	++ (95)	+++ (68)
6	++++ (95)	+++ (75)	104	+++ (104-106)	+++ (43-47)
7	+++++ (94)	+++ (29)	105	++ (90)	++ (<10 at 1 μM)
8	+++++ (90)	+++ (57)	106	++ (95)	++ (37)
9	+++++ (100)	+++ (48)	107	++ (57)	++++ (124)
10	++++ (95)	+++ (32)	108	- (18 at 1 μM)	++ (69)
11	++++ (96)	+++ (39)	109	+++ (101)	++ (36)
12	+++ (91)	++++ (85)	110	++ (88)	++ (33)
13	+++ (69)	+++ (25)	111	++ (94)	++ (12 at 1 μM)
14	++++ (81)	++ (<10)	112	++ (94)	++ (26 at 1 μM)
15	++++ (93)	+++ (20)	113	++ (89)	++ (52)
16	+++++ (97)	+++ (22)	114	++++/+++ (94-103)	+++ (42-63)
17	++++ (92)	+++ (55)	115	+++ (91)	+++ (67)
18	+++++ (101)	++++ (80)	116	+++++ (98)	++ (50)
19	+++++ (93)	++++ (50)	117	+++ (92)	++ (70)
20	++++ (91)	+++ (22)	118	+++++ (95)	+++ (35)
21	+++++ (95)	+++ (20)	119	+++++ (97)	++ (41)
22	++++ (90)	++++ (46)	120	+++ (91)	- (6 at 1 μM)
23	+++ (83)	+++ (37)	121	++++ (90)	++ (27)
24	++++ (92)	+++ (15)	122	+++ (91)	- (<1 at 1 μM)

25	+++ (86)	+++ (43)	123	+++ (104)	++++ (111)
26	++++ (95)	+++ (64)	124	++ (73)	- (10 at 1 μ M)
27	++++ (95)	+++ (45)	125	++ (94-100)	+++ (54-60)
28	++++ (101)	+++ (57)	126	++ (84)	++ (42-51)
29	+++ (98)	+++ (11)	127	+++ (95-107)	+++ (98-102)
30	++++ (97)	+++ (59)	128	+++ (99)	+++ / ++ (68)
31	+++ (102)	++ (37)	129	+++ / ++ (91-95)	++++ / +++ (102-109)
32	+++++ (103)	+++ (65)	130	++++ (114)	+++ (64)
33	++++ (100)	++ (43)	131	+++ (95)	- (3.2)
34	++++ (107)	+++ (20-38)	132	+++++ (103-114)	+++ (61-64)
35	++++ (110)	+++ (20-37)	133	+++ (98)	++++ (104)
36	+++++ / ++++ (108)	+++++ / +++ (51-75)	134	+++++ (103-108)	++ (30)
37	+++++ / ++++ (110)	+++ (10-21)	135	+++++ / +++++ (106-111)	++ (15-22)
38	+++++ (97-104)	+++ (18-43)	136	++ (91-94)	++++ (105)
39	+++++ / +++++ (102-104)	+++++ / +++ (40-60)	137	+++ (103)	++ (8)
40	+++++ (101-105)	+++ (14-34)	138	+++ (87)	+++ (81)
41	+++++ (100-104)	+++ (75)	139	++++ (102)	+++ (79)
42	+++++ / +++++ (102-109)	+++++ / +++ (28-46)	140	+++++ (107)	+++ (63)
43	++++ (93-97)	+++ (60-73)	141	+++ (98-100)	++ (46-50)
44	++++ (97-99)	+++ (54-67)	142	+++++ (101-105)	++ (14.2-17)
45	+++++ (100)	+++ (42)	143	++++ (99-108)	+++ (99-107)
46	+++ (100)	+++ (46)	144	+++ (93-119)	+++++ (127-140)
47	+++++ (100)	+++ (24)	145	+++ (100-104)	+++++ / +++++ (125)
48	++++ (104)	++++ (65)	146	+++ (86-92)	+++ (83-97)
49	++++ (101)	++++ (48)	147	+++ (87-97)	+++++ (114-128)
50	++++ (103)	+++ (26)	148	++++ (99)	+++ (64-67)
51	++++ (98)	+++ (65)	149	+++ (86-92)	+++++ (113)
52	+++++ (101)	+++ (56-61)	150	+++ (95-113)	+++++ / +++++ (118-130)
53	+++ (99)	+++ (62)	151	+++ (103-107)	++++ (117-119)
54	+++++ (107)	(6 at 1 μ M)	152	++ (85)	+++ (103)

55	++++ (104)	+++ (47)	153	+++++ (107)	++ (75-85)
56	++++ (110)	+++ (60)	154	+++ (80)	+++ (78)
57	++++ (109)	(7 at 1 μ M)	155	++++ (102)	+++ (80)
58	++++ (108)	+++ (26)	156	+++ (95-100)	+++++ (116-118)
59	+++++ (108)	+++ (31)	157	+++ / +++ (93-95)	++++ / +++ (103-105)
60	++++ (98)	+++ (37)	158	++ (31-38)	++++ (104-107)
61	+++ (96)	+++ (56)	159	++ (87-91)	+++ (89-92)
62	+++ (101)	+++ (48)	160	+++ (85-95)	++++ (109-113)
63	+++ (91)	+++ (24)	161	++ (89-101)	+++ / ++ (58- 107)
64	+++++ (97)	+++ (35)	162	++ (42-46)	++++ / +++ (103-107)
65	++++ (96)	+++ (42)	163	++ (73)	+++++ (106)
66	+++++ (113)	+++ (11)	164	++ (68)	++ (99-105)
67	++++ (100)	+++ (65)	165	++++ (101-106)	+++ (91-98)
68	++++ (109)	++++ (87)	166	+++++ (109)	+++ / ++ (77-84)
69	++++ (104)	+++ (75)	167	++++ / +++ (94-99)	- (<1 at 1 μ M)
70	++++ (102)	+++ (86)	168	+++ (92)	- (6-14 at 1 μ M)
71	++++ / +++ (102)	+++ (77-87)	169	+++ (96)	- (6-8 at 1 μ M)
72	++++ (105)	++++ (87)	170	+++ (99)	- (5-8 at 1 μ M)
73	++++ (93)	++ (78)	171	+++ (93-98)	- (6.5 at 1 μ M)
74	++++ (92)	+++ (47)	172	+++ (98-101)	++ (63-71)
75	++++ (99)	+++ (39)	173	+++ (90-105)	++++ (92-111)
76	+++ (95)	++++ (89)	174	++ / + (17-73)	+ (30-66)
77	++++ (90)	++++ (82)	175	++ (87-94)	++ (38)
78	++++ (94)	+++ (58)	176	++ (92)	- (1.8 at 1 μ M)
79	++++ (102)	++++ (77)	177	+++ (96)	- (9 at 1 μ M)
80	++++ (92)	+++ (73)	178	+++ (97)	+ (38)
81	++++ (96)	++++ (89)	179	++++ (103)	- (2 at 1 μ M)
82	+++ (95)	+++ (82)	180	++ (94)	++ (84)
83	++++ (106)	+++ (73)	181	++ (103)	+++ (102)
84	++++ (107)	+++ (53)	182	++++ (96)	+ (12 at 1 μ M)
85	+++ (103)	++++ (83)	183	++ (95)	- (1.4 at 1 μ M)
86	++++ (110)	+++ (61)	184	+++ (99)	++ (43)
87	+++ (89)	+++ (62)	185	++++ (97)	- (8.6 at 1 μ M)

88	+++ (108)	+++ (102)	186	+++ (94)	- (4 at 1 μ M)
89	+++ (108)	++++ (81)	187	++ (89)	++ (58)
90	+++ (108)	+++ (74)	188	++ (101)	+++ (107)
91	+++ (98)	+++ (85)	189	+++ (94)	- (4.5 at 1 μ M)
92	+++ (94-104)	++++ (85-88)	190	+++ (97-119)	++++/+++ (88-119)
93	++++ (99)	+++ (73)	191	+++ (97)	++ (68)
94	+++ (89)	+++ (46)	192	++++ (111)	++ (63)
95	++ (84)	+++ (20)	193	+++ (117)	++ (44)
96	+++ (94)	++++ (90)	194	+++ (98)	- (12 at 1 μ M)
97	+++ (99)	++++ (93)	195	++++/+++ (93-113)	++++/+++ (46-87)
98	++++ (96)	- (<5 at 1 μ M)	196	++++/+++ (93-104)	+++/++ (41-86)

Table 3A

Comp ound #	EC ₅₀ (E _{max}) GLP-1R/nM	EC ₅₀ (E _{max}) GIP-R/nM	Comp ound #	EC ₅₀ (E _{max}) GLP-1R/nM	EC ₅₀ (E _{max}) GIP-R/nM
1	++++ (97)	++ (23)	99	+++ (102)	-
2	+++++ (99)	+++ (46)	100	++ (95)	+++ (100)
3	+++++ (96)	-	101	++ (92)	-
4	+++++ (100)	++ (23)	102	+++ (104)	++ (34)
5	+++++ (95)	+++ (74)	103	++ (95)	+++ (68)
6	+++++ (95)	+++ (75)	104	+++ (104-106)	+++ (43-47)
7	+++++ (94)	++ (29)	105	++ (90)	-
8	+++++ (90)	+++ (57)	106	++ (95)	++ (37)
9	+++++ (100)	+++ (48)	107	++ (57)	++++ (124)
10	++++ (95)	+++ (32)	108	- (18 at 1 μ M)	++ (69)
11	++++ (96)	+++ (39)	109	+++ (101)	++ (36)
12	+++ (91)	++++ (85)	110	++ (88)	++ (33)
13	+++ (69)	++ (25)	111	++ (94)	+ (12 at 1 μ M)
14	++++ (81)	-	112	++ (94)	++ (26 at 1 μ M)
15	++++ (93)	++ (20)	113	++ (89)	++ (52)
16	+++++ (97)	++ (22)	114	++++/+++ (94-103)	+++ (42-63)
17	++++ (92)	+++ (55)	115	+++ (91)	+++ (67)
18	+++++ (101)	++++ (80)	116	+++++ (98)	++ (50)

19	+++++ (93)	++++ (50)	117	+++ (92)	++ (70)
20	++++ (91)	++ (22)	118	+++++ (95)	+++ (35)
21	+++++ (95)	++ (20)	119	+++++ (97)	++ (41)
22	++++ (90)	++++ (46)	120	+++ (91)	-
23	+++ (83)	+++ (37)	121	++++ (90)	++ (27)
24	++++ (92)	+ (15)	122	+++ (91)	-
25	+++ (86)	+++ (43)	123	+++ (104)	++++ (111)
26	++++ (95)	+++ (64)	124	++ (73)	-
27	++++ (95)	+++ (45)	125	++ (94-100)	+++ (54-60)
28	++++ (101)	+++ (57)	126	++ (84)	++ (42-51)
29	+++ (98)	+ (11)	127	+++ (95-107)	+++ (98-102)
30	++++ (97)	+++ (59)	128	+++ (99)	+++ / ++ (68)
31	+++ (102)	++ (37)	129	+++ / ++ (91-95)	++++ / +++ (102-109)
32	+++++ (103)	+++ (65)	130	++++ (114)	+++ (64)
33	++++ (100)	++ (43)	131	+++ (95)	-
34	++++ (107)	++ / +++ (20-38)	132	+++++ (103-114)	+++ (61-64)
35	++++ (110)	++ / +++ (20-37)	133	+++ (98)	++++ (104)
36	+++++ / ++++ (108)	+++++ / +++ (51-75)	134	+++++ (103-108)	++ (30)
37	+++++ / ++++ (110)	+ / +++ (10-21)	135	+++++ / +++++ (106-111)	+ / ++ (15-22)
38	++++ (97-104)	+ / +++ (18-43)	136	++ (91-94)	++++ (105)
39	+++++ / +++++ (102-104)	+++++ / +++ (40-60)	137	+++ (103)	-
40	++++ (101-105)	+ / +++ (14-34)	138	+++ (87)	+++ (81)
41	++++ (100-104)	+++ (75)	139	++++ (102)	+++ (79)
42	+++++ / +++++ (102-109)	+++++ / ++ (28-46)	140	+++++ (107)	+++ (63)
43	++++ (93-97)	+++ (60-73)	141	+++ (98-100)	++ (46-50)
44	++++ (97-99)	+++ (54-67)	142	+++++ (101-105)	+ (14.2-17)
45	++++ (100)	+++ (42)	143	++++ (99-108)	+++ (99-107)
46	+++ (100)	+++ (46)	144	+++ (93-119)	+++++ (127-140)
47	+++++ (100)	++ (24)	145	+++ (100-104)	+++++ / +++++ (125)
48	++++ (104)	++++ (65)	146	+++ (86-92)	+++ (83-97)

49	++++ (101)	++++ (48)	147	+++ (87-97)	+++++ (114-128)
50	++++ (103)	++ (26)	148	++++ (99)	+++ (64-67)
51	++++ (98)	+++ (65)	149	+++ (86-92)	+++++ (113)
52	+++++ (101)	+++ (56-61)	150	+++ (95-113)	+++++/++++ (118-130)
53	+++ (99)	+++ (62)	151	+++ (103-107)	++++ (117-119)
54	+++++ (107)	-	152	++ (85)	+++ (103)
55	++++ (104)	+++ (47)	153	+++++ (107)	++ (75-85)
56	++++ (110)	+++ (60)	154	+++ (80)	+++ (78)
57	++++ (109)	-	155	+++++ (102)	+++ (80)
58	++++ (108)	++ (26)	156	+++ (95-100)	+++++ (116-118)
59	+++++ (108)	+++ (31)	157	+++ / +++ (93-95)	++++ / +++ (103-105)
60	++++ (98)	+++ (37)	158	++ (31-38)	++++ (104-107)
61	+++ (96)	+++ (56)	159	++ (87-91)	+++ (89-92)
62	+++ (101)	+++ (48)	160	+++ (85-95)	++++ (109-113)
63	+++ (91)	++ (24)	161	++ (89-101)	+++ / +++ (58-107)
64	+++++ (97)	+++ (35)	162	++ (42-46)	++++ / +++ (103-107)
65	++++ (96)	+++ (42)	163	++ (73)	+++++ (106)
66	+++++ (113)	++ (11)	164	++ (68)	++ (99-105)
67	++++ (100)	+++ (65)	165	++++ (101-106)	+++ (91-98)
68	++++ (109)	++++ (87)	166	+++++ (109)	+++ / +++ (77-84)
69	++++ (104)	+++ (75)	167	++++ / +++ (94-99)	-
70	++++ (102)	+++ (86)	168	+++ (92)	-
71	++++ / +++ (102)	+++ (77-87)	169	+++ (96)	-
72	++++ (105)	++++ (87)	170	+++ (99)	-
73	++++ (93)	++ (78)	171	+++ (93-98)	-
74	++++ (92)	+++ (47)	172	+++ (98-101)	++ (63-71)
75	++++ (99)	+++ (39)	173	+++ (90-105)	++++ (92-111)
76	+++ (95)	++++ (89)	174	++ / + (17-73)	+ (30-66)
77	++++ (90)	++++ (82)	175	++ (87-94)	++ (38)
78	++++ (94)	+++ (58)	176	++ (92)	-
79	++++ (102)	++++ (77)	177	+++ (96)	-
80	++++ (92)	+++ (73)	178	+++ (97)	+ (38)
81	++++ (96)	++++ (89)	179	++++ (103)	-

82	+++ (95)	+++ (82)	180	++ (94)	++ (84)
83	++++ (106)	+++ (73)	181	++ (103)	+++ (102)
84	++++ (107)	+++ (53)	182	++++ (96)	+ (12 at 1 μ M)
85	+++ (103)	++++ (83)	183	++ (95)	-
86	++++ (110)	+++ (61)	184	+++ (99)	++ (43)
87	+++ (89)	+++ (62)	185	++++ (97)	-
88	+++ (108)	+++ (102)	186	+++ (94)	-
89	+++ (108)	++++ (81)	187	++ (89)	++ (58)
90	+++ (108)	+++ (74)	188	++ (101)	+++ (107)
91	+++ (98)	+++ (85)	189	+++ (94)	-
92	+++ (94-104)	++++ (85-88)	190	+++ (97-119)	++++/+++ (88-119)
93	++++ (99)	+++ (73)	191	+++ (97)	++ (68)
94	+++ (89)	+++ (46)	192	++++ (111)	++ (63)
95	++ (84)	++ (20)	193	+++ (117)	++ (44)
96	+++ (94)	++++ (90)	194	+++ (98)	-
97	+++ (99)	++++ (93)	195	++++/+++ (93-113)	++++/+++ (46-87)
98	++++ (96)	-	196	++++/+++ (93-104)	+++/++ (41-86)
197	++ (95)	+ (20)	247	++++ (102)	+++++ (110)
198	++ (95)	++ (81)	248	++ (80)	+++ (105)
199	++++ (92)	+++ (78)	249	++ (101)	+++ (105)
200	++ (89)	+(66)	220	+++	-
201	+++ (99)	+++ (105)	254	+++++	+++ (80)
202	+++++	++++ (67)	257	+++++	++ (40)
203	++++	+++ (44)	260	+++	+
204	+++++	++ (98)	264	+++++ (100)	+++ (90)
208	+++++	+++ (59)	265	+++++ (100)	++++ (80)
207	++++	+++ (68)	266	+++++ (100)	+++ (70)
205	+++++	+++ (61)	267	+++++ (100)	+++ (40)
206	+++++	+(18)	270	+++ (90)	+++ (90)
209	+++++ (94)	++ (27)	225	++++	+++ (70-80)
210	+++++ (90)	++ (40)	285	+++++ (99)	++++ (97)
211	+++++ (91)	++++ (50)	291	++++ (100)	+++ (60)
212	+++++ (90)	+++ (50)	289	+++++ (100)	++ (20)
213	+++++ (90)	++++ (59)	290	+++++ (100)	++ (10)
214	+++++ (95)	+++ (45)	292	+++ (90)	++ (50)
217	+++++ (97)	+++ (58)			

226	+++ (89)	+(17)			
219	++ (89)	+++ (75)			
223	+++++ (101)	++++ (91)			
218	++++ (96)	+ / ++ (19-23)			
221	+++ (95)	+++ (68)			
222	+++ (99)	> 1 mM			
224	++++ (98)	++ (76)			
232	++++ (95)	+++ (78)			
233	+++++ (96)	+++ (77)			
234	++++ (97)	+++ (76)			
238	++++ (95)	+++ (82)			
239	++++ (100)	++ (46)			
240	++++ (97)	+++ (60)			
241	+++ (100)	++ (46)			
215	+++ (103)	-			
243	+++++ (103)	++ (20)			
244	+++++ (100)	+++ (50)			

b) Glucose tolerance test (GTT)

Materials:

5 Freestyle Lite glucometer and strips; compounds to be tested; sterilized glucose solution 200mg/ml.

Procedure:

Compounds were diluted in PBS from the 1mM DMSO stocks right before injection. Body weight and baseline blood glucose level for each mouse were measured.

10 Tails were snipped using sterile scissors; blood from tails was used to measure glucose. For 0.25h GTT, mice were fasted for 5-6h and injected with compound subcutaneously 15mins before glucose injection. For 4h GTT, mice were fasted O/N for 16h and injected with compound subcutaneously 4h before glucose injection. For 16h GTT, mice were injected with compound subcutaneously 16h before glucose injection; food was removed

15 at the same time. For 24h GTT, mice were injected with compound subcutaneously 24h before glucose injection; food was removed 5-6h before glucose injection. 20% glucose in water was prepared; the solution was sterilized by 0.2 µm-filtration. An intraperitoneal

injection of glucose (2g/kg) was given to the mouse. Continued to take blood samples from the tail. Blood glucose was measured at 10, 20, 30, 40, 60, 90, and 120 minutes after glucose injection. Between each of these time points, the mouse was returned to its cage and monitored (at least 6 replicate mice were used for each time-point). The average glucose measurements were plotted as a function of time and the area under the curve (AUC) was determined. AUC results of the GTT test are presented in **Table 4**, below.

Table 4: 24h Glucose Tolerance Test (GTT)

Compound #	Dose range (nmol/kg)	AUC score
1	2-5	3
2	2-5	2
5	2-5	2
16	2-5	2
18	2-5	2
32	2-5	2
41	2-5	4
59	2-5	3
64	2-5	3
65	2-5	2
66	2-5	2
68	2-5	2
69	2-5	2
77	5.1-15	2
79	5.1-15	2
81	2-5	3
83	2-5	2
91	2-5	3
96	5.1-15	4
98	5.1-15	2
114	2-5	3
195	2-5	2
233	2-5	2
234	2-5	3
264	2-5	3

266	2-5	2
Liraglutide	50	4
Liraglutide	200	2
Semaglutide	2.5	3

Note: AUC score is based on percent compared to vehicle which is set to 100%; AUC score 1 = 0-25%, AUC score 2 = 26-50%, AUC score 3 = 51-75%, AUC score 4 = 76-100%.

5 **c) PathHunter β -arrestin Assay**

5,000 cells were seeded in appropriate cell culture media per well in a low volume 384-well tissue culture plate. The assay plate was incubated with cells overnight at 37°C and 5% CO₂. The media was removed, and 5 μ L of appropriate cell culture media containing 0.2% BSA was added. Agonist serial dilutions in a separate 384 well dilution plate in a 22-point series of 2X dilutions of agonist in DMSO were performed as follows. 80 μ L of the highest concentration of Agonist/DMSO was added to well No. 1. 40 μ L was removed from well No. 1, and added to well No. 2, followed by gentle mixing. 40 μ L was removed from well No. 2 and added to well No. 3, followed by gentle mixing. This process was repeated until well No. 22. Additional serial dilutions for additional agonists were set up in a similar manner. 100nL of each 2X agonist serial dilution was added in duplicate to the designated agonist rows of the assay plate using the Labcyte ECHO. Assay plate was incubated for 90 minutes at 37°C and 5% CO₂. A stock of Working Detection Solution in a separate 15 ml polypropylene tube was prepared by mixing 19 parts of Cell Assay Buffer, 5 parts of Substrate Reagent 1, 1 part Substrate Reagent 2. Following agonist incubation, 3 μ L of Working Detection Solution was added to all wells of the assay plate [Note: *Do not* pipette up and down in the vial to mix or vortex plates]. Plates were spun down briefly. Assay plate was incubated for 3 hour at room temperature in the dark for the immunocompetition reaction to occur. Samples were read on Tecan i-control plate reader using luminescence mode with 100ms integration time. Data analysis was performed using GraphPad Prism. EC₅₀ values were only assigned to compounds with an Emax greater than

10% of positive controls (GLP-1 and liraglutide were used as positive controls for this assay). The results of the PathHunter β -arrestin assay was summarized in **Table 5**, below.

Table 5: β -arrestin activity

Compound #	EC ₅₀	Compound #	EC ₅₀
1	> 1 μ M	114	> 1 μ M
2	> 1 μ M	116	> 1 μ M
3	> 1 μ M	118	> 1 μ M
4	0.01-1 μ M	119	< 0.01 μ M
5	0.01-1 μ M	121	> 1 μ M
6	> 1 μ M	123	> 1 μ M
7	> 1 μ M	128	> 1 μ M
8	> 1 μ M	129	> 1 μ M
9	> 1 μ M	130	> 1 μ M
10	> 1 μ M	132	0.01-1 μ M
11	> 1 μ M	133	> 1 μ M
12	> 1 μ M	134	0.01-1 μ M
13	> 1 μ M	135	> 1 μ M
14	> 1 μ M	136	> 1 μ M
15	> 1 μ M	137	> 1 μ M
16	< 0.01 μ M	138	> 1 μ M
17	> 1 μ M	139	> 1 μ M
18	< 0.01 μ M	140	> 1 μ M
19	< 0.01 μ M	141	> 1 μ M
20	> 1 μ M	142	0.01-1 μ M
21	> 1 μ M	143	> 1 μ M
22	> 1 μ M	144	> 1 μ M
23	> 1 μ M	145	> 1 μ M
24	> 1 μ M	146	> 1 μ M
25	> 1 μ M	147	> 1 μ M
26	> 1 μ M	148	> 1 μ M
27	> 1 μ M	149	> 1 μ M
28	> 1 μ M	150	> 1 μ M
29	> 1 μ M	151	> 1 μ M
30	> 1 μ M	152	> 1 μ M
31	> 1 μ M	153	0.01-1 μ M
32	> 1 μ M	154	> 1 μ M
33	> 1 μ M	155	> 1 μ M

34	> 1 μ M	156	> 1 μ M
35	> 1 μ M	157	> 1 μ M
36	> 1 μ M	158	> 1 μ M
37	> 1 μ M	159	> 1 μ M
38	> 1 μ M	160	> 1 μ M
39	> 1 μ M	161	> 1 μ M
40	> 1 μ M	162	> 1 μ M
41	> 1 μ M	163	> 1 μ M
42	> 1 μ M	164	> 1 μ M
43	> 1 μ M	165	> 1 μ M
44	> 1 μ M	166	> 1 μ M
60	> 1 μ M	167	> 1 μ M
64	> 1 μ M	170	> 1 μ M
65	> 1 μ M	171	> 1 μ M
66	> 1 μ M	172	> 1 μ M
68	> 1 μ M	173	> 1 μ M
69	> 1 μ M	176	> 1 μ M
71	> 1 μ M	177	> 1 μ M
72	> 1 μ M	178	> 1 μ M
73	> 1 μ M	179	0.01-1 μ M
74	> 1 μ M	180	> 1 μ M
75	> 1 μ M	181	> 1 μ M
77	> 1 μ M	182	> 1 μ M
79	> 1 μ M	183	> 1 μ M
81	> 1 μ M	184	> 1 μ M
83	> 1 μ M	185	> 1 μ M
85	> 1 μ M	186	> 1 μ M
86	> 1 μ M	187	> 1 μ M
91	> 1 μ M	188	> 1 μ M
92	> 1 μ M	189	> 1 μ M
93	> 1 μ M	190	> 1 μ M
94	> 1 μ M	191	> 1 μ M
96	> 1 μ M	192	> 1 μ M
97	> 1 μ M	193	> 1 μ M
98	> 1 μ M	194	> 1 μ M
104	> 1 μ M	195	> 1 μ M
111	> 1 μ M	196	> 1 μ M
GLP-1	< 0.01 μ M	liraglutide	0.01-1 μ M

202	> 1 μ M	234	> 1 μ M
203	> 1 μ M	238	> 1 μ M
204	0.02-1 μ M	239	> 1 μ M
208	> 1 μ M	240	> 1 μ M
207	> 1 μ M	241	> 1 μ M
205	> 1 μ M	243	> 1 μ M
206	> 1 μ M	244	0.01-1 μ M
209	0.01-1 μ M	264	< 0.01 μ M
210	0.01-1 μ M	265	< 0.01 μ M
211	0.01-1 μ M	266	< 0.01 μ M
212	0.01-1 μ M	225	> 1 μ M
213	0.01-1 μ M	285	> 1 μ M
214	0.01-1 μ M		
217	> 1 μ M		
226	> 1 μ M		
223	0.01-1 μ M		
218	> 1 μ M		
232	> 1 μ M		
233	0.01-1 μ M		

d) Conditioned taste aversion (CTA) in mice

- 5 One week before start of experiment (Day -7), animals were transferred to single house double grommet cages. A 50ml water bottle was placed, and consistently replaced when refilled in the same grommet to habituate the animal to a “water” side. After 7 days of baseline water consumption, animals began the taste preference procedure. On Day 1, the animals were weighed and deprived of water at 6pm. On acquisition day (Day 2), mice
- 10 had access to a single bottle containing 0.15% saccharin solution, on the opposite side to the “water” habituated side and allowed to consume for 3h, from 6pm until 9pm. The saccharine bottles were then removed and weighed to record the 3h consumption. The mice were assigned to form balanced groups based on saccharine consumption and animals that did not consume saccharine were removed from the study. After the groups were formed,
- 15 the animals were either injected subcutaneously with test drug, vehicle (solvent) or positive

aversive drug (200nmol/kg liraglutide) based on weight from Day 1 and returned to cages with weighed water bottles. On Day 3, the water was removed and weighed at 6pm. On Day 4, both saccharine and water bottles were weighed and returned simultaneously to respective grommet at 6pm. On Day 5, the bottles were removed at 6pm and weighed. Saccharine consumption was measured as a percent of the total amount of fluid consumed. The reduction of saccharin consumption during the retrieval was used as a measure of CTA strength. Liraglutide and semaglutide were used as positive controls. The results are summarized in **Table 6**.

Table 6: Conditioned taste aversion (CTA)

Compound #	Dose (nmol/kg)	CTA score
2	30	2
5	30	1
16	30	1
32	30	2
65	30	3
66	50	2
68	30	3
69	30	3/4
83	30	2
91	30	4
96	30	4
98	30	4
114	50	2
195	30	3
202	30	4
233	30	1
234	30	1
264	30	1
266	30	1
Liraglutide	50	2
Liraglutide	200	1
Semaglutide	10	2
Semaglutide	20	1


Note: Saccharine preference score is compared to vehicle (preferred saccharine solution) which is set to 100%; Score 1 = 0-25%, Score 2 = 26-50%, Score 3 = 51-75%, Score 4 = 76-100%.

5

A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.

WHAT IS CLAIMED IS:

1. A compound having formula (IAA), or a pharmaceutically acceptable salt thereof:



5 wherein:

ring A is:

(i) a saturated or unsaturated monocyclic ring that includes from 3-8 ring atoms (inclusive of **G** and the nitrogen atom labelled **N***); or

10 (ii) a saturated or unsaturated bicyclic or tricyclic ring that includes from 6-14 ring atoms (inclusive of **G** and the nitrogen atom labelled **N***), wherein:

- **G** is C(O), S(O), or SO₂; and
- the dotted, circular line connecting **G** and **N*** is a divalent group that includes from 1-6 ring atoms; wherein:

15 (a) from 0-2 of the divalent group's ring atoms are ring heteroatoms, which are each independently selected from the group consisting of N, N(**R^a**), O, S, and SO₂; and

(b) from 1-6 of the divalent group's ring atoms are ring carbon atoms, which are each independently selected from the group consisting of C, CH, CH₂, CR^b, C(R^b)₂, and CHR^b;

20 wherein:

(1) when **ring A** is a monocyclic ring, then each of the divalent group's 1-6 ring carbon atoms is independently selected from the group consisting of CH, CH₂, CR^b, C(R^b)₂, and CHR^b; and

(2) when **ring A** is a bicyclic or tricyclic ring, then (A) or (B) applies:

(A) two or three adjacent ring carbon atoms of the divalent group are each independently selected from the group consisting of C, CH, CH₂, CR^b, C(R^b)₂, and CHR^b and are fused to a second ring that is selected from the group consisting of:

5 (a) C₆₋₁₀ aryl optionally substituted with from 1-5 independently selected R^c;

(b) heteroaryl including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, N(R^a), O, and S, wherein the heteroaryl is optionally substituted with from 1-3 independently selected R^c;

10 (c) C₃₋₁₀ cycloalkyl optionally substituted with from 1-4 independently selected R^d;

(d) heterocyclyl including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(R^a), O, and S, wherein the heterocyclyl is optionally substituted with from 1-4 independently selected R^d; or

(B) one of the divalent group's ring carbon atoms is C and is spiro-fused to a second ring that is selected from the group consisting of:

20 (a) C₃₋₁₀ cycloalkyl optionally substituted with from 1-4 independently selected R^d;

(b) heterocyclyl including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(R^a), O, and S, wherein the heterocyclyl is optionally substituted with from 1-4 independently selected R^d;

25

L is:

(i) -(CH₂)_m-X¹-(CH₂)_n-X²-(CH₂)_p- (formula VIII), wherein m is from 1-6; n is from 0-2; and p is from 0-8;

30 (ii) -C(O)-(CH₂)_n-X³-(CH₂)_p- (formula IX), wherein n is from 0-2; and p is from 0-8;

(iii) $-(CH_2)_q-$, wherein q is from 1-10;

(iv) $-C(O)-$; or

(v) $-(CH_2)_m-X^1-(CH_2)_p-$ (formula VIII), wherein m is from 1-6; and p is from 0-8;

5 X^1 is $-C(O)-$; $-N(R')C(O)-$; $-C(O)N(R')-$; or $-N(R')C(O)NR'-$; wherein each occurrence of R' is independently selected from the group consisting of: H and C_{1-4} alkyl;

X^2 is:

(i) $-O-$;

10 (ii) $-S-$;

(iii) $-S(O)_t-$, wherein t is 1 or 2;

(iv) $-C(Q^1)(Q^2)-$, wherein each of Q^1 and Q^2 is independently selected from the group consisting of H and C_{1-4} alkyl; or Q^1 and Q^2 , together with the carbon atom to which each is attached forms C_{3-10} cycloalkyl that is optionally substituted with from 1-4 independently selected R^d and optionally fused to phenyl;

(v) C_{6-10} arylene optionally substituted with from 1-5 independently selected R^e ;

(vi) heteroarylene including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, $N(R^a)$, O, and S; and which is optionally substituted with from 1-5 independently selected R^e ;

20 (vii) C_{3-10} cycloalkylene optionally substituted with from 1-4 independently selected R^d ;

(viii) heterocycloalkylene including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of $N(R^a)$, O, and S; and which is optionally substituted with from 1-5 independently selected R^d ;

25 (ix) C_2-C_4 alkenylene optionally substituted with from 1-2 R^e ; or

(x) C_2-C_4 alkynylene optionally substituted with from 1-2 R^e ;


X^3 is: $-O-$; $-S-$; or $-S(O)_t-$, wherein t is 1 or 2;

each of R^1 , R^2 , and R^4 is independently selected from the group consisting of H and unsubstituted C_{1-3} alkyl;

$R^{2'}$ is as defined according to (AA) or (BB) below:

5

(AA)



$R^{2'}$ is , wherein:

R^3 is $-C(O)OH$, $-C(O)OR^{31}$, $-CH(C(O)OH)_2$ or a carboxylic acid isostere (e.g., amide or tetrazolyl);

10

a is 0-5;

a' is 0 or 1; and

each of R^{3a} and R^{3b} is independently H or C_{1-3} alkyl;

(BB)

15

$R^{2'}$ and R^4 taken together with the atoms connecting them form a ring including from 5-8 ring atoms, wherein from 3-7 are ring carbon atoms each substituted with from 1-2 substituents independently selected from H, halo, hydroxy, oxo, and C_{1-3} alkyl; and from 0-1 is a heteroatom (in addition to the N attached to R^1) selected from O, $-NH$, $-N(C_{1-3} \text{ alkyl})$, and S (e.g., R^4 and R^3 , taken together with the atoms to which each is attached form a ring including 5-8 ring atoms);

20

R^{31} is:

(i) C_{1-6} alkyl optionally substituted with from 1-2 independently selected R^e ;

25

(ii) $-(C_{0-3} \text{ alkylene})-C_{3-10}$ cycloalkyl, wherein the cycloalkyl is optionally substituted with from 1-4 independently selected R^d ;

(iii) $-(C_{0-3} \text{ alkylene})$ -heterocyclyl including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of $N(R^a)$, O, and

S, wherein the heterocyclyl is optionally substituted with from 1-4 independently selected R^d ;

(iv) $-(C_{0-3} \text{ alkylene})-C_{6-10} \text{ aryl}$, wherein the aryl is optionally substituted with from 1-5 independently selected R^c ; or

5 (v) $-(C_{0-3} \text{ alkylene})\text{-heteroaryl}$ including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, N(R^a), O, and S, wherein the heteroaryl is optionally substituted with from 1-3 independently selected R^c ;

10 each occurrence of R^a is independently selected from the group consisting of: H; C_{1-4} alkyl; C_{3-6} cycloalkyl; $-C(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)O(C_{1-6} \text{ alkyl})$; and $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$;

15 each occurrence of R^b is independently selected from the group consisting of: R^{31} ; C_{1-4} haloalkyl; $-OH$; oxo; $-F$; $-N(R^a)(R'')$; C_{1-4} alkoxy; C_{1-4} haloalkoxy; $-C(=O)(C_{1-4} \text{ alkyl})$; $-C(=O)O(C_{1-6} \text{ alkyl})$; $-C(=O)OH$; $-C(=O)N(R''')(R''''')$; $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$; and cyano;

20 each occurrence of R^c is independently selected from the group consisting of: C_{1-6} alkyl optionally substituted with from 1-2 independently selected R^e ; C_{3-6} cycloalkyl; C_{1-4} haloalkyl; $-OH$; $-halo$; $-NO_2$; N_3 ; $-N(R^a)(R'')$; C_{1-4} alkoxy; C_{1-4} thioalkoxy; C_{1-4} haloalkoxy; $-OC(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)O(C_{1-6} \text{ alkyl})$; $-C(=O)OH$; $-C(=O)N(R''')(R''''')$; $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$; and cyano;

25 each occurrence of R^d is independently selected from the group consisting of: C_{1-6} alkyl optionally substituted with from 1-2 independently selected R^e ; C_{1-4} haloalkyl; $-OH$; $-F$; Cl ; $-N(R^a)(R'')$; oxo; C_{1-4} alkoxy; C_{1-4} haloalkoxy; $-OC(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)O(C_{1-6} \text{ alkyl})$; $-C(=O)OH$; $-C(=O)N(R''')(R''''')$; $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$; and cyano;

30


each occurrence of R^e is independently selected from the group consisting of: $-OH$; $-N(R^a)(R'')$; C_{1-4} alkoxy; C_{1-4} haloalkoxy; $-OC(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)O(C_{1-6} \text{ alkyl})$; $-C(=O)OH$; $-C(=O)N(R''')(R''''')$; $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$; and cyano;

5 each occurrence of R'' , R''' , and R'''' is independently selected from the group consisting of: H and C_{1-6} alkyl; and

W is a peptide having the formula $W'-R^5$, wherein W' is a sequence of from 5-60 amino acids, and R^5 is a C-terminal amino acid, amino acid ester, or amino acid amide that
10 is optionally substituted with from 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group); and

provided that one or more of the compound provisions delineated herein apply.

15 2. The compound of claim 1, wherein the compound has formula (IA), or a pharmaceutically acceptable salt thereof:



wherein:

20 **ring A** is:

(i) a saturated or unsaturated monocyclic ring that includes from 3-8 ring atoms (inclusive of G and the nitrogen atom labelled N^*); or

(ii) a saturated or unsaturated bicyclic or tricyclic ring that includes from 6-14 ring atoms (inclusive of G and the nitrogen atom labelled N^*), wherein:

25 • G is $C(O)$, $S(O)$, or SO_2 ; and

- the dotted, circular line connecting **G** and **N*** is a divalent group that includes from 1-6 ring atoms; wherein:

(a) from 0-2 of the divalent group's ring atoms are ring heteroatoms, which are each independently selected from the group consisting of N, N(**R^a**), O, S, and SO₂; and

(b) from 1-6 of the divalent group's ring atoms are ring carbon atoms, which are each independently selected from the group consisting of C, CH, CH₂, CR^b, C(R^b)₂, and CHR^b; wherein:

(1) when **ring A** is a monocyclic ring, then each of the divalent group's 1-6 ring carbon atoms is independently selected from the group consisting of CH, CH₂, CR^b, C(R^b)₂, and CHR^b; and

(2) when **ring A** is a bicyclic or tricyclic ring, then (A) or (B) applies:

(A) two or three adjacent ring carbon atoms of the divalent group are each independently selected from the group consisting of C, CH, and, CR^b and are fused to a second ring that is selected from the group consisting of:

(a) C₆₋₁₀ aryl optionally substituted with from 1-5 independently selected **R^c**;

(b) heteroaryl including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, N(**R^a**), O, and S, wherein the heteroaryl is optionally substituted with from 1-3 independently selected **R^c**;

(c) C₃₋₁₀ cycloalkyl optionally substituted with from 1-4 independently selected **R^d**;

(d) heterocyclyl including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(**R^a**), O, and S, wherein the heterocyclyl is optionally substituted with from 1-4 independently selected **R^d**; or

(B) one of the divalent group's ring carbon atoms is C and is spiro-fused to a second ring that is selected from the group consisting of:

(a) C₃₋₁₀ cycloalkyl optionally substituted with from 1-4 independently selected **R^d**,

(b) heterocyclyl including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(**R^a**), O, and S, wherein the heterocyclyl is optionally substituted with from 1-4 independently selected **R^d**;

L is:

(i) -(CH₂)_m-**X¹**-(CH₂)_n-**X²**-(CH₂)_p- (formula VIII), wherein **m** is from 1-6; **n** is from 0-2; and **p** is from 0-8;

(ii) -C(O)-(CH₂)_n-**X³**-(CH₂)_p- (formula IX), wherein **n** is from 0-2; and **p** is from 0-8;

(iii) -(CH₂)_q-, wherein **q** is from 1-10;

(iv) -C(O)-; or

(v) -(CH₂)_m-**X¹**-(CH₂)_p- (formula VIII), wherein **m** is from 1-6; and **p** is from 0-8;

X¹ is -C(O)-; -N(**R'**)C(O)-; -C(O)N(**R'**)-; or -N(**R'**)C(O)NR'-; wherein each occurrence of **R'** is independently selected from the group consisting of: H and C₁₋₄ alkyl;

X² is:

(i) -O-;

(ii) -S-;

(iii) -S(O)_t-, wherein **t** is 1 or 2;

(iv) -C(Q¹)(Q²)-, wherein each of **Q¹** and **Q²** is independently selected from the group consisting of H and C₁₋₄ alkyl; or **Q¹** and **Q²**, together with the carbon atom to which each is attached forms C₃₋₁₀ cycloalkyl that is optionally substituted with from 1-4 independently selected **R^d** and optionally fused to phenyl;

(v) C₆₋₁₀ arylene optionally substituted with from 1-5 independently selected **R^c**;

(vi) heteroarylene including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, N(R^a), O, and S; and which is optionally substituted with from 1-5 independently selected R^e;

5 (vii) C₃₋₁₀ cycloalkylene optionally substituted with from 1-4 independently selected R^d;

(viii) heterocycloalkylene including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(R^a), O, and S; and which is optionally substituted with from 1-5 independently selected R^d;

(ix) C₂₋₄ alkenylene optionally substituted with from 1-2 R^e; or

10 (x) C₂₋₄ alkynylene optionally substituted with from 1-2 R^e;

X³ is: -O-; -S-; or -S(O)_t, wherein t is 1 or 2;

15 each of R¹, R², and R⁴ is independently selected from the group consisting of H and unsubstituted C₁₋₃ alkyl;

R³ is -C(O)OH, -C(O)OR³¹, -CH(C(O)OH)₂ or a carboxylic acid isostere (e.g., amide or tetrazolyl);

a is 0-5;

20 a' is 0 or 1;

each of R^{3a} and R^{3b} is independently H or C₁₋₃ alkyl;

R³¹ is:

(i) C₁₋₆ alkyl optionally substituted with from 1-2 independently selected R^e;

25 (ii) -(C₀₋₃ alkylene)-C₃₋₁₀ cycloalkyl, wherein the cycloalkyl is optionally substituted with from 1-4 independently selected R^d;

(iii) -(C₀₋₃ alkylene)-heterocyclyl including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(R^a), O, and S, wherein the heterocyclyl is optionally substituted with from 1-4 independently selected R^d;

30 R^d;

(iv) $-(C_{0-3} \text{ alkylene})-C_{6-10} \text{ aryl}$, wherein the aryl is optionally substituted with from 1-5 independently selected R^c ; or

(v) $-(C_{0-3} \text{ alkylene})\text{-heteroaryl}$ including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, $N(R^a)$, O, and S, wherein the heteroaryl is optionally substituted with from 1-3 independently selected R^c ;

each occurrence of R^a is independently selected from the group consisting of: H; C_{1-4} alkyl; C_{3-6} cycloalkyl; $-C(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)O(C_{1-6} \text{ alkyl})$; and $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$;

each occurrence of R^b is independently selected from the group consisting of: R^{31} ; C_{1-4} haloalkyl; $-OH$; oxo; $-F$; $-N(R^a)(R'')$; C_{1-4} alkoxy; C_{1-4} haloalkoxy; $-C(=O)(C_{1-4} \text{ alkyl})$; $-C(=O)O(C_{1-6} \text{ alkyl})$; $-C(=O)OH$; $-C(=O)N(R''')(R''''')$; $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$; and cyano;

each occurrence of R^c is independently selected from the group consisting of: C_{1-6} alkyl optionally substituted with from 1-2 independently selected R^e ; C_{3-6} cycloalkyl; C_{1-4} haloalkyl; $-OH$; $-halo$; $-NO_2$; N_3 ; $-N(R^a)(R'')$; C_{1-4} alkoxy; C_{1-4} thioalkoxy; C_{1-4} haloalkoxy; $-OC(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)O(C_{1-6} \text{ alkyl})$; $-C(=O)OH$; $-C(=O)N(R''')(R''''')$; $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$; and cyano;

each occurrence of R^d is independently selected from the group consisting of: C_{1-6} alkyl optionally substituted with from 1-2 independently selected R^e ; C_{1-4} haloalkyl; $-OH$; $-F$; $-Cl$; $-N(R^a)(R'')$; oxo; C_{1-4} alkoxy; C_{1-4} haloalkoxy; $-OC(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)O(C_{1-6} \text{ alkyl})$; $-C(=O)OH$; $-C(=O)N(R''')(R''''')$; $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$; and cyano;


each occurrence of R^e is independently selected from the group consisting of: $-OH$; $-N(R^a)(R'')$; C_{1-4} alkoxy; C_{1-4} haloalkoxy; $-OC(=O)(C_{1-6} \text{ alkyl})$; $-C(=O)O(C_{1-6} \text{ alkyl})$; $-C(=O)OH$; $-C(=O)N(R''')(R''''')$; $-S(O)_{1-2}(C_{1-6} \text{ alkyl})$; and cyano;

- 5 each occurrence of R'' , R''' , and R'''' is independently selected from the group consisting of: H and C_{1-6} alkyl; and

W is a peptide having the formula $W'-R^5$, wherein W' is a sequence of from 5-60 amino acids, and R^5 is a C-terminal amino acid, amino acid ester, or amino acid amide that
10 is optionally substituted with from 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group); and

provided that one or more of the compound provisions delineated herein apply.

- 15 3. The compound of any one of claims 1-2, wherein the compound has formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

20 **ring A** is:

(i) a saturated or unsaturated monocyclic ring that includes from 3-8 ring atoms (inclusive of **G** and the nitrogen atom labelled N^*); or

(ii) a saturated or unsaturated bicyclic or tricyclic ring that includes from 6-14 ring atoms (inclusive of **G** and the nitrogen atom labelled N^*), wherein:

- 25 • **G** is $C(O)$, $S(O)$, or SO_2 ; and

- the dotted, circular line connecting **G** and **N*** is a divalent group that includes from 1-6 ring atoms; wherein:

(a) from 0-2 of the divalent group's ring atoms are ring heteroatoms, which are each independently selected from the group consisting of N, N(**R^a**), O, S, and SO₂; and

5 (b) from 1-6 of the divalent group's ring atoms are ring carbon atoms, which are each independently selected from the group consisting of C, CH, CH₂, CR^b, C(R^b)₂, and CHR^b;

wherein:

10 (1) when **ring A** is a monocyclic ring, then each of the divalent group's 1-6 ring carbon atoms is independently selected from the group consisting of CH, CH₂, CR^b, C(R^b)₂, and CHR^b; and

(2) when **ring A** is a bicyclic or tricyclic ring, then (A) or (B) applies:

15 (A) two or three adjacent ring carbon atoms of the divalent group are each independently selected from the group consisting of C, CH, and, CR^b and are fused to a second ring that is selected from the group consisting of:

(a) C₆₋₁₀ aryl optionally substituted with from 1-5 independently selected **R^c**;

(b) heteroaryl including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, N(**R^a**), O, and S, wherein the heteroaryl is optionally substituted with from 1-3 independently selected **R^c**;

20 (c) C₃₋₁₀ cycloalkyl optionally substituted with from 1-4 independently selected **R^d**;

(d) heterocyclyl including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(**R^a**), O, and S, wherein the heterocyclyl is optionally substituted with from 1-4 independently selected **R^d**; or

25 (B) one of the divalent group's ring carbon atoms is C and is spiro-fused to a second ring that is selected from the group consisting of:

(a) C₃₋₁₀ cycloalkyl optionally substituted with from 1-4 independently selected **R^d**;

(b) heterocyclyl including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(**R^a**), O, and S, wherein the heterocyclyl is optionally substituted with from 1-4 independently selected **R^d**;

30

L is:

(i) $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$ (formula VIII), wherein **m** is from 1-6; **n** is from 0-2; and **p** is from 0-8;

5 (ii) $-C(O)-(CH_2)_n-X^3-(CH_2)_p-$ (formula IX), wherein **n** is from 0-2; and **p** is from 0-8;

(iii) $-(CH_2)_q-$, wherein **q** is from 1-10;

(iv) $-C(O)-$; or

(v) $-(CH_2)_m-X^1-(CH_2)_p-$ (formula VIII), wherein **m** is from 1-6; and **p** is from 0-8;

10 **X¹** is $-C(O)-$; $-N(R')C(O)-$; $-C(O)N(R')-$; or $-N(R')C(O)NR'-$; wherein each occurrence of **R'** is independently selected from the group consisting of: H and C₁₋₄ alkyl;

X² is:

(i) $-O-$;

15 (ii) $-S-$;

(iii) $-S(O)_t-$, wherein **t** is 1 or 2;

(iv) $-C(Q^1)(Q^2)-$, wherein each of **Q¹** and **Q²** is independently selected from the group consisting of H and C₁₋₄ alkyl; or **Q¹** and **Q²**, together with the carbon atom to which each is attached forms C₃₋₁₀ cycloalkyl that is optionally substituted with from 1-4 independently selected **R^d** and optionally fused to phenyl;

(v) C₆₋₁₀ arylene optionally substituted with from 1-5 independently selected **R^c**;

(vi) heteroarylene including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, N(**R^a**), O, and S; and which is optionally substituted with from 1-5 independently selected **R^c**;

25 (vii) C₃₋₁₀ cycloalkylene optionally substituted with from 1-4 independently selected **R^d**;

(viii) heterocycloalkylene including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(**R^a**), O, and S; and which is optionally substituted with from 1-5 independently selected **R^d**;

30 (ix) C₂-C₄ alkenylene optionally substituted with from 1-2 **R^c**; or

(x) C₂-C₄ alkynylene optionally substituted with from 1-2 R^e;

X³ is: -O-; -S-; or -S(O)_t-, wherein t is 1 or 2;

5 each of R¹, R², and R⁴ is independently selected from the group consisting of H and unsubstituted C₁₋₃ alkyl;

R³ is -C(O)OH, -C(O)OR³¹, or a carboxylic acid isostere; wherein R³¹ is:

(i) C₁₋₆ alkyl optionally substituted with from 1-2 independently selected R^e;

10 (ii) -(C₀₋₃ alkylene)-C₃₋₁₀ cycloalkyl, wherein the cycloalkyl is optionally substituted with from 1-4 independently selected R^d;

(iii) -(C₀₋₃ alkylene)-heterocyclyl including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(R^a), O, and S, wherein the heterocyclyl is optionally substituted with from 1-4 independently selected
15 R^d;

(iv) -(C₀₋₃ alkylene)-C₆₋₁₀ aryl, wherein the aryl is optionally substituted with from 1-5 independently selected R^e; or

(v) -(C₀₋₃ alkylene)-heteroaryl including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, N(R^a), O, and
20 S, wherein the heteroaryl is optionally substituted with from 1-3 independently selected R^e;

a is 0-5;

25 each occurrence of R^a is independently selected from the group consisting of: H; C₁₋₄ alkyl; C₃₋₆ cycloalkyl; -C(=O)(C₁₋₆ alkyl); -C(=O)O(C₁₋₆ alkyl); and -S(O)₁₋₂(C₁₋₆ alkyl);

each occurrence of R^b is independently selected from the group consisting of: R³¹;
30 C₁₋₄ haloalkyl; -OH; oxo; -F; -N(R^a)(R''); C₁₋₄ alkoxy; C₁₋₄ haloalkoxy; -C(=O)(C₁₋₄

alkyl); -C(=O)O(C₁₋₆ alkyl); -C(=O)OH, -C(=O)N(R''')(R''''), -S(O)₁₋₂(C₁₋₆ alkyl); and cyano;

each occurrence of **R^e** is independently selected from the group consisting of: C₁₋₆ alkyl optionally substituted with from 1-2 independently selected **R^e**; C₃₋₆ cycloalkyl; C₁₋₄ haloalkyl; -OH; -halo; -NO₂; N₃; -N(R^a)(R''); C₁₋₄ alkoxy; C₁₋₄ thioalkoxy; C₁₋₄ haloalkoxy; -OC(=O)(C₁₋₆ alkyl); -C(=O)(C₁₋₆ alkyl); -C(=O)O(C₁₋₆ alkyl); -C(=O)OH, -C(=O)N(R''')(R''''), -S(O)₁₋₂(C₁₋₆ alkyl); and cyano;

each occurrence of **R^d** is independently selected from the group consisting of: C₁₋₆ alkyl optionally substituted with from 1-2 independently selected **R^e**; C₁₋₄ haloalkyl; -OH; -F; Cl; -N(R^a)(R''); oxo; C₁₋₄ alkoxy; C₁₋₄ haloalkoxy; -OC(=O)(C₁₋₆ alkyl); -C(=O)(C₁₋₆ alkyl); -C(=O)O(C₁₋₆ alkyl); -C(=O)OH, -C(=O)N(R''')(R''''), -S(O)₁₋₂(C₁₋₆ alkyl); and cyano;


each occurrence of **R^e** is independently selected from the group consisting of: -OH; -N(R^a)(R''); C₁₋₄ alkoxy; C₁₋₄ haloalkoxy; -OC(=O)(C₁₋₆ alkyl); -C(=O)O(C₁₋₆ alkyl); -C(=O)OH, -C(=O)N(R''')(R''''), -S(O)₁₋₂(C₁₋₆ alkyl); and cyano;

each occurrence of **R''**, **R'''**, and **R''''** is independently selected from the group consisting of: H and C₁₋₆ alkyl; and

W is a peptide having the formula W'-R⁵, wherein **W'** is a sequence of from 5-60 amino acids, and **R⁵** is a C-terminal amino acid, amino acid ester, or amino acid amide that is optionally substituted with from 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group); and

provided that one or more of the compound provisions delineated herein apply.

4. The compound of any one of claims 1-2, wherein the compound has formula (IIA):



5

5. The compound of any one of claims 1-4, wherein **G** is C(O).

6. The compound of any one of claims 1-4, wherein **G** is S(O) or SO₂.

10


7. The compound of any one of claims 1-6, wherein ring A is a saturated or unsaturated monocyclic ring that includes from 3-8 (e.g., 4-8) ring atoms.

8. The compound of any one of claims 1-7, wherein ring A is a saturated monocyclic ring that includes from 3-8 (e.g., 4-8) ring atoms.

15

9. The compound of any one of claims 1-8, wherein ring A is a saturated monocyclic ring that includes from 5-7 ring atoms.

10. The compound of any one of claims 1, 2, 4, 5, and 7-9, wherein ring A has the following formula (III):



437

SUBSTITUTE SHEET (RULE 26)

wherein:

A₁ is a bond, **A**^{1A}-**A**^{1B}, C(O), CH₂, CHR^b, or C(R^b)₂;

each of **A**^{1A} and **A**^{1B} is independently C(O), CH₂, CHR^b, or C(R^b)₂;

A₂ is C(O), CH₂, CHR^b, or C(R^b)₂;

5 **A**₃ is C(O), CH₂, CHR^b, or C(R^b)₂; O; S; SO₂, or N(R^a);

A₄ is C(O), CH₂, CHR^b, or C(R^b)₂; O; S; or N(R^a); provided that **A**₃ and **A**₄
cannot both be O; S; or N(R^a); or a combination thereof.

10 11. The compound of claim 10, wherein **A**₁ is a C(O), CH₂, CHR^b, or C(R^b)₂,
and ring A is a 6-membered ring.

12. The compound of claim 10 or 11, wherein **A**₁ is a CH₂, CHR^b, or C(R^b)₂.

13. The compound of any one of claims 10-12, wherein **A**₁ is a CH₂.

15

14. The compound of claim 10 or 11, wherein **A**₁ is C(O).

15. The compound of any one of claims 10-14, wherein **A**₂ is CH₂, CHR^b, or
C(R^b)₂.

20

16. The compound of any one of claims 10-15, wherein **A**₂ is CH₂.

17. The compound of any one of claims 10-16, wherein **A**₃ is CH₂, CHR^b, or
C(R^b)₂.

25

18. The compound of any one of claims 10-17, wherein **A**₃ is CH₂.

19. The compound of any one of claims 10-16, wherein **A**₃ is O; S; SO₂, or
N(R^a).

30

20. The compound of any one of claims 10-19, wherein **A**₄ is CH₂, CHR^b, or C(R^b)₂.

21. The compound of any one of claims 10-20, wherein **A**₄ is CH₂.

5

22. The compound of claim 10 or 11, wherein **A**₂, **A**₃ and **A**₄ are each independently selected from the group consisting of CH₂, CHR^b, and C(R^b)₂.

23. The compound of claim 22, wherein one or two of **A**₂, **A**₃ and **A**₄ are independently selected from the group consisting of CHR^b and C(R^b)₂, and the others are CH₂.

10

24. The compound of claim 22, wherein **A**₂, **A**₃ and **A**₄ are each CH₂.

15


25. The compound of claim 10 or 11, wherein **A**₁, **A**₂, **A**₃ and **A**₄ are each independently selected from the group consisting of CH₂, CHR^b, and C(R^b)₂.

26. The compound of claim 25, wherein one or two of **A**₁, **A**₂, **A**₃ and **A**₄ are independently selected from CHR^b and C(R^b)₂, and the others are CH₂.

20

27. The compound of claim 26, wherein **A**₁, **A**₂, **A**₃ and **A**₄ are each CH₂.

28. The compound of claim 10, wherein **A**₁ is a bond, and ring A has the following formula:



(III-A).

25

29. The compound of claim 28, wherein **A**₂ is C(=O).

30. The compound of claim 29, wherein **A**₃ is O; S; or N(**R**^e), and **A**₄ is CH₂, CHR^b, or C(**R**^b)₂.

5 31. The compound of claim 30, wherein **A**₃ is S.

32. The compound of claim 30, wherein **A**₃ is N(**R**^a) (e.g., **A**₃ is NH).

33. The compound of any one of claims 30-32, wherein **A**₄ is CH₂.

10

34. The compound of any one of claims 30-32, wherein **A**₄ is CHR^b or C(**R**^b)₂.

35. The compound of claim 29, wherein each of **A**₃ and **A**₄ is independently selected from CH₂, CHR^b, or C(**R**^b)₂.

15

36. The compound of claim 35, wherein each of **A**₃ and **A**₄ is CH₂.

37. The compound of claim 35, wherein one of **A**₃ and **A**₄ is CH₂, and the other of **A**₃ and **A**₄ is CHR^b or C(**R**^b)₂.

20

38. The compound of claim 35, wherein each of **A**₃ and **A**₄ is independently selected from CHR^b or C(**R**^b)₂.

39. The compound of claim 28, wherein **A**₂ is CH₂, CHR^b, or C(**R**^b)₂.

25

40. The compound of claim 39, wherein **A**₂ is CH₂.

41. The compound of claim 39 or 40, wherein each of **A**₃ and **A**₄ is independently selected from CH₂, CHR^b, or C(**R**^b)₂ (e.g., each of **A**₃ and **A**₄ is CH₂).

30

42. The compound of claim 10, wherein A^1 is $A^{1A}-A^{1B}$.

43. The compound of claim 42, wherein each of A^{1A} and A^{1B} is independently CH_2 , CHR^b , or $C(R^b)_2$.

5

44. The compound of claim 43, wherein wherein each of A^{1A} and A^{1B} is independently CH_2 .

45. The compound of any one of claims 42-44, wherein A^2 is CH_2 , CHR^b , or $C(R^b)_2$.

10

46. The compound of claim 45, wherein A^2 is CH_2 .

47. The compound of any one of claims 42-46, wherein A^3 is CH_2 , CHR^b , or $C(R^b)_2$.

15

48. The compound of claim 47, wherein A^3 is CH_2 .

49. The compound of any one of claims 42-48, wherein A^4 is CH_2 , CHR^b , or $C(R^b)_2$.

20

50. The compound of claim 49, wherein A^4 is CH_2 .

51. The compound of any one of claims 1-6, wherein ring A is an unsaturated monocyclic ring that includes from 3-8 (e.g., 4-8) ring atoms.


25

52. The compound of any one of claims 1-6 and 51, wherein ring A is an unsaturated monocyclic ring that includes from 5-6 ring atoms.

53. The compound of any one of claims 1-6, 51, and 52, wherein ring A is an unsaturated monocyclic ring that includes 6 ring atoms.

30

54. The compound of any one of claims 51-53, wherein ring A has formula (IV):



wherein:

each of **A₆** and **A₇** is independently selected from CH and CR^b; and
 each of **A₅** and **A₈** is independently N, CH, or CR^b.

55. The compound of claim 54, wherein **A₅**, **A₆**, **A₇**, and **A₈** are each independently selected from CH and CR^b.

56. The compound of claim 54 or 55 wherein one or two of **A₅**, **A₆**, **A₇**, and **A₈** are an independently selected CR^b, and the others are CH.

57. The compound of claim 54, wherein **A₅**, **A₆**, **A₇**, and **A₈** are each CH.

58. The compound of claim 54, wherein **A₅**, **A₆**, and **A₇** are each independently selected from CH and CR^b, and **A₈** is N.

59. The compound of claim 54, wherein **A₅** is N; and each of **A₆**, **A₇**, and **A₈** is independently selected from CH and CR^b (e.g., one of **A₆**, **A₇**, and **A₈** is CR^b (e.g., C-OH)).

60. The compound of any one of claims 54-56 and 58-59, wherein each occurrence of **R^b** is independently selected from the group consisting of: **R³¹**; -OH; -N(**R^a**)(**R''**); C₁₋₄ alkoxy; and C₁₋₄ haloalkoxy.

- 5 61. The compound of any one of claims 54-56 and 58-59, wherein each occurrence of **R^b** is independently selected from the group consisting of:
- (i) C₁₋₆ alkyl optionally substituted with from 1-2 independently selected **R^e**;
 - (ii) -(C₀₋₃ alkylene)-C₆₋₁₀ aryl, wherein the aryl is optionally substituted with from 1-5 independently selected **R^e**;
 - 10 (iii) -(C₀₋₃ alkylene)-heteroaryl including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, N(**R^a**), O, and S, wherein the heteroaryl is optionally substituted with from 1-3 independently selected **R^e**;
 - (iv) -OH;
 - 15 (v) -N(**R^a**)(**R''**);
 - (vi) C₁₋₄ alkoxy;
 - (vii) C₁₋₄ haloalkoxy; and
 - (viii) -F.

- 20 62. The compound of any one of claims 10-50, wherein each occurrence of **R^b** is independently selected from the group consisting of: **R³¹**; -OH; -N(**R^a**)(**R''**); C₁₋₄ alkoxy; and C₁₋₄ haloalkoxy.

- 25 63. The compound of any one of claims 10-50, wherein each occurrence of **R^b** is independently selected from the group consisting of:
- (i) C₁₋₆ alkyl optionally substituted with from 1-2 independently selected **R^e**;
 - (ii) -(C₀₋₃ alkylene)-C₆₋₁₀ aryl, wherein the aryl is optionally substituted with from 1-5 independently selected **R^e**;
 - 30 (iii) -(C₀₋₃ alkylene)-heteroaryl including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, N(**R^a**), O, and

S, wherein the heteroaryl is optionally substituted with from 1-3 independently selected **R^c**;

- (iv) -OH;
- (v) -N(R^a)(R'');
- 5 (vi) C₁₋₄ alkoxy;
- (vii) C₁₋₄ haloalkoxy; and
- (viii) -F.

64. The compound of any one of claims 10-50, wherein each occurrence of **R^b** is independently selected from the group consisting of:

- (i) C₁₋₆ alkyl;
- (iv) -OH;
- (v) -N(R^a)(R'');
- (vi) C₁₋₄ alkoxy;
- 15 (vii) C₁₋₄ haloalkoxy; and
- (viii) -F.


65. The compound of any one of claims 1-6, wherein ring A is a saturated or unsaturated bicyclic or tricyclic ring that includes from 6-14 (e.g., 8-10) ring atoms.

66. The compound of any one of claims 1-6, wherein ring A is an unsaturated bicyclic or tricyclic ring that includes from 6-14 (e.g., 8-10) ring atoms.

25 67. The compound of claim 65 or 66, wherein (**A**) applies.

68. The compound of any one of claims 65-67, wherein ring A is optionally further substituted with 1 oxo.

69. The compound of any one of claims 65-68, wherein ring A has formula (VI):




5 70. The compound of claim 69, wherein fused ring B is fused C₆₋₁₀ aryl optionally substituted with from 1-5 independently selected R^c.

71. The compound of claims 69 or 70, wherein fused ring B is fused phenyl optionally substituted with from 1-5 independently selected R^c.

10

72. The compound of any one of claims 69-71, wherein ring A has formula (VI-A):



wherein R^{c'} is H or R^c (e.g., C₁₋₆ alkyl, e.g., CH₃).


15

73. The compound of any one of claims 69-70, wherein ring B is fused C₁₀ aryl optionally substituted with from 1-5 independently selected R^c (e.g., unsubstituted).

74. The compound of claim 69, wherein ring B is fused heteroaryl including from 5-10 (e.g., 6) ring atoms, wherein from 1-4 (e.g., 1) ring atoms are each independently selected from the group consisting of N, N(R^a), O, and S, wherein the heteroaryl is optionally substituted with from 1-3 independently selected R^c.

20

75. The compound of any one of claims 65-68, wherein ring **A** is selected from one of the follows:



5 76. The compound of claim 75, wherein each fused ring **B** is independently selected from:

 fused heteroaryl including from 5-10 (e.g., 6) ring atoms, wherein from 1-4 (e.g., 1) ring atoms are each independently selected from the group consisting of N, N(**R^a**), O, and S, wherein the heteroaryl is optionally substituted with from 1-3 independently selected **R^c**; and

 fused C₆₋₁₀ (e.g., C₆) aryl optionally substituted with from 1-5 (e.g., from 1-2) independently selected **R^c**.


15 77. The compound of claim 75, wherein each fused ring **B** is independently a fused C₆₋₁₀ (e.g., C₆) aryl optionally substituted with from 1-5 (e.g., from 1-2) independently selected **R^c**.

20 78. The compound of any one of claims 1-6, wherein ring **A** is a saturated bicyclic or tricyclic ring that includes from 8-10 ring atoms.

 79. The compound of claim 78, wherein (**A**) applies.

25 80. The compound of claim 78 or 79, wherein ring **A** is optionally further substituted with 1 oxo.

81. The compound of any one of claims 78-80, wherein ring A has formula (VI):




5 82. The compound of claim 81, wherein fused ring B is fused C₃₋₁₀ cycloalkyl optionally substituted with from 1-4 independently selected R^d.

83. The compound of 81 or 82, wherein fused ring B is fused C₃₋₆ cycloalkyl (e.g., C₃₋₄ cycloalkyl) optionally substituted with from 1-4 independently selected R^d
 10 (e.g., C₁₋₃ alkyl).

84. The compound of claim 78, wherein (B) applies.

85. The compound of claim 84, wherein ring A includes from 5-6 ring atoms
 15 and is optionally further substituted with 1 oxo.

86. The compound of claim 84 or 85, wherein ring A has formula (VII):



87. The compound of claim 86, wherein the spiro-fused ring B is spiro-fused
 20 C₃₋₁₀ cycloalkyl optionally substituted with from 1-4 independently selected R^d.

88. The compound of any one of claims 84-87, wherein the spiro-fused ring B is spiro-fused C₃₋₆ cycloalkyl (e.g., C₃₋₄ cycloalkyl) optionally substituted with from 1-4 independently selected **R^d** (e.g., C₁₋₃ alkyl).

5 89. The compound of any one of claims 1-88, wherein **L** has formula (VIII) :
-(CH₂)_m-**X¹**-(CH₂)_n-**X²**-(CH₂)_p-.

90. The compound of claim 89, wherein **m** is from 2-6.

10 91. The compound of claim 89 or 90, wherein **m** is 2.

92. The compound of claim 89, wherein **m** is 1.

93. The compound of any one of claims 89-92, wherein **X¹** is -N(R')C(O)-.

15

94. The compound of any one of claims 89-93, wherein **X¹** is -N(H)C(O)-.

95. The compound of any one of claims 89-94, wherein **n + p** ≥ 2.

20 96. The compound of any one of claims 89-94, wherein **n + p** = 2 (e.g., each of **n** and **p** is 1).

97. The compound of any one of claims 89-94, wherein **n + p** < 2.

25 98. The compound of any one of claims 89-94, wherein **n + p** = 0.

99. The compound of any one of claims 89-98, wherein **X²** is: -O-; -S-; or -S(O)_t-, wherein **t** is 1 or 2.

30 100. The compound of any one of claims 89-99, wherein **X²** is: -S-.

101. The compound of any one of claims 89-98, wherein X^2 is $-C(Q^1)(Q^2)-$.

102. The compound of claim 101, wherein each of Q^1 and Q^2 is independently
5 H and C_{1-4} alkyl.

103. The compound of claim 101, wherein each of Q^1 and Q^2 is H.

104. The compound of claim 101, wherein each of Q^1 and Q^2 is an
10 independently selected C_{1-4} alkyl.

105. The compound of claim 102, wherein Q^1 is H; and Q^2 is C_{1-4} alkyl.

106. The compound of claim 101, wherein Q^1 and Q^2 , together with the carbon
15 atom to which each is attached forms C_{3-10} cycloalkyl that is optionally substituted with
from 1-4 independently selected R^d and optionally fused to phenyl.

107. The compound of claim 106, wherein Q^1 and Q^2 , together with the carbon
atom to which each is attached forms C_{3-6} cycloalkyl that is optionally substituted with
20 from 1-4 independently selected R^d and optionally fused to phenyl.

108. The compound of claim 107, wherein Q^1 and Q^2 , together with the carbon
atom to which each is attached forms C_{4-6} (e.g., C_4) cycloalkyl that is optionally substituted
with from 1-2 independently selected R^d .

25

109. The compound of any one of claims 89-98, wherein X^2 is:

(v) C_{6-10} arylene optionally substituted with from 1-5 independently selected R^c ;

(vi) heteroarylene including from 5-10 ring atoms, wherein from 1-4 ring atoms
are each independently selected from the group consisting of N, $N(R^a)$, O, and S; and
30 which is optionally substituted with from 1-5 independently selected R^c ;

(vii) C₃₋₁₀ cycloalkylene optionally substituted with from 1-4 independently selected **R^d**, or

(viii) heterocycloalkylene including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of N(**R^a**), O, and S; and
 5 which is optionally substituted with from 1-5 independently selected **R^d**.

110. The compound of any one of claims 89-98, wherein **X²** is:


(v) C₆₋₁₀ arylene optionally substituted with from 1-5 independently selected **R^c**;

or

10 (vii) C₃₋₁₀ cycloalkylene optionally substituted with from 1-4 independently selected **R^d**.

111. The compound of claim 109, wherein **X²** is (viii) heterocycloalkylene including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently
 15 selected from the group consisting of N(**R^a**), O, and S; and which is optionally substituted with from 1-5 independently selected **R^d**.

112. The compound of claim 111, wherein **X²** is (viii) heterocycloalkylene including from 4-6 (e.g., 4) ring atoms, wherein from 1-3 (e.g., 1) ring atoms are each
 20 independently selected from the group consisting of N(**R^a**), O, and S; and which is optionally substituted with from 1-5 independently selected **R^d** (e.g., **X²** can be



113. The compound of any one of claims 1-89, wherein:

25 **m** is from 2-6;

n + p ≥ 2; and

X² is: -O-, -S-, -S(O)_t-, or CH₂.

114. The compound of claim 113, wherein **m** is 2.

115. The compound of claim 113 or 114, wherein $\mathbf{X}^1$ is $-\mathbf{N}(\mathbf{R}')\mathbf{C}(\mathbf{O})-$ (e.g., $-\mathbf{X}^1$ is $\mathbf{N}(\mathbf{H})\mathbf{C}(\mathbf{O})-$).

5 116. The compound of any one of claims 113-115, wherein $\mathbf{n} + \mathbf{p} > 2$.

117. The compound of any one of claims 113-115, wherein $\mathbf{n} + \mathbf{p} = 2$ (e.g., each of $\mathbf{n}$ and $\mathbf{p}$ is 1).

10 118. The compound of any one of claims 113-117, wherein $\mathbf{X}^2$ is $-\mathbf{S}-$.

119. The compound of any one of claims 1-89, wherein:

$\mathbf{m}$ is from 2-6;

$\mathbf{n} + \mathbf{p} < 2$; and

15 $\mathbf{X}^2$ is:

(i) $-\mathbf{C}(\mathbf{Q}^1)(\mathbf{Q}^2)-$, wherein each of $\mathbf{Q}^1$ and $\mathbf{Q}^2$ is an independently selected $\mathbf{C}_{1-4}$ alkyl; or $\mathbf{Q}^1$ and $\mathbf{Q}^2$, together with the carbon atom to which each is attached forms $\mathbf{C}_{3-10}$ cycloalkyl that is optionally substituted with from 1-4 independently selected $\mathbf{R}^d$ and optionally fused to phenyl.;

20 (v) $\mathbf{C}_{6-10}$ arylene optionally substituted with from 1-5 independently selected $\mathbf{R}^c$;

(vi) heteroarylene including from 5-10 ring atoms, wherein from 1-4 ring atoms are each independently selected from the group consisting of N, $\mathbf{N}(\mathbf{R}^a)$, O, and S; and which is optionally substituted with from 1-5 independently selected $\mathbf{R}^c$;

25 (vii) $\mathbf{C}_{3-10}$ cycloalkylene optionally substituted with from 1-4 independently selected $\mathbf{R}^d$; or

(viii) heterocycloalkylene including from 3-10 ring atoms, wherein from 1-3 ring atoms are each independently selected from the group consisting of $\mathbf{N}(\mathbf{R}^a)$, O, and S; and which is optionally substituted with from 1-5 independently selected $\mathbf{R}^d$.

30 120. The compound of claim 119, wherein $\mathbf{m}$ is 2.

121. The compound of claim 119 or 120, wherein X^1 is $-N(R')C(O)-$ (e.g., $-N(H)C(O)-$).

5 122. The compound of any one of claims 119-121, wherein $n + p = 0$.

123. The compound of any one of claims 119-122, wherein X^2 is $-C(Q^1)(Q^2)-$.

124. The compound of claim 123, wherein each of Q^1 and Q^2 is H.

10

125. The compound of claim 123, wherein Q^1 is C_{1-4} alkyl.

126. The compound of claim 125 wherein Q^2 is C_{1-4} alkyl.

15

127. The compound of any one of claims 119-122, wherein Q^1 and Q^2 , together with the carbon atom to which each is attached forms C_{3-6} cycloalkyl that is optionally substituted with from 1-4 independently selected R^d and optionally fused to phenyl.

128. The compound of any one of claims 119-122, wherein X^2 is:

20


(v) C_{6-10} arylene optionally substituted with from 1-5 independently selected R^c ;

or

(vii) C_{3-10} cycloalkylene optionally substituted with from 1-4 independently selected R^d .

25

129. The compound of any one of claims 119-122, wherein X^2 is (viii) heterocycloalkylene including from 4-6 (e.g., 4) ring atoms, wherein from 1-3 (e.g., 1) ring atoms are each independently selected from the group consisting of $N(R^a)$, O, and S; and which is optionally substituted with from 1-5 independently selected R^d (e.g., X^2 can be




130. The compound of any one of claims 1-89, wherein:
m is 1;
n + p $\leq$ 2; and
5 **X²** is: -O-; -S-; -S(O)_t-, or C(**Q**¹)(**Q**²).
131. The compound of claim 130, wherein **n + p** = 2.
132. The compound of claim 131, wherein **X²** is -S-.
- 10 133. The compound of claim 130, wherein **n + p** < 2 (e.g., **n + p** = 0; or **n + p** = 1).
134. The compound of claim 133, wherein **X²** is C(**Q**¹)(**Q**²).
- 15 135. The compound of claim 134, wherein each of **Q**¹ and **Q**² is H.
136. The compound of claim 134, wherein each of **Q**¹ and **Q**² is C₁₋₄ alkyl.
- 20 137. The compound of claim 134, wherein **Q**¹ is H; and **Q**² is C₁₋₄ alkyl.
138. The compound of any one of claims 1-89, wherein **L** has formula (IX): -C(O)-(CH₂)_n-**X**³-(CH₂)_p-.
- 25 139. The compound of claim 138, wherein **n + p** $\geq$ 2.
140. The compound of claim 138 or 139, wherein **n + p** = 2 (e.g., each of **n** and **p** is 1).
- 30 141. The compound of any one of claims 138-140, wherein **X**³ is -S-.

142. The compound of any one of claims 1-141, wherein $\mathbf{R}^1$ is H.
143. The compound of any one of claims 1-142, wherein $\mathbf{R}^2$ is H.
- 5 144. The compound of any one of claims 1-143, wherein $\mathbf{R}^4$ is H.
145. The compound of any one of claims 1-144, wherein each of $\mathbf{R}^1$, $\mathbf{R}^2$, and $\mathbf{R}^4$ is H.
- 10 146. The compound of any one of claims 1-142, wherein $\mathbf{R}^2$ is unsubstituted C_{1-3} alkyl (e.g., methyl).
147. The compound of claim 146, wherein each of $\mathbf{R}^1$ and $\mathbf{R}^4$ is H.
- 15 148. The compound of any one of claims 1 and 5-147, wherein $\mathbf{R}^{2'}$ is as defined according to (AA).
149. The compound of any one of claims 1-2, and 4-148, wherein $\mathbf{a}'$ is 1.
- 20 150. The compound of any one of claims 1-2, and 4-149, wherein each of $\mathbf{R}^{3a}$ and $\mathbf{R}^{3b}$ is H.
151. The compound of any one of claims 1, 2, and 4-149, wherein each of $\mathbf{R}^{3a}$ and $\mathbf{R}^{3b}$ is C_{1-3} alkyl (e.g., methyl).
- 25 152. The compound of any one of claims 1, 2, and 4-148, wherein $\mathbf{a}'$ is 0.
153. The compound of any one of claims 1-152, wherein $\mathbf{R}^3$ is $-\text{C}(\text{O})\text{OH}$.

30

154. The compound of any one of claims 1-152, wherein **R**³ is a carboxylic acid isostere.

155. The compound of any one of claims 1-152 and 154, wherein **R**³ is an optionally substituted tetrazolyl, an amide, or an optionally substituted isoxazolyl (e.g.,



156. The compound of any one of claims 1-155, wherein **a** is 0, 1, 2, or 3 (e.g., **a** = 0; or **a** = 1; or **a** = 2).

10

157. The compound of claim 157, wherein **a** is 1.

158. The compound of any one of claims 1-157, wherein **W** is a sequence of from 25-45 (e.g., 30-45) amino acids.

15

159. The compound of any one of claims 1-158, wherein **W** is a sequence of 36 amino acids.

160. The compound of any one of claims 1-158, wherein **W** has formula (X): -
-GTF-**W**''-**R**⁵, wherein **W**' is a sequence of 30-40 (e.g., 31-36, 33) amino acids.

20

161. The compound of any one of claims 1-158 and 160, wherein **W** is represented by any one of SEQ ID 1-34 (e.g., SEQ. ID 5-27; e.g., SEQ ID 5-29; (e.g., SEQ ID 6); e.g., SEQ ID 28-29; e.g., SEQ ID 30-34).


25

162. The compound of any one of claims 1-161, wherein **R**⁵ is a C-terminal amino acid amide that is optionally substituted with from 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group).

163. The compound of any one of claims 1-162, wherein R^5 is a C-terminal lysyl amide residue that is optionally substituted with from 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group).

5 164. The compound of any one of claims 1-163, wherein R^5 is a C-terminal *L*-lysyl amide residue that is optionally substituted with from 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group).


165. The compound of any one of claims 1-164, wherein R^5 has formula (XI):



wherein R^* is H or a modifying group (e.g., an acyl group and a PEG group).

166. The compound of any one of claims 1-165, wherein W has formula (XII):

15



wherein **W''** is a sequence of 30-40 (e.g., 31-36, 33) amino acids, and **R*** is H or H or a modifying group (e.g., an acyl group and a PEG group).

5

167. The compound of any one of claims 1-161, wherein **R⁵** is a C-terminal amino acid that is optionally substituted with from 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group).


10

168. The compound of any one of claims 1-161 and 167, wherein **R⁵** is a C-terminal lysine that is optionally substituted with from 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group).

15


169. The compound of any one of claims 1-161 and 167-168, wherein **R⁵** is a C-terminal *L*-lysine that is optionally substituted with from 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group).

170. The compound of any one of claims 1-161 and 168-169, wherein **R⁵** has formula (XI-OH):



wherein R^* is H or a modifying group (e.g., an acyl group and a PEG group).

171. The compound of any one of claims 1-161 and 168-170, wherein **W** has
5 formula (XII-OH):



wherein **W''** is a sequence of 30-40 (e.g., 31-36, 33) amino acids, and R^* is H or
H or a modifying group (e.g., an acyl group and a PEG group).

10


172. The compound of any one of claims 165-166 and 170-171, wherein R^* is
H.

173. The compound of any one of claims 165-166 and 170-171, wherein R^* is C_{2-30} (e.g., C_{2-20}) acyl group that is optionally substituted with from 1-2 independently selected R^f ; wherein each occurrence of R^f is selected from the group consisting of -
 5 C(=O)(OH); -C(=O)(C_{2-20} alkyl); -C(=O)O(C_{2-20} alkyl); -S(O)₁₋₂(C_{1-6} alkyl); oxo; F; C_{1-10} alkoxy; C_{1-10} haloalkoxy; and -N(R^g)(R^h); and wherein each occurrence of R^g and R^h is independently selected from the group consisting of H; C_{1-4} alkyl; -C(=O)(C_{2-20} alkyl); -C(=O)O(C_{2-20} alkyl); and -S(O)₁₋₂(C_{1-6} alkyl).

10 174. The compound of any one of claims 165-166, 170-171, and 173, wherein R^* is C_{2-30} (e.g., C_{2-20}) acyl group that is substituted with from 1-2 independently selected R^f .


15 175. The compound of claim 174, wherein each occurrence of R^f is independently selected from the group consisting of -C(=O)(OH) and -N(R^g)(R^h).

176. The compound of any one of claims 165-166, 170-171, and 173-175, wherein R^* is:




20

177. The compound of claim 176, wherein R^* is:



178. The compound of claim 176, wherein R* is:



5

179. The compound of any one of claims 1-161, wherein **R⁵** is a C-terminal amino acid selected from serine, glycine, and arginine.

10 180. The compound of any one of claims 1-161, wherein **R⁵** is a C-terminal amino acid amide selected from serinyl amide, glycyl amide, and argininy amide.

181. The compound of any of claims 1-2 and 162-180, wherein:

the compound has formula (IA-A), (IA-AA), or (IA-AB);

15 **ring A** is a saturated monocyclic ring that includes from 3-8 (e.g., 4-8, 4-7, 5-6) ring atoms; and

L has formula (VIII): $-(CH_2)_m-X^1-(CH_2)_n-X^2-(CH_2)_p-$.

20 182. The compound of any of claims 1-2 and 162-181, wherein **W** is represented by formula (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-B), (XV), or any of SEQ ID 1-34.

183. The compound of any of claims 1-2 and 162-182, wherein **W** is represented by any of SEQ ID 5-29.

25

184. The compound of any of claims 1-2 and 162-183, wherein **W** is represented by SEQ ID 6.

185. The compound of any of claims 1-2 and 162-184, wherein:

5 (i) **m** is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), and **n + p = 2** (e.g., each of **n** and **p** is 1), and **X²** is -S-; or


(ii) **m** is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), **n + p = 0**, **X²** is -C(Q¹)(Q²)-, and **Q¹** and **Q²**, together with the carbon atom to which each is attached forms C₃₋₆ cycloalkyl that is optionally substituted with from 1-4 independently selected **R^d** and optionally fused to phenyl; or

10 (iii) **m** is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), **n + p = 0**, **X²** is -C(Q¹)(Q²)-, and **Q¹** and **Q²** is an independently selected C₁₋₄ alkyl (e.g., CH₃); or

(iv) **m** is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), **n + p = 0**, and **X²** is:
 (v) C₆₋₁₀ arylene (e.g., phenylene) optionally substituted with from 1-5 independently selected **R^c**; or (vii) C₃₋₁₀ cycloalkylene optionally substituted with from 1-4 independently selected **R^d**.

186. The compound of any one of claims 1-2 and 162-184, wherein:

20 (iv) **m** is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), **n + p = 0**, and **X²** is: heterocycloalkylene including from 4-6 (e.g., 4) ring atoms, wherein from 1-3 (e.g., 1) ring atoms are each independently selected from the group consisting of N(R^a), O, and S; and which is optionally substituted with from 1-5 independently selected **R^d** (e.g., **X²** can be



25 187. The compound of any of claims 1-2 and 162-185, wherein **m** is 2-6 (e.g., 2), **X¹** is -N(R')C(O)- (e.g., -N(H)C(O)-), and **n + p = 2** (e.g., each of **n** and **p** is 1), and **X²** is -S-.

188. The compound of any of claims 1-2, 162-184, and 187, wherein **L** is -
CH₂CH₂NHC(O)CH₂SCH₂-.

5 189. The compound of any of claims 1-2 and 162-188, wherein ring A has
formula (III).

190. The compound of any of claims 1-2 and 162-189, wherein ring A is defined
as in any one or more of claims 11-27.

10 191. The compound of any of claims 1-2 and 162-189, wherein ring A has
formula (III-A).

192. The compound of any of claims 1-2 and 162-188 and 190, wherein ring A
is defined as in any one or more of claims 29-41.

15 193. The compound of any of claims 1-2 and 162-189, wherein ring A is defined
as in any one or more of claims 42-50.

20 194. The compound of any one of claims 1-2 and 162-193, wherein one, two, or
three of **R**¹, **R**², and **R**⁴ are H.

195. The compound of any one of claims 1-2 and 162-194, wherein one, two, or
three of **R**¹, **R**², and **R**⁴ are H.

25 196. The compound of any one of claims 1-2 and 162-195, wherein, **R**³ is -
C(O)OH.

197. The compound of any one of claims 1-2 and 162-196, wherein **a**['] is 1; and
each of **R**^{3a} and **R**^{3b} is independently H.

30

198. The compound of any one of claims 1 and 162-197, wherein **a** is 0, 1, or 2 (e.g., 1).

199. The compound of any one of claims 1-2 and 162-198, wherein each of **R¹**, **R²**, and **R⁴** is H, **a** is 0, 1, or 2 (e.g., 1), and **R³** is -C(O)OH.

200. The compound of claim 1, wherein the compound is selected from the group consisting of those delineated in **FIG. 1**.

201. A pharmaceutical composition comprising a compound or salt as claimed in any one of claims 1-200 and one or more pharmaceutically acceptable excipients.

202. A method for modulating GLP-1R and/or GIPR activity, the method comprising contacting GLP-1R and/or GIPR with a compound as claimed in any one of claims 1-200.

203. The method of claim 202, wherein the modulating comprises agonizing GLP-1R and/or GIPR.

204. The method of claim 202, wherein the modulating comprises partially agonizing or antagonizing GLP-1R and/or GIPR.

205. The method of any one of claims 202-204, which is carried out *in vitro*.

206. The method of any one of claims 202-204, which is carried out *in vivo*.

207. A method for modulating GLP-1R and/or GIPR induced aversion, nausea and/or vomiting, the method comprising contacting GLP-1R and/or GIPR with a compound as claimed in any one of claims 1-200.

208. A method for modulating (e.g., increasing) insulin levels in a subject in need of such modulating, the method comprising administering to the subject an effective amount of a compound as claimed in any one of claims 1-200.

5 209. A method for modulating (e.g., decreasing) glucose levels in a subject in need of such modulating, the method comprising administering to the subject an effective amount of a compound as claimed in any one of claims 1-200.

10 210. A method for treating a disease, disorder, or condition, in which modulating GLP-1R and/or GIPR signaling can alter the pathology and/or symptoms and/or progression of the disease, disorder, or condition, the method comprising administering to the subject in need thereof an effective amount of a compound as claimed in any one of claims 1-200.

15 211. The method of claim 210, wherein the disease, disorder, or condition or disorder is diabetes.

 212. The method of claim 210, wherein the disease, disorder, or condition or disorder is NASH.

20 213. The method of claim 210, wherein the disease, disorder, or condition or disorder is obesity.

 214. The method of claim 210, wherein the disease, disorder, or condition or disorder is fatty liver disease.

25 215. The method of claim 210, wherein the disease, disorder, or condition or disorder is steatohepatitis.

216. The method of any one of claims 210-215, wherein the method further comprises identifying the subject.

217. The method of any one of claims 210-216, wherein the subject is a human.

5

218. A method for treating a disease, disorder, or condition, in which modulating GLP-1R and/or GIPR signaling causes aversion, nausea or vomiting, the method comprising administering to the subject in need thereof an effective amount of a compound as claimed in any one of claims 1-200.

10